(lp0
(dp1
S'contVal'
p2
NsS'drug2'
p3
S'http://bio2rdf.org/drugbank:DB00526'
p4
sS'drug1'
p5
S'http://bio2rdf.org/drugbank:DB00544'
p6
sS'objectUri'
p7
NsS'evidence'
p8
NsS'ddiPkMechanism'
p9
NsS'whoAnnotated'
p10
NsS'contraindication'
p11
NsS'researchStatementLabel'
p12
NsS'severity'
p13
NsS'label'
p14
NsS'effectConcept'
p15
NsS'source'
p16
S'DDI-Corpus-2013'
p17
sS'ddiPkEffect'
p18
NsS'homepage'
p19
NsS'pathway'
p20
NsS'ddiType'
p21
S'mechanism'
p22
sS'researchStatement'
p23
NsS'dateAnnotated'
p24
NsS'object'
p25
S'\xef\xbb\xbf5-FU'
p26
sS'evidenceSource'
p27
NsS'evidenceStatement'
p28
S'Increases of 5-FU plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 ELOXATIN dosed every 3 weeks. | \r'
p29
sS'precipUri'
p30
NsS'certainty'
p31
NsS'uri'
p32
NsS'evidenceType'
p33
NsS'numericVal'
p34
NsS'precaution'
p35
NsS'precipitant'
p36
S'Eloxatin'
p37
sa(dp38
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p39
sg5
S'http://bio2rdf.org/drugbank:DB01238'
p40
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p41
sg23
Nsg24
Nsg25
S'Abilify'
p42
sg27
Nsg28
S'Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol.| \r'
p43
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p44
sa(dp45
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p46
sg5
S'http://bio2rdf.org/drugbank:DB00316'
p47
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p48
sg23
Nsg24
Nsg25
S'ACETAMINOPHEN'
p49
sg27
Nsg28
S'Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.| \r'
p50
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p51
sa(dp52
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01008'
p53
sg5
S'http://bio2rdf.org/drugbank:DB00316'
p54
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p55
sg23
Nsg24
Nsg25
S'ACETAMINOPHEN'
p56
sg27
Nsg28
S'Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.| \r'
p57
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Busulfex'
p58
sa(dp59
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00201'
p60
sg5
S'http://bio2rdf.org/drugbank:DB00316'
p61
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p62
sg23
Nsg24
Nsg25
S'ACETAMINOPHEN'
p63
sg27
Nsg28
S'Increased hepatotoxicity of acetaminophen by concomitant administration of caffeine in the rat.| Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.| \r'
p64
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CAFFEINE'
p65
sa(dp66
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00475'
p67
sg5
S'http://bio2rdf.org/drugbank:DB00316'
p68
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p69
sg23
Nsg24
Nsg25
S'ACETAMINOPHEN'
p70
sg27
Nsg28
S'Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.| \r'
p71
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CHLORDIAZEPOXIDE'
p72
sa(dp73
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00619'
p74
sg5
S'http://bio2rdf.org/drugbank:DB00316'
p75
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p76
sg23
Nsg24
Nsg25
S'ACETAMINOPHEN'
p77
sg27
Nsg28
S'Systemic exposure to acetaminophen is expected to be increased when coadministered with Gleevec.| \r'
p78
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Gleevec'
p79
sa(dp80
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00951'
p81
sg5
S'http://bio2rdf.org/drugbank:DB00316'
p82
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p83
sg23
Nsg24
Nsg25
S'ACETAMINOPHEN'
p84
sg27
Nsg28
S'Acetaminophen: A report of severe acetaminophen toxicity was reported in a patient receiving Isoniazid.| \r'
p85
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ISONIAZID'
p86
sa(dp87
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p88
sg5
S'http://bio2rdf.org/drugbank:DB00316'
p89
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p90
sg23
Nsg24
Nsg25
S'ACETAMINOPHEN'
p91
sg27
Nsg28
S'Acetaminophen diminished the binding of theophylline to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L. | Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. | \r'
p92
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p93
sa(dp94
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p95
sg5
S'http://bio2rdf.org/drugbank:DB00316'
p96
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p97
sg23
Nsg24
Nsg25
S'ACETAMINOPHEN'
p98
sg27
Nsg28
S'Acetaminophen diminished the binding of theophylline to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L. | Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. | \r'
p99
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p100
sa(dp101
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p102
sg5
S'http://bio2rdf.org/drugbank:DB00819'
p103
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p104
sg23
Nsg24
Nsg25
S'ACETAZOLAMIDE'
p105
sg27
Nsg28
S'Acetazolamide may elevate cyclosporine levels.| \r'
p106
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSPORINE'
p107
sa(dp108
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p109
sg5
S'http://bio2rdf.org/drugbank:DB00819'
p110
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p111
sg23
Nsg24
Nsg25
S'ACETAZOLAMIDE'
p112
sg27
Nsg28
S'Acetazolamide increases lithium excretion and the lithium may be decreased.| \r'
p113
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM CATION'
p114
sa(dp115
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p116
sg5
S'http://bio2rdf.org/drugbank:DB00819'
p117
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p118
sg23
Nsg24
Nsg25
S'ACETAZOLAMIDE'
p119
sg27
Nsg28
S'Acetazolamide increases lithium excretion and the lithium may be decreased.| \r'
p120
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM'
p121
sa(dp122
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00908'
p123
sg5
S'http://bio2rdf.org/drugbank:DB00819'
p124
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p125
sg23
Nsg24
Nsg25
S'ACETAZOLAMIDE'
p126
sg27
Nsg28
S'Acetazolamide reduces urinary excretion of quinidine and may enhance its effect.| \r'
p127
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'QUINIDINE'
p128
sa(dp129
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01390'
p130
sg5
S'http://bio2rdf.org/drugbank:DB00819'
p131
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p132
sg23
Nsg24
Nsg25
S'ACETAZOLAMIDE'
p133
sg27
Nsg28
S'Acetazolamide and sodium bicarbonate used concurrently increases the risk of renal calculus formation.| \r'
p134
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SODIUM BICARBONATE'
p135
sa(dp136
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00870'
p137
sg5
S'http://bio2rdf.org/drugbank:DB03128'
p138
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p139
sg23
Nsg24
Nsg25
S'ACETYLCHOLINE CHLORIDE'
p140
sg27
Nsg28
S'Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.| \r'
p141
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Suprofen'
p142
sa(dp143
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00166'
p144
sg5
S'http://bio2rdf.org/drugbank:DB08842'
p145
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p146
sg23
Nsg24
Nsg25
S'acetyl-L-carnitine'
p147
sg27
Nsg28
S'(ii) acetyl-l-carnitine elicits a significant protective effect on DEB induced toxicity, which was potentiated by  alpha-lipoic acid.| \r'
p148
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'alpha-Lipoic acid'
p149
sa(dp150
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p151
sg5
S'http://bio2rdf.org/drugbank:DB00459'
p152
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p153
sg23
Nsg24
Nsg25
S'ACITRETIN'
p154
sg27
Nsg28
S'Ethanol:Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and ethanol.| \r'
p155
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p156
sa(dp157
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01016'
p158
sg5
S'http://bio2rdf.org/drugbank:DB00459'
p159
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p160
sg23
Nsg24
Nsg25
S'ACITRETIN'
p161
sg27
Nsg28
S'Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.| \r'
p162
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Glibenclamide'
p163
sa(dp164
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p165
sg5
S'http://bio2rdf.org/drugbank:DB00459'
p166
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p167
sg23
Nsg24
Nsg25
S'ACITRETIN'
p168
sg27
Nsg28
S'Phenytoin: If acitretin is given concurrently with phenytoin, the protein binding of phenytoin may be reduced.| \r'
p169
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p170
sa(dp171
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00681'
p172
sg5
S'http://bio2rdf.org/drugbank:DB01285'
p173
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p174
sg23
Nsg24
Nsg25
S'ACTH'
p175
sg27
Nsg28
S'Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.| \r'
p176
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPHOTERICIN B'
p177
sa(dp178
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00437'
p179
sg5
S'http://bio2rdf.org/drugbank:DB00415'
p180
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p181
sg23
Nsg24
Nsg25
S'ADENOSINE PHOSPHATE'
p182
sg27
Nsg28
S'It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.| Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.| \r'
p183
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALLOPURINOL'
p184
sa(dp185
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00201'
p186
sg5
S'http://bio2rdf.org/drugbank:DB00640'
p187
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p188
sg23
Nsg24
Nsg25
S'ADENOSINE'
p189
sg27
Nsg28
S'The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.| \r'
p190
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CAFFEINE'
p191
sa(dp192
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p193
sg5
S'http://bio2rdf.org/drugbank:DB00640'
p194
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p195
sg23
Nsg24
Nsg25
S'ADENOSINE'
p196
sg27
Nsg28
S'As the primary effect of adenosine is to decrease conduction through the A-V node, higher degrees of heart block may be produced in the presence of carbamazepine.| \r'
p197
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CARBAMAZEPINE'
p198
sa(dp199
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00975'
p200
sg5
S'http://bio2rdf.org/drugbank:DB00640'
p201
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p202
sg23
Nsg24
Nsg25
S'ADENOSINE'
p203
sg27
Nsg28
S'Adenosine effects are potentiated by dipyridamole.| Thus, smaller doses of adenosine may be effective in the presence of dipyridamole.| \r'
p204
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIPYRIDAMOLE'
p205
sa(dp206
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p207
sg5
S'http://bio2rdf.org/drugbank:DB00640'
p208
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p209
sg23
Nsg24
Nsg25
S'ADENOSINE'
p210
sg27
Nsg28
S'The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.| \r'
p211
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p212
sa(dp213
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p214
sg5
S'http://bio2rdf.org/drugbank:DB06274'
p215
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p216
sg23
Nsg24
Nsg25
S'ADL 8-2698'
p217
sg27
Nsg28
S'ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia.&#x0D;| We conclude that ADL 8-2698 prevents morphine-induced increases in gastrointestinal transit time by means of selective peripheral opioid anitagonism without affecting central opioid analgesia.| \r'
p218
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MORPHINE'
p219
sa(dp220
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01159'
p221
sg5
S'http://bio2rdf.org/drugbank:DB00668'
p222
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p223
sg23
Nsg24
Nsg25
S'Adrenaline'
p224
sg27
Nsg28
S'Caution should be exercised during the administration of adrenaline to patients anaesthetised with FLUOTHANE as arrhythmias may be precipitated.| \r'
p225
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Fluothane'
p226
sa(dp227
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p228
sg5
S'http://bio2rdf.org/drugbank:DB00775'
p229
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p230
sg23
Nsg24
Nsg25
S'Aggrastat'
p231
sg27
Nsg28
S'The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see| \r'
p232
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p233
sa(dp234
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00454'
p235
sg5
S'http://bio2rdf.org/drugbank:DB00810'
p236
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p237
sg23
Nsg24
Nsg25
S'Akineton'
p238
sg27
Nsg28
S'Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.| \r'
p239
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MEPERIDINE'
p240
sa(dp241
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00908'
p242
sg5
S'http://bio2rdf.org/drugbank:DB00810'
p243
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p244
sg23
Nsg24
Nsg25
S'Akineton'
p245
sg27
Nsg28
S'Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.| \r'
p246
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'QUINIDINE'
p247
sa(dp248
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01048'
p249
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p250
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p251
sg23
Nsg24
Nsg25
S'ALCOHOL'
p252
sg27
Nsg28
S'Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. | \r'
p253
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ABACAVIR'
p254
sa(dp255
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01238'
p256
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p257
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p258
sg23
Nsg24
Nsg25
S'ALCOHOL'
p259
sg27
Nsg28
S'As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY| \r'
p260
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Abilify'
p261
sa(dp262
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01213'
p263
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p264
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p265
sg23
Nsg24
Nsg25
S'ALCOHOL'
p266
sg27
Nsg28
S'Similarly, ethanol decreased the rate of elimination of Antizol (by approximately 50%) by the same mechanism.| \r'
p267
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Antizol'
p268
sa(dp269
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p270
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p271
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p272
sg23
Nsg24
Nsg25
S'ALCOHOL'
p273
sg27
Nsg28
S'Alcohol: Has a synergistic effect with aspirin in causing gastrointestinal bleeding.| \r'
p274
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p275
sa(dp276
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00327'
p277
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p278
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p279
sg23
Nsg24
Nsg25
S'ALCOHOL'
p280
sg27
Nsg28
S'Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.| \r'
p281
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Dilaudid'
p282
sa(dp283
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00822'
p284
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p285
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p286
sg23
Nsg24
Nsg25
S'ALCOHOL'
p287
sg27
Nsg28
S'Core temperature was decreased in rats in a dose-dependent manner when ethanol was administered to rats treated with disulfiram 8 hours before the ethanol challenge. | \r'
p288
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DISULFIRAM'
p289
sa(dp290
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00956'
p291
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p292
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p293
sg23
Nsg24
Nsg25
S'ALCOHOL'
p294
sg27
Nsg28
S'Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.| \r'
p295
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HYDROCODONE'
p296
sa(dp297
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p298
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p299
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p300
sg23
Nsg24
Nsg25
S'ALCOHOL'
p301
sg27
Nsg28
S'Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.| \r'
p302
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Lexapro'
p303
sa(dp304
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01107'
p305
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p306
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p307
sg23
Nsg24
Nsg25
S'ALCOHOL'
p308
sg27
Nsg28
S'Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.| \r'
p309
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Methyprylon'
p310
sa(dp311
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00652'
p312
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p313
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p314
sg23
Nsg24
Nsg25
S'ALCOHOL'
p315
sg27
Nsg28
S'Usage with Alcohol: Due to the potential for increased CNS depressants effects, alcohol should be used with caution in patients who are currently receiving pentazocine.| \r'
p316
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PENTAZOCINE, (-)-'
p317
sa(dp318
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00140'
p319
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p320
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p321
sg23
Nsg24
Nsg25
S'ALCOHOL'
p322
sg27
Nsg28
S'Interactions for Vitamin B2 (Riboflavin):  Alcohol - impairs the intestinal absorption of riboflavin| \r'
p323
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIBOFLAVIN'
p324
sa(dp325
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01142'
p326
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p327
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p328
sg23
Nsg24
Nsg25
S'ALCOHOL'
p329
sg27
Nsg28
S'Alcohol: It should be borne in mind that alcohol ingestion may increase the danger inherent in any intentional or unintentional SINEQUAN overdosage.| \r'
p330
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sinequan'
p331
sa(dp332
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00906'
p333
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p334
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p335
sg23
Nsg24
Nsg25
S'ALCOHOL'
p336
sg27
Nsg28
S'Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.| \r'
p337
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TIAGABINE'
p338
sa(dp339
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00115'
p340
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p341
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p342
sg23
Nsg24
Nsg25
S'ALCOHOL'
p343
sg27
Nsg28
S'Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.| \r'
p344
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Vitamin B12'
p345
sa(dp346
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01156'
p347
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p348
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p349
sg23
Nsg24
Nsg25
S'ALCOHOL'
p350
sg27
Nsg28
S'Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN.| The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS)| \r'
p351
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Wellbutrin'
p352
sa(dp353
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01156'
p354
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p355
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p356
sg23
Nsg24
Nsg25
S'ALCOHOL'
p357
sg27
Nsg28
S'Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN.| The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS)| \r'
p358
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Wellbutrin'
p359
sa(dp360
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p361
sg5
S'http://bio2rdf.org/drugbank:DB00802'
p362
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p363
sg23
Nsg24
Nsg25
S'ALFENTANIL'
p364
sg27
Nsg28
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p365
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sprycel'
p366
sa(dp367
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p368
sg5
S'http://bio2rdf.org/drugbank:DB00802'
p369
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p370
sg23
Nsg24
Nsg25
S'Alfentanyl'
p371
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p372
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p373
sa(dp374
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p375
sg5
S'http://bio2rdf.org/drugbank:DB00802'
p376
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p377
sg23
Nsg24
Nsg25
S'Alfentanyl'
p378
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p379
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p380
sa(dp381
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00695'
p382
sg5
S'http://bio2rdf.org/drugbank:DB01258'
p383
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p384
sg23
Nsg24
Nsg25
S'ALISKIREN'
p385
sg27
Nsg28
S'Furosemide: When aliskiren was co-administered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.| \r'
p386
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FUROSEMIDE'
p387
sa(dp388
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01370'
p389
sg5
S'http://bio2rdf.org/drugbank:DB00950'
p390
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p391
sg23
Nsg24
Nsg25
S'Allegra'
p392
sg27
Nsg28
S'ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.| \r'
p393
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALUMINUM'
p394
sa(dp395
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01378'
p396
sg5
S'http://bio2rdf.org/drugbank:DB00950'
p397
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p398
sg23
Nsg24
Nsg25
S'Allegra'
p399
sg27
Nsg28
S'ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.| \r'
p400
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MAGNESIUM CATION'
p401
sa(dp402
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01378'
p403
sg5
S'http://bio2rdf.org/drugbank:DB00950'
p404
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p405
sg23
Nsg24
Nsg25
S'Allegra'
p406
sg27
Nsg28
S'ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.| \r'
p407
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MAGNESIUM'
p408
sa(dp409
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p410
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p411
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p412
sg23
Nsg24
Nsg25
S'ALLOPURINOL'
p413
sg27
Nsg28
S'The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.| \r'
p414
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ADENOSINE PHOSPHATE'
p415
sa(dp416
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p417
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p418
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p419
sg23
Nsg24
Nsg25
S'ALLOPURINOL'
p420
sg27
Nsg28
S'The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.| \r'
p421
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPICILLIN'
p422
sa(dp423
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00993'
p424
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p425
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p426
sg23
Nsg24
Nsg25
S'ALLOPURINOL'
p427
sg27
Nsg28
S'In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.| Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.| \r'
p428
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AZATHIOPRINE'
p429
sa(dp430
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00993'
p431
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p432
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p433
sg23
Nsg24
Nsg25
S'ALLOPURINOL'
p434
sg27
Nsg28
S'In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.| Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.| \r'
p435
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AZATHIOPRINE'
p436
sa(dp437
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00672'
p438
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p439
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p440
sg23
Nsg24
Nsg25
S'ALLOPURINOL'
p441
sg27
Nsg28
S'The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.| Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.| \r'
p442
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CHLORPROPAMIDE'
p443
sa(dp444
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00672'
p445
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p446
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p447
sg23
Nsg24
Nsg25
S'ALLOPURINOL'
p448
sg27
Nsg28
S'The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.| Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.| \r'
p449
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CHLORPROPAMIDE'
p450
sa(dp451
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00266'
p452
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p453
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p454
sg23
Nsg24
Nsg25
S'ALLOPURINOL'
p455
sg27
Nsg28
S'Dicumarol: It has been reported that allopurinol prolongs the half-life of the anticoagulant, dicumarol.| \r'
p456
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DICUMAROL'
p457
sa(dp458
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01033'
p459
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p460
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p461
sg23
Nsg24
Nsg25
S'ALLOPURINOL'
p462
sg27
Nsg28
S'In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.| Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.| \r'
p463
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MERCAPTOPURINE'
p464
sa(dp465
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01033'
p466
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p467
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p468
sg23
Nsg24
Nsg25
S'ALLOPURINOL'
p469
sg27
Nsg28
S'In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.| Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.| \r'
p470
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MERCAPTOPURINE'
p471
sa(dp472
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p473
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p474
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p475
sg23
Nsg24
Nsg25
S'ALLOPURINOL'
p476
sg27
Nsg28
S'Allopurinol: The AUC of didanosine was increased about 4-fold when allopurinol at 300 mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and 18 mL/min).| \r'
p477
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Videx'
p478
sa(dp479
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p480
sg5
S'http://bio2rdf.org/drugbank:DB00918'
p481
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p482
sg23
Nsg24
Nsg25
S'ALMOTRIPTAN'
p483
sg27
Nsg28
S'Coadministration of almotriptan and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.| \r'
p484
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p485
sa(dp486
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p487
sg5
S'http://bio2rdf.org/drugbank:DB00918'
p488
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p489
sg23
Nsg24
Nsg25
S'ALMOTRIPTAN'
p490
sg27
Nsg28
S'Verapamil: Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of almotriptan.| \r'
p491
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Verapamil'
p492
sa(dp493
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p494
sg5
S'http://bio2rdf.org/drugbank:DB00969'
p495
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p496
sg23
Nsg24
Nsg25
S'ALOSETRON'
p497
sg27
Nsg28
S'Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.| \r'
p498
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIMETIDINE'
p499
sa(dp500
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01211'
p501
sg5
S'http://bio2rdf.org/drugbank:DB00969'
p502
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p503
sg23
Nsg24
Nsg25
S'ALOSETRON'
p504
sg27
Nsg28
S'Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.| \r'
p505
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLARITHROMYCIN'
p506
sa(dp507
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p508
sg5
S'http://bio2rdf.org/drugbank:DB00969'
p509
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p510
sg23
Nsg24
Nsg25
S'ALOSETRON'
p511
sg27
Nsg28
S'Concomitant administration of alosetron and fluvoxamine is contraindicated.| \r'
p512
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p513
sa(dp514
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01275'
p515
sg5
S'http://bio2rdf.org/drugbank:DB00969'
p516
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p517
sg23
Nsg24
Nsg25
S'ALOSETRON'
p518
sg27
Nsg28
S'Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.| \r'
p519
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HYDRALAZINE'
p520
sa(dp521
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00951'
p522
sg5
S'http://bio2rdf.org/drugbank:DB00969'
p523
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p524
sg23
Nsg24
Nsg25
S'ALOSETRON'
p525
sg27
Nsg28
S'Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.| \r'
p526
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ISONIAZID'
p527
sa(dp528
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p529
sg5
S'http://bio2rdf.org/drugbank:DB00969'
p530
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p531
sg23
Nsg24
Nsg25
S'ALOSETRON'
p532
sg27
Nsg28
S'Caution should be used when alosetron and ketoconazole are administered concomitantly.| \r'
p533
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p534
sa(dp535
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01035'
p536
sg5
S'http://bio2rdf.org/drugbank:DB00969'
p537
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p538
sg23
Nsg24
Nsg25
S'ALOSETRON'
p539
sg27
Nsg28
S'Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.| \r'
p540
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROCAINAMIDE'
p541
sa(dp542
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00976'
p543
sg5
S'http://bio2rdf.org/drugbank:DB00969'
p544
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p545
sg23
Nsg24
Nsg25
S'ALOSETRON'
p546
sg27
Nsg28
S'Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.| \r'
p547
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TELITHROMYCIN'
p548
sa(dp549
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00582'
p550
sg5
S'http://bio2rdf.org/drugbank:DB00969'
p551
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p552
sg23
Nsg24
Nsg25
S'ALOSETRON'
p553
sg27
Nsg28
S'Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.| \r'
p554
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VORICONAZOLE'
p555
sa(dp556
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p557
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p558
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p559
sg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p560
sg27
Nsg28
S'The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.| \r'
p561
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p562
sa(dp563
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01118'
p564
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p565
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p566
sg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p567
sg27
Nsg28
S'Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.| \r'
p568
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMIODARONE'
p569
sa(dp570
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p571
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p572
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p573
sg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p574
sg27
Nsg28
S'The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.| \r'
p575
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'APREPITANT'
p576
sa(dp577
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01211'
p578
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p579
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p580
sg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p581
sg27
Nsg28
S'Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.| \r'
p582
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLARITHROMYCIN'
p583
sa(dp584
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p585
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p586
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p587
sg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p588
sg27
Nsg28
S'Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.| \r'
p589
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSPORINE'
p590
sa(dp591
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p592
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p593
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p594
sg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p595
sg27
Nsg28
S'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| \r'
p596
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p597
sa(dp598
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p599
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p600
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p601
sg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p602
sg27
Nsg28
S'Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.| \r'
p603
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DILTIAZEM'
p604
sa(dp605
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00696'
p606
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p607
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p608
sg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p609
sg27
Nsg28
S'Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.| \r'
p610
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERGOTAMINE'
p611
sa(dp612
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p613
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p614
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p615
sg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p616
sg27
Nsg28
S'Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.| \r'
p617
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERYTHROMYCIN'
p618
sa(dp619
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p620
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p621
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p622
sg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p623
sg27
Nsg28
S'This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.| Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.| Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| \r'
p624
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p625
sa(dp626
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p627
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p628
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p629
sg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p630
sg27
Nsg28
S'This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.| Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.| Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| \r'
p631
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p632
sa(dp633
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p634
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p635
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p636
sg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p637
sg27
Nsg28
S'This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.| Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.| Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| \r'
p638
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p639
sa(dp640
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00951'
p641
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p642
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p643
sg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p644
sg27
Nsg28
S'Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.| \r'
p645
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ISONIAZID'
p646
sa(dp647
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01115'
p648
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p649
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p650
sg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p651
sg27
Nsg28
S'Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.| \r'
p652
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NIFEDIPINE'
p653
sa(dp654
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p655
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p656
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p657
sg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p658
sg27
Nsg28
S'Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.| \r'
p659
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PAROXETINE'
p660
sa(dp661
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p662
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p663
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p664
sg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p665
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p666
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p667
sa(dp668
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p669
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p670
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p671
sg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p672
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p673
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p674
sa(dp675
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01104'
p676
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p677
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p678
sg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p679
sg27
Nsg28
S'Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.| \r'
p680
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SERTRALINE'
p681
sa(dp682
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00467'
p683
sg5
S'http://bio2rdf.org/drugbank:DB06723'
p684
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p685
sg23
Nsg24
Nsg25
S'ALUMINUM HYDROXIDE'
p686
sg27
Nsg28
S'Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.| \r'
p687
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ENOXACIN'
p688
sa(dp689
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00492'
p690
sg5
S'http://bio2rdf.org/drugbank:DB06723'
p691
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p692
sg23
Nsg24
Nsg25
S'ALUMINUM HYDROXIDE'
p693
sg27
Nsg28
S'Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.| \r'
p694
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FOSINOPRIL'
p695
sa(dp696
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01155'
p697
sg5
S'http://bio2rdf.org/drugbank:DB01370'
p698
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p699
sg23
Nsg24
Nsg25
S'ALUMINUM'
p700
sg27
Nsg28
S'Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| \r'
p701
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Factive'
p702
sa(dp703
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00710'
p704
sg5
S'http://bio2rdf.org/drugbank:DB01370'
p705
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p706
sg23
Nsg24
Nsg25
S'ALUMINUM'
p707
sg27
Nsg28
S'Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.| \r'
p708
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'IBANDRONIC ACID'
p709
sa(dp710
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01133'
p711
sg5
S'http://bio2rdf.org/drugbank:DB01370'
p712
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p713
sg23
Nsg24
Nsg25
S'ALUMINUM'
p714
sg27
Nsg28
S'The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. | \r'
p715
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Skelid'
p716
sa(dp717
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p718
sg5
S'http://bio2rdf.org/drugbank:DB01370'
p719
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p720
sg23
Nsg24
Nsg25
S'ALUMINUM'
p721
sg27
Nsg28
S'Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.| \r'
p722
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Videx'
p723
sa(dp724
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p725
sg5
S'http://bio2rdf.org/drugbank:DB00594'
p726
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p727
sg23
Nsg24
Nsg25
S'AMILORIDE'
p728
sg27
Nsg28
S'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.| \r'
p729
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOFETILIDE'
p730
sa(dp731
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p732
sg5
S'http://bio2rdf.org/drugbank:DB00233'
p733
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p734
sg23
Nsg24
Nsg25
S'AMINOSALICYLIC ACID'
p735
sg27
Nsg28
S'Aminosalicylic acid may decrease the amount of digoxin (Lanoxin, Lanoxicaps) that gets absorbed into your body.| \r'
p736
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p737
sa(dp738
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p739
sg5
S'http://bio2rdf.org/drugbank:DB00233'
p740
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p741
sg23
Nsg24
Nsg25
S'AMINOSALICYLIC ACID'
p742
sg27
Nsg28
S'Aminosalicylic acid may decrease the amount of digoxin (Lanoxin, Lanoxicaps) that gets absorbed into your body.| \r'
p743
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Lanoxin'
p744
sa(dp745
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00115'
p746
sg5
S'http://bio2rdf.org/drugbank:DB00233'
p747
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p748
sg23
Nsg24
Nsg25
S'AMINOSALICYLIC ACID'
p749
sg27
Nsg28
S'Aminosalicylic acid may also decrease the absorption of vitamin B12, which can lead to a deficiency.| \r'
p750
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Vitamin B12'
p751
sa(dp752
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p753
sg5
S'http://bio2rdf.org/drugbank:DB01118'
p754
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p755
sg23
Nsg24
Nsg25
S'AMIODARONE'
p756
sg27
Nsg28
S'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| During amiodarone administration, systemic clearance of digoxin was reduced from 234 +/- 72 ml/min (mean +/- standard deviation) to 172 +/- 33 ml/min (p less than 0.01). | Amiodarone is known to raise serum digoxin levels. | \r'
p757
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p758
sa(dp759
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p760
sg5
S'http://bio2rdf.org/drugbank:DB01118'
p761
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p762
sg23
Nsg24
Nsg25
S'AMIODARONE'
p763
sg27
Nsg28
S'A case report of one patient taking amiodarone 200 mg and indinavir 800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L.| \r'
p764
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDINAVIR ANHYDROUS'
p765
sa(dp766
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p767
sg5
S'http://bio2rdf.org/drugbank:DB01118'
p768
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p769
sg23
Nsg24
Nsg25
S'AMIODARONE'
p770
sg27
Nsg28
S'A case report of one patient taking amiodarone 200 mg and indinavir 800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L.| \r'
p771
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDINAVIR'
p772
sa(dp773
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p774
sg5
S'http://bio2rdf.org/drugbank:DB01118'
p775
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p776
sg23
Nsg24
Nsg25
S'AMIODARONE'
p777
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p778
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p779
sa(dp780
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p781
sg5
S'http://bio2rdf.org/drugbank:DB01118'
p782
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p783
sg23
Nsg24
Nsg25
S'AMIODARONE'
p784
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p785
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p786
sa(dp787
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p788
sg5
S'http://bio2rdf.org/drugbank:DB01118'
p789
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p790
sg23
Nsg24
Nsg25
S'AMIODARONE'
p791
sg27
Nsg28
S'Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| \r'
p792
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tikosyn'
p793
sa(dp794
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00575'
p795
sg5
S'http://bio2rdf.org/drugbank:DB00321'
p796
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p797
sg23
Nsg24
Nsg25
S'AMITRIPTYLINE'
p798
sg27
Nsg28
S'Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.| \r'
p799
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLONIDINE'
p800
sa(dp801
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00437'
p802
sg5
S'http://bio2rdf.org/drugbank:DB01060'
p803
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p804
sg23
Nsg24
Nsg25
S'AMOXICILLIN ANHYDROUS'
p805
sg27
Nsg28
S'Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.| \r'
p806
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALLOPURINOL'
p807
sa(dp808
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00437'
p809
sg5
S'http://bio2rdf.org/drugbank:DB01060'
p810
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p811
sg23
Nsg24
Nsg25
S'AMOXICILLIN'
p812
sg27
Nsg28
S'Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.| \r'
p813
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALLOPURINOL'
p814
sa(dp815
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01099'
p816
sg5
S'http://bio2rdf.org/drugbank:DB00681'
p817
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p818
sg23
Nsg24
Nsg25
S'AMPHOTERICIN B'
p819
sg27
Nsg28
S'Flucytosine: while a synergistic relationship with amphotericin B has been reported, concomitant use may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion.| \r'
p820
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCYTOSINE'
p821
sa(dp822
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00741'
p823
sg5
S'http://bio2rdf.org/drugbank:DB00681'
p824
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p825
sg23
Nsg24
Nsg25
S'AMPHOTERICIN B'
p826
sg27
Nsg28
S'In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.| \r'
p827
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HYDROCORTISONE'
p828
sa(dp829
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01199'
p830
sg5
S'http://bio2rdf.org/drugbank:DB00681'
p831
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p832
sg23
Nsg24
Nsg25
S'AMPHOTERICIN B'
p833
sg27
Nsg28
S'Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).| \r'
p834
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TUBOCURARINE'
p835
sa(dp836
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p837
sg5
S'http://bio2rdf.org/drugbank:DB00681'
p838
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p839
sg23
Nsg24
Nsg25
S'Amphotericin'
p840
sg27
Nsg28
S'Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).| \r'
p841
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HIVID'
p842
sa(dp843
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p844
sg5
S'http://bio2rdf.org/drugbank:DB00681'
p845
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p846
sg23
Nsg24
Nsg25
S'Amphotericin'
p847
sg27
Nsg28
S'Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).| \r'
p848
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZALCITABINE'
p849
sa(dp850
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00437'
p851
sg5
S'http://bio2rdf.org/drugbank:DB00415'
p852
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p853
sg23
Nsg24
Nsg25
S'AMPICILLIN'
p854
sg27
Nsg28
S'Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.| It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.| \r'
p855
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALLOPURINOL'
p856
sa(dp857
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00615'
p858
sg5
S'http://bio2rdf.org/drugbank:DB00701'
p859
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p860
sg23
Nsg24
Nsg25
S'AMPRENAVIR'
p861
sg27
Nsg28
S'Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. | Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. | Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. | \r'
p862
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFABUTIN'
p863
sa(dp864
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00615'
p865
sg5
S'http://bio2rdf.org/drugbank:DB00701'
p866
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p867
sg23
Nsg24
Nsg25
S'AMPRENAVIR'
p868
sg27
Nsg28
S'Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. | Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. | Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. | \r'
p869
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFABUTIN'
p870
sa(dp871
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p872
sg5
S'http://bio2rdf.org/drugbank:DB00701'
p873
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p874
sg23
Nsg24
Nsg25
S'AMPRENAVIR'
p875
sg27
Nsg28
S'Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.| Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.| \r'
p876
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p877
sa(dp878
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p879
sg5
S'http://bio2rdf.org/drugbank:DB00701'
p880
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p881
sg23
Nsg24
Nsg25
S'AMPRENAVIR'
p882
sg27
Nsg28
S'Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.| Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.| \r'
p883
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p884
sa(dp885
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p886
sg5
S'http://bio2rdf.org/drugbank:DB01242'
p887
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p888
sg23
Nsg24
Nsg25
S'Anafranil'
p889
sg27
Nsg28
S'Because Anafranil is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e.g., warfarin, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.| \r'
p890
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p891
sa(dp892
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p893
sg5
S'http://bio2rdf.org/drugbank:DB00261'
p894
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p895
sg23
Nsg24
Nsg25
S'ANAGRELIDE'
p896
sg27
Nsg28
S'Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin.| \r'
p897
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p898
sa(dp899
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p900
sg5
S'http://bio2rdf.org/drugbank:DB00261'
p901
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p902
sg23
Nsg24
Nsg25
S'ANAGRELIDE'
p903
sg27
Nsg28
S'Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. theophylline.| \r'
p904
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p905
sa(dp906
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00675'
p907
sg5
S'http://bio2rdf.org/drugbank:DB01217'
p908
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p909
sg23
Nsg24
Nsg25
S'ANASTROZOLE'
p910
sg27
Nsg28
S'Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.| \r'
p911
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TAMOXIFEN'
p912
sa(dp913
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p914
sg5
S'http://bio2rdf.org/drugbank:DB01213'
p915
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p916
sg23
Nsg24
Nsg25
S'Antizol'
p917
sg27
Nsg28
S'Oral doses of Antizol (10-20 mg/kg), via alcohol dehydrogenase inhibition, significantly reduced the rate of elimination of ethanol (by approximately 40%) given to healthy volunteers in moderate doses.| \r'
p918
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p919
sa(dp920
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p921
sg5
S'http://bio2rdf.org/drugbank:DB01213'
p922
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p923
sg23
Nsg24
Nsg25
S'Antizol'
p924
sg27
Nsg28
S'Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied| \r'
p925
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CARBAMAZEPINE'
p926
sa(dp927
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p928
sg5
S'http://bio2rdf.org/drugbank:DB01213'
p929
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p930
sg23
Nsg24
Nsg25
S'Antizol'
p931
sg27
Nsg28
S'Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied| \r'
p932
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIMETIDINE'
p933
sa(dp934
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p935
sg5
S'http://bio2rdf.org/drugbank:DB01213'
p936
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p937
sg23
Nsg24
Nsg25
S'Antizol'
p938
sg27
Nsg28
S'Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied| \r'
p939
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p940
sa(dp941
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p942
sg5
S'http://bio2rdf.org/drugbank:DB01213'
p943
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p944
sg23
Nsg24
Nsg25
S'Antizol'
p945
sg27
Nsg28
S'Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied| \r'
p946
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p947
sa(dp948
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00969'
p949
sg5
S'http://bio2rdf.org/drugbank:DB00714'
p950
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p951
sg23
Nsg24
Nsg25
S'APOMORPHINE'
p952
sg27
Nsg28
S'5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .| \r'
p953
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALOSETRON'
p954
sa(dp955
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00757'
p956
sg5
S'http://bio2rdf.org/drugbank:DB00714'
p957
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p958
sg23
Nsg24
Nsg25
S'APOMORPHINE'
p959
sg27
Nsg28
S'5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .| \r'
p960
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOLASETRON'
p961
sa(dp962
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00889'
p963
sg5
S'http://bio2rdf.org/drugbank:DB00714'
p964
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p965
sg23
Nsg24
Nsg25
S'APOMORPHINE'
p966
sg27
Nsg28
S'5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .| \r'
p967
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GRANISETRON'
p968
sa(dp969
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00377'
p970
sg5
S'http://bio2rdf.org/drugbank:DB00714'
p971
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p972
sg23
Nsg24
Nsg25
S'APOMORPHINE'
p973
sg27
Nsg28
S'5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .| \r'
p974
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PALONOSETRON'
p975
sa(dp976
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p977
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p978
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p979
sg23
Nsg24
Nsg25
S'APREPITANT'
p980
sg27
Nsg28
S'therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.| \r'
p981
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'APREPITANT'
p982
sa(dp983
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01211'
p984
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p985
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p986
sg23
Nsg24
Nsg25
S'APREPITANT'
p987
sg27
Nsg28
S'Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| \r'
p988
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLARITHROMYCIN'
p989
sa(dp990
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01234'
p991
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p992
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p993
sg23
Nsg24
Nsg25
S'APREPITANT'
p994
sg27
Nsg28
S'Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.| \r'
p995
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DEXAMETHASONE'
p996
sa(dp997
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p998
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p999
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1000
sg23
Nsg24
Nsg25
S'APREPITANT'
p1001
sg27
Nsg28
S'Diltiazem: In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with diltiazem 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of diltiazem AUC.| \r'
p1002
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DILTIAZEM'
p1003
sa(dp1004
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00977'
p1005
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p1006
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1007
sg23
Nsg24
Nsg25
S'APREPITANT'
p1008
sg27
Nsg28
S'Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;| \r'
p1009
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ETHINYL ESTRADIOL'
p1010
sa(dp1011
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1012
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p1013
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1014
sg23
Nsg24
Nsg25
S'APREPITANT'
p1015
sg27
Nsg28
S'Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.| Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| \r'
p1016
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p1017
sa(dp1018
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1019
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p1020
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1021
sg23
Nsg24
Nsg25
S'APREPITANT'
p1022
sg27
Nsg28
S'Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.| Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| \r'
p1023
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p1024
sa(dp1025
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p1026
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p1027
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1028
sg23
Nsg24
Nsg25
S'APREPITANT'
p1029
sg27
Nsg28
S'Aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.| \r'
p1030
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHYLPREDNISOLONE'
p1031
sa(dp1032
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p1033
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p1034
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1035
sg23
Nsg24
Nsg25
S'APREPITANT'
p1036
sg27
Nsg28
S'Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.| Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.| \r'
p1037
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIDAZOLAM'
p1038
sa(dp1039
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01149'
p1040
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p1041
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1042
sg23
Nsg24
Nsg25
S'APREPITANT'
p1043
sg27
Nsg28
S'Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| \r'
p1044
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NEFAZODONE'
p1045
sa(dp1046
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB05251'
p1047
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p1048
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1049
sg23
Nsg24
Nsg25
S'APREPITANT'
p1050
sg27
Nsg28
S'Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| \r'
p1051
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NELFINAVIR'
p1052
sa(dp1053
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00717'
p1054
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p1055
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1056
sg23
Nsg24
Nsg25
S'APREPITANT'
p1057
sg27
Nsg28
S'Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;| \r'
p1058
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NORETHINDRONE'
p1059
sa(dp1060
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p1061
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p1062
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1063
sg23
Nsg24
Nsg25
S'APREPITANT'
p1064
sg27
Nsg28
S'Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.| \r'
p1065
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PAROXETINE'
p1066
sa(dp1067
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p1068
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p1069
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1070
sg23
Nsg24
Nsg25
S'APREPITANT'
p1071
sg27
Nsg28
S'therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.| Coadministration of Aprepitant with these drugs or other drugs that are known to be metabolized by CYP2C9, such as phenytoin, may result in lower plasma concentrations of these drugs.| \r'
p1072
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p1073
sa(dp1074
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p1075
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p1076
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1077
sg23
Nsg24
Nsg25
S'APREPITANT'
p1078
sg27
Nsg28
S'Rifampin: When a single 375-mg dose of Aprepitant was administered on Day9 of a 14-day regimen of 600 mg/day of rifampin, a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold.| therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.| \r'
p1079
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFAMPIN'
p1080
sa(dp1081
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p1082
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p1083
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1084
sg23
Nsg24
Nsg25
S'APREPITANT'
p1085
sg27
Nsg28
S'Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| \r'
p1086
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p1087
sa(dp1088
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p1089
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p1090
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1091
sg23
Nsg24
Nsg25
S'APREPITANT'
p1092
sg27
Nsg28
S'Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9.| \r'
p1093
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TOLBUTAMIDE'
p1094
sa(dp1095
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01361'
p1096
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p1097
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1098
sg23
Nsg24
Nsg25
S'APREPITANT'
p1099
sg27
Nsg28
S'Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| \r'
p1100
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TROLEANDOMYCIN'
p1101
sa(dp1102
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p1103
sg5
S'http://bio2rdf.org/drugbank:DB01097'
p1104
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1105
sg23
Nsg24
Nsg25
S'Arava'
p1106
sg27
Nsg28
S'In a small (n=30) combination study of ARAVA with methotrexate, a 2- to 3-fold elevation in liver enzymes was seen in 5 of 30 patients.| \r'
p1107
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHOTREXATE'
p1108
sa(dp1109
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p1110
sg5
S'http://bio2rdf.org/drugbank:DB01097'
p1111
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1112
sg23
Nsg24
Nsg25
S'Arava'
p1113
sg27
Nsg28
S'Rifampin: Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin, M1 peak levels were increased (~40%) over those seen when ARAVA was given alone.| Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin.| \r'
p1114
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFAMPIN'
p1115
sa(dp1116
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p1117
sg5
S'http://bio2rdf.org/drugbank:DB01097'
p1118
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1119
sg23
Nsg24
Nsg25
S'Arava'
p1120
sg27
Nsg28
S'Rifampin: Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin, M1 peak levels were increased (~40%) over those seen when ARAVA was given alone.| Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin.| \r'
p1121
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFAMPIN'
p1122
sa(dp1123
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00908'
p1124
sg5
S'http://bio2rdf.org/drugbank:DB01238'
p1125
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1126
sg23
Nsg24
Nsg25
S'ARIPIPRAZOLE'
p1127
sg27
Nsg28
S'Quinidine: Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydroaripiprazole, by 35%.| \r'
p1128
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'QUINIDINE'
p1129
sa(dp1130
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00482'
p1131
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1132
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1133
sg23
Nsg24
Nsg25
S'ASPIRIN'
p1134
sg27
Nsg28
S'However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.| \r'
p1135
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Celebrex'
p1136
sa(dp1137
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01399'
p1138
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1139
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1140
sg23
Nsg24
Nsg25
S'ASPIRIN'
p1141
sg27
Nsg28
S'ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. | \r'
p1142
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Disalcid'
p1143
sa(dp1144
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00573'
p1145
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1146
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1147
sg23
Nsg24
Nsg25
S'ASPIRIN'
p1148
sg27
Nsg28
S'The coadministration of aspirin decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine.| \r'
p1149
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Fenoprofen'
p1150
sa(dp1151
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00712'
p1152
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1153
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1154
sg23
Nsg24
Nsg25
S'ASPIRIN'
p1155
sg27
Nsg28
S'Aspirin: Concurrent administration of aspirin and flurbiprofen resulted in 50% lower serum flurbiprofen concentrations.| \r'
p1156
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Flurbiprofen'
p1157
sa(dp1158
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00710'
p1159
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1160
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1161
sg23
Nsg24
Nsg25
S'ASPIRIN'
p1162
sg27
Nsg28
S'However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.| \r'
p1163
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'IBANDRONIC ACID'
p1164
sa(dp1165
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00328'
p1166
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1167
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1168
sg23
Nsg24
Nsg25
S'ASPIRIN'
p1169
sg27
Nsg28
S'In a study in normal volunteers, it was found that chronic concurrent administration of 3.6 g of aspirin per day decreases indomethacin blood levels approximately 20%.| \r'
p1170
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDOMETHACIN'
p1171
sa(dp1172
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00814'
p1173
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1174
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1175
sg23
Nsg24
Nsg25
S'ASPIRIN'
p1176
sg27
Nsg28
S'Aspirin: Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of meloxicam. | \r'
p1177
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MELOXICAM'
p1178
sa(dp1179
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00703'
p1180
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1181
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1182
sg23
Nsg24
Nsg25
S'ASPIRIN'
p1183
sg27
Nsg28
S'Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.| \r'
p1184
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHAZOLAMIDE'
p1185
sa(dp1186
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00814'
p1187
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1188
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1189
sg23
Nsg24
Nsg25
S'ASPIRIN'
p1190
sg27
Nsg28
S'Concomitant administration of low-dose aspirin with MOBIC may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone. | \r'
p1191
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Mobic'
p1192
sa(dp1193
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00573'
p1194
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1195
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1196
sg23
Nsg24
Nsg25
S'ASPIRIN'
p1197
sg27
Nsg28
S'Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.| \r'
p1198
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nalfon'
p1199
sa(dp1200
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00627'
p1201
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1202
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1203
sg23
Nsg24
Nsg25
S'ASPIRIN'
p1204
sg27
Nsg28
S'Aspirin: Concomitant aspirin may decrease the metabolic clearance of nicotinic acid.| \r'
p1205
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nicotinic Acid'
p1206
sa(dp1207
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00585'
p1208
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1209
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1210
sg23
Nsg24
Nsg25
S'ASPIRIN'
p1211
sg27
Nsg28
S'In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently.| \r'
p1212
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NIZATIDINE'
p1213
sa(dp1214
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00812'
p1215
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1216
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1217
sg23
Nsg24
Nsg25
S'ASPIRIN'
p1218
sg27
Nsg28
S'Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.| \r'
p1219
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYLBUTAZONE'
p1220
sa(dp1221
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p1222
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1223
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1224
sg23
Nsg24
Nsg25
S'ASPIRIN'
p1225
sg27
Nsg28
S'Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.| \r'
p1226
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROBENECID'
p1227
sa(dp1228
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00015'
p1229
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1230
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1231
sg23
Nsg24
Nsg25
S'ASPIRIN'
p1232
sg27
Nsg28
S'In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.| \r'
p1233
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Retavase'
p1234
sa(dp1235
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01133'
p1236
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1237
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1238
sg23
Nsg24
Nsg25
S'ASPIRIN'
p1239
sg27
Nsg28
S'Aspirin may decrease bioavailability of SKELID by up to 50% when taken 2 hours after SKELID. | \r'
p1240
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Skelid'
p1241
sa(dp1242
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00580'
p1243
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1244
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1245
sg23
Nsg24
Nsg25
S'ASPIRIN'
p1246
sg27
Nsg28
S'Aspirin: Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.| \r'
p1247
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VALDECOXIB'
p1248
sa(dp1249
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00533'
p1250
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1251
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1252
sg23
Nsg24
Nsg25
S'ASPIRIN'
p1253
sg27
Nsg28
S'Aspirin: Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.| \r'
p1254
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Vioxx'
p1255
sa(dp1256
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00009'
p1257
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1258
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p1259
sg23
Nsg24
Nsg25
S'ASPIRIN'
p1260
sg27
Nsg28
S'In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.| \r'
p1261
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Activase'
p1262
sa(dp1263
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00031'
p1264
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1265
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1266
sg23
Nsg24
Nsg25
S'ASPIRIN'
p1267
sg27
Nsg28
S'Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. | \r'
p1268
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TNKase'
p1269
sa(dp1270
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1271
sg5
S'http://bio2rdf.org/drugbank:DB00637'
p1272
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1273
sg23
Nsg24
Nsg25
S'ASTEMIZOLE'
p1274
sg27
Nsg28
S'Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.| Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.| \r'
p1275
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p1276
sa(dp1277
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1278
sg5
S'http://bio2rdf.org/drugbank:DB00637'
p1279
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1280
sg23
Nsg24
Nsg25
S'ASTEMIZOLE'
p1281
sg27
Nsg28
S'Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.| Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.| \r'
p1282
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p1283
sa(dp1284
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p1285
sg5
S'http://bio2rdf.org/drugbank:DB00637'
p1286
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1287
sg23
Nsg24
Nsg25
S'ASTEMIZOLE'
p1288
sg27
Nsg28
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p1289
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sprycel'
p1290
sa(dp1291
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01258'
p1292
sg5
S'http://bio2rdf.org/drugbank:DB01076'
p1293
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1294
sg23
Nsg24
Nsg25
S'ATORVASTATIN'
p1295
sg27
Nsg28
S'Co-administration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.| \r'
p1296
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALISKIREN'
p1297
sa(dp1298
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p1299
sg5
S'http://bio2rdf.org/drugbank:DB01076'
p1300
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1301
sg23
Nsg24
Nsg25
S'ATORVASTATIN'
p1302
sg27
Nsg28
S'Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or rosuvastatin in combination with CRIXIVAN.| \r'
p1303
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Crixivan'
p1304
sa(dp1305
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p1306
sg5
S'http://bio2rdf.org/drugbank:DB01076'
p1307
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1308
sg23
Nsg24
Nsg25
S'ATORVASTATIN'
p1309
sg27
Nsg28
S'Digoxin: When multiple doses of atorvastatin and digoxin were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.| \r'
p1310
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p1311
sa(dp1312
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p1313
sg5
S'http://bio2rdf.org/drugbank:DB01076'
p1314
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1315
sg23
Nsg24
Nsg25
S'ATORVASTATIN'
p1316
sg27
Nsg28
S'Erythromycin: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4.| \r'
p1317
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERYTHROMYCIN'
p1318
sa(dp1319
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00977'
p1320
sg5
S'http://bio2rdf.org/drugbank:DB01076'
p1321
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1322
sg23
Nsg24
Nsg25
S'ATORVASTATIN'
p1323
sg27
Nsg28
S'Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.| Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.| \r'
p1324
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ETHINYL ESTRADIOL'
p1325
sa(dp1326
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00717'
p1327
sg5
S'http://bio2rdf.org/drugbank:DB01076'
p1328
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1329
sg23
Nsg24
Nsg25
S'ATORVASTATIN'
p1330
sg27
Nsg28
S'Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.| Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.| \r'
p1331
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NORETHINDRONE'
p1332
sa(dp1333
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p1334
sg5
S'http://bio2rdf.org/drugbank:DB00636'
p1335
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1336
sg23
Nsg24
Nsg25
S'Atromid-S'
p1337
sg27
Nsg28
S'Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.| \r'
p1338
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p1339
sa(dp1340
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p1341
sg5
S'http://bio2rdf.org/drugbank:DB00636'
p1342
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1343
sg23
Nsg24
Nsg25
S'Atromid-S'
p1344
sg27
Nsg28
S'Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.| \r'
p1345
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TOLBUTAMIDE'
p1346
sa(dp1347
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00733'
p1348
sg5
S'http://bio2rdf.org/drugbank:DB00572'
p1349
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1350
sg23
Nsg24
Nsg25
S'Atropine'
p1351
sg27
Nsg28
S'The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of atropine and pralidoxime.| When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone. | When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.| \r'
p1352
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PRALIDOXIME'
p1353
sa(dp1354
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00733'
p1355
sg5
S'http://bio2rdf.org/drugbank:DB00572'
p1356
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1357
sg23
Nsg24
Nsg25
S'Atropine'
p1358
sg27
Nsg28
S'The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of atropine and pralidoxime.| When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone. | When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.| \r'
p1359
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PRALIDOXIME'
p1360
sa(dp1361
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00427'
p1362
sg5
S'http://bio2rdf.org/drugbank:DB00572'
p1363
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1364
sg23
Nsg24
Nsg25
S'Atropine'
p1365
sg27
Nsg28
S'The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. | \r'
p1366
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TRIPROLIDINE'
p1367
sa(dp1368
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00859'
p1369
sg5
S'http://bio2rdf.org/drugbank:DB00995'
p1370
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1371
sg23
Nsg24
Nsg25
S'AURANOFIN'
p1372
sg27
Nsg28
S'Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.| \r'
p1373
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cuprimine'
p1374
sa(dp1375
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00859'
p1376
sg5
S'http://bio2rdf.org/drugbank:DB00995'
p1377
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1378
sg23
Nsg24
Nsg25
S'AURANOFIN'
p1379
sg27
Nsg28
S'Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.| \r'
p1380
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Depen'
p1381
sa(dp1382
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00859'
p1383
sg5
S'http://bio2rdf.org/drugbank:DB00995'
p1384
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1385
sg23
Nsg24
Nsg25
S'AURANOFIN'
p1386
sg27
Nsg28
S'Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.| \r'
p1387
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PENICILLAMINE'
p1388
sa(dp1389
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00108'
p1390
sg5
S'http://bio2rdf.org/drugbank:DB00060'
p1391
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1392
sg23
Nsg24
Nsg25
S'Avonex'
p1393
sg27
Nsg28
S'After multiple dosing, interferon beta-1a (AVONEX  30 mcg IM once weekly) reduced TYSABRI  clearance by approximately 30%.| \r'
p1394
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tysabri'
p1395
sa(dp1396
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00437'
p1397
sg5
S'http://bio2rdf.org/drugbank:DB00993'
p1398
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1399
sg23
Nsg24
Nsg25
S'AZATHIOPRINE'
p1400
sg27
Nsg28
S'Use with Allopurinol: The principal pathway for detoxification of azathioprine is inhibited by allopurinol.| Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose.| \r'
p1401
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALLOPURINOL'
p1402
sa(dp1403
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00437'
p1404
sg5
S'http://bio2rdf.org/drugbank:DB00993'
p1405
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1406
sg23
Nsg24
Nsg25
S'AZATHIOPRINE'
p1407
sg27
Nsg28
S'Use with Allopurinol: The principal pathway for detoxification of azathioprine is inhibited by allopurinol.| Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose.| \r'
p1408
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALLOPURINOL'
p1409
sa(dp1410
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00479'
p1411
sg5
S'http://bio2rdf.org/drugbank:DB01061'
p1412
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1413
sg23
Nsg24
Nsg25
S'AZLOCILLIN'
p1414
sg27
Nsg28
S'Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.| \r'
p1415
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMIKACIN'
p1416
sa(dp1417
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00537'
p1418
sg5
S'http://bio2rdf.org/drugbank:DB01061'
p1419
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1420
sg23
Nsg24
Nsg25
S'AZLOCILLIN'
p1421
sg27
Nsg28
S'Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.| \r'
p1422
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIPROFLOXACIN'
p1423
sa(dp1424
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00955'
p1425
sg5
S'http://bio2rdf.org/drugbank:DB01061'
p1426
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1427
sg23
Nsg24
Nsg25
S'AZLOCILLIN'
p1428
sg27
Nsg28
S'Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.| \r'
p1429
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NETILMICIN'
p1430
sa(dp1431
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00684'
p1432
sg5
S'http://bio2rdf.org/drugbank:DB01061'
p1433
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1434
sg23
Nsg24
Nsg25
S'AZLOCILLIN'
p1435
sg27
Nsg28
S'Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.| \r'
p1436
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TOBRAMYCIN'
p1437
sa(dp1438
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p1439
sg5
S'http://bio2rdf.org/drugbank:DB00522'
p1440
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p1441
sg23
Nsg24
Nsg25
S'BENTIROMIDE'
p1442
sg27
Nsg28
S'Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| \r'
p1443
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACETAMINOPHEN'
p1444
sa(dp1445
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01086'
p1446
sg5
S'http://bio2rdf.org/drugbank:DB00522'
p1447
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p1448
sg23
Nsg24
Nsg25
S'BENTIROMIDE'
p1449
sg27
Nsg28
S'Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| \r'
p1450
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BENZOCAINE'
p1451
sa(dp1452
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00446'
p1453
sg5
S'http://bio2rdf.org/drugbank:DB00522'
p1454
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p1455
sg23
Nsg24
Nsg25
S'BENTIROMIDE'
p1456
sg27
Nsg28
S'Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| \r'
p1457
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CHLORAMPHENICOL'
p1458
sa(dp1459
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00446'
p1460
sg5
S'http://bio2rdf.org/drugbank:DB00522'
p1461
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p1462
sg23
Nsg24
Nsg25
S'BENTIROMIDE'
p1463
sg27
Nsg28
S'Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| \r'
p1464
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Chloromycetin'
p1465
sa(dp1466
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB05291'
p1467
sg5
S'http://bio2rdf.org/drugbank:DB00522'
p1468
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p1469
sg23
Nsg24
Nsg25
S'BENTIROMIDE'
p1470
sg27
Nsg28
S'Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| \r'
p1471
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LIDOCAINE'
p1472
sa(dp1473
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01035'
p1474
sg5
S'http://bio2rdf.org/drugbank:DB00522'
p1475
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p1476
sg23
Nsg24
Nsg25
S'BENTIROMIDE'
p1477
sg27
Nsg28
S'Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| \r'
p1478
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROCAINAMIDE'
p1479
sa(dp1480
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01035'
p1481
sg5
S'http://bio2rdf.org/drugbank:DB00522'
p1482
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p1483
sg23
Nsg24
Nsg25
S'BENTIROMIDE'
p1484
sg27
Nsg28
S'Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| \r'
p1485
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Pronestyl'
p1486
sa(dp1487
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p1488
sg5
S'http://bio2rdf.org/drugbank:DB00522'
p1489
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p1490
sg23
Nsg24
Nsg25
S'BENTIROMIDE'
p1491
sg27
Nsg28
S'Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| \r'
p1492
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tylenol'
p1493
sa(dp1494
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p1495
sg5
S'http://bio2rdf.org/drugbank:DB00562'
p1496
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p1497
sg23
Nsg24
Nsg25
S'BENZTHIAZIDE'
p1498
sg27
Nsg28
S'Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.| \r'
p1499
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p1500
sa(dp1501
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00788'
p1502
sg5
S'http://bio2rdf.org/drugbank:DB00562'
p1503
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p1504
sg23
Nsg24
Nsg25
S'BENZTHIAZIDE'
p1505
sg27
Nsg28
S'Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.| \r'
p1506
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aleve'
p1507
sa(dp1508
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p1509
sg5
S'http://bio2rdf.org/drugbank:DB00562'
p1510
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p1511
sg23
Nsg24
Nsg25
S'BENZTHIAZIDE'
p1512
sg27
Nsg28
S'Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.| \r'
p1513
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM CATION'
p1514
sa(dp1515
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p1516
sg5
S'http://bio2rdf.org/drugbank:DB00562'
p1517
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p1518
sg23
Nsg24
Nsg25
S'BENZTHIAZIDE'
p1519
sg27
Nsg28
S'Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.| \r'
p1520
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM'
p1521
sa(dp1522
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00368'
p1523
sg5
S'http://bio2rdf.org/drugbank:DB00562'
p1524
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p1525
sg23
Nsg24
Nsg25
S'BENZTHIAZIDE'
p1526
sg27
Nsg28
S'Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.| \r'
p1527
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NOREPINEPHRINE'
p1528
sa(dp1529
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00668'
p1530
sg5
S'http://bio2rdf.org/drugbank:DB01210'
p1531
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1532
sg23
Nsg24
Nsg25
S'Betagan'
p1533
sg27
Nsg28
S'Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and epinephrine may occur.| \r'
p1534
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EPINEPHRINE'
p1535
sa(dp1536
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01435'
p1537
sg5
S'http://bio2rdf.org/drugbank:DB00068'
p1538
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1539
sg23
Nsg24
Nsg25
S'Betaseron'
p1540
sg27
Nsg28
S'Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown.| \r'
p1541
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ANTIPYRINE'
p1542
sa(dp1543
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p1544
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p1545
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1546
sg23
Nsg24
Nsg25
S'Bextra'
p1547
sg27
Nsg28
S'Lithium serum concentrations should be monitored closely when initiating or changing therapy with BEXTRA in patients receiving lithium.| \r'
p1548
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM CATION'
p1549
sa(dp1550
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p1551
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p1552
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1553
sg23
Nsg24
Nsg25
S'Bextra'
p1554
sg27
Nsg28
S'Lithium serum concentrations should be monitored closely when initiating or changing therapy with BEXTRA in patients receiving lithium.| \r'
p1555
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM'
p1556
sa(dp1557
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00467'
p1558
sg5
S'http://bio2rdf.org/drugbank:DB01294'
p1559
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1560
sg23
Nsg24
Nsg25
S'BISMUTH SUBSALICYLATE'
p1561
sg27
Nsg28
S'Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.| \r'
p1562
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ENOXACIN'
p1563
sa(dp1564
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01076'
p1565
sg5
S'http://bio2rdf.org/drugbank:DB00559'
p1566
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1567
sg23
Nsg24
Nsg25
S'BOSENTAN ANHYDROUS'
p1568
sg27
Nsg28
S'Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.| \r'
p1569
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ATORVASTATIN'
p1570
sa(dp1571
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01016'
p1572
sg5
S'http://bio2rdf.org/drugbank:DB00559'
p1573
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1574
sg23
Nsg24
Nsg25
S'BOSENTAN ANHYDROUS'
p1575
sg27
Nsg28
S'Co-administration of bosentan decreased the plasma concentrations of glyburide by approximately 40%.| \r'
p1576
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GLYBURIDE'
p1577
sa(dp1578
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1579
sg5
S'http://bio2rdf.org/drugbank:DB00559'
p1580
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1581
sg23
Nsg24
Nsg25
S'BOSENTAN ANHYDROUS'
p1582
sg27
Nsg28
S'Ketoconazole: Co-administration of bosentan 125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.| \r'
p1583
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p1584
sa(dp1585
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00227'
p1586
sg5
S'http://bio2rdf.org/drugbank:DB00559'
p1587
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1588
sg23
Nsg24
Nsg25
S'BOSENTAN ANHYDROUS'
p1589
sg27
Nsg28
S'Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.| \r'
p1590
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LOVASTATIN'
p1591
sa(dp1592
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00641'
p1593
sg5
S'http://bio2rdf.org/drugbank:DB00559'
p1594
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1595
sg23
Nsg24
Nsg25
S'BOSENTAN ANHYDROUS'
p1596
sg27
Nsg28
S'Simvastatin and Other Statins: Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.| \r'
p1597
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SIMVASTATIN'
p1598
sa(dp1599
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01076'
p1600
sg5
S'http://bio2rdf.org/drugbank:DB00559'
p1601
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1602
sg23
Nsg24
Nsg25
S'BOSENTAN'
p1603
sg27
Nsg28
S'Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.| \r'
p1604
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ATORVASTATIN'
p1605
sa(dp1606
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01016'
p1607
sg5
S'http://bio2rdf.org/drugbank:DB00559'
p1608
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1609
sg23
Nsg24
Nsg25
S'BOSENTAN'
p1610
sg27
Nsg28
S'Co-administration of bosentan decreased the plasma concentrations of glyburide by approximately 40%.| \r'
p1611
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GLYBURIDE'
p1612
sa(dp1613
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1614
sg5
S'http://bio2rdf.org/drugbank:DB00559'
p1615
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1616
sg23
Nsg24
Nsg25
S'BOSENTAN'
p1617
sg27
Nsg28
S'Ketoconazole: Co-administration of bosentan 125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.| \r'
p1618
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p1619
sa(dp1620
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00227'
p1621
sg5
S'http://bio2rdf.org/drugbank:DB00559'
p1622
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1623
sg23
Nsg24
Nsg25
S'BOSENTAN'
p1624
sg27
Nsg28
S'Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.| \r'
p1625
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LOVASTATIN'
p1626
sa(dp1627
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00641'
p1628
sg5
S'http://bio2rdf.org/drugbank:DB00559'
p1629
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1630
sg23
Nsg24
Nsg25
S'BOSENTAN'
p1631
sg27
Nsg28
S'Simvastatin and Other Statins: Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.| \r'
p1632
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SIMVASTATIN'
p1633
sa(dp1634
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p1635
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p1636
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1637
sg23
Nsg24
Nsg25
S'Brevibloc'
p1638
sg27
Nsg28
S'Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.| \r'
p1639
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p1640
sa(dp1641
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00988'
p1642
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p1643
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1644
sg23
Nsg24
Nsg25
S'Brevibloc'
p1645
sg27
Nsg28
S'Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.| \r'
p1646
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOPAMINE'
p1647
sa(dp1648
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00668'
p1649
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p1650
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1651
sg23
Nsg24
Nsg25
S'Brevibloc'
p1652
sg27
Nsg28
S'Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.| \r'
p1653
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EPINEPHRINE'
p1654
sa(dp1655
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p1656
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p1657
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1658
sg23
Nsg24
Nsg25
S'Brevibloc'
p1659
sg27
Nsg28
S'Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.| When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.| \r'
p1660
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MORPHINE'
p1661
sa(dp1662
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p1663
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p1664
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1665
sg23
Nsg24
Nsg25
S'Brevibloc'
p1666
sg27
Nsg28
S'Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.| When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.| \r'
p1667
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MORPHINE'
p1668
sa(dp1669
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00368'
p1670
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p1671
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1672
sg23
Nsg24
Nsg25
S'Brevibloc'
p1673
sg27
Nsg28
S'Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.| \r'
p1674
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NOREPINEPHRINE'
p1675
sa(dp1676
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00202'
p1677
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p1678
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1679
sg23
Nsg24
Nsg25
S'Brevibloc'
p1680
sg27
Nsg28
S'Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.| \r'
p1681
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUCCINYLCHOLINE'
p1682
sa(dp1683
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p1684
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p1685
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1686
sg23
Nsg24
Nsg25
S'Brevibloc'
p1687
sg27
Nsg28
S'Caution should be exercised when considering the use of BREVIBLOC and verapamil in patients with depressed myocardial function.| \r'
p1688
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Verapamil'
p1689
sa(dp1690
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00854'
p1691
sg5
S'http://bio2rdf.org/drugbank:DB00921'
p1692
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1693
sg23
Nsg24
Nsg25
S'BUPRENORPHINE'
p1694
sg27
Nsg28
S'Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| \r'
p1695
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Levo-Dromoran'
p1696
sa(dp1697
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p1698
sg5
S'http://bio2rdf.org/drugbank:DB00490'
p1699
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1700
sg23
Nsg24
Nsg25
S'BUSPIRONE'
p1701
sg27
Nsg28
S'In vitro, buspirone may displace less firmly bound drugs like digoxin.| \r'
p1702
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p1703
sa(dp1704
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p1705
sg5
S'http://bio2rdf.org/drugbank:DB01008'
p1706
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1707
sg23
Nsg24
Nsg25
S'Busulfex'
p1708
sg27
Nsg28
S'Since the pharmacokinetics of BUSULFEX were studied in patients treated with phenytoin, the clearance of BUSULFEX at the recommended dose may be lower and exposure (AUC) higher in patients not treated with phenytoin.| \r'
p1709
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p1710
sa(dp1711
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p1712
sg5
S'http://bio2rdf.org/drugbank:DB00241'
p1713
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1714
sg23
Nsg24
Nsg25
S'BUTALBITAL'
p1715
sg27
Nsg28
S'Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.| \r'
p1716
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p1717
sa(dp1718
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00475'
p1719
sg5
S'http://bio2rdf.org/drugbank:DB00241'
p1720
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1721
sg23
Nsg24
Nsg25
S'BUTALBITAL'
p1722
sg27
Nsg28
S'Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.| \r'
p1723
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CHLORDIAZEPOXIDE'
p1724
sa(dp1725
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p1726
sg5
S'http://bio2rdf.org/drugbank:DB00611'
p1727
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1728
sg23
Nsg24
Nsg25
S'BUTORPHANOL'
p1729
sg27
Nsg28
S'Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.| \r'
p1730
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p1731
sa(dp1732
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p1733
sg5
S'http://bio2rdf.org/drugbank:DB00611'
p1734
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1735
sg23
Nsg24
Nsg25
S'BUTORPHANOL'
p1736
sg27
Nsg28
S'It is not known if the effects of butorphanol are altered by concomitant medications that affect hepatic metabolism of drugs (erythromycin, etc.), but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed.| \r'
p1737
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERYTHROMYCIN'
p1738
sa(dp1739
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00854'
p1740
sg5
S'http://bio2rdf.org/drugbank:DB00611'
p1741
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1742
sg23
Nsg24
Nsg25
S'BUTORPHANOL'
p1743
sg27
Nsg28
S'Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| \r'
p1744
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Levo-Dromoran'
p1745
sa(dp1746
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p1747
sg5
S'http://bio2rdf.org/drugbank:DB00201'
p1748
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1749
sg23
Nsg24
Nsg25
S'CAFFEINE'
p1750
sg27
Nsg28
S'Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.| \r'
p1751
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p1752
sa(dp1753
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00475'
p1754
sg5
S'http://bio2rdf.org/drugbank:DB00201'
p1755
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1756
sg23
Nsg24
Nsg25
S'CAFFEINE'
p1757
sg27
Nsg28
S'Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.| \r'
p1758
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CHLORDIAZEPOXIDE'
p1759
sa(dp1760
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p1761
sg5
S'http://bio2rdf.org/drugbank:DB00201'
p1762
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1763
sg23
Nsg24
Nsg25
S'CAFFEINE'
p1764
sg27
Nsg28
S'Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).| \r'
p1765
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIMETIDINE'
p1766
sa(dp1767
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00363'
p1768
sg5
S'http://bio2rdf.org/drugbank:DB00201'
p1769
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1770
sg23
Nsg24
Nsg25
S'CAFFEINE'
p1771
sg27
Nsg28
S'Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.| \r'
p1772
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLOZAPINE'
p1773
sa(dp1774
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00467'
p1775
sg5
S'http://bio2rdf.org/drugbank:DB00201'
p1776
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1777
sg23
Nsg24
Nsg25
S'CAFFEINE'
p1778
sg27
Nsg28
S'Caffeine-related adverse effects have occurred in patients consuming caffeine while on therapy with enoxacin.| Trough plasma enoxacin levels were also 20% higher when caffeine and enoxacin were administered concomitantly.| \r'
p1779
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ENOXACIN'
p1780
sa(dp1781
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00467'
p1782
sg5
S'http://bio2rdf.org/drugbank:DB00201'
p1783
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1784
sg23
Nsg24
Nsg25
S'CAFFEINE'
p1785
sg27
Nsg28
S'Caffeine-related adverse effects have occurred in patients consuming caffeine while on therapy with enoxacin.| Trough plasma enoxacin levels were also 20% higher when caffeine and enoxacin were administered concomitantly.| \r'
p1786
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ENOXACIN'
p1787
sa(dp1788
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1789
sg5
S'http://bio2rdf.org/drugbank:DB00201'
p1790
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1791
sg23
Nsg24
Nsg25
S'CAFFEINE'
p1792
sg27
Nsg28
S'Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).| \r'
p1793
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p1794
sa(dp1795
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01403'
p1796
sg5
S'http://bio2rdf.org/drugbank:DB00201'
p1797
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1798
sg23
Nsg24
Nsg25
S'CAFFEINE'
p1799
sg27
Nsg28
S'Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. | \r'
p1800
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LEVOMEPROMAZINE'
p1801
sa(dp1802
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00379'
p1803
sg5
S'http://bio2rdf.org/drugbank:DB00201'
p1804
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1805
sg23
Nsg24
Nsg25
S'CAFFEINE'
p1806
sg27
Nsg28
S'Additionally, in one controlled study in five normal subjects and seven patients, the clearance of caffeine was decreased 50% following the administration of Mexitil   .| \r'
p1807
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Mexitil'
p1808
sa(dp1809
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p1810
sg5
S'http://bio2rdf.org/drugbank:DB00201'
p1811
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1812
sg23
Nsg24
Nsg25
S'CAFFEINE'
p1813
sg27
Nsg28
S'Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).| \r'
p1814
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p1815
sa(dp1816
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p1817
sg5
S'http://bio2rdf.org/drugbank:DB00201'
p1818
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1819
sg23
Nsg24
Nsg25
S'CAFFEINE'
p1820
sg27
Nsg28
S'Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).| \r'
p1821
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p1822
sa(dp1823
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00630'
p1824
sg5
S'http://bio2rdf.org/drugbank:DB01373'
p1825
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1826
sg23
Nsg24
Nsg25
S'CALCIUM'
p1827
sg27
Nsg28
S'Products containing calcium and other multivalent cations likely will interfere with absorption of alendronate.| \r'
p1828
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALENDRONIC ACID'
p1829
sa(dp1830
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01196'
p1831
sg5
S'http://bio2rdf.org/drugbank:DB01373'
p1832
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1833
sg23
Nsg24
Nsg25
S'CALCIUM'
p1834
sg27
Nsg28
S'Milk, milk products, and calcium-rich foods or drugs may impair the absorption of EMCYT.| \r'
p1835
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Emcyt'
p1836
sa(dp1837
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00710'
p1838
sg5
S'http://bio2rdf.org/drugbank:DB01373'
p1839
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1840
sg23
Nsg24
Nsg25
S'CALCIUM'
p1841
sg27
Nsg28
S'Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.| \r'
p1842
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'IBANDRONIC ACID'
p1843
sa(dp1844
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01592'
p1845
sg5
S'http://bio2rdf.org/drugbank:DB01373'
p1846
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1847
sg23
Nsg24
Nsg25
S'CALCIUM'
p1848
sg27
Nsg28
S'However, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies. | \r'
p1849
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'IRON'
p1850
sa(dp1851
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01234'
p1852
sg5
S'http://bio2rdf.org/drugbank:DB00762'
p1853
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1854
sg23
Nsg24
Nsg25
S'Camptosar'
p1855
sg27
Nsg28
S'Lymphocytopenia has been reported in patients receiving CAMPTOSAR, and it is possible that the administration of dexamethasone as antiemetic prophylaxis may have enhanced the likelihood of this effect.| \r'
p1856
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DEXAMETHASONE'
p1857
sa(dp1858
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p1859
sg5
S'http://bio2rdf.org/drugbank:DB00520'
p1860
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1861
sg23
Nsg24
Nsg25
S'Cancidas'
p1862
sg27
Nsg28
S'When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered| \r'
p1863
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CARBAMAZEPINE'
p1864
sa(dp1865
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p1866
sg5
S'http://bio2rdf.org/drugbank:DB00520'
p1867
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1868
sg23
Nsg24
Nsg25
S'Cancidas'
p1869
sg27
Nsg28
S'There were transient increases in liver ALT and AST when CANCIDAS and cyclosporine were co-administered.| \r'
p1870
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSPORINE'
p1871
sa(dp1872
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01234'
p1873
sg5
S'http://bio2rdf.org/drugbank:DB00520'
p1874
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1875
sg23
Nsg24
Nsg25
S'Cancidas'
p1876
sg27
Nsg28
S'When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered| \r'
p1877
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DEXAMETHASONE'
p1878
sa(dp1879
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00625'
p1880
sg5
S'http://bio2rdf.org/drugbank:DB00520'
p1881
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1882
sg23
Nsg24
Nsg25
S'Cancidas'
p1883
sg27
Nsg28
S'When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered| \r'
p1884
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EFAVIRENZ'
p1885
sa(dp1886
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00238'
p1887
sg5
S'http://bio2rdf.org/drugbank:DB00520'
p1888
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1889
sg23
Nsg24
Nsg25
S'Cancidas'
p1890
sg27
Nsg28
S'When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered| \r'
p1891
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NEVIRAPINE'
p1892
sa(dp1893
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p1894
sg5
S'http://bio2rdf.org/drugbank:DB00520'
p1895
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1896
sg23
Nsg24
Nsg25
S'Cancidas'
p1897
sg27
Nsg28
S'When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered| \r'
p1898
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p1899
sa(dp1900
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00864'
p1901
sg5
S'http://bio2rdf.org/drugbank:DB00520'
p1902
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1903
sg23
Nsg24
Nsg25
S'Cancidas'
p1904
sg27
Nsg28
S'CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.| \r'
p1905
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TACROLIMUS ANHYDROUS'
p1906
sa(dp1907
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00864'
p1908
sg5
S'http://bio2rdf.org/drugbank:DB00520'
p1909
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1910
sg23
Nsg24
Nsg25
S'Cancidas'
p1911
sg27
Nsg28
S'CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.| \r'
p1912
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TACROLIMUS'
p1913
sa(dp1914
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00870'
p1915
sg5
S'http://bio2rdf.org/drugbank:DB00411'
p1916
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p1917
sg23
Nsg24
Nsg25
S'CARBACHOL'
p1918
sg27
Nsg28
S'Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.| \r'
p1919
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Suprofen'
p1920
sa(dp1921
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01238'
p1922
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p1923
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p1924
sg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p1925
sg27
Nsg28
S'Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels.| Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.| When carbamazepine is withdrawn from the combination therapy, aripiprazole dose should then be reduced.| When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled.| \r'
p1926
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ARIPIPRAZOLE'
p1927
sa(dp1928
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01238'
p1929
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p1930
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1931
sg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p1932
sg27
Nsg28
S'Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels.| Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.| When carbamazepine is withdrawn from the combination therapy, aripiprazole dose should then be reduced.| When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled.| \r'
p1933
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ARIPIPRAZOLE'
p1934
sa(dp1935
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00520'
p1936
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p1937
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1938
sg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p1939
sg27
Nsg28
S'In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.| \r'
p1940
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cancidas'
p1941
sa(dp1942
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01068'
p1943
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p1944
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1945
sg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p1946
sg27
Nsg28
S'Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.| \r'
p1947
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLONAZEPAM'
p1948
sa(dp1949
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00363'
p1950
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p1951
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1952
sg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p1953
sg27
Nsg28
S'Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.| \r'
p1954
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLOZAPINE'
p1955
sa(dp1956
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00254'
p1957
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p1958
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1959
sg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p1960
sg27
Nsg28
S'Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.| \r'
p1961
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOXYCYCLINE'
p1962
sa(dp1963
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p1964
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p1965
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1966
sg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p1967
sg27
Nsg28
S'Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.| \r'
p1968
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ESCITALOPRAM OXALATE'
p1969
sa(dp1970
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p1971
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p1972
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1973
sg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p1974
sg27
Nsg28
S'Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.| \r'
p1975
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ESCITALOPRAM'
p1976
sa(dp1977
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00977'
p1978
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p1979
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1980
sg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p1981
sg27
Nsg28
S'Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.| \r'
p1982
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ETHINYL ESTRADIOL'
p1983
sa(dp1984
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00990'
p1985
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p1986
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1987
sg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p1988
sg27
Nsg28
S'Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.| \r'
p1989
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EXEMESTANE'
p1990
sa(dp1991
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00949'
p1992
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p1993
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p1994
sg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p1995
sg27
Nsg28
S'The carbamazepine steady-state Cmin decreased 31% to 5 1 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered.| \r'
p1996
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FELBAMATE'
p1997
sa(dp1998
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00949'
p1999
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p2000
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2001
sg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p2002
sg27
Nsg28
S'Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.| \r'
p2003
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Felbatol'
p2004
sa(dp2005
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00951'
p2006
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p2007
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2008
sg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p2009
sg27
Nsg28
S'Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.| \r'
p2010
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ISONIAZID'
p2011
sa(dp2012
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01259'
p2013
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p2014
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2015
sg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p2016
sg27
Nsg28
S'Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.| \r'
p2017
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LAPATINIB DITOSYLATE'
p2018
sa(dp2019
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01259'
p2020
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p2021
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2022
sg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p2023
sg27
Nsg28
S'Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.| \r'
p2024
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LAPATINIB'
p2025
sa(dp2026
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p2027
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p2028
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2029
sg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p2030
sg27
Nsg28
S'Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects.| \r'
p2031
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM CATION'
p2032
sa(dp2033
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p2034
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p2035
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2036
sg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p2037
sg27
Nsg28
S'Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects.| \r'
p2038
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM'
p2039
sa(dp2040
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p2041
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p2042
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2043
sg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p2044
sg27
Nsg28
S'Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. | \r'
p2045
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIDAZOLAM'
p2046
sa(dp2047
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00834'
p2048
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p2049
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2050
sg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p2051
sg27
Nsg28
S'John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). | \r'
p2052
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIFEPRISTONE'
p2053
sa(dp2054
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01226'
p2055
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p2056
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2057
sg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p2058
sg27
Nsg28
S'While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. | \r'
p2059
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Mivacron'
p2060
sa(dp2061
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00565'
p2062
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p2063
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2064
sg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p2065
sg27
Nsg28
S'While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.| \r'
p2066
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nimbex'
p2067
sa(dp2068
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p2069
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p2070
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2071
sg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p2072
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| \r'
p2073
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p2074
sa(dp2075
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p2076
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p2077
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2078
sg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p2079
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| \r'
p2080
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p2081
sa(dp2082
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00671'
p2083
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p2084
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2085
sg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p2086
sg27
Nsg28
S'Carbamazepine: Elevated carbamazepine levels have been reported in postmarketing experience when SUPRAX is administered concomitantly.| \r'
p2087
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Suprax'
p2088
sa(dp2089
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00870'
p2090
sg5
S'http://bio2rdf.org/drugbank:DB00411'
p2091
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2092
sg23
Nsg24
Nsg25
S'Carboptic'
p2093
sg27
Nsg28
S'Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.| \r'
p2094
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Suprofen'
p2095
sa(dp2096
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01592'
p2097
sg5
S'http://bio2rdf.org/drugbank:DB00535'
p2098
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2099
sg23
Nsg24
Nsg25
S'CEFDINIR'
p2100
sg27
Nsg28
S'The reddish color is due to the formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.| Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.| \r'
p2101
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'IRON'
p2102
sa(dp2103
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p2104
sg5
S'http://bio2rdf.org/drugbank:DB00482'
p2105
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2106
sg23
Nsg24
Nsg25
S'Celebrex'
p2107
sg27
Nsg28
S'Aspirin: CELEBREX can be used with low dose aspirin.| \r'
p2108
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p2109
sa(dp2110
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p2111
sg5
S'http://bio2rdf.org/drugbank:DB00482'
p2112
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2113
sg23
Nsg24
Nsg25
S'Celebrex'
p2114
sg27
Nsg28
S'CELEBREX should be introduced at the lowest recommended dose in patients receiving fluconazole.| \r'
p2115
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p2116
sa(dp2117
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00997'
p2118
sg5
S'http://bio2rdf.org/drugbank:DB00482'
p2119
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2120
sg23
Nsg24
Nsg25
S'CELECOXIB'
p2121
sg27
Nsg28
S'We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells. | \r'
p2122
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOXORUBICIN'
p2123
sa(dp2124
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p2125
sg5
S'http://bio2rdf.org/drugbank:DB00482'
p2126
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2127
sg23
Nsg24
Nsg25
S'CELECOXIB'
p2128
sg27
Nsg28
S'Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.| This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).| \r'
p2129
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p2130
sa(dp2131
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p2132
sg5
S'http://bio2rdf.org/drugbank:DB00482'
p2133
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2134
sg23
Nsg24
Nsg25
S'CELECOXIB'
p2135
sg27
Nsg28
S'Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.| This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).| \r'
p2136
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p2137
sa(dp2138
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p2139
sg5
S'http://bio2rdf.org/drugbank:DB00482'
p2140
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2141
sg23
Nsg24
Nsg25
S'CELECOXIB'
p2142
sg27
Nsg28
S'Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.| \r'
p2143
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM CATION'
p2144
sa(dp2145
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p2146
sg5
S'http://bio2rdf.org/drugbank:DB00482'
p2147
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2148
sg23
Nsg24
Nsg25
S'CELECOXIB'
p2149
sg27
Nsg28
S'Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.| \r'
p2150
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM'
p2151
sa(dp2152
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00331'
p2153
sg5
S'http://bio2rdf.org/drugbank:DB00567'
p2154
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2155
sg23
Nsg24
Nsg25
S'CEPHALEXIN ANHYDROUS'
p2156
sg27
Nsg28
S'Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.| Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.| Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.| \r'
p2157
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METFORMIN'
p2158
sa(dp2159
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00331'
p2160
sg5
S'http://bio2rdf.org/drugbank:DB00567'
p2161
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2162
sg23
Nsg24
Nsg25
S'CEPHALEXIN ANHYDROUS'
p2163
sg27
Nsg28
S'Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.| Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.| Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.| \r'
p2164
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METFORMIN'
p2165
sa(dp2166
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p2167
sg5
S'http://bio2rdf.org/drugbank:DB00567'
p2168
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2169
sg23
Nsg24
Nsg25
S'CEPHALEXIN ANHYDROUS'
p2170
sg27
Nsg28
S'Probenecid: As with other b-lactams, the renal excretion of cephalexin is inhibited by probenecid.| \r'
p2171
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROBENECID'
p2172
sa(dp2173
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00331'
p2174
sg5
S'http://bio2rdf.org/drugbank:DB00567'
p2175
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2176
sg23
Nsg24
Nsg25
S'CEPHALEXIN'
p2177
sg27
Nsg28
S'Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.| Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.| Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.| \r'
p2178
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METFORMIN'
p2179
sa(dp2180
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00331'
p2181
sg5
S'http://bio2rdf.org/drugbank:DB00567'
p2182
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2183
sg23
Nsg24
Nsg25
S'CEPHALEXIN'
p2184
sg27
Nsg28
S'Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.| Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.| Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.| \r'
p2185
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METFORMIN'
p2186
sa(dp2187
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p2188
sg5
S'http://bio2rdf.org/drugbank:DB00567'
p2189
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2190
sg23
Nsg24
Nsg25
S'CEPHALEXIN'
p2191
sg27
Nsg28
S'Probenecid: As with other b-lactams, the renal excretion of cephalexin is inhibited by probenecid.| \r'
p2192
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROBENECID'
p2193
sa(dp2194
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00419'
p2195
sg5
S'http://bio2rdf.org/drugbank:DB00053'
p2196
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2197
sg23
Nsg24
Nsg25
S'Cerezyme'
p2198
sg27
Nsg28
S'Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.| \r'
p2199
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Zavesca'
p2200
sa(dp2201
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p2202
sg5
S'http://bio2rdf.org/drugbank:DB00439'
p2203
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2204
sg23
Nsg24
Nsg25
S'CERIVASTATIN'
p2205
sg27
Nsg28
S'ERYTHROMYCIN: In hypercholesterolemic patients, steady-state cerivastatin AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of erythromycin, a known inhibitor of cytochrome P450 3A4.| \r'
p2206
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERYTHROMYCIN'
p2207
sa(dp2208
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00997'
p2209
sg5
S'http://bio2rdf.org/drugbank:DB00694'
p2210
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2211
sg23
Nsg24
Nsg25
S'Cerubidine'
p2212
sg27
Nsg28
S'Cerubidine should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or Cerubidine.| Use of Cerubidine in a patient who has previously received doxorubicin increases the risk of cardiotoxicity.| \r'
p2213
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOXORUBICIN'
p2214
sa(dp2215
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00997'
p2216
sg5
S'http://bio2rdf.org/drugbank:DB00694'
p2217
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2218
sg23
Nsg24
Nsg25
S'Cerubidine'
p2219
sg27
Nsg28
S'Cerubidine should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or Cerubidine.| Use of Cerubidine in a patient who has previously received doxorubicin increases the risk of cardiotoxicity.| \r'
p2220
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOXORUBICIN'
p2221
sa(dp2222
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00438'
p2223
sg5
S'http://bio2rdf.org/drugbank:DB00446'
p2224
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2225
sg23
Nsg24
Nsg25
S'CHLORAMPHENICOL'
p2226
sg27
Nsg28
S'Chloramphenicol has been shown to be antagonistic to beta-lactam antibiotics, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.| \r'
p2227
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CEFTAZIDIME'
p2228
sa(dp2229
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p2230
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p2231
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2232
sg23
Nsg24
Nsg25
S'CHLOROTRIANISENE'
p2233
sg27
Nsg28
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p2234
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p2235
sa(dp2236
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01200'
p2237
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p2238
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2239
sg23
Nsg24
Nsg25
S'CHLOROTRIANISENE'
p2240
sg27
Nsg28
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p2241
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BROMOCRIPTINE'
p2242
sa(dp2243
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01373'
p2244
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p2245
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2246
sg23
Nsg24
Nsg25
S'CHLOROTRIANISENE'
p2247
sg27
Nsg28
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p2248
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CALCIUM'
p2249
sa(dp2250
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p2251
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p2252
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2253
sg23
Nsg24
Nsg25
S'CHLOROTRIANISENE'
p2254
sg27
Nsg28
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p2255
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSPORINE'
p2256
sa(dp2257
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01219'
p2258
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p2259
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2260
sg23
Nsg24
Nsg25
S'CHLOROTRIANISENE'
p2261
sg27
Nsg28
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p2262
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DANTROLENE'
p2263
sa(dp2264
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00184'
p2265
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p2266
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2267
sg23
Nsg24
Nsg25
S'CHLOROTRIANISENE'
p2268
sg27
Nsg28
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p2269
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NICOTINE'
p2270
sa(dp2271
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00052'
p2272
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p2273
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2274
sg23
Nsg24
Nsg25
S'CHLOROTRIANISENE'
p2275
sg27
Nsg28
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p2276
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Somatropin'
p2277
sa(dp2278
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00675'
p2279
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p2280
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p2281
sg23
Nsg24
Nsg25
S'CHLOROTRIANISENE'
p2282
sg27
Nsg28
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p2283
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TAMOXIFEN'
p2284
sa(dp2285
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00321'
p2286
sg5
S'http://bio2rdf.org/drugbank:DB00477'
p2287
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2288
sg23
Nsg24
Nsg25
S'CHLORPROMAZINE'
p2289
sg27
Nsg28
S'The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.| \r'
p2290
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMITRIPTYLINE'
p2291
sa(dp2292
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00437'
p2293
sg5
S'http://bio2rdf.org/drugbank:DB00672'
p2294
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2295
sg23
Nsg24
Nsg25
S'CHLORPROPAMIDE'
p2296
sg27
Nsg28
S'Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.| \r'
p2297
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALLOPURINOL'
p2298
sa(dp2299
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00413'
p2300
sg5
S'http://bio2rdf.org/drugbank:DB00672'
p2301
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2302
sg23
Nsg24
Nsg25
S'CHLORPROPAMIDE'
p2303
sg27
Nsg28
S'Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | \r'
p2304
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PRAMIPEXOLE'
p2305
sa(dp2306
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p2307
sg5
S'http://bio2rdf.org/drugbank:DB01239'
p2308
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2309
sg23
Nsg24
Nsg25
S'CHLORPROTHIXENE'
p2310
sg27
Nsg28
S'Chlorprothixene may increase the plasma-level of concomitantly given lithium.| \r'
p2311
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM CATION'
p2312
sa(dp2313
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p2314
sg5
S'http://bio2rdf.org/drugbank:DB01239'
p2315
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2316
sg23
Nsg24
Nsg25
S'CHLORPROTHIXENE'
p2317
sg27
Nsg28
S'Chlorprothixene may increase the plasma-level of concomitantly given lithium.| \r'
p2318
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM'
p2319
sa(dp2320
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00193'
p2321
sg5
S'http://bio2rdf.org/drugbank:DB01239'
p2322
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2323
sg23
Nsg24
Nsg25
S'CHLORPROTHIXENE'
p2324
sg27
Nsg28
S'Avoid the concomitant use of chlorprothixene and tramadol (Ultram).| \r'
p2325
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ultram'
p2326
sa(dp2327
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p2328
sg5
S'http://bio2rdf.org/drugbank:DB01410'
p2329
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2330
sg23
Nsg24
Nsg25
S'CICLESONIDE'
p2331
sg27
Nsg28
S'In another drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.| \r'
p2332
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p2333
sa(dp2334
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00261'
p2335
sg5
S'http://bio2rdf.org/drugbank:DB01166'
p2336
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2337
sg23
Nsg24
Nsg25
S'CILOSTAZOL'
p2338
sg27
Nsg28
S'The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.| \r'
p2339
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ANAGRELIDE'
p2340
sa(dp2341
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p2342
sg5
S'http://bio2rdf.org/drugbank:DB01166'
p2343
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2344
sg23
Nsg24
Nsg25
S'CILOSTAZOL'
p2345
sg27
Nsg28
S'Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of C.P.A..| \r'
p2346
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DILTIAZEM'
p2347
sa(dp2348
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00802'
p2349
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2350
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2351
sg23
Nsg24
Nsg25
S'CIMETIDINE'
p2352
sg27
Nsg28
S'Cimetidine reduces the clearance of ALFENTA.| \r'
p2353
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alfenta'
p2354
sa(dp2355
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00488'
p2356
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2357
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2358
sg23
Nsg24
Nsg25
S'CIMETIDINE'
p2359
sg27
Nsg28
S'Concurrent administration of HEXALEN and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension.Cimetidine, an inhibitor of microsomal drug metabolism, increased altretamines half-life and toxicity in a rat model.| \r'
p2360
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALTRETAMINE'
p2361
sa(dp2362
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p2363
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2364
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2365
sg23
Nsg24
Nsg25
S'CIMETIDINE'
p2366
sg27
Nsg28
S'The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.| H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.| \r'
p2367
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p2368
sa(dp2369
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00363'
p2370
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2371
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2372
sg23
Nsg24
Nsg25
S'CIMETIDINE'
p2373
sg27
Nsg28
S'Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.| \r'
p2374
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLOZAPINE'
p2375
sa(dp2376
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p2377
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2378
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2379
sg23
Nsg24
Nsg25
S'CIMETIDINE'
p2380
sg27
Nsg28
S'A study in six healthy volunteers has shown a significant increase in peak diltiazem plasma levels (58%) and AUC (53%) after a 1-week course of cimetidine 1200 mg/day and a single dose of diltiazem 60mg.| The effect may be mediated by cimetidines known inhibition of hepatic cytochrome P-450, the enzyme system responsible for the first-pass metabolism of diltiazem.| \r'
p2381
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DILTIAZEM'
p2382
sa(dp2383
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p2384
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2385
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2386
sg23
Nsg24
Nsg25
S'CIMETIDINE'
p2387
sg27
Nsg28
S'Cimetidine at doses of 100 mg BID (OTC dose) resulted in a 13% increase in dofetilide plasma levels (500 mcg single dose).| \r'
p2388
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOFETILIDE'
p2389
sa(dp2390
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00445'
p2391
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2392
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2393
sg23
Nsg24
Nsg25
S'CIMETIDINE'
p2394
sg27
Nsg28
S'Cimetidine treatment should be stopped during treatment with ELLENCE.| \r'
p2395
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ellence'
p2396
sa(dp2397
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00445'
p2398
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2399
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2400
sg23
Nsg24
Nsg25
S'CIMETIDINE'
p2401
sg27
Nsg28
S'Cimetidine increased the AUC of epirubicin by 50%.| \r'
p2402
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EPIRUBICIN'
p2403
sa(dp2404
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00996'
p2405
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2406
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2407
sg23
Nsg24
Nsg25
S'CIMETIDINE'
p2408
sg27
Nsg28
S'Cimetidine: In the presence of cimetidine at 300 mg QID (N=12) the mean apparent oral clearance of gabapentin fell by 14% and creatinine clearance fell by 10%.| Thus cimetidine appeared to alter the renal excretion of both gabapentin and creatinine, an endogenous marker of renal function.| \r'
p2409
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GABAPENTIN'
p2410
sa(dp2411
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00317'
p2412
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2413
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2414
sg23
Nsg24
Nsg25
S'CIMETIDINE'
p2415
sg27
Nsg28
S'Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.| \r'
p2416
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Iressa'
p2417
sa(dp2418
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00643'
p2419
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2420
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2421
sg23
Nsg24
Nsg25
S'CIMETIDINE'
p2422
sg27
Nsg28
S'Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.| \r'
p2423
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MEBENDAZOLE'
p2424
sa(dp2425
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00379'
p2426
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2427
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2428
sg23
Nsg24
Nsg25
S'CIMETIDINE'
p2429
sg27
Nsg28
S'Concurrent administration of cimetidine and Mexitil    has been reported to increase, decrease, or leave unchanged Mexitil    plasma levels; | \r'
p2430
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Mexitil'
p2431
sa(dp2432
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01115'
p2433
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2434
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2435
sg23
Nsg24
Nsg25
S'CIMETIDINE'
p2436
sg27
Nsg28
S'Cimetidine: A study in 6 healthy volunteers has shown a significant increase in peak nifedipine plasma levels (80%) and area-under-the-curve (74%) after a 1 week course of cimetidine at 1000 mg per day and nifedipine at 40 mg per day.| \r'
p2437
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NIFEDIPINE'
p2438
sa(dp2439
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00413'
p2440
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2441
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2442
sg23
Nsg24
Nsg25
S'CIMETIDINE'
p2443
sg27
Nsg28
S'Cimetidine: Cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole AUC and a 40% increase in half-life (N= 12). | Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | \r'
p2444
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PRAMIPEXOLE'
p2445
sa(dp2446
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00533'
p2447
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2448
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2449
sg23
Nsg24
Nsg25
S'CIMETIDINE'
p2450
sg27
Nsg28
S'Cimetidine: Co-administration with high doses of cimetidine [800 mg twice daily] increased the Cmax of rofecoxib by 21%, the AUC0-120hr by 23% and the t1/2 by 15%.| \r'
p2451
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ROFECOXIB'
p2452
sa(dp2453
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p2454
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2455
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2456
sg23
Nsg24
Nsg25
S'CIMETIDINE'
p2457
sg27
Nsg28
S'Cimetidine at 400 mg BID (the usual prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide plasma levels by 58%.| \r'
p2458
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tikosyn'
p2459
sa(dp2460
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01157'
p2461
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2462
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2463
sg23
Nsg24
Nsg25
S'CIMETIDINE'
p2464
sg27
Nsg28
S'In vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in trimetrexate metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites. | \r'
p2465
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TRIMETREXATE'
p2466
sa(dp2467
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00404'
p2468
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2469
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2470
sg23
Nsg24
Nsg25
S'CIMETIDINE'
p2471
sg27
Nsg28
S'Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).| \r'
p2472
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Xanax'
p2473
sa(dp2474
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p2475
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2476
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2477
sg23
Nsg24
Nsg25
S'CIMETIDINE'
p2478
sg27
Nsg28
S'Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.| \r'
p2479
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZALCITABINE'
p2480
sa(dp2481
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00962'
p2482
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2483
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2484
sg23
Nsg24
Nsg25
S'CIMETIDINE'
p2485
sg27
Nsg28
S'Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 Cimetidine: Cimetidine inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary and secondary enzymes, respectively, responsible for zaleplon metabolism.| \r'
p2486
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZALEPLON'
p2487
sa(dp2488
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00321'
p2489
sg5
S'http://bio2rdf.org/drugbank:DB01012'
p2490
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2491
sg23
Nsg24
Nsg25
S'CINACALCET'
p2492
sg27
Nsg28
S'Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.| \r'
p2493
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMITRIPTYLINE'
p2494
sa(dp2495
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00201'
p2496
sg5
S'http://bio2rdf.org/drugbank:DB00827'
p2497
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2498
sg23
Nsg24
Nsg25
S'CINOXACIN'
p2499
sg27
Nsg28
S'Although this interaction has not been reported with cinoxacin, caution should be exercised when cinoxacin is given concomitantly with caffeine-containing products.| \r'
p2500
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CAFFEINE'
p2501
sa(dp2502
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01370'
p2503
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p2504
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2505
sg23
Nsg24
Nsg25
S'CIPROFLOXACIN'
p2506
sg27
Nsg28
S'Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.| Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| \r'
p2507
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALUMINUM'
p2508
sa(dp2509
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00201'
p2510
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p2511
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2512
sg23
Nsg24
Nsg25
S'CIPROFLOXACIN'
p2513
sg27
Nsg28
S'Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine.| \r'
p2514
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CAFFEINE'
p2515
sa(dp2516
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01373'
p2517
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p2518
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2519
sg23
Nsg24
Nsg25
S'CIPROFLOXACIN'
p2520
sg27
Nsg28
S'Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.| Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| \r'
p2521
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CALCIUM'
p2522
sa(dp2523
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00537'
p2524
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p2525
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2526
sg23
Nsg24
Nsg25
S'CIPROFLOXACIN'
p2527
sg27
Nsg28
S'Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| \r'
p2528
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIPROFLOXACIN'
p2529
sa(dp2530
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p2531
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p2532
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2533
sg23
Nsg24
Nsg25
S'CIPROFLOXACIN'
p2534
sg27
Nsg28
S'Some quinolones, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.| \r'
p2535
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSPORINE'
p2536
sa(dp2537
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p2538
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p2539
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2540
sg23
Nsg24
Nsg25
S'CIPROFLOXACIN'
p2541
sg27
Nsg28
S'In a single subject given one dose of ciprofloxacin 2 hours after a dose of didanosine-placebo tablets, a greater than 50% reduction in the AUC of ciprofloxacin was observed.| The AUC of ciprofloxacin was decreased an average of 15-fold in 12 healthy subjects given ciprofloxacin and didanosine-placebo tablets concurrently.| \r'
p2542
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIDANOSINE'
p2543
sa(dp2544
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01016'
p2545
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p2546
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2547
sg23
Nsg24
Nsg25
S'CIPROFLOXACIN'
p2548
sg27
Nsg28
S'Glyburide: The concomitant administration of ciprofloxacin with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.| \r'
p2549
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GLYBURIDE'
p2550
sa(dp2551
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01592'
p2552
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p2553
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2554
sg23
Nsg24
Nsg25
S'CIPROFLOXACIN'
p2555
sg27
Nsg28
S'Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| \r'
p2556
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'IRON'
p2557
sa(dp2558
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01378'
p2559
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p2560
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2561
sg23
Nsg24
Nsg25
S'CIPROFLOXACIN'
p2562
sg27
Nsg28
S'Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.| Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| \r'
p2563
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MAGNESIUM CATION'
p2564
sa(dp2565
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01378'
p2566
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p2567
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2568
sg23
Nsg24
Nsg25
S'CIPROFLOXACIN'
p2569
sg27
Nsg28
S'Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.| Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| \r'
p2570
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MAGNESIUM'
p2571
sa(dp2572
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p2573
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p2574
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2575
sg23
Nsg24
Nsg25
S'CIPROFLOXACIN'
p2576
sg27
Nsg28
S'Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. | \r'
p2577
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MORPHINE'
p2578
sa(dp2579
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p2580
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p2581
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2582
sg23
Nsg24
Nsg25
S'CIPROFLOXACIN'
p2583
sg27
Nsg28
S'Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.| \r'
p2584
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p2585
sa(dp2586
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p2587
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p2588
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2589
sg23
Nsg24
Nsg25
S'CIPROFLOXACIN'
p2590
sg27
Nsg28
S'Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| In eight HIV-infected patients, the steady-state AUC of ciprofloxacin was decreased an average of 26% (95% CI = 14%, 37%) when ciprofloxacin was administered 2 hours prior to a marketed chewable/dispersible tablet formulation of VIDEX.| \r'
p2591
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Videx'
p2592
sa(dp2593
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01593'
p2594
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p2595
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2596
sg23
Nsg24
Nsg25
S'CIPROFLOXACIN'
p2597
sg27
Nsg28
S'Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| \r'
p2598
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZINC'
p2599
sa(dp2600
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p2601
sg5
S'http://bio2rdf.org/drugbank:DB00604'
p2602
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2603
sg23
Nsg24
Nsg25
S'Cisapride'
p2604
sg27
Nsg28
S'There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.| \r'
p2605
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERYTHROMYCIN'
p2606
sa(dp2607
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p2608
sg5
S'http://bio2rdf.org/drugbank:DB00604'
p2609
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2610
sg23
Nsg24
Nsg25
S'Cisapride'
p2611
sg27
Nsg28
S'A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.| Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.| \r'
p2612
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p2613
sa(dp2614
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p2615
sg5
S'http://bio2rdf.org/drugbank:DB00604'
p2616
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2617
sg23
Nsg24
Nsg25
S'Cisapride'
p2618
sg27
Nsg28
S'A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.| Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.| \r'
p2619
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p2620
sa(dp2621
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01035'
p2622
sg5
S'http://bio2rdf.org/drugbank:DB00604'
p2623
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2624
sg23
Nsg24
Nsg25
S'Cisapride'
p2625
sg27
Nsg28
S'Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);| \r'
p2626
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROCAINAMIDE'
p2627
sa(dp2628
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00908'
p2629
sg5
S'http://bio2rdf.org/drugbank:DB00604'
p2630
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2631
sg23
Nsg24
Nsg25
S'Cisapride'
p2632
sg27
Nsg28
S'Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);| \r'
p2633
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'QUINIDINE'
p2634
sa(dp2635
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00489'
p2636
sg5
S'http://bio2rdf.org/drugbank:DB00604'
p2637
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2638
sg23
Nsg24
Nsg25
S'Cisapride'
p2639
sg27
Nsg28
S'Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);| \r'
p2640
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sotalol'
p2641
sa(dp2642
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p2643
sg5
S'http://bio2rdf.org/drugbank:DB00604'
p2644
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2645
sg23
Nsg24
Nsg25
S'Cisapride'
p2646
sg27
Nsg28
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p2647
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sprycel'
p2648
sa(dp2649
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p2650
sg5
S'http://bio2rdf.org/drugbank:DB01211'
p2651
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2652
sg23
Nsg24
Nsg25
S'CLARITHROMYCIN'
p2653
sg27
Nsg28
S'Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| \r'
p2654
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p2655
sa(dp2656
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p2657
sg5
S'http://bio2rdf.org/drugbank:DB01211'
p2658
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2659
sg23
Nsg24
Nsg25
S'CLARITHROMYCIN'
p2660
sg27
Nsg28
S'Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.| \r'
p2661
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p2662
sa(dp2663
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00238'
p2664
sg5
S'http://bio2rdf.org/drugbank:DB01211'
p2665
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2666
sg23
Nsg24
Nsg25
S'CLARITHROMYCIN'
p2667
sg27
Nsg28
S'Clarithromycin exposure was significantly decreased by nevirapine;| \r'
p2668
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NEVIRAPINE'
p2669
sa(dp2670
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01100'
p2671
sg5
S'http://bio2rdf.org/drugbank:DB01211'
p2672
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2673
sg23
Nsg24
Nsg25
S'CLARITHROMYCIN'
p2674
sg27
Nsg28
S'Concomitant administration of clarithromycin with pimozide is contraindicated.| \r'
p2675
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PIMOZIDE'
p2676
sa(dp2677
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00641'
p2678
sg5
S'http://bio2rdf.org/drugbank:DB01211'
p2679
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2680
sg23
Nsg24
Nsg25
S'CLARITHROMYCIN'
p2681
sg27
Nsg28
S'DISCUSSION: Clarithromycin is a potent inhibitor of CYP3A4, the major enzyme responsible for simvastatin metabolism. | \r'
p2682
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SIMVASTATIN'
p2683
sa(dp2684
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p2685
sg5
S'http://bio2rdf.org/drugbank:DB01190'
p2686
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2687
sg23
Nsg24
Nsg25
S'CLINDAMYCIN'
p2688
sg27
Nsg28
S'Antagonism has been demonstrated between clindamycin and erythromycin in vitro.| \r'
p2689
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERYTHROMYCIN'
p2690
sa(dp2691
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00782'
p2692
sg5
S'http://bio2rdf.org/drugbank:DB01068'
p2693
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2694
sg23
Nsg24
Nsg25
S'CLONAZEPAM'
p2695
sg27
Nsg28
S'In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.| \r'
p2696
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROPANTHELINE'
p2697
sa(dp2698
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p2699
sg5
S'http://bio2rdf.org/drugbank:DB00575'
p2700
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2701
sg23
Nsg24
Nsg25
S'CLONIDINE'
p2702
sg27
Nsg28
S'Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.| \r'
p2703
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p2704
sa(dp2705
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00736'
p2706
sg5
S'http://bio2rdf.org/drugbank:DB00758'
p2707
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2708
sg23
Nsg24
Nsg25
S'CLOPIDOGREL'
p2709
sg27
Nsg28
S'Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided. | \r'
p2710
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ESOMEPRAZOLE'
p2711
sa(dp2712
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01157'
p2713
sg5
S'http://bio2rdf.org/drugbank:DB00257'
p2714
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2715
sg23
Nsg24
Nsg25
S'CLOTRIMAZOLE'
p2716
sg27
Nsg28
S'Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. | \r'
p2717
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TRIMETREXATE'
p2718
sa(dp2719
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p2720
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p2721
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2722
sg23
Nsg24
Nsg25
S'CLOZAPINE'
p2723
sg27
Nsg28
S'Given the primary CNS effects of Clozapine, caution is advised in using it concomitantly with other CNS-active drugs or alcohol.| \r'
p2724
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p2725
sa(dp2726
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00572'
p2727
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p2728
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2729
sg23
Nsg24
Nsg25
S'CLOZAPINE'
p2730
sg27
Nsg28
S'Clozapine may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of atropine-type drugs.| \r'
p2731
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Atropine'
p2732
sa(dp2733
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p2734
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p2735
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2736
sg23
Nsg24
Nsg25
S'CLOZAPINE'
p2737
sg27
Nsg28
S'Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.| Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.| \r'
p2738
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CARBAMAZEPINE'
p2739
sa(dp2740
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01228'
p2741
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p2742
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2743
sg23
Nsg24
Nsg25
S'CLOZAPINE'
p2744
sg27
Nsg28
S'Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.| \r'
p2745
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Encainide'
p2746
sa(dp2747
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p2748
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p2749
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2750
sg23
Nsg24
Nsg25
S'CLOZAPINE'
p2751
sg27
Nsg28
S'Therefore, such combined treatment should be approached with caution and patients should be monitored closely when Clozapine is combined with these drugs, particularly with fluvoxamine.| \r'
p2752
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p2753
sa(dp2754
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p2755
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p2756
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2757
sg23
Nsg24
Nsg25
S'CLOZAPINE'
p2758
sg27
Nsg28
S'However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.| \r'
p2759
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PAROXETINE'
p2760
sa(dp2761
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00908'
p2762
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p2763
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2764
sg23
Nsg24
Nsg25
S'CLOZAPINE'
p2765
sg27
Nsg28
S'Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.| \r'
p2766
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'QUINIDINE'
p2767
sa(dp2768
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01104'
p2769
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p2770
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2771
sg23
Nsg24
Nsg25
S'CLOZAPINE'
p2772
sg27
Nsg28
S'However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.| \r'
p2773
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SERTRALINE'
p2774
sa(dp2775
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01452'
p2776
sg5
S'http://bio2rdf.org/drugbank:DB00907'
p2777
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2778
sg23
Nsg24
Nsg25
S'COCAINE'
p2779
sg27
Nsg28
S'Cocaine sometimes proves to be fatal when used in combination with heroin.| \r'
p2780
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIACETYLMORPHINE'
p2781
sa(dp2782
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00368'
p2783
sg5
S'http://bio2rdf.org/drugbank:DB00907'
p2784
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2785
sg23
Nsg24
Nsg25
S'COCAINE'
p2786
sg27
Nsg28
S'The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p &lt; 0.05) but not in functional class IV myocardium. | \r'
p2787
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NOREPINEPHRINE'
p2788
sa(dp2789
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p2790
sg5
S'http://bio2rdf.org/drugbank:DB00318'
p2791
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2792
sg23
Nsg24
Nsg25
S'CODEINE'
p2793
sg27
Nsg28
S'The use of codeine may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.| Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.| \r'
p2794
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p2795
sa(dp2796
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00115'
p2797
sg5
S'http://bio2rdf.org/drugbank:DB01394'
p2798
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2799
sg23
Nsg24
Nsg25
S'COLCHICINE'
p2800
sg27
Nsg28
S'Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.| \r'
p2801
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Vitamin B12'
p2802
sa(dp2803
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p2804
sg5
S'http://bio2rdf.org/drugbank:DB00811'
p2805
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2806
sg23
Nsg24
Nsg25
S'Copegus'
p2807
sg27
Nsg28
S'Nucleoside Analogues Didanosine Co-administration of COPEGUS and didanosine is not recommended.| \r'
p2808
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIDANOSINE'
p2809
sa(dp2810
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p2811
sg5
S'http://bio2rdf.org/drugbank:DB01136'
p2812
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2813
sg23
Nsg24
Nsg25
S'Coreg'
p2814
sg27
Nsg28
S'As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.| Calcium Channel Blockers: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when COREG is co-administered with diltiazem.| \r'
p2815
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DILTIAZEM'
p2816
sa(dp2817
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p2818
sg5
S'http://bio2rdf.org/drugbank:DB01136'
p2819
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2820
sg23
Nsg24
Nsg25
S'Coreg'
p2821
sg27
Nsg28
S'As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.| Calcium Channel Blockers: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when COREG is co-administered with diltiazem.| \r'
p2822
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DILTIAZEM'
p2823
sa(dp2824
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p2825
sg5
S'http://bio2rdf.org/drugbank:DB01136'
p2826
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2827
sg23
Nsg24
Nsg25
S'Coreg'
p2828
sg27
Nsg28
S'As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.| \r'
p2829
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Verapamil'
p2830
sa(dp2831
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01072'
p2832
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p2833
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2834
sg23
Nsg24
Nsg25
S'Crixivan'
p2835
sg27
Nsg28
S'Combinations of these drugs have not been studied and coadministration of CRIXIVAN and atazanavir is not recommended.| \r'
p2836
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ATAZANAVIR'
p2837
sa(dp2838
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00705'
p2839
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p2840
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2841
sg23
Nsg24
Nsg25
S'Crixivan'
p2842
sg27
Nsg28
S'Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered when taking delavirdine 400 mg three times a day.| \r'
p2843
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DELAVIRDINE'
p2844
sa(dp2845
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p2846
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p2847
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2848
sg23
Nsg24
Nsg25
S'Crixivan'
p2849
sg27
Nsg28
S'CRIXIVAN may not be effective due to decreased indinavir concentrations in patients taking these agents concomitantly.| \r'
p2850
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDINAVIR ANHYDROUS'
p2851
sa(dp2852
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p2853
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p2854
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2855
sg23
Nsg24
Nsg25
S'Crixivan'
p2856
sg27
Nsg28
S'CRIXIVAN may not be effective due to decreased indinavir concentrations in patients taking these agents concomitantly.| \r'
p2857
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDINAVIR'
p2858
sa(dp2859
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00437'
p2860
sg5
S'http://bio2rdf.org/drugbank:DB00531'
p2861
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2862
sg23
Nsg24
Nsg25
S'Cyclophosphamide'
p2863
sg27
Nsg28
S'Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.| \r'
p2864
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALLOPURINOL'
p2865
sa(dp2866
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00694'
p2867
sg5
S'http://bio2rdf.org/drugbank:DB00531'
p2868
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2869
sg23
Nsg24
Nsg25
S'Cyclophosphamide'
p2870
sg27
Nsg28
S'Cyclophosphamide used concurrently with Cerubidine may also result in increased cardiotoxicity.| \r'
p2871
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cerubidine'
p2872
sa(dp2873
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p2874
sg5
S'http://bio2rdf.org/drugbank:DB00531'
p2875
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2876
sg23
Nsg24
Nsg25
S'Cyclophosphamide'
p2877
sg27
Nsg28
S'The rate of metabolism and the leukopenic activity of cyclophosphamide reportedly are increased by chronic administration of high doses of phenobarbital.| \r'
p2878
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p2879
sa(dp2880
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00773'
p2881
sg5
S'http://bio2rdf.org/drugbank:DB00091'
p2882
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2883
sg23
Nsg24
Nsg25
S'Cyclosporin A'
p2884
sg27
Nsg28
S'High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.| \r'
p2885
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ETOPOSIDE'
p2886
sa(dp2887
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p2888
sg5
S'http://bio2rdf.org/drugbank:DB00091'
p2889
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2890
sg23
Nsg24
Nsg25
S'CYCLOSPORINE'
p2891
sg27
Nsg28
S'In renal and cardiac transplant recipients, a reduction of cyclosporine dose ranging from 15% to 48% was necessary to maintain cyclosporine trough concentrations similar to those seen prior to the addition of diltiazem.| If these agents are to be administered concurrently, cyclosporine concentrations should be monitored, especially when diltiazem therapy is initiated, adjusted, or discontinued.| \r'
p2892
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DILTIAZEM'
p2893
sa(dp2894
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p2895
sg5
S'http://bio2rdf.org/drugbank:DB00091'
p2896
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2897
sg23
Nsg24
Nsg25
S'CYCLOSPORINE'
p2898
sg27
Nsg28
S'In renal and cardiac transplant recipients, a reduction of cyclosporine dose ranging from 15% to 48% was necessary to maintain cyclosporine trough concentrations similar to those seen prior to the addition of diltiazem.| If these agents are to be administered concurrently, cyclosporine concentrations should be monitored, especially when diltiazem therapy is initiated, adjusted, or discontinued.| \r'
p2899
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DILTIAZEM'
p2900
sa(dp2901
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01059'
p2902
sg5
S'http://bio2rdf.org/drugbank:DB00091'
p2903
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2904
sg23
Nsg24
Nsg25
S'CYCLOSPORINE'
p2905
sg27
Nsg28
S'Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with norfloxacin.| \r'
p2906
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NORFLOXACIN'
p2907
sa(dp2908
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p2909
sg5
S'http://bio2rdf.org/drugbank:DB00091'
p2910
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2911
sg23
Nsg24
Nsg25
S'CYCLOSPORINE'
p2912
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p2913
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p2914
sa(dp2915
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p2916
sg5
S'http://bio2rdf.org/drugbank:DB00091'
p2917
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2918
sg23
Nsg24
Nsg25
S'CYCLOSPORINE'
p2919
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p2920
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p2921
sa(dp2922
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p2923
sg5
S'http://bio2rdf.org/drugbank:DB00091'
p2924
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2925
sg23
Nsg24
Nsg25
S'CYCLOSPORINE'
p2926
sg27
Nsg28
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p2927
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sprycel'
p2928
sa(dp2929
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01234'
p2930
sg5
S'http://bio2rdf.org/drugbank:DB00357'
p2931
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2932
sg23
Nsg24
Nsg25
S'Cytadren'
p2933
sg27
Nsg28
S'Cytadren accelerates the metabolism of dexamethasone;| \r'
p2934
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DEXAMETHASONE'
p2935
sa(dp2936
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01099'
p2937
sg5
S'http://bio2rdf.org/drugbank:DB00987'
p2938
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2939
sg23
Nsg24
Nsg25
S'Cytosine arabinoside'
p2940
sg27
Nsg28
S'Cytosine arabinoside, a cytostatic agent, has been reported to inactivate the antifungal activity of flucytosine by competitive inhibition.| \r'
p2941
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCYTOSINE'
p2942
sa(dp2943
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01151'
p2944
sg5
S'http://bio2rdf.org/drugbank:DB01576'
p2945
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2946
sg23
Nsg24
Nsg25
S'd-amphetamine'
p2947
sg27
Nsg28
S'd-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;| \r'
p2948
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DESIPRAMINE'
p2949
sa(dp2950
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00344'
p2951
sg5
S'http://bio2rdf.org/drugbank:DB01576'
p2952
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2953
sg23
Nsg24
Nsg25
S'd-amphetamine'
p2954
sg27
Nsg28
S'd-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;| \r'
p2955
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROTRIPTYLINE'
p2956
sa(dp2957
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00227'
p2958
sg5
S'http://bio2rdf.org/drugbank:DB01406'
p2959
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2960
sg23
Nsg24
Nsg25
S'DANAZOL'
p2961
sg27
Nsg28
S'Danazol: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of danazol particularly with higher doses of lovastatin (see WARNINGS, Myopathy/Rhabdomyolysis).| \r'
p2962
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LOVASTATIN'
p2963
sa(dp2964
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01339'
p2965
sg5
S'http://bio2rdf.org/drugbank:DB01219'
p2966
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2967
sg23
Nsg24
Nsg25
S'DANTROLENE'
p2968
sg27
Nsg28
S'Administration of dantrolene may potentiate vecuronium-induced neuromuscular block.| \r'
p2969
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VECURONIUM'
p2970
sa(dp2971
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00845'
p2972
sg5
S'http://bio2rdf.org/drugbank:DB00250'
p2973
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p2974
sg23
Nsg24
Nsg25
S'DAPSONE'
p2975
sg27
Nsg28
S'If leprosy-associated inflammatory reactions develop in patients being treated with dapsone and clofazimine, it is still advisable to continue treatment with both drugs.| \r'
p2976
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLOFAZIMINE'
p2977
sa(dp2978
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00845'
p2979
sg5
S'http://bio2rdf.org/drugbank:DB00250'
p2980
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2981
sg23
Nsg24
Nsg25
S'DAPSONE'
p2982
sg27
Nsg28
S'Preliminary data which suggest that dapsone may inhibit the anti-inflammatory activity of Lamprene have not been confirmed.| \r'
p2983
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Lamprene'
p2984
sa(dp2985
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00205'
p2986
sg5
S'http://bio2rdf.org/drugbank:DB00250'
p2987
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p2988
sg23
Nsg24
Nsg25
S'DAPSONE'
p2989
sg27
Nsg28
S'With oral dapsone treatment, folic acid antagonists such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions| \r'
p2990
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PYRIMETHAMINE'
p2991
sa(dp2992
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p2993
sg5
S'http://bio2rdf.org/drugbank:DB00250'
p2994
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p2995
sg23
Nsg24
Nsg25
S'DAPSONE'
p2996
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p2997
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p2998
sa(dp2999
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p3000
sg5
S'http://bio2rdf.org/drugbank:DB00250'
p3001
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3002
sg23
Nsg24
Nsg25
S'DAPSONE'
p3003
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p3004
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p3005
sa(dp3006
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01229'
p3007
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p3008
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3009
sg23
Nsg24
Nsg25
S'DASATINIB ANHYDROUS'
p3010
sg27
Nsg28
S'Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); | HEY cells treated with dasatinib plus paclitaxel formed fewer colonies than did cells treated with either agent alone. | Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that dasatinib-mediated induction of p27(Kip1) enhanced paclitaxel-induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression. | The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.&#x0D;| Inhibition of Src family and Abl kinases with either siRNAs or dasatinib enhances paclitaxel sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.| \r'
p3011
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PACLITAXEL'
p3012
sa(dp3013
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01229'
p3014
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p3015
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3016
sg23
Nsg24
Nsg25
S'DASATINIB'
p3017
sg27
Nsg28
S'HEY cells treated with dasatinib plus paclitaxel formed fewer colonies than did cells treated with either agent alone. | Inhibition of Src family and Abl kinases with either siRNAs or dasatinib enhances paclitaxel sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.| The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.&#x0D;| Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); | Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that dasatinib-mediated induction of p27(Kip1) enhanced paclitaxel-induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression. | \r'
p3018
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PACLITAXEL'
p3019
sa(dp3020
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01111'
p3021
sg5
S'http://bio2rdf.org/drugbank:DB01245'
p3022
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3023
sg23
Nsg24
Nsg25
S'DECAMETHONIUM'
p3024
sg27
Nsg28
S'Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.| \r'
p3025
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Coly-Mycin M'
p3026
sa(dp3027
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p3028
sg5
S'http://bio2rdf.org/drugbank:DB00705'
p3029
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3030
sg23
Nsg24
Nsg25
S'DELAVIRDINE'
p3031
sg27
Nsg28
S'To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.| Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.| \r'
p3032
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Videx'
p3033
sa(dp3034
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p3035
sg5
S'http://bio2rdf.org/drugbank:DB00705'
p3036
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3037
sg23
Nsg24
Nsg25
S'DELAVIRDINE'
p3038
sg27
Nsg28
S'To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.| Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.| \r'
p3039
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Videx'
p3040
sa(dp3041
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p3042
sg5
S'http://bio2rdf.org/drugbank:DB00765'
p3043
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3044
sg23
Nsg24
Nsg25
S'Demser'
p3045
sg27
Nsg28
S'Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.| \r'
p3046
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p3047
sa(dp3048
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00502'
p3049
sg5
S'http://bio2rdf.org/drugbank:DB00765'
p3050
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3051
sg23
Nsg24
Nsg25
S'Demser'
p3052
sg27
Nsg28
S'Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. | \r'
p3053
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HALOPERIDOL'
p3054
sa(dp3055
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00404'
p3056
sg5
S'http://bio2rdf.org/drugbank:DB01151'
p3057
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3058
sg23
Nsg24
Nsg25
S'DESIPRAMINE'
p3059
sg27
Nsg28
S'The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.| \r'
p3060
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALPRAZOLAM'
p3061
sa(dp3062
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00475'
p3063
sg5
S'http://bio2rdf.org/drugbank:DB01151'
p3064
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3065
sg23
Nsg24
Nsg25
S'DESIPRAMINE'
p3066
sg27
Nsg28
S'If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.| \r'
p3067
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CHLORDIAZEPOXIDE'
p3068
sa(dp3069
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p3070
sg5
S'http://bio2rdf.org/drugbank:DB01151'
p3071
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3072
sg23
Nsg24
Nsg25
S'DESIPRAMINE'
p3073
sg27
Nsg28
S'If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.| \r'
p3074
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIAZEPAM'
p3075
sa(dp3076
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00368'
p3077
sg5
S'http://bio2rdf.org/drugbank:DB01151'
p3078
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3079
sg23
Nsg24
Nsg25
S'DESIPRAMINE'
p3080
sg27
Nsg28
S'The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p &lt; 0.05) but not in functional class IV myocardium. | \r'
p3081
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NOREPINEPHRINE'
p3082
sa(dp3083
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00518'
p3084
sg5
S'http://bio2rdf.org/drugbank:DB01234'
p3085
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3086
sg23
Nsg24
Nsg25
S'DEXAMETHASONE'
p3087
sg27
Nsg28
S'Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg dexamethasone was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.| \r'
p3088
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALBENDAZOLE'
p3089
sa(dp3090
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p3091
sg5
S'http://bio2rdf.org/drugbank:DB01234'
p3092
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3093
sg23
Nsg24
Nsg25
S'DEXAMETHASONE'
p3094
sg27
Nsg28
S'The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.| The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant.| \r'
p3095
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'APREPITANT'
p3096
sa(dp3097
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p3098
sg5
S'http://bio2rdf.org/drugbank:DB01234'
p3099
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3100
sg23
Nsg24
Nsg25
S'DEXAMETHASONE'
p3101
sg27
Nsg28
S'The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.| The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant.| \r'
p3102
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'APREPITANT'
p3103
sa(dp3104
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00520'
p3105
sg5
S'http://bio2rdf.org/drugbank:DB01234'
p3106
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3107
sg23
Nsg24
Nsg25
S'DEXAMETHASONE'
p3108
sg27
Nsg28
S'In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.| \r'
p3109
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cancidas'
p3110
sa(dp3111
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p3112
sg5
S'http://bio2rdf.org/drugbank:DB01234'
p3113
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3114
sg23
Nsg24
Nsg25
S'DEXAMETHASONE'
p3115
sg27
Nsg28
S'Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| \r'
p3116
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p3117
sa(dp3118
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p3119
sg5
S'http://bio2rdf.org/drugbank:DB01234'
p3120
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3121
sg23
Nsg24
Nsg25
S'DEXAMETHASONE'
p3122
sg27
Nsg28
S'Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| \r'
p3123
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p3124
sa(dp3125
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p3126
sg5
S'http://bio2rdf.org/drugbank:DB00405'
p3127
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3128
sg23
Nsg24
Nsg25
S'DEXBROMPHENIRAMINE'
p3129
sg27
Nsg28
S'Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).| Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).| \r'
p3130
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p3131
sa(dp3132
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p3133
sg5
S'http://bio2rdf.org/drugbank:DB00405'
p3134
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p3135
sg23
Nsg24
Nsg25
S'DEXBROMPHENIRAMINE'
p3136
sg27
Nsg28
S'Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).| Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).| \r'
p3137
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p3138
sa(dp3139
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01364'
p3140
sg5
S'http://bio2rdf.org/drugbank:DB00633'
p3141
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3142
sg23
Nsg24
Nsg25
S'DEXMEDETOMIDINE'
p3143
sg27
Nsg28
S'In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. | At the same time, the locomotor inhibitory effect of dexmedetomidine was counteracted by ephedrine. | We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.| \r'
p3144
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EPHEDRINE'
p3145
sa(dp3146
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00580'
p3147
sg5
S'http://bio2rdf.org/drugbank:DB00514'
p3148
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3149
sg23
Nsg24
Nsg25
S'DEXTROMETHORPHAN'
p3150
sg27
Nsg28
S'Even so dextromethorphan plasma concentrations in the presence of high doses of valdecoxib were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.| \r'
p3151
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VALDECOXIB'
p3152
sa(dp3153
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00854'
p3154
sg5
S'http://bio2rdf.org/drugbank:DB01209'
p3155
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3156
sg23
Nsg24
Nsg25
S'DEZOCINE'
p3157
sg27
Nsg28
S'Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| \r'
p3158
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Levo-Dromoran'
p3159
sa(dp3160
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p3161
sg5
S'http://bio2rdf.org/drugbank:DB01452'
p3162
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3163
sg23
Nsg24
Nsg25
S'DIACETYLMORPHINE'
p3164
sg27
Nsg28
S'Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.| \r'
p3165
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p3166
sa(dp3167
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p3168
sg5
S'http://bio2rdf.org/drugbank:DB01452'
p3169
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3170
sg23
Nsg24
Nsg25
S'DIACETYLMORPHINE'
p3171
sg27
Nsg28
S'Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.| \r'
p3172
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIAZEPAM'
p3173
sa(dp3174
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p3175
sg5
S'http://bio2rdf.org/drugbank:DB01452'
p3176
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3177
sg23
Nsg24
Nsg25
S'DIACETYLMORPHINE'
p3178
sg27
Nsg28
S'Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.| \r'
p3179
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Valium'
p3180
sa(dp3181
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p3182
sg5
S'http://bio2rdf.org/drugbank:DB00819'
p3183
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3184
sg23
Nsg24
Nsg25
S'Diamox'
p3185
sg27
Nsg28
S'DIAMOX modifies phenytoin metabolism with increased serum levels of phenytoin.| \r'
p3186
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p3187
sa(dp3188
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00794'
p3189
sg5
S'http://bio2rdf.org/drugbank:DB00819'
p3190
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3191
sg23
Nsg24
Nsg25
S'Diamox'
p3192
sg27
Nsg28
S'By decreasing the gastrointestinal absorption of primidone, DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect.| Caution is advised when beginning, discontinuing, or changing the dose of DIAMOX in patients receiving primidone.| \r'
p3193
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PRIMIDONE'
p3194
sa(dp3195
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00794'
p3196
sg5
S'http://bio2rdf.org/drugbank:DB00819'
p3197
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3198
sg23
Nsg24
Nsg25
S'Diamox'
p3199
sg27
Nsg28
S'By decreasing the gastrointestinal absorption of primidone, DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect.| Caution is advised when beginning, discontinuing, or changing the dose of DIAMOX in patients receiving primidone.| \r'
p3200
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PRIMIDONE'
p3201
sa(dp3202
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p3203
sg5
S'http://bio2rdf.org/drugbank:DB00829'
p3204
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3205
sg23
Nsg24
Nsg25
S'DIAZEPAM'
p3206
sg27
Nsg28
S'Accordingly, diazepam and fluvoxamine should not ordinarily be co-administered.| \r'
p3207
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p3208
sa(dp3209
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00328'
p3210
sg5
S'http://bio2rdf.org/drugbank:DB00829'
p3211
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3212
sg23
Nsg24
Nsg25
S'DIAZEPAM'
p3213
sg27
Nsg28
S'Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin. | \r'
p3214
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDOMETHACIN'
p3215
sa(dp3216
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p3217
sg5
S'http://bio2rdf.org/drugbank:DB00829'
p3218
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3219
sg23
Nsg24
Nsg25
S'DIAZEPAM'
p3220
sg27
Nsg28
S'Diazepam at doses of 0.25 mg/kg and 2.5 mg/kg injected with morphine was found to decrease the antinociceptive effect of morphine. | \r'
p3221
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MORPHINE'
p3222
sa(dp3223
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00580'
p3224
sg5
S'http://bio2rdf.org/drugbank:DB00829'
p3225
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3226
sg23
Nsg24
Nsg25
S'DIAZEPAM'
p3227
sg27
Nsg28
S'Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.| \r'
p3228
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VALDECOXIB'
p3229
sa(dp3230
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01275'
p3231
sg5
S'http://bio2rdf.org/drugbank:DB01119'
p3232
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3233
sg23
Nsg24
Nsg25
S'DIAZOXIDE'
p3234
sg27
Nsg28
S'Profound hypotensive episodes may occur when diazoxide infection and hydralazine are used concomitantly.| \r'
p3235
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HYDRALAZINE'
p3236
sa(dp3237
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p3238
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p3239
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3240
sg23
Nsg24
Nsg25
S'DICLOFENAC'
p3241
sg27
Nsg28
S'Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.| Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.| \r'
p3242
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p3243
sa(dp3244
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p3245
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p3246
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3247
sg23
Nsg24
Nsg25
S'DICLOFENAC'
p3248
sg27
Nsg28
S'Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.| Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.| \r'
p3249
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p3250
sa(dp3251
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p3252
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p3253
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3254
sg23
Nsg24
Nsg25
S'DICLOFENAC'
p3255
sg27
Nsg28
S'Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.| Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.| \r'
p3256
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSPORINE'
p3257
sa(dp3258
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p3259
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p3260
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3261
sg23
Nsg24
Nsg25
S'DICLOFENAC'
p3262
sg27
Nsg28
S'Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.| Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.| \r'
p3263
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p3264
sa(dp3265
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p3266
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p3267
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3268
sg23
Nsg24
Nsg25
S'DICLOFENAC'
p3269
sg27
Nsg28
S'Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.| Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.| \r'
p3270
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p3271
sa(dp3272
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p3273
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p3274
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3275
sg23
Nsg24
Nsg25
S'DICLOFENAC'
p3276
sg27
Nsg28
S'Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.| In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.| \r'
p3277
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM CATION'
p3278
sa(dp3279
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p3280
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p3281
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3282
sg23
Nsg24
Nsg25
S'DICLOFENAC'
p3283
sg27
Nsg28
S'Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.| In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.| \r'
p3284
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM CATION'
p3285
sa(dp3286
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p3287
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p3288
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3289
sg23
Nsg24
Nsg25
S'DICLOFENAC'
p3290
sg27
Nsg28
S'In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.| Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.| \r'
p3291
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM'
p3292
sa(dp3293
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p3294
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p3295
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3296
sg23
Nsg24
Nsg25
S'DICLOFENAC'
p3297
sg27
Nsg28
S'In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.| Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.| \r'
p3298
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM'
p3299
sa(dp3300
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p3301
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p3302
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3303
sg23
Nsg24
Nsg25
S'DICLOFENAC'
p3304
sg27
Nsg28
S'Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.| Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.| \r'
p3305
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHOTREXATE'
p3306
sa(dp3307
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p3308
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p3309
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3310
sg23
Nsg24
Nsg25
S'DICLOFENAC'
p3311
sg27
Nsg28
S'Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.| Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.| \r'
p3312
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHOTREXATE'
p3313
sa(dp3314
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00860'
p3315
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p3316
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3317
sg23
Nsg24
Nsg25
S'DICLOFENAC'
p3318
sg27
Nsg28
S'Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.| \r'
p3319
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PREDNISOLONE'
p3320
sa(dp3321
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00936'
p3322
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p3323
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3324
sg23
Nsg24
Nsg25
S'DICLOFENAC'
p3325
sg27
Nsg28
S'Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.| \r'
p3326
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SALICYLIC ACID'
p3327
sa(dp3328
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p3329
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p3330
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3331
sg23
Nsg24
Nsg25
S'DICLOFENAC'
p3332
sg27
Nsg28
S'Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.| \r'
p3333
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TOLBUTAMIDE'
p3334
sa(dp3335
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p3336
sg5
S'http://bio2rdf.org/drugbank:DB00804'
p3337
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3338
sg23
Nsg24
Nsg25
S'DICYCLOMINE'
p3339
sg27
Nsg28
S'Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.| \r'
p3340
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p3341
sa(dp3342
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01155'
p3343
sg5
S'http://bio2rdf.org/drugbank:DB00900'
p3344
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3345
sg23
Nsg24
Nsg25
S'DIDANOSINE'
p3346
sg27
Nsg28
S'Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| \r'
p3347
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Factive'
p3348
sa(dp3349
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01059'
p3350
sg5
S'http://bio2rdf.org/drugbank:DB00900'
p3351
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3352
sg23
Nsg24
Nsg25
S'DIDANOSINE'
p3353
sg27
Nsg28
S'Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.| \r'
p3354
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NORFLOXACIN'
p3355
sa(dp3356
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p3357
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p3358
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3359
sg23
Nsg24
Nsg25
S'Diflucan'
p3360
sg27
Nsg28
S'Cyclosporine: DIFLUCAN may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment. | Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and cyclosporine. | \r'
p3361
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSPORINE'
p3362
sa(dp3363
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p3364
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p3365
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3366
sg23
Nsg24
Nsg25
S'Diflucan'
p3367
sg27
Nsg28
S'Cyclosporine: DIFLUCAN may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment. | Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and cyclosporine. | \r'
p3368
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSPORINE'
p3369
sa(dp3370
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01067'
p3371
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p3372
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3373
sg23
Nsg24
Nsg25
S'Diflucan'
p3374
sg27
Nsg28
S'DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. | \r'
p3375
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GLIPIZIDE'
p3376
sa(dp3377
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01016'
p3378
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p3379
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3380
sg23
Nsg24
Nsg25
S'Diflucan'
p3381
sg27
Nsg28
S'one fatality has been reported from hypoglycemia in association with combined DIFLUCAN and glyburide use. | DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. | \r'
p3382
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GLYBURIDE'
p3383
sa(dp3384
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01016'
p3385
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p3386
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3387
sg23
Nsg24
Nsg25
S'Diflucan'
p3388
sg27
Nsg28
S'one fatality has been reported from hypoglycemia in association with combined DIFLUCAN and glyburide use. | DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. | \r'
p3389
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GLYBURIDE'
p3390
sa(dp3391
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p3392
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p3393
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3394
sg23
Nsg24
Nsg25
S'Diflucan'
p3395
sg27
Nsg28
S'Phenytoin: DIFLUCAN increases the plasma concentrations of phenytoin. | Careful monitoring of phenytoin concentrations in patients receiving DIFLUCAN and phenytoin is recommended. | \r'
p3396
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p3397
sa(dp3398
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p3399
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p3400
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3401
sg23
Nsg24
Nsg25
S'Diflucan'
p3402
sg27
Nsg28
S'Phenytoin: DIFLUCAN increases the plasma concentrations of phenytoin. | Careful monitoring of phenytoin concentrations in patients receiving DIFLUCAN and phenytoin is recommended. | \r'
p3403
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p3404
sa(dp3405
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p3406
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p3407
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3408
sg23
Nsg24
Nsg25
S'Diflucan'
p3409
sg27
Nsg28
S'Depending on clinical circumstances, consideration should be given to increasing the dose of DIFLUCAN when it is administered with rifampin. | \r'
p3410
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFAMPIN'
p3411
sa(dp3412
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p3413
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p3414
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3415
sg23
Nsg24
Nsg25
S'Diflucan'
p3416
sg27
Nsg28
S'Careful monitoring of serum theophylline concentrations in patients receiving DIFLUCAN and theophylline is recommended. | Theophylline: DIFLUCAN increases the serum concentrations of theophylline. | \r'
p3417
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p3418
sa(dp3419
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p3420
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p3421
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3422
sg23
Nsg24
Nsg25
S'Diflucan'
p3423
sg27
Nsg28
S'Careful monitoring of serum theophylline concentrations in patients receiving DIFLUCAN and theophylline is recommended. | Theophylline: DIFLUCAN increases the serum concentrations of theophylline. | \r'
p3424
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p3425
sa(dp3426
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p3427
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p3428
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3429
sg23
Nsg24
Nsg25
S'Diflucan'
p3430
sg27
Nsg28
S'DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. | \r'
p3431
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TOLBUTAMIDE'
p3432
sa(dp3433
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p3434
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p3435
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3436
sg23
Nsg24
Nsg25
S'DIFLUNISAL'
p3437
sg27
Nsg28
S'Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.| Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.| Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.| \r'
p3438
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACETAMINOPHEN'
p3439
sa(dp3440
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p3441
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p3442
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3443
sg23
Nsg24
Nsg25
S'DIFLUNISAL'
p3444
sg27
Nsg28
S'Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.| Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.| Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.| \r'
p3445
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACETAMINOPHEN'
p3446
sa(dp3447
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p3448
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p3449
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3450
sg23
Nsg24
Nsg25
S'DIFLUNISAL'
p3451
sg27
Nsg28
S'Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.| Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.| Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.| \r'
p3452
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACETAMINOPHEN'
p3453
sa(dp3454
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p3455
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p3456
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3457
sg23
Nsg24
Nsg25
S'DIFLUNISAL'
p3458
sg27
Nsg28
S'Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.| \r'
p3459
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p3460
sa(dp3461
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00695'
p3462
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p3463
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3464
sg23
Nsg24
Nsg25
S'DIFLUNISAL'
p3465
sg27
Nsg28
S'Diflunisal decreased the hyperuricemic effect of furosemide.| \r'
p3466
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FUROSEMIDE'
p3467
sa(dp3468
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00999'
p3469
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p3470
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3471
sg23
Nsg24
Nsg25
S'DIFLUNISAL'
p3472
sg27
Nsg28
S'Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.| Diflunisal decreased the hyperuricemic effect of hydrochlorothiazide.| \r'
p3473
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HYDROCHLOROTHIAZIDE'
p3474
sa(dp3475
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00999'
p3476
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p3477
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3478
sg23
Nsg24
Nsg25
S'DIFLUNISAL'
p3479
sg27
Nsg28
S'Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.| Diflunisal decreased the hyperuricemic effect of hydrochlorothiazide.| \r'
p3480
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HYDROCHLOROTHIAZIDE'
p3481
sa(dp3482
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00328'
p3483
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p3484
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3485
sg23
Nsg24
Nsg25
S'DIFLUNISAL'
p3486
sg27
Nsg28
S'Therefore, diflunisal and INDOCIN should not be used concomitantly.| \r'
p3487
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Indocin'
p3488
sa(dp3489
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00328'
p3490
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p3491
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3492
sg23
Nsg24
Nsg25
S'DIFLUNISAL'
p3493
sg27
Nsg28
S'Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.| In normal volunteers receiving indomethacin, the administration of diflunisal decreased the renal clearance and significantly increased the plasma levels of indomethacin.| \r'
p3494
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDOMETHACIN'
p3495
sa(dp3496
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p3497
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p3498
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3499
sg23
Nsg24
Nsg25
S'DIFLUNISAL'
p3500
sg27
Nsg28
S'Methotrexate: Caution should be used if diflunisal is administered concomitantly with methotrexate.| \r'
p3501
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHOTREXATE'
p3502
sa(dp3503
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00788'
p3504
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p3505
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3506
sg23
Nsg24
Nsg25
S'DIFLUNISAL'
p3507
sg27
Nsg28
S'Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.| \r'
p3508
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NAPROXEN'
p3509
sa(dp3510
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00640'
p3511
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3512
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3513
sg23
Nsg24
Nsg25
S'DIGOXIN'
p3514
sg27
Nsg28
S'Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.| \r'
p3515
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Adenocard'
p3516
sa(dp3517
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00233'
p3518
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3519
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3520
sg23
Nsg24
Nsg25
S'DIGOXIN'
p3521
sg27
Nsg28
S'In the case that you are taking digoxin while taking aminosalicylic acid, higher doses of digoxin may be needed.| \r'
p3522
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMINOSALICYLIC ACID'
p3523
sa(dp3524
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01118'
p3525
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3526
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3527
sg23
Nsg24
Nsg25
S'DIGOXIN'
p3528
sg27
Nsg28
S'These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically.| \r'
p3529
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMIODARONE'
p3530
sa(dp3531
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00187'
p3532
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3533
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3534
sg23
Nsg24
Nsg25
S'DIGOXIN'
p3535
sg27
Nsg28
S'When digoxin and BREVIBLOC were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points.| \r'
p3536
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Brevibloc'
p3537
sa(dp3538
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00872'
p3539
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3540
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3541
sg23
Nsg24
Nsg25
S'DIGOXIN'
p3542
sg27
Nsg28
S'Digoxin: Coadministration of digoxin, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.| \r'
p3543
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CONIVAPTAN'
p3544
sa(dp3545
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01136'
p3546
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3547
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3548
sg23
Nsg24
Nsg25
S'DIGOXIN'
p3549
sg27
Nsg28
S'Both digoxin and COREG slow AV conduction.| Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG.| \r'
p3550
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Coreg'
p3551
sa(dp3552
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01136'
p3553
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3554
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3555
sg23
Nsg24
Nsg25
S'DIGOXIN'
p3556
sg27
Nsg28
S'Both digoxin and COREG slow AV conduction.| Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG.| \r'
p3557
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Coreg'
p3558
sa(dp3559
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p3560
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3561
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3562
sg23
Nsg24
Nsg25
S'DIGOXIN'
p3563
sg27
Nsg28
S'Extended Release Tablets: Administration of nifedipine with digoxin increased digoxin levels in 9 of 12 normal volunteers.| \r'
p3564
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p3565
sa(dp3566
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p3567
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3568
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3569
sg23
Nsg24
Nsg25
S'DIGOXIN'
p3570
sg27
Nsg28
S'In patients, the concomitant administration of digoxin with dofetilide was associated with a higher occurrence of torsade de pointes.| \r'
p3571
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOFETILIDE'
p3572
sa(dp3573
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01240'
p3574
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3575
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3576
sg23
Nsg24
Nsg25
S'DIGOXIN'
p3577
sg27
Nsg28
S'However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to digoxin toxicity.| In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.| \r'
p3578
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Flolan'
p3579
sa(dp3580
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p3581
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3582
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3583
sg23
Nsg24
Nsg25
S'DIGOXIN'
p3584
sg27
Nsg28
S'It is, therefore, advisable to monitor digoxin concentrations in patients receiving ketoconazole.| \r'
p3585
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p3586
sa(dp3587
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01233'
p3588
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3589
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3590
sg23
Nsg24
Nsg25
S'DIGOXIN'
p3591
sg27
Nsg28
S'Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). | \r'
p3592
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METOCLOPRAMIDE'
p3593
sa(dp3594
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01115'
p3595
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3596
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3597
sg23
Nsg24
Nsg25
S'DIGOXIN'
p3598
sg27
Nsg28
S'Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.| Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.| Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.| \r'
p3599
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NIFEDIPINE'
p3600
sa(dp3601
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01115'
p3602
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3603
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p3604
sg23
Nsg24
Nsg25
S'DIGOXIN'
p3605
sg27
Nsg28
S'Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.| Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.| Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.| \r'
p3606
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NIFEDIPINE'
p3607
sa(dp3608
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00790'
p3609
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3610
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3611
sg23
Nsg24
Nsg25
S'DIGOXIN'
p3612
sg27
Nsg28
S'Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. | \r'
p3613
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PERINDOPRIL'
p3614
sa(dp3615
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01261'
p3616
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3617
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3618
sg23
Nsg24
Nsg25
S'DIGOXIN'
p3619
sg27
Nsg28
S'Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days. | \r'
p3620
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SITAGLIPTIN PHOSPHATE'
p3621
sa(dp3622
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01261'
p3623
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3624
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3625
sg23
Nsg24
Nsg25
S'DIGOXIN'
p3626
sg27
Nsg28
S'Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days. | \r'
p3627
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SITAGLIPTIN'
p3628
sa(dp3629
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00795'
p3630
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3631
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3632
sg23
Nsg24
Nsg25
S'DIGOXIN'
p3633
sg27
Nsg28
S'Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine. | \r'
p3634
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SULFASALAZINE'
p3635
sa(dp3636
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00872'
p3637
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3638
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3639
sg23
Nsg24
Nsg25
S'DIGOXIN'
p3640
sg27
Nsg28
S'Therefore, if digoxin is administered with VAPRISOL, the clinician should be alert to the possibility of increases in digoxin levels.| \r'
p3641
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Vaprisol'
p3642
sa(dp3643
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00918'
p3644
sg5
S'http://bio2rdf.org/drugbank:DB00320'
p3645
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3646
sg23
Nsg24
Nsg25
S'DIHYDROERGOTAMINE'
p3647
sg27
Nsg28
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.| \r'
p3648
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Axert'
p3649
sa(dp3650
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00998'
p3651
sg5
S'http://bio2rdf.org/drugbank:DB00320'
p3652
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3653
sg23
Nsg24
Nsg25
S'DIHYDROERGOTAMINE'
p3654
sg27
Nsg28
S'Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).| \r'
p3655
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Frova'
p3656
sa(dp3657
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00952'
p3658
sg5
S'http://bio2rdf.org/drugbank:DB00320'
p3659
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3660
sg23
Nsg24
Nsg25
S'DIHYDROERGOTAMINE'
p3661
sg27
Nsg28
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.| \r'
p3662
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NARATRIPTAN'
p3663
sa(dp3664
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00211'
p3665
sg5
S'http://bio2rdf.org/drugbank:DB00320'
p3666
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3667
sg23
Nsg24
Nsg25
S'DIHYDROERGOTAMINE'
p3668
sg27
Nsg28
S'The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. | \r'
p3669
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ProAmatine'
p3670
sa(dp3671
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p3672
sg5
S'http://bio2rdf.org/drugbank:DB00320'
p3673
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3674
sg23
Nsg24
Nsg25
S'DIHYDROERGOTAMINE'
p3675
sg27
Nsg28
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p3676
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sprycel'
p3677
sa(dp3678
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p3679
sg5
S'http://bio2rdf.org/drugbank:DB00320'
p3680
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3681
sg23
Nsg24
Nsg25
S'DIHYDROERGOTAMINE'
p3682
sg27
Nsg28
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. | \r'
p3683
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUMATRIPTAN SUCCINATE'
p3684
sa(dp3685
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p3686
sg5
S'http://bio2rdf.org/drugbank:DB00320'
p3687
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3688
sg23
Nsg24
Nsg25
S'DIHYDROERGOTAMINE'
p3689
sg27
Nsg28
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. | \r'
p3690
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUMATRIPTAN'
p3691
sa(dp3692
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p3693
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p3694
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3695
sg23
Nsg24
Nsg25
S'DILTIAZEM'
p3696
sg27
Nsg28
S'Because moderate CYP3A4 inhibitors (e.g., diltiazem) result in 2-fold increase in plasma concentrations of aprepitant, concomitant administration should also be approached with caution.| \r'
p3697
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'APREPITANT'
p3698
sa(dp3699
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p3700
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p3701
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3702
sg23
Nsg24
Nsg25
S'DILTIAZEM'
p3703
sg27
Nsg28
S'Concomitant administration of diltiazem with carbamazepine has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase), resulting in toxicity in some cases.| \r'
p3704
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CARBAMAZEPINE'
p3705
sa(dp3706
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p3707
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p3708
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3709
sg23
Nsg24
Nsg25
S'DILTIAZEM'
p3710
sg27
Nsg28
S'Patients currently receiving diltiazem therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with cimetidine.| \r'
p3711
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIMETIDINE'
p3712
sa(dp3713
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p3714
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p3715
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p3716
sg23
Nsg24
Nsg25
S'DILTIAZEM'
p3717
sg27
Nsg28
S'A pharmacokinetic interaction between diltiazem and cyclosporine has been observed during studies involving renal and cardiac transplant patients.| \r'
p3718
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSPORINE'
p3719
sa(dp3720
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00813'
p3721
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p3722
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3723
sg23
Nsg24
Nsg25
S'DILTIAZEM'
p3724
sg27
Nsg28
S'The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.| \r'
p3725
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FENTANYL'
p3726
sa(dp3727
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00227'
p3728
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p3729
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3730
sg23
Nsg24
Nsg25
S'DILTIAZEM'
p3731
sg27
Nsg28
S'In a ten-subject study, coadministration of diltiazem (120 mg bid) with lovastatin resulted in a 3-4 times increase in mean lovastatin AUC and Cmax vs. lovastatin alone;| \r'
p3732
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LOVASTATIN'
p3733
sa(dp3734
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p3735
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p3736
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3737
sg23
Nsg24
Nsg25
S'DILTIAZEM'
p3738
sg27
Nsg28
S'Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. | Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.| These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.| \r'
p3739
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIDAZOLAM'
p3740
sa(dp3741
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p3742
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p3743
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3744
sg23
Nsg24
Nsg25
S'DILTIAZEM'
p3745
sg27
Nsg28
S'Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. | Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.| These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.| \r'
p3746
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIDAZOLAM'
p3747
sa(dp3748
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00413'
p3749
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p3750
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3751
sg23
Nsg24
Nsg25
S'DILTIAZEM'
p3752
sg27
Nsg28
S'Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | \r'
p3753
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PRAMIPEXOLE'
p3754
sa(dp3755
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p3756
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p3757
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3758
sg23
Nsg24
Nsg25
S'DILTIAZEM'
p3759
sg27
Nsg28
S'Coadministration of diltiazem with rifampin or any known CYP3A4 inducer should be avoided when possible, and alternative therapy considered.| \r'
p3760
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFAMPIN'
p3761
sa(dp3762
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00877'
p3763
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p3764
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3765
sg23
Nsg24
Nsg25
S'DILTIAZEM'
p3766
sg27
Nsg28
S'CONCLUSIONS: Single-dose diltiazem coadministration leads to higher sirolimus exposure, presumably by inhibition of the first-pass metabolism of sirolimus. | Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers.&#x0D;| \r'
p3767
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SIROLIMUS'
p3768
sa(dp3769
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p3770
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p3771
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3772
sg23
Nsg24
Nsg25
S'DILTIAZEM'
p3773
sg27
Nsg28
S'Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| \r'
p3774
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tikosyn'
p3775
sa(dp3776
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00897'
p3777
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p3778
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3779
sg23
Nsg24
Nsg25
S'DILTIAZEM'
p3780
sg27
Nsg28
S'These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.| Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.| \r'
p3781
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TRIAZOLAM'
p3782
sa(dp3783
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00897'
p3784
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p3785
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3786
sg23
Nsg24
Nsg25
S'DILTIAZEM'
p3787
sg27
Nsg28
S'These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.| Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.| \r'
p3788
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TRIAZOLAM'
p3789
sa(dp3790
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00714'
p3791
sg5
S'http://bio2rdf.org/drugbank:DB00985'
p3792
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3793
sg23
Nsg24
Nsg25
S'DIMENHYDRINATE'
p3794
sg27
Nsg28
S'Dimenhydrinate may decrease emetic response to apomorphine.| \r'
p3795
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'APOMORPHINE'
p3796
sa(dp3797
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00714'
p3798
sg5
S'http://bio2rdf.org/drugbank:DB01231'
p3799
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3800
sg23
Nsg24
Nsg25
S'DIPHENIDOL'
p3801
sg27
Nsg28
S'apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.| \r'
p3802
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'APOMORPHINE'
p3803
sa(dp3804
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p3805
sg5
S'http://bio2rdf.org/drugbank:DB00313'
p3806
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3807
sg23
Nsg24
Nsg25
S'DIPHENOLIC ACID'
p3808
sg27
Nsg28
S'Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L. | Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. | \r'
p3809
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p3810
sa(dp3811
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p3812
sg5
S'http://bio2rdf.org/drugbank:DB00313'
p3813
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3814
sg23
Nsg24
Nsg25
S'DIPHENOLIC ACID'
p3815
sg27
Nsg28
S'Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L. | Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. | \r'
p3816
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p3817
sa(dp3818
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00853'
p3819
sg5
S'http://bio2rdf.org/drugbank:DB00313'
p3820
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3821
sg23
Nsg24
Nsg25
S'DIPHENOLIC ACID'
p3822
sg27
Nsg28
S'Administration of valproic acid decreases oral clearance of temozolomide by about 5%. | \r'
p3823
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TEMOZOLOMIDE'
p3824
sa(dp3825
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p3826
sg5
S'http://bio2rdf.org/drugbank:DB01081'
p3827
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3828
sg23
Nsg24
Nsg25
S'DIPHENOXYLATE'
p3829
sg27
Nsg28
S'Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.| \r'
p3830
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p3831
sa(dp3832
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00813'
p3833
sg5
S'http://bio2rdf.org/drugbank:DB00818'
p3834
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3835
sg23
Nsg24
Nsg25
S'Diprivan'
p3836
sg27
Nsg28
S'The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) | \r'
p3837
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FENTANYL'
p3838
sa(dp3839
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00454'
p3840
sg5
S'http://bio2rdf.org/drugbank:DB00818'
p3841
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3842
sg23
Nsg24
Nsg25
S'Diprivan'
p3843
sg27
Nsg28
S'The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) | \r'
p3844
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MEPERIDINE'
p3845
sa(dp3846
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p3847
sg5
S'http://bio2rdf.org/drugbank:DB00818'
p3848
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3849
sg23
Nsg24
Nsg25
S'Diprivan'
p3850
sg27
Nsg28
S'The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) | \r'
p3851
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MORPHINE'
p3852
sa(dp3853
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00009'
p3854
sg5
S'http://bio2rdf.org/drugbank:DB00975'
p3855
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3856
sg23
Nsg24
Nsg25
S'DIPYRIDAMOLE'
p3857
sg27
Nsg28
S'In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.| \r'
p3858
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Activase'
p3859
sa(dp3860
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00640'
p3861
sg5
S'http://bio2rdf.org/drugbank:DB00975'
p3862
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3863
sg23
Nsg24
Nsg25
S'DIPYRIDAMOLE'
p3864
sg27
Nsg28
S'Adenosine: Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine.| \r'
p3865
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ADENOSINE'
p3866
sa(dp3867
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00015'
p3868
sg5
S'http://bio2rdf.org/drugbank:DB00975'
p3869
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3870
sg23
Nsg24
Nsg25
S'DIPYRIDAMOLE'
p3871
sg27
Nsg28
S'In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.| \r'
p3872
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Retavase'
p3873
sa(dp3874
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00031'
p3875
sg5
S'http://bio2rdf.org/drugbank:DB00975'
p3876
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3877
sg23
Nsg24
Nsg25
S'DIPYRIDAMOLE'
p3878
sg27
Nsg28
S'Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. | \r'
p3879
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TNKase'
p3880
sa(dp3881
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p3882
sg5
S'http://bio2rdf.org/drugbank:DB04817'
p3883
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3884
sg23
Nsg24
Nsg25
S'DIPYRONE'
p3885
sg27
Nsg28
S'Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.| \r'
p3886
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p3887
sa(dp3888
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p3889
sg5
S'http://bio2rdf.org/drugbank:DB00822'
p3890
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3891
sg23
Nsg24
Nsg25
S'DISULFIRAM'
p3892
sg27
Nsg28
S'SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.| DISULFIRAM SHOULD BE USED WITH CAUTION IN THOSE PATIENTS REVEIVING PHENYTOIN AND ITS CONGENERS.| \r'
p3893
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p3894
sa(dp3895
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p3896
sg5
S'http://bio2rdf.org/drugbank:DB00822'
p3897
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3898
sg23
Nsg24
Nsg25
S'DISULFIRAM'
p3899
sg27
Nsg28
S'SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.| DISULFIRAM SHOULD BE USED WITH CAUTION IN THOSE PATIENTS REVEIVING PHENYTOIN AND ITS CONGENERS.| \r'
p3900
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p3901
sa(dp3902
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00325'
p3903
sg5
S'http://bio2rdf.org/drugbank:DB00841'
p3904
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3905
sg23
Nsg24
Nsg25
S'Dobutamine'
p3906
sg27
Nsg28
S'Preliminary studies indicate that the concomitant use of dobutamine and nitroprusside results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone.| \r'
p3907
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NITROPRUSSIDE'
p3908
sa(dp3909
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01390'
p3910
sg5
S'http://bio2rdf.org/drugbank:DB00841'
p3911
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p3912
sg23
Nsg24
Nsg25
S'Dobutamine'
p3913
sg27
Nsg28
S'norepinephrine and dobutamine are incompatible with sodium bicarbonate solution. | \r'
p3914
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SODIUM BICARBONATE'
p3915
sa(dp3916
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p3917
sg5
S'http://bio2rdf.org/drugbank:DB01248'
p3918
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3919
sg23
Nsg24
Nsg25
S'DOCETAXEL'
p3920
sg27
Nsg28
S'In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.| \r'
p3921
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSPORINE'
p3922
sa(dp3923
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p3924
sg5
S'http://bio2rdf.org/drugbank:DB01248'
p3925
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3926
sg23
Nsg24
Nsg25
S'DOCETAXEL'
p3927
sg27
Nsg28
S'In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.| \r'
p3928
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERYTHROMYCIN'
p3929
sa(dp3930
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p3931
sg5
S'http://bio2rdf.org/drugbank:DB01248'
p3932
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3933
sg23
Nsg24
Nsg25
S'DOCETAXEL'
p3934
sg27
Nsg28
S'In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.| \r'
p3935
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p3936
sa(dp3937
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01268'
p3938
sg5
S'http://bio2rdf.org/drugbank:DB01248'
p3939
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3940
sg23
Nsg24
Nsg25
S'DOCETAXEL'
p3941
sg27
Nsg28
S'The molecular basis of this synergism is that the signaling pathways that were initially activated by docetaxel exposure were efficiently suppressed by the subsequent exposure to sunitinib. | Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.| When cells were exposed to docetaxel followed by sunitinib, synergism was observed. | \r'
p3942
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUNITINIB'
p3943
sa(dp3944
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01361'
p3945
sg5
S'http://bio2rdf.org/drugbank:DB01248'
p3946
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3947
sg23
Nsg24
Nsg25
S'DOCETAXEL'
p3948
sg27
Nsg28
S'In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.| \r'
p3949
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TROLEANDOMYCIN'
p3950
sa(dp3951
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p3952
sg5
S'http://bio2rdf.org/drugbank:DB00757'
p3953
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3954
sg23
Nsg24
Nsg25
S'DOLASETRON'
p3955
sg27
Nsg28
S'Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.| \r'
p3956
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIMETIDINE'
p3957
sa(dp3958
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p3959
sg5
S'http://bio2rdf.org/drugbank:DB00757'
p3960
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p3961
sg23
Nsg24
Nsg25
S'DOLASETRON'
p3962
sg27
Nsg28
S'Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.| \r'
p3963
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFAMPIN'
p3964
sa(dp3965
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01158'
p3966
sg5
S'http://bio2rdf.org/drugbank:DB00988'
p3967
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3968
sg23
Nsg24
Nsg25
S'DOPAMINE'
p3969
sg27
Nsg28
S'The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.| \r'
p3970
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Bretylium tosylate'
p3971
sa(dp3972
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01233'
p3973
sg5
S'http://bio2rdf.org/drugbank:DB00248'
p3974
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3975
sg23
Nsg24
Nsg25
S'Dostinex'
p3976
sg27
Nsg28
S'DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.| \r'
p3977
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METOCLOPRAMIDE'
p3978
sa(dp3979
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00398'
p3980
sg5
S'http://bio2rdf.org/drugbank:DB00997'
p3981
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p3982
sg23
Nsg24
Nsg25
S'DOXORUBICIN'
p3983
sg27
Nsg28
S'Caution is recommended when administering doxorubicin with NEXAVAR. | \r'
p3984
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nexavar'
p3985
sa(dp3986
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00041'
p3987
sg5
S'http://bio2rdf.org/drugbank:DB00997'
p3988
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3989
sg23
Nsg24
Nsg25
S'DOXORUBICIN'
p3990
sg27
Nsg28
S'Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.| \r'
p3991
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Proleukin'
p3992
sa(dp3993
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p3994
sg5
S'http://bio2rdf.org/drugbank:DB00997'
p3995
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p3996
sg23
Nsg24
Nsg25
S'DOXORUBICIN'
p3997
sg27
Nsg28
S'Doxorubicin: Doxorubicin caused a decrease in zalcitabine phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt 4 cells.| \r'
p3998
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZALCITABINE'
p3999
sa(dp4000
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00428'
p4001
sg5
S'http://bio2rdf.org/drugbank:DB00997'
p4002
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4003
sg23
Nsg24
Nsg25
S'DOXORUBICIN'
p4004
sg27
Nsg28
S'a reduction of the doxorubicin dosage should be considered in patients receiving ZANOSAR concurrently. | \r'
p4005
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Zanosar'
p4006
sa(dp4007
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00321'
p4008
sg5
S'http://bio2rdf.org/drugbank:DB00476'
p4009
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4010
sg23
Nsg24
Nsg25
S'DULOXETINE'
p4011
sg27
Nsg28
S'Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.| \r'
p4012
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMITRIPTYLINE'
p4013
sa(dp4014
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01151'
p4015
sg5
S'http://bio2rdf.org/drugbank:DB00476'
p4016
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4017
sg23
Nsg24
Nsg25
S'DULOXETINE'
p4018
sg27
Nsg28
S'When duloxetine was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold.| \r'
p4019
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DESIPRAMINE'
p4020
sa(dp4021
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p4022
sg5
S'http://bio2rdf.org/drugbank:DB00476'
p4023
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4024
sg23
Nsg24
Nsg25
S'DULOXETINE'
p4025
sg27
Nsg28
S'Inhibitors of CYP1A2: Concomitant use of duloxetine with fluvoxamine, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of duloxetine.| \r'
p4026
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p4027
sa(dp4028
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00458'
p4029
sg5
S'http://bio2rdf.org/drugbank:DB00476'
p4030
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4031
sg23
Nsg24
Nsg25
S'DULOXETINE'
p4032
sg27
Nsg28
S'Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.| \r'
p4033
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'IMIPRAMINE'
p4034
sa(dp4035
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00540'
p4036
sg5
S'http://bio2rdf.org/drugbank:DB00476'
p4037
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4038
sg23
Nsg24
Nsg25
S'DULOXETINE'
p4039
sg27
Nsg28
S'Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.| \r'
p4040
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NORTRIPTYLINE'
p4041
sa(dp4042
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p4043
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p4044
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4045
sg23
Nsg24
Nsg25
S'Duragesic'
p4046
sg27
Nsg28
S'Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.| \r'
p4047
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p4048
sa(dp4049
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00520'
p4050
sg5
S'http://bio2rdf.org/drugbank:DB00625'
p4051
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4052
sg23
Nsg24
Nsg25
S'EFAVIRENZ'
p4053
sg27
Nsg28
S'In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.| \r'
p4054
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cancidas'
p4055
sa(dp4056
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p4057
sg5
S'http://bio2rdf.org/drugbank:DB00023'
p4058
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4059
sg23
Nsg24
Nsg25
S'Elspar'
p4060
sg27
Nsg28
S'Tissue culture and animal studies indicate that ELSPAR can diminish or abolish the effect of methotrexate on malignant cells.14 This effect on methotrexate activity persists as long as plasma asparagine levels are suppressed.| \r'
p4061
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHOTREXATE'
p4062
sa(dp4063
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01211'
p4064
sg5
S'http://bio2rdf.org/drugbank:DB00496'
p4065
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4066
sg23
Nsg24
Nsg25
S'Enablex'
p4067
sg27
Nsg28
S'The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .| \r'
p4068
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLARITHROMYCIN'
p4069
sa(dp4070
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p4071
sg5
S'http://bio2rdf.org/drugbank:DB00496'
p4072
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4073
sg23
Nsg24
Nsg25
S'Enablex'
p4074
sg27
Nsg28
S'The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .| \r'
p4075
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p4076
sa(dp4077
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB05251'
p4078
sg5
S'http://bio2rdf.org/drugbank:DB00496'
p4079
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4080
sg23
Nsg24
Nsg25
S'Enablex'
p4081
sg27
Nsg28
S'The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .| \r'
p4082
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NELFINAVIR'
p4083
sa(dp4084
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p4085
sg5
S'http://bio2rdf.org/drugbank:DB00496'
p4086
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4087
sg23
Nsg24
Nsg25
S'Enablex'
p4088
sg27
Nsg28
S'The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .| \r'
p4089
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p4090
sa(dp4091
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p4092
sg5
S'http://bio2rdf.org/drugbank:DB00584'
p4093
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4094
sg23
Nsg24
Nsg25
S'ENALAPRIL'
p4095
sg27
Nsg28
S'It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.| \r'
p4096
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM CATION'
p4097
sa(dp4098
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p4099
sg5
S'http://bio2rdf.org/drugbank:DB00584'
p4100
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4101
sg23
Nsg24
Nsg25
S'ENALAPRIL'
p4102
sg27
Nsg28
S'It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.| \r'
p4103
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM'
p4104
sa(dp4105
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01294'
p4106
sg5
S'http://bio2rdf.org/drugbank:DB00467'
p4107
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4108
sg23
Nsg24
Nsg25
S'ENOXACIN'
p4109
sg27
Nsg28
S'Thus, concomitant administration of enoxacin and bismuth subsalicylate should be avoided.| \r'
p4110
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BISMUTH SUBSALICYLATE'
p4111
sa(dp4112
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00201'
p4113
sg5
S'http://bio2rdf.org/drugbank:DB00467'
p4114
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4115
sg23
Nsg24
Nsg25
S'ENOXACIN'
p4116
sg27
Nsg28
S'In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.| \r'
p4117
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CAFFEINE'
p4118
sa(dp4119
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p4120
sg5
S'http://bio2rdf.org/drugbank:DB00467'
p4121
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4122
sg23
Nsg24
Nsg25
S'ENOXACIN'
p4123
sg27
Nsg28
S'If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.| Digoxin: Enoxacin may raise serum digoxin levels in some individuals.| \r'
p4124
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p4125
sa(dp4126
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p4127
sg5
S'http://bio2rdf.org/drugbank:DB00467'
p4128
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4129
sg23
Nsg24
Nsg25
S'ENOXACIN'
p4130
sg27
Nsg28
S'If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.| Digoxin: Enoxacin may raise serum digoxin levels in some individuals.| \r'
p4131
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p4132
sa(dp4133
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00863'
p4134
sg5
S'http://bio2rdf.org/drugbank:DB00467'
p4135
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4136
sg23
Nsg24
Nsg25
S'ENOXACIN'
p4137
sg27
Nsg28
S'The oral bioavailability of enoxacin is reduced by 60% with coadministration of ranitidine.| \r'
p4138
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RANITIDINE'
p4139
sa(dp4140
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p4141
sg5
S'http://bio2rdf.org/drugbank:DB00467'
p4142
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4143
sg23
Nsg24
Nsg25
S'ENOXACIN'
p4144
sg27
Nsg28
S'Enoxacin interferes with the metabolism of theophylline resulting in a 42% to 74% dose-related decrease in theophylline clearance and a subsequent 260% to 350% increase in serum theophylline levels.| \r'
p4145
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p4146
sa(dp4147
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00261'
p4148
sg5
S'http://bio2rdf.org/drugbank:DB04880'
p4149
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4150
sg23
Nsg24
Nsg25
S'ENOXIMONE'
p4151
sg27
Nsg28
S'The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.| \r'
p4152
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ANAGRELIDE'
p4153
sa(dp4154
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p4155
sg5
S'http://bio2rdf.org/drugbank:DB00159'
p4156
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4157
sg23
Nsg24
Nsg25
S'EPA'
p4158
sg27
Nsg28
S'Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).| \r'
p4159
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p4160
sa(dp4161
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00633'
p4162
sg5
S'http://bio2rdf.org/drugbank:DB01364'
p4163
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4164
sg23
Nsg24
Nsg25
S'EPHEDRINE'
p4165
sg27
Nsg28
S'Ephedrine enhances the antinociceptive effect of dexmedetomidine in mice.&#x0D;| \r'
p4166
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DEXMEDETOMIDINE'
p4167
sa(dp4168
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01403'
p4169
sg5
S'http://bio2rdf.org/drugbank:DB01364'
p4170
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4171
sg23
Nsg24
Nsg25
S'EPHEDRINE'
p4172
sg27
Nsg28
S'Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. | \r'
p4173
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LEVOMEPROMAZINE'
p4174
sa(dp4175
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00211'
p4176
sg5
S'http://bio2rdf.org/drugbank:DB01364'
p4177
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4178
sg23
Nsg24
Nsg25
S'EPHEDRINE'
p4179
sg27
Nsg28
S'The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. | \r'
p4180
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ProAmatine'
p4181
sa(dp4182
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01170'
p4183
sg5
S'http://bio2rdf.org/drugbank:DB00668'
p4184
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4185
sg23
Nsg24
Nsg25
S'EPINEPHRINE'
p4186
sg27
Nsg28
S'Epinephrine may antagonize the neuron blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter.| \r'
p4187
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GUANETHIDINE'
p4188
sa(dp4189
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01064'
p4190
sg5
S'http://bio2rdf.org/drugbank:DB00668'
p4191
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4192
sg23
Nsg24
Nsg25
S'EPINEPHRINE'
p4193
sg27
Nsg28
S'Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.| \r'
p4194
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Isoproterenol'
p4195
sa(dp4196
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p4197
sg5
S'http://bio2rdf.org/drugbank:DB00700'
p4198
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4199
sg23
Nsg24
Nsg25
S'EPLERENONE'
p4200
sg27
Nsg28
S'Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.| \r'
p4201
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERYTHROMYCIN'
p4202
sa(dp4203
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p4204
sg5
S'http://bio2rdf.org/drugbank:DB00700'
p4205
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4206
sg23
Nsg24
Nsg25
S'EPLERENONE'
p4207
sg27
Nsg28
S'Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.| \r'
p4208
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p4209
sa(dp4210
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p4211
sg5
S'http://bio2rdf.org/drugbank:DB00700'
p4212
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4213
sg23
Nsg24
Nsg25
S'EPLERENONE'
p4214
sg27
Nsg28
S'Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.| \r'
p4215
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p4216
sa(dp4217
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p4218
sg5
S'http://bio2rdf.org/drugbank:DB00700'
p4219
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4220
sg23
Nsg24
Nsg25
S'EPLERENONE'
p4221
sg27
Nsg28
S'Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.| \r'
p4222
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p4223
sa(dp4224
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p4225
sg5
S'http://bio2rdf.org/drugbank:DB00700'
p4226
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4227
sg23
Nsg24
Nsg25
S'EPLERENONE'
p4228
sg27
Nsg28
S'Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.| \r'
p4229
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Verapamil'
p4230
sa(dp4231
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p4232
sg5
S'http://bio2rdf.org/drugbank:DB00848'
p4233
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4234
sg23
Nsg24
Nsg25
S'Ergamisol'
p4235
sg27
Nsg28
S'ERGAMISOL  (levamisole hydrochloride) has been reported to produce ANTABUSE-like side effects when given concomitantly with alcohol.| \r'
p4236
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p4237
sa(dp4238
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01361'
p4239
sg5
S'http://bio2rdf.org/drugbank:DB00696'
p4240
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4241
sg23
Nsg24
Nsg25
S'Ergomar'
p4242
sg27
Nsg28
S'The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.| \r'
p4243
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Triacetyloleandomycin'
p4244
sa(dp4245
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00918'
p4246
sg5
S'http://bio2rdf.org/drugbank:DB00696'
p4247
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4248
sg23
Nsg24
Nsg25
S'ERGOTAMINE'
p4249
sg27
Nsg28
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.| \r'
p4250
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Axert'
p4251
sa(dp4252
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00998'
p4253
sg5
S'http://bio2rdf.org/drugbank:DB00696'
p4254
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4255
sg23
Nsg24
Nsg25
S'ERGOTAMINE'
p4256
sg27
Nsg28
S'Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).| \r'
p4257
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Frova'
p4258
sa(dp4259
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00952'
p4260
sg5
S'http://bio2rdf.org/drugbank:DB00696'
p4261
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4262
sg23
Nsg24
Nsg25
S'ERGOTAMINE'
p4263
sg27
Nsg28
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.| \r'
p4264
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NARATRIPTAN'
p4265
sa(dp4266
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p4267
sg5
S'http://bio2rdf.org/drugbank:DB00696'
p4268
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4269
sg23
Nsg24
Nsg25
S'ERGOTAMINE'
p4270
sg27
Nsg28
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p4271
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sprycel'
p4272
sa(dp4273
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p4274
sg5
S'http://bio2rdf.org/drugbank:DB00696'
p4275
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4276
sg23
Nsg24
Nsg25
S'ERGOTAMINE'
p4277
sg27
Nsg28
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. | \r'
p4278
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUMATRIPTAN SUCCINATE'
p4279
sa(dp4280
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p4281
sg5
S'http://bio2rdf.org/drugbank:DB00696'
p4282
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4283
sg23
Nsg24
Nsg25
S'ERGOTAMINE'
p4284
sg27
Nsg28
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. | \r'
p4285
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUMATRIPTAN'
p4286
sa(dp4287
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p4288
sg5
S'http://bio2rdf.org/drugbank:DB00303'
p4289
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4290
sg23
Nsg24
Nsg25
S'ERTAPENEM'
p4291
sg27
Nsg28
S'Based on total ertapenem concentrations, probenecid increased the AUC by 25% and reduced the plasma and renal clearances by 20% and 35%, respectively.| \r'
p4292
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROBENECID'
p4293
sa(dp4294
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00802'
p4295
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4296
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4297
sg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p4298
sg27
Nsg28
S'Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.| \r'
p4299
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alfenta'
p4300
sa(dp4301
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00802'
p4302
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4303
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4304
sg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p4305
sg27
Nsg28
S'Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| \r'
p4306
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALFENTANIL'
p4307
sa(dp4308
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00918'
p4309
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4310
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4311
sg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p4312
sg27
Nsg28
S'Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.| \r'
p4313
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALMOTRIPTAN'
p4314
sa(dp4315
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p4316
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4317
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4318
sg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p4319
sg27
Nsg28
S'There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.| \r'
p4320
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASTEMIZOLE'
p4321
sa(dp4322
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p4323
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4324
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4325
sg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p4326
sg27
Nsg28
S'There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.| \r'
p4327
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASTEMIZOLE'
p4328
sa(dp4329
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p4330
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4331
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4332
sg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p4333
sg27
Nsg28
S'On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.| \r'
p4334
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BEXAROTENE'
p4335
sa(dp4336
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01200'
p4337
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4338
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4339
sg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p4340
sg27
Nsg28
S'There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| \r'
p4341
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BROMOCRIPTINE'
p4342
sa(dp4343
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p4344
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4345
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4346
sg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p4347
sg27
Nsg28
S'There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| \r'
p4348
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CARBAMAZEPINE'
p4349
sa(dp4350
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01166'
p4351
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4352
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4353
sg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p4354
sg27
Nsg28
S'Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.| \r'
p4355
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CILOSTAZOL'
p4356
sa(dp4357
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p4358
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4359
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4360
sg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p4361
sg27
Nsg28
S'Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| \r'
p4362
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p4363
sa(dp4364
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p4365
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4366
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4367
sg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p4368
sg27
Nsg28
S'Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| \r'
p4369
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p4370
sa(dp4371
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p4372
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4373
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4374
sg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p4375
sg27
Nsg28
S'Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| \r'
p4376
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p4377
sa(dp4378
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00363'
p4379
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4380
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4381
sg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p4382
sg27
Nsg28
S'Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.| \r'
p4383
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLOZAPINE'
p4384
sa(dp4385
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p4386
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4387
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4388
sg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p4389
sg27
Nsg28
S'Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| \r'
p4390
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSPORINE'
p4391
sa(dp4392
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p4393
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4394
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4395
sg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p4396
sg27
Nsg28
S'Digoxin: Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.| Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.| Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.| \r'
p4397
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p4398
sa(dp4399
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00320'
p4400
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4401
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4402
sg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p4403
sg27
Nsg28
S'Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.| Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.| \r'
p4404
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIHYDROERGOTAMINE'
p4405
sa(dp4406
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00696'
p4407
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4408
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4409
sg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p4410
sg27
Nsg28
S'Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.| Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.| \r'
p4411
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERGOTAMINE'
p4412
sa(dp4413
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00813'
p4414
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4415
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4416
sg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p4417
sg27
Nsg28
S'The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.| \r'
p4418
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FENTANYL'
p4419
sa(dp4420
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00455'
p4421
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4422
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4423
sg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p4424
sg27
Nsg28
S'Plasma concentrations (AUC 0-24 hrs) of erythromycin decreased 15% with coadministration of loratadine relative to that observed with erythromycin alone.| \r'
p4425
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LORATADINE'
p4426
sa(dp4427
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00227'
p4428
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4429
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4430
sg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p4431
sg27
Nsg28
S'Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| \r'
p4432
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LOVASTATIN'
p4433
sa(dp4434
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p4435
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4436
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4437
sg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p4438
sg27
Nsg28
S'Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. | Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.| \r'
p4439
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIDAZOLAM'
p4440
sa(dp4441
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00834'
p4442
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4443
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4444
sg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p4445
sg27
Nsg28
S'Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). | \r'
p4446
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIFEPRISTONE'
p4447
sa(dp4448
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p4449
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4450
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4451
sg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p4452
sg27
Nsg28
S'Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| \r'
p4453
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p4454
sa(dp4455
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00864'
p4456
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4457
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4458
sg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p4459
sg27
Nsg28
S'There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| \r'
p4460
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TACROLIMUS ANHYDROUS'
p4461
sa(dp4462
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00864'
p4463
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4464
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4465
sg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p4466
sg27
Nsg28
S'There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| \r'
p4467
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TACROLIMUS'
p4468
sa(dp4469
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p4470
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4471
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4472
sg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p4473
sg27
Nsg28
S'Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.| \r'
p4474
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p4475
sa(dp4476
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00897'
p4477
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4478
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4479
sg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p4480
sg27
Nsg28
S'Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.| Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.| Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.| \r'
p4481
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TRIAZOLAM'
p4482
sa(dp4483
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00897'
p4484
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4485
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4486
sg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p4487
sg27
Nsg28
S'Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.| Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.| Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.| \r'
p4488
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TRIAZOLAM'
p4489
sa(dp4490
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p4491
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4492
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4493
sg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p4494
sg27
Nsg28
S'Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| \r'
p4495
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Valproate'
p4496
sa(dp4497
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00862'
p4498
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4499
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4500
sg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p4501
sg27
Nsg28
S'Erythromycin (500 mg t.i.d) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax when co-administered with Vardenafil 5 mg in healthy volunteers.| \r'
p4502
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VARDENAFIL'
p4503
sa(dp4504
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00215'
p4505
sg5
S'http://bio2rdf.org/drugbank:DB01175'
p4506
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4507
sg23
Nsg24
Nsg25
S'ESCITALOPRAM OXALATE'
p4508
sg27
Nsg28
S'Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.| \r'
p4509
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Celexa'
p4510
sa(dp4511
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01151'
p4512
sg5
S'http://bio2rdf.org/drugbank:DB01175'
p4513
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4514
sg23
Nsg24
Nsg25
S'ESCITALOPRAM OXALATE'
p4515
sg27
Nsg28
S'However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.| \r'
p4516
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DESIPRAMINE'
p4517
sa(dp4518
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00215'
p4519
sg5
S'http://bio2rdf.org/drugbank:DB01175'
p4520
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4521
sg23
Nsg24
Nsg25
S'ESCITALOPRAM'
p4522
sg27
Nsg28
S'Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.| \r'
p4523
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Celexa'
p4524
sa(dp4525
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01151'
p4526
sg5
S'http://bio2rdf.org/drugbank:DB01175'
p4527
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4528
sg23
Nsg24
Nsg25
S'ESCITALOPRAM'
p4529
sg27
Nsg28
S'However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.| \r'
p4530
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DESIPRAMINE'
p4531
sa(dp4532
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p4533
sg5
S'http://bio2rdf.org/drugbank:DB00736'
p4534
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4535
sg23
Nsg24
Nsg25
S'ESOMEPRAZOLE'
p4536
sg27
Nsg28
S'Coadministration of esomeprazole 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam.| \r'
p4537
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIAZEPAM'
p4538
sa(dp4539
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p4540
sg5
S'http://bio2rdf.org/drugbank:DB00736'
p4541
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4542
sg23
Nsg24
Nsg25
S'ESOMEPRAZOLE'
p4543
sg27
Nsg28
S'Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).| \r'
p4544
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p4545
sa(dp4546
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01592'
p4547
sg5
S'http://bio2rdf.org/drugbank:DB00736'
p4548
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4549
sg23
Nsg24
Nsg25
S'ESOMEPRAZOLE'
p4550
sg27
Nsg28
S'Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).| \r'
p4551
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'IRON'
p4552
sa(dp4553
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p4554
sg5
S'http://bio2rdf.org/drugbank:DB00736'
p4555
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4556
sg23
Nsg24
Nsg25
S'ESOMEPRAZOLE'
p4557
sg27
Nsg28
S'Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).| \r'
p4558
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p4559
sa(dp4560
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p4561
sg5
S'http://bio2rdf.org/drugbank:DB01215'
p4562
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4563
sg23
Nsg24
Nsg25
S'ESTAZOLAM'
p4564
sg27
Nsg28
S'While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.| \r'
p4565
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CARBAMAZEPINE'
p4566
sa(dp4567
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01215'
p4568
sg5
S'http://bio2rdf.org/drugbank:DB01215'
p4569
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4570
sg23
Nsg24
Nsg25
S'ESTAZOLAM'
p4571
sg27
Nsg28
S'While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.| \r'
p4572
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ESTAZOLAM'
p4573
sa(dp4574
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p4575
sg5
S'http://bio2rdf.org/drugbank:DB01215'
p4576
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4577
sg23
Nsg24
Nsg25
S'ESTAZOLAM'
p4578
sg27
Nsg28
S'Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A.| \r'
p4579
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p4580
sa(dp4581
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p4582
sg5
S'http://bio2rdf.org/drugbank:DB01215'
p4583
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4584
sg23
Nsg24
Nsg25
S'ESTAZOLAM'
p4585
sg27
Nsg28
S'While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.| \r'
p4586
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p4587
sa(dp4588
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p4589
sg5
S'http://bio2rdf.org/drugbank:DB01215'
p4590
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4591
sg23
Nsg24
Nsg25
S'ESTAZOLAM'
p4592
sg27
Nsg28
S'While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.| \r'
p4593
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFAMPIN'
p4594
sa(dp4595
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00368'
p4596
sg5
S'http://bio2rdf.org/drugbank:DB00783'
p4597
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4598
sg23
Nsg24
Nsg25
S'ESTRADIOL'
p4599
sg27
Nsg28
S'Aortic rings with intact endothelium from the high-dose (4 mg/kg/day) estradiol group were supersensitive to noradrenaline compared to the vehicle or low-dose (10 microg/kg/day) estradiol groups (pD2 values = 7.86+/-0.09, 7.30+/-0.11 and 7.35+/-0.04, respectively). | Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). | \r'
p4600
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Noradrenaline'
p4601
sa(dp4602
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p4603
sg5
S'http://bio2rdf.org/drugbank:DB00402'
p4604
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4605
sg23
Nsg24
Nsg25
S'ESZOPICLONE'
p4606
sg27
Nsg28
S'CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.| \r'
p4607
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p4608
sa(dp4609
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p4610
sg5
S'http://bio2rdf.org/drugbank:DB00402'
p4611
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4612
sg23
Nsg24
Nsg25
S'ESZOPICLONE'
p4613
sg27
Nsg28
S'The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days.| \r'
p4614
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p4615
sa(dp4616
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00334'
p4617
sg5
S'http://bio2rdf.org/drugbank:DB00402'
p4618
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4619
sg23
Nsg24
Nsg25
S'ESZOPICLONE'
p4620
sg27
Nsg28
S'Olanzapine: Coadministration of eszopiclone 3 mg and olanzapine 10 mg produced a decrease in DSST scores.| \r'
p4621
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'OLANZAPINE'
p4622
sa(dp4623
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB06723'
p4624
sg5
S'http://bio2rdf.org/drugbank:DB00330'
p4625
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4626
sg23
Nsg24
Nsg25
S'ETHAMBUTOL'
p4627
sg27
Nsg28
S'The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.| It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing antacids for at least 4 hours following ethambutol administration.| \r'
p4628
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALUMINUM HYDROXIDE'
p4629
sa(dp4630
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB06723'
p4631
sg5
S'http://bio2rdf.org/drugbank:DB00330'
p4632
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4633
sg23
Nsg24
Nsg25
S'ETHAMBUTOL'
p4634
sg27
Nsg28
S'The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.| It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing antacids for at least 4 hours following ethambutol administration.| \r'
p4635
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALUMINUM HYDROXIDE'
p4636
sa(dp4637
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00860'
p4638
sg5
S'http://bio2rdf.org/drugbank:DB00977'
p4639
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4640
sg23
Nsg24
Nsg25
S'ETHINYL ESTRADIOL'
p4641
sg27
Nsg28
S'Prednisolone: Ethinyl estradiol may inhibit the metabolism of prednisolone, leading to increased plasma concentrations.| \r'
p4642
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PREDNISOLONE'
p4643
sa(dp4644
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p4645
sg5
S'http://bio2rdf.org/drugbank:DB00977'
p4646
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p4647
sg23
Nsg24
Nsg25
S'ETHINYL ESTRADIOL'
p4648
sg27
Nsg28
S'Theophylline: Ethinyl estradiol may inhibit the metabolism of theophylline, leading to increased plasma concentrations.| \r'
p4649
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p4650
sa(dp4651
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00260'
p4652
sg5
S'http://bio2rdf.org/drugbank:DB00609'
p4653
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4654
sg23
Nsg24
Nsg25
S'ETHIONAMIDE'
p4655
sg27
Nsg28
S'In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs.| \r'
p4656
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSERINE'
p4657
sa(dp4658
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00681'
p4659
sg5
S'http://bio2rdf.org/drugbank:DB00311'
p4660
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4661
sg23
Nsg24
Nsg25
S'ETHOXZOLAMIDE'
p4662
sg27
Nsg28
S'Coadministration of ethoxzolamide with other diuretics, amphotericin B, and corticosteroids may cause hypokalemia.| \r'
p4663
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPHOTERICIN B'
p4664
sa(dp4665
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01035'
p4666
sg5
S'http://bio2rdf.org/drugbank:DB00311'
p4667
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4668
sg23
Nsg24
Nsg25
S'ETHOXZOLAMIDE'
p4669
sg27
Nsg28
S'Ethoxzolamide may increase the action of tricyclics, amphetamines, procainamide, and quinidine.| \r'
p4670
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROCAINAMIDE'
p4671
sa(dp4672
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00908'
p4673
sg5
S'http://bio2rdf.org/drugbank:DB00311'
p4674
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p4675
sg23
Nsg24
Nsg25
S'ETHOXZOLAMIDE'
p4676
sg27
Nsg28
S'Ethoxzolamide may increase the action of tricyclics, amphetamines, procainamide, and quinidine.| \r'
p4677
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'QUINIDINE'
p4678
sa(dp4679
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00812'
p4680
sg5
S'http://bio2rdf.org/drugbank:DB00749'
p4681
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4682
sg23
Nsg24
Nsg25
S'Etodolac'
p4683
sg27
Nsg28
S'Although in vivo studies have not been done to see if etodolac clearance is changed by coadministration of phenylbutazone, it is not recommended that they be coadministered.| \r'
p4684
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYLBUTAZONE'
p4685
sa(dp4686
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p4687
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4688
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4689
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4690
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4691
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACETAMINOPHEN'
p4692
sa(dp4693
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p4694
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4695
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4696
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4697
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4698
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ADENOSINE PHOSPHATE'
p4699
sa(dp4700
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00701'
p4701
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4702
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4703
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4704
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4705
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Agenerase'
p4706
sa(dp4707
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p4708
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4709
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4710
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4711
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4712
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPICILLIN'
p4713
sa(dp4714
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00126'
p4715
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4716
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4717
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4718
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4719
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASCORBIC ACID'
p4720
sa(dp4721
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01076'
p4722
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4723
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4724
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4725
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4726
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ATORVASTATIN'
p4727
sa(dp4728
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00636'
p4729
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4730
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4731
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4732
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4733
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Atromid-S'
p4734
sa(dp4735
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00636'
p4736
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4737
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4738
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4739
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4740
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLOFIBRATE'
p4741
sa(dp4742
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p4743
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4744
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4745
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4746
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4747
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Crixivan'
p4748
sa(dp4749
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p4750
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4751
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4752
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4753
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4754
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSPORINE'
p4755
sa(dp4756
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p4757
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4758
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4759
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4760
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4761
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Dilantin'
p4762
sa(dp4763
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00949'
p4764
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4765
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4766
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4767
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4768
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Felbatol'
p4769
sa(dp4770
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p4771
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4772
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4773
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4774
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4775
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Fortovase'
p4776
sa(dp4777
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00400'
p4778
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4779
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4780
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4781
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4782
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Gris-PEG'
p4783
sa(dp4784
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p4785
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4786
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4787
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4788
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4789
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Invirase'
p4790
sa(dp4791
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p4792
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4793
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4794
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4795
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4796
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Kadian'
p4797
sa(dp4798
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01076'
p4799
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4800
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4801
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4802
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4803
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Lipitor'
p4804
sa(dp4805
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p4806
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4807
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4808
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4809
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4810
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MORPHINE'
p4811
sa(dp4812
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p4813
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4814
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4815
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4816
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4817
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MS Contin'
p4818
sa(dp4819
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p4820
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4821
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4822
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4823
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4824
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Neoral '
p4825
sa(dp4826
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p4827
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4828
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4829
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4830
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4831
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nizoral'
p4832
sa(dp4833
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p4834
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4835
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4836
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4837
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4838
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Norvir'
p4839
sa(dp4840
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p4841
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4842
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4843
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4844
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4845
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p4846
sa(dp4847
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00812'
p4848
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4849
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4850
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4851
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4852
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYLBUTAZONE'
p4853
sa(dp4854
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00860'
p4855
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4856
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4857
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4858
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4859
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PREDNISOLONE'
p4860
sa(dp4861
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00860'
p4862
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4863
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4864
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4865
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4866
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Prelone'
p4867
sa(dp4868
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p4869
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4870
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4871
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4872
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4873
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Rifadin'
p4874
sa(dp4875
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p4876
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4877
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4878
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4879
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4880
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFAMPIN'
p4881
sa(dp4882
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p4883
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4884
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4885
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4886
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4887
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sandimmune '
p4888
sa(dp4889
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01167'
p4890
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4891
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4892
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4893
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4894
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sporanox'
p4895
sa(dp4896
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p4897
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4898
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4899
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4900
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4901
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TEGretol'
p4902
sa(dp4903
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00759'
p4904
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4905
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4906
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4907
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4908
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TETRACYCLINE'
p4909
sa(dp4910
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p4911
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4912
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4913
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4914
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4915
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Theo-Dur'
p4916
sa(dp4917
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p4918
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4919
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4920
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4921
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4922
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p4923
sa(dp4924
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00273'
p4925
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4926
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4927
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4928
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4929
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Topamax'
p4930
sa(dp4931
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00776'
p4932
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4933
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4934
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4935
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4936
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Trileptal'
p4937
sa(dp4938
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p4939
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4940
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4941
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4942
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4943
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tylenol'
p4944
sa(dp4945
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p4946
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4947
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p4948
sg23
Nsg24
Nsg25
S'ETONOGESTREL'
p4949
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4950
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Viracept'
p4951
sa(dp4952
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00636'
p4953
sg5
S'http://bio2rdf.org/drugbank:DB00481'
p4954
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4955
sg23
Nsg24
Nsg25
S'Evista'
p4956
sg27
Nsg28
S'Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. | \r'
p4957
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLOFIBRATE'
p4958
sa(dp4959
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p4960
sg5
S'http://bio2rdf.org/drugbank:DB00481'
p4961
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4962
sg23
Nsg24
Nsg25
S'Evista'
p4963
sg27
Nsg28
S'Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. | \r'
p4964
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIAZEPAM'
p4965
sa(dp4966
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01119'
p4967
sg5
S'http://bio2rdf.org/drugbank:DB00481'
p4968
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4969
sg23
Nsg24
Nsg25
S'Evista'
p4970
sg27
Nsg28
S'Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. | \r'
p4971
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIAZOXIDE'
p4972
sa(dp4973
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00328'
p4974
sg5
S'http://bio2rdf.org/drugbank:DB00481'
p4975
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4976
sg23
Nsg24
Nsg25
S'Evista'
p4977
sg27
Nsg28
S'Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. | \r'
p4978
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDOMETHACIN'
p4979
sa(dp4980
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00788'
p4981
sg5
S'http://bio2rdf.org/drugbank:DB00481'
p4982
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4983
sg23
Nsg24
Nsg25
S'Evista'
p4984
sg27
Nsg28
S'Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. | \r'
p4985
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NAPROXEN'
p4986
sa(dp4987
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01370'
p4988
sg5
S'http://bio2rdf.org/drugbank:DB01609'
p4989
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4990
sg23
Nsg24
Nsg25
S'Exjade'
p4991
sg27
Nsg28
S'Although deferasirox has a lower affinity for aluminum than for iron, Exjade should not be taken with aluminum-containing antacid preparations.| \r'
p4992
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALUMINUM'
p4993
sa(dp4994
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p4995
sg5
S'http://bio2rdf.org/drugbank:DB00973'
p4996
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p4997
sg23
Nsg24
Nsg25
S'EZETIMIBE'
p4998
sg27
Nsg28
S'Cyclosporine: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine. | Patients who take both ezetimibe and cyclosporine should be carefully monitored. | \r'
p4999
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSPORINE'
p5000
sa(dp5001
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p5002
sg5
S'http://bio2rdf.org/drugbank:DB00973'
p5003
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5004
sg23
Nsg24
Nsg25
S'EZETIMIBE'
p5005
sg27
Nsg28
S'Cyclosporine: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine. | Patients who take both ezetimibe and cyclosporine should be carefully monitored. | \r'
p5006
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSPORINE'
p5007
sa(dp5008
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB06724'
p5009
sg5
S'http://bio2rdf.org/drugbank:DB01155'
p5010
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5011
sg23
Nsg24
Nsg25
S'Factive'
p5012
sg27
Nsg28
S'Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.| \r'
p5013
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CALCIUM CARBONATE'
p5014
sa(dp5015
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p5016
sg5
S'http://bio2rdf.org/drugbank:DB01155'
p5017
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5018
sg23
Nsg24
Nsg25
S'Factive'
p5019
sg27
Nsg28
S'Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.| \r'
p5020
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIMETIDINE'
p5021
sa(dp5022
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p5023
sg5
S'http://bio2rdf.org/drugbank:DB01155'
p5024
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5025
sg23
Nsg24
Nsg25
S'Factive'
p5026
sg27
Nsg28
S'Concomitant administration of FACTIVE with probenecid resulted in a 45% increase in systemic exposure to gemifloxacin.| \r'
p5027
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROBENECID'
p5028
sa(dp5029
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00396'
p5030
sg5
S'http://bio2rdf.org/drugbank:DB01155'
p5031
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5032
sg23
Nsg24
Nsg25
S'Factive'
p5033
sg27
Nsg28
S'Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.| \r'
p5034
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROGESTERONE'
p5035
sa(dp5036
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01066'
p5037
sg5
S'http://bio2rdf.org/drugbank:DB00927'
p5038
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5039
sg23
Nsg24
Nsg25
S'FAMOTIDINE'
p5040
sg27
Nsg28
S'H2-Receptor Antagonists: Co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single 400 mg dose of cefditoren pivoxil administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.| \r'
p5041
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CEFDITOREN PIVOXIL'
p5042
sa(dp5043
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p5044
sg5
S'http://bio2rdf.org/drugbank:DB00927'
p5045
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5046
sg23
Nsg24
Nsg25
S'FAMOTIDINE'
p5047
sg27
Nsg28
S'H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.| \r'
p5048
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DASATINIB ANHYDROUS'
p5049
sa(dp5050
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p5051
sg5
S'http://bio2rdf.org/drugbank:DB00927'
p5052
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5053
sg23
Nsg24
Nsg25
S'FAMOTIDINE'
p5054
sg27
Nsg28
S'H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.| \r'
p5055
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DASATINIB'
p5056
sa(dp5057
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00977'
p5058
sg5
S'http://bio2rdf.org/drugbank:DB00949'
p5059
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5060
sg23
Nsg24
Nsg25
S'FELBAMATE'
p5061
sg27
Nsg28
S'Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.| \r'
p5062
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ETHINYL ESTRADIOL'
p5063
sa(dp5064
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB06730'
p5065
sg5
S'http://bio2rdf.org/drugbank:DB00949'
p5066
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5067
sg23
Nsg24
Nsg25
S'FELBAMATE'
p5068
sg27
Nsg28
S'Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol.| \r'
p5069
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GESTODENE'
p5070
sa(dp5071
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p5072
sg5
S'http://bio2rdf.org/drugbank:DB00949'
p5073
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5074
sg23
Nsg24
Nsg25
S'FELBAMATE'
p5075
sg27
Nsg28
S'Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.| \r'
p5076
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p5077
sa(dp5078
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p5079
sg5
S'http://bio2rdf.org/drugbank:DB00949'
p5080
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5081
sg23
Nsg24
Nsg25
S'FELBAMATE'
p5082
sg27
Nsg28
S'In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.| Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25 7 micrograms/mL.| \r'
p5083
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p5084
sa(dp5085
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p5086
sg5
S'http://bio2rdf.org/drugbank:DB00949'
p5087
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5088
sg23
Nsg24
Nsg25
S'FELBAMATE'
p5089
sg27
Nsg28
S'In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.| Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25 7 micrograms/mL.| \r'
p5090
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p5091
sa(dp5092
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p5093
sg5
S'http://bio2rdf.org/drugbank:DB00949'
p5094
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5095
sg23
Nsg24
Nsg25
S'FELBAMATE'
p5096
sg27
Nsg28
S'Increasing the felbamate dose to 2400 mg/day increased the steadystate valproate Cmin to 96 25 micrograms/mL.| \r'
p5097
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Valproate'
p5098
sa(dp5099
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p5100
sg5
S'http://bio2rdf.org/drugbank:DB00949'
p5101
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5102
sg23
Nsg24
Nsg25
S'Felbatol'
p5103
sg27
Nsg28
S'Carbamazepine: Felbatol  causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.| \r'
p5104
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CARBAMAZEPINE'
p5105
sa(dp5106
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p5107
sg5
S'http://bio2rdf.org/drugbank:DB00949'
p5108
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5109
sg23
Nsg24
Nsg25
S'Felbatol'
p5110
sg27
Nsg28
S'Specific Effects of Felbatol  on Other Antiepileptic Drugs Phenytoin: Felbatol  causes an increase in steady-state phenytoin plasma concentrations.| \r'
p5111
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p5112
sa(dp5113
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p5114
sg5
S'http://bio2rdf.org/drugbank:DB00949'
p5115
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5116
sg23
Nsg24
Nsg25
S'Felbatol'
p5117
sg27
Nsg28
S'Valproate: Felbatol  causes an increase in steady-state valproate concentrations.| \r'
p5118
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Valproate'
p5119
sa(dp5120
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p5121
sg5
S'http://bio2rdf.org/drugbank:DB00554'
p5122
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5123
sg23
Nsg24
Nsg25
S'Feldene'
p5124
sg27
Nsg28
S'Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. | \r'
p5125
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p5126
sa(dp5127
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p5128
sg5
S'http://bio2rdf.org/drugbank:DB00554'
p5129
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5130
sg23
Nsg24
Nsg25
S'Feldene'
p5131
sg27
Nsg28
S'Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. | \r'
p5132
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM CATION'
p5133
sa(dp5134
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p5135
sg5
S'http://bio2rdf.org/drugbank:DB00554'
p5136
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5137
sg23
Nsg24
Nsg25
S'Feldene'
p5138
sg27
Nsg28
S'Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. | \r'
p5139
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM'
p5140
sa(dp5141
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p5142
sg5
S'http://bio2rdf.org/drugbank:DB01023'
p5143
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5144
sg23
Nsg24
Nsg25
S'Felodipine'
p5145
sg27
Nsg28
S'Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.| \r'
p5146
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CARBAMAZEPINE'
p5147
sa(dp5148
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p5149
sg5
S'http://bio2rdf.org/drugbank:DB01023'
p5150
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5151
sg23
Nsg24
Nsg25
S'Felodipine'
p5152
sg27
Nsg28
S'Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.| \r'
p5153
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p5154
sa(dp5155
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p5156
sg5
S'http://bio2rdf.org/drugbank:DB01023'
p5157
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5158
sg23
Nsg24
Nsg25
S'Felodipine'
p5159
sg27
Nsg28
S'Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.| \r'
p5160
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p5161
sa(dp5162
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00675'
p5163
sg5
S'http://bio2rdf.org/drugbank:DB01006'
p5164
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5165
sg23
Nsg24
Nsg25
S'Femara'
p5166
sg27
Nsg28
S'(See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.| \r'
p5167
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TAMOXIFEN'
p5168
sa(dp5169
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01076'
p5170
sg5
S'http://bio2rdf.org/drugbank:DB01039'
p5171
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5172
sg23
Nsg24
Nsg25
S'FENOFIBRATE'
p5173
sg27
Nsg28
S'Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.| \r'
p5174
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ATORVASTATIN'
p5175
sa(dp5176
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00973'
p5177
sg5
S'http://bio2rdf.org/drugbank:DB01039'
p5178
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5179
sg23
Nsg24
Nsg25
S'FENOFIBRATE'
p5180
sg27
Nsg28
S'Fenofibrate: In a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold. | \r'
p5181
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EZETIMIBE'
p5182
sa(dp5183
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00175'
p5184
sg5
S'http://bio2rdf.org/drugbank:DB01039'
p5185
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5186
sg23
Nsg24
Nsg25
S'FENOFIBRATE'
p5187
sg27
Nsg28
S'Concomitant administration of fenofibrate (equivalent to 145mg TRICOR) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.| \r'
p5188
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PRAVASTATIN'
p5189
sa(dp5190
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01076'
p5191
sg5
S'http://bio2rdf.org/drugbank:DB01039'
p5192
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5193
sg23
Nsg24
Nsg25
S'FENOFIBRIC ACID'
p5194
sg27
Nsg28
S'Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.| \r'
p5195
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ATORVASTATIN'
p5196
sa(dp5197
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00973'
p5198
sg5
S'http://bio2rdf.org/drugbank:DB01039'
p5199
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5200
sg23
Nsg24
Nsg25
S'FENOFIBRIC ACID'
p5201
sg27
Nsg28
S'Fenofibrate: In a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold. | \r'
p5202
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EZETIMIBE'
p5203
sa(dp5204
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00175'
p5205
sg5
S'http://bio2rdf.org/drugbank:DB01039'
p5206
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5207
sg23
Nsg24
Nsg25
S'FENOFIBRIC ACID'
p5208
sg27
Nsg28
S'Concomitant administration of fenofibrate (equivalent to 145mg TRICOR) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.| \r'
p5209
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PRAVASTATIN'
p5210
sa(dp5211
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p5212
sg5
S'http://bio2rdf.org/drugbank:DB00573'
p5213
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5214
sg23
Nsg24
Nsg25
S'Fenoprofen'
p5215
sg27
Nsg28
S'Although the mechanism of interaction between fenoprofen and aspirin is not totally known, enzyme induction and displacement of fenoprofen from plasma albumin binding sites are possibilities.| \r'
p5216
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p5217
sa(dp5218
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p5219
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p5220
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5221
sg23
Nsg24
Nsg25
S'FENTANYL'
p5222
sg27
Nsg28
S'Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.| \r'
p5223
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p5224
sa(dp5225
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01211'
p5226
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p5227
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5228
sg23
Nsg24
Nsg25
S'FENTANYL'
p5229
sg27
Nsg28
S'The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| \r'
p5230
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLARITHROMYCIN'
p5231
sa(dp5232
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p5233
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p5234
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5235
sg23
Nsg24
Nsg25
S'FENTANYL'
p5236
sg27
Nsg28
S'The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| \r'
p5237
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p5238
sa(dp5239
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB05251'
p5240
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p5241
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5242
sg23
Nsg24
Nsg25
S'FENTANYL'
p5243
sg27
Nsg28
S'The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| \r'
p5244
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NELFINAVIR'
p5245
sa(dp5246
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p5247
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p5248
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5249
sg23
Nsg24
Nsg25
S'FENTANYL'
p5250
sg27
Nsg28
S'The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| \r'
p5251
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p5252
sa(dp5253
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p5254
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p5255
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5256
sg23
Nsg24
Nsg25
S'FENTANYL'
p5257
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p5258
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p5259
sa(dp5260
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p5261
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p5262
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5263
sg23
Nsg24
Nsg25
S'FENTANYL'
p5264
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p5265
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p5266
sa(dp5267
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p5268
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p5269
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5270
sg23
Nsg24
Nsg25
S'FENTANYL'
p5271
sg27
Nsg28
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p5272
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sprycel'
p5273
sa(dp5274
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01361'
p5275
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p5276
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5277
sg23
Nsg24
Nsg25
S'FENTANYL'
p5278
sg27
Nsg28
S'The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| \r'
p5279
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TROLEANDOMYCIN'
p5280
sa(dp5281
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p5282
sg5
S'http://bio2rdf.org/drugbank:DB00924'
p5283
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5284
sg23
Nsg24
Nsg25
S'Flexeril'
p5285
sg27
Nsg28
S'FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.| \r'
p5286
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p5287
sa(dp5288
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p5289
sg5
S'http://bio2rdf.org/drugbank:DB00706'
p5290
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5291
sg23
Nsg24
Nsg25
S'Flomax'
p5292
sg27
Nsg28
S'Therefore, FLOMAX capsules should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg. | \r'
p5293
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIMETIDINE'
p5294
sa(dp5295
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p5296
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p5297
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5298
sg23
Nsg24
Nsg25
S'FLUCONAZOLE'
p5299
sg27
Nsg28
S'Astemizole: The use of fluconazole in patients concurrently taking astemizole or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs. | \r'
p5300
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASTEMIZOLE'
p5301
sa(dp5302
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00482'
p5303
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p5304
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5305
sg23
Nsg24
Nsg25
S'FLUCONAZOLE'
p5306
sg27
Nsg28
S'Fluconazole: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.| \r'
p5307
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CELECOXIB'
p5308
sa(dp5309
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p5310
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p5311
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5312
sg23
Nsg24
Nsg25
S'FLUCONAZOLE'
p5313
sg27
Nsg28
S'The combined use of fluconazole with cisapride is contraindicated. | Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered. | A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.| \r'
p5314
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p5315
sa(dp5316
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p5317
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p5318
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5319
sg23
Nsg24
Nsg25
S'FLUCONAZOLE'
p5320
sg27
Nsg28
S'The combined use of fluconazole with cisapride is contraindicated. | Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered. | A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.| \r'
p5321
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p5322
sa(dp5323
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p5324
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p5325
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5326
sg23
Nsg24
Nsg25
S'FLUCONAZOLE'
p5327
sg27
Nsg28
S'The combined use of fluconazole with cisapride is contraindicated. | Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered. | A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.| \r'
p5328
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p5329
sa(dp5330
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00977'
p5331
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p5332
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5333
sg23
Nsg24
Nsg25
S'FLUCONAZOLE'
p5334
sg27
Nsg28
S'While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. | Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; | \r'
p5335
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ETHINYL ESTRADIOL'
p5336
sa(dp5337
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01067'
p5338
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p5339
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p5340
sg23
Nsg24
Nsg25
S'FLUCONAZOLE'
p5341
sg27
Nsg28
S'The effect of concomitant administration of fluconazole and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers.| \r'
p5342
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GLIPIZIDE'
p5343
sa(dp5344
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00367'
p5345
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p5346
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5347
sg23
Nsg24
Nsg25
S'FLUCONAZOLE'
p5348
sg27
Nsg28
S'Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; | While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. | \r'
p5349
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LEVONORGESTREL'
p5350
sa(dp5351
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00678'
p5352
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p5353
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5354
sg23
Nsg24
Nsg25
S'FLUCONAZOLE'
p5355
sg27
Nsg28
S'Fluconazole, an inhibitor of P450 2C9, decreased active metabolite concentration and increased losartan concentration.| \r'
p5356
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LOSARTAN'
p5357
sa(dp5358
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p5359
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p5360
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5361
sg23
Nsg24
Nsg25
S'FLUCONAZOLE'
p5362
sg27
Nsg28
S'Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. | \r'
p5363
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIDAZOLAM'
p5364
sa(dp5365
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00615'
p5366
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p5367
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5368
sg23
Nsg24
Nsg25
S'FLUCONAZOLE'
p5369
sg27
Nsg28
S'Rifabutin: There have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered. | \r'
p5370
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFABUTIN'
p5371
sa(dp5372
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00864'
p5373
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p5374
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5375
sg23
Nsg24
Nsg25
S'FLUCONAZOLE'
p5376
sg27
Nsg28
S'Tacrolimus: There have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were coadministered. | \r'
p5377
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TACROLIMUS ANHYDROUS'
p5378
sa(dp5379
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00864'
p5380
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p5381
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5382
sg23
Nsg24
Nsg25
S'FLUCONAZOLE'
p5383
sg27
Nsg28
S'Tacrolimus: There have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were coadministered. | \r'
p5384
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TACROLIMUS'
p5385
sa(dp5386
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00552'
p5387
sg5
S'http://bio2rdf.org/drugbank:DB01073'
p5388
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5389
sg23
Nsg24
Nsg25
S'Fludara'
p5390
sg27
Nsg28
S'The use of FLUDARA FOR INJECTION in combination with pentostatin is not recommended due to the risk of severe pulmonary toxicity.| \r'
p5391
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PENTOSTATIN'
p5392
sa(dp5393
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01199'
p5394
sg5
S'http://bio2rdf.org/drugbank:DB01159'
p5395
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5396
sg23
Nsg24
Nsg25
S'Fluothane'
p5397
sg27
Nsg28
S'FLUOTHANE may augment the hypotension caused by the ganglionic-blocking effect of tubocurarine.| \r'
p5398
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TUBOCURARINE'
p5399
sa(dp5400
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p5401
sg5
S'http://bio2rdf.org/drugbank:DB00875'
p5402
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5403
sg23
Nsg24
Nsg25
S'Flupenthixol'
p5404
sg27
Nsg28
S'Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants| \r'
p5405
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p5406
sa(dp5407
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00575'
p5408
sg5
S'http://bio2rdf.org/drugbank:DB00623'
p5409
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5410
sg23
Nsg24
Nsg25
S'FLUPHENAZINE'
p5411
sg27
Nsg28
S'There is one reported case of a patient with acute delirium associated with the simultaneous use of fluphenazine and oral clonidine.| \r'
p5412
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLONIDINE'
p5413
sa(dp5414
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p5415
sg5
S'http://bio2rdf.org/drugbank:DB00712'
p5416
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5417
sg23
Nsg24
Nsg25
S'Flurbiprofen'
p5418
sg27
Nsg28
S'Concurrent use of flurbiprofen and aspirin is therefore not recommended.| \r'
p5419
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p5420
sa(dp5421
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p5422
sg5
S'http://bio2rdf.org/drugbank:DB00712'
p5423
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5424
sg23
Nsg24
Nsg25
S'Flurbiprofen'
p5425
sg27
Nsg28
S'Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.| \r'
p5426
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIMETIDINE'
p5427
sa(dp5428
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00695'
p5429
sg5
S'http://bio2rdf.org/drugbank:DB00712'
p5430
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5431
sg23
Nsg24
Nsg25
S'Flurbiprofen'
p5432
sg27
Nsg28
S'Patients receiving flurbiprofen and furosemide or other diuretics should be observed closely to determine if the desired effect is obtained.| Diuretics: Studies in normal volunteers have shown that flurbiprofen like other nonsteroidal anti-inflammatory drugs, can interfere with the effects of furosemide.| \r'
p5433
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FUROSEMIDE'
p5434
sa(dp5435
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00695'
p5436
sg5
S'http://bio2rdf.org/drugbank:DB00712'
p5437
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5438
sg23
Nsg24
Nsg25
S'Flurbiprofen'
p5439
sg27
Nsg28
S'Patients receiving flurbiprofen and furosemide or other diuretics should be observed closely to determine if the desired effect is obtained.| Diuretics: Studies in normal volunteers have shown that flurbiprofen like other nonsteroidal anti-inflammatory drugs, can interfere with the effects of furosemide.| \r'
p5440
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FUROSEMIDE'
p5441
sa(dp5442
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00969'
p5443
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p5444
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5445
sg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p5446
sg27
Nsg28
S'Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold.| \r'
p5447
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALOSETRON'
p5448
sa(dp5449
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00404'
p5450
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p5451
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p5452
sg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p5453
sg27
Nsg28
S'Although it has not been definitively demonstrated that fluvoxamine is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of fluvoxamine with alprazolam.| \r'
p5454
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALPRAZOLAM'
p5455
sa(dp5456
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00261'
p5457
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p5458
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5459
sg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p5460
sg27
Nsg28
S'It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine, and such medicinal products could theoretically adversely influence the clearance of anagrelide.| \r'
p5461
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ANAGRELIDE'
p5462
sa(dp5463
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p5464
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p5465
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5466
sg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p5467
sg27
Nsg28
S'Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.| \r'
p5468
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASTEMIZOLE'
p5469
sa(dp5470
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p5471
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p5472
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5473
sg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p5474
sg27
Nsg28
S'Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.| \r'
p5475
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p5476
sa(dp5477
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p5478
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p5479
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5480
sg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p5481
sg27
Nsg28
S'Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.| Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.| Diazepam: The co-administration of Fluvoxamine Tablets and diazepam is generally not advisable.| \r'
p5482
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIAZEPAM'
p5483
sa(dp5484
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p5485
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p5486
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5487
sg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p5488
sg27
Nsg28
S'Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.| Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.| Diazepam: The co-administration of Fluvoxamine Tablets and diazepam is generally not advisable.| \r'
p5489
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIAZEPAM'
p5490
sa(dp5491
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00296'
p5492
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p5493
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p5494
sg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p5495
sg27
Nsg28
S'Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. | \r'
p5496
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ROPIVACAINE'
p5497
sa(dp5498
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p5499
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p5500
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5501
sg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p5502
sg27
Nsg28
S'Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | \r'
p5503
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUMATRIPTAN SUCCINATE'
p5504
sa(dp5505
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p5506
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p5507
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5508
sg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p5509
sg27
Nsg28
S'Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | \r'
p5510
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUMATRIPTAN'
p5511
sa(dp5512
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00857'
p5513
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p5514
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5515
sg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p5516
sg27
Nsg28
S'Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.| \r'
p5517
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TERBINAFINE'
p5518
sa(dp5519
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p5520
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p5521
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5522
sg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p5523
sg27
Nsg28
S'Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.| RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d. | \r'
p5524
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TOLBUTAMIDE'
p5525
sa(dp5526
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00404'
p5527
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p5528
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5529
sg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p5530
sg27
Nsg28
S'Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).| \r'
p5531
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Xanax'
p5532
sa(dp5533
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p5534
sg5
S'http://bio2rdf.org/drugbank:DB00158'
p5535
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5536
sg23
Nsg24
Nsg25
S'FOLIC ACID'
p5537
sg27
Nsg28
S'Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.| \r'
p5538
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p5539
sa(dp5540
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p5541
sg5
S'http://bio2rdf.org/drugbank:DB00158'
p5542
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5543
sg23
Nsg24
Nsg25
S'FOLIC ACID'
p5544
sg27
Nsg28
S'Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.| \r'
p5545
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p5546
sa(dp5547
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00794'
p5548
sg5
S'http://bio2rdf.org/drugbank:DB00158'
p5549
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5550
sg23
Nsg24
Nsg25
S'FOLIC ACID'
p5551
sg27
Nsg28
S'Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.| \r'
p5552
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PRIMIDONE'
p5553
sa(dp5554
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00795'
p5555
sg5
S'http://bio2rdf.org/drugbank:DB00158'
p5556
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5557
sg23
Nsg24
Nsg25
S'FOLIC ACID'
p5558
sg27
Nsg28
S'Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine. | \r'
p5559
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SULFASALAZINE'
p5560
sa(dp5561
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p5562
sg5
S'http://bio2rdf.org/drugbank:DB00529'
p5563
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5564
sg23
Nsg24
Nsg25
S'FOSCARNET'
p5565
sg27
Nsg28
S'Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).| \r'
p5566
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HIVID'
p5567
sa(dp5568
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p5569
sg5
S'http://bio2rdf.org/drugbank:DB00529'
p5570
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5571
sg23
Nsg24
Nsg25
S'FOSCARNET'
p5572
sg27
Nsg28
S'Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).| \r'
p5573
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZALCITABINE'
p5574
sa(dp5575
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00681'
p5576
sg5
S'http://bio2rdf.org/drugbank:DB00529'
p5577
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5578
sg23
Nsg24
Nsg25
S'Foscavir'
p5579
sg27
Nsg28
S'Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.| \r'
p5580
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPHOTERICIN B'
p5581
sa(dp5582
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00738'
p5583
sg5
S'http://bio2rdf.org/drugbank:DB00529'
p5584
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5585
sg23
Nsg24
Nsg25
S'Foscavir'
p5586
sg27
Nsg28
S'A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.| Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.| Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;| \r'
p5587
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PENTAMIDINE'
p5588
sa(dp5589
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00738'
p5590
sg5
S'http://bio2rdf.org/drugbank:DB00529'
p5591
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5592
sg23
Nsg24
Nsg25
S'Foscavir'
p5593
sg27
Nsg28
S'A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.| Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.| Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;| \r'
p5594
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PENTAMIDINE'
p5595
sa(dp5596
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00738'
p5597
sg5
S'http://bio2rdf.org/drugbank:DB00529'
p5598
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p5599
sg23
Nsg24
Nsg25
S'Foscavir'
p5600
sg27
Nsg28
S'A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.| Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.| Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;| \r'
p5601
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PENTAMIDINE'
p5602
sa(dp5603
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p5604
sg5
S'http://bio2rdf.org/drugbank:DB00695'
p5605
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5606
sg23
Nsg24
Nsg25
S'FUROSEMIDE'
p5607
sg27
Nsg28
S'Tablets, Injection, and Oral Solution One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency.| \r'
p5608
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p5609
sa(dp5610
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00903'
p5611
sg5
S'http://bio2rdf.org/drugbank:DB00695'
p5612
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5613
sg23
Nsg24
Nsg25
S'FUROSEMIDE'
p5614
sg27
Nsg28
S'Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity.| \r'
p5615
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ETHACRYNIC ACID'
p5616
sa(dp5617
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01240'
p5618
sg5
S'http://bio2rdf.org/drugbank:DB00695'
p5619
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5620
sg23
Nsg24
Nsg25
S'FUROSEMIDE'
p5621
sg27
Nsg28
S'In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.| \r'
p5622
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Flolan'
p5623
sa(dp5624
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00524'
p5625
sg5
S'http://bio2rdf.org/drugbank:DB00695'
p5626
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5627
sg23
Nsg24
Nsg25
S'FUROSEMIDE'
p5628
sg27
Nsg28
S'Diuretics: Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes. | \r'
p5629
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Metolazone'
p5630
sa(dp5631
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00814'
p5632
sg5
S'http://bio2rdf.org/drugbank:DB00695'
p5633
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5634
sg23
Nsg24
Nsg25
S'FUROSEMIDE'
p5635
sg27
Nsg28
S'Nevertheless, during concomitant therapy with furosemide and MOBIC, patients should be observed closely for signs of declining renal function, as well as to assure diuretic efficacy. | \r'
p5636
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Mobic'
p5637
sa(dp5638
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00368'
p5639
sg5
S'http://bio2rdf.org/drugbank:DB00695'
p5640
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5641
sg23
Nsg24
Nsg25
S'FUROSEMIDE'
p5642
sg27
Nsg28
S'Furosemide may decrease arterial responsiveness to norepinephrine.| \r'
p5643
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NOREPINEPHRINE'
p5644
sa(dp5645
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00202'
p5646
sg5
S'http://bio2rdf.org/drugbank:DB00695'
p5647
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5648
sg23
Nsg24
Nsg25
S'FUROSEMIDE'
p5649
sg27
Nsg28
S'Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.| \r'
p5650
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUCCINYLCHOLINE'
p5651
sa(dp5652
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01199'
p5653
sg5
S'http://bio2rdf.org/drugbank:DB00695'
p5654
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5655
sg23
Nsg24
Nsg25
S'FUROSEMIDE'
p5656
sg27
Nsg28
S'Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.| \r'
p5657
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TUBOCURARINE'
p5658
sa(dp5659
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p5660
sg5
S'http://bio2rdf.org/drugbank:DB00996'
p5661
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5662
sg23
Nsg24
Nsg25
S'GABAPENTIN'
p5663
sg27
Nsg28
S'This small decrease in excretion of gabapentin by cimetidine is not expected to be of clinical importance.| \r'
p5664
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIMETIDINE'
p5665
sa(dp5666
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p5667
sg5
S'http://bio2rdf.org/drugbank:DB01241'
p5668
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5669
sg23
Nsg24
Nsg25
S'GEMFIBROZIL'
p5670
sg27
Nsg28
S'On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.| \r'
p5671
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BEXAROTENE'
p5672
sa(dp5673
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p5674
sg5
S'http://bio2rdf.org/drugbank:DB01241'
p5675
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5676
sg23
Nsg24
Nsg25
S'GEMFIBROZIL'
p5677
sg27
Nsg28
S'Concomitant administration of gemfibrozil with Targretin capsules is not recommended.| \r'
p5678
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Targretin'
p5679
sa(dp5680
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01211'
p5681
sg5
S'http://bio2rdf.org/drugbank:DB00619'
p5682
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5683
sg23
Nsg24
Nsg25
S'Gleevec'
p5684
sg27
Nsg28
S'Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).| \r'
p5685
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLARITHROMYCIN'
p5686
sa(dp5687
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p5688
sg5
S'http://bio2rdf.org/drugbank:DB00619'
p5689
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5690
sg23
Nsg24
Nsg25
S'Gleevec'
p5691
sg27
Nsg28
S'Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).| \r'
p5692
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSPORINE'
p5693
sa(dp5694
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p5695
sg5
S'http://bio2rdf.org/drugbank:DB00619'
p5696
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5697
sg23
Nsg24
Nsg25
S'Gleevec'
p5698
sg27
Nsg28
S'Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).| \r'
p5699
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERYTHROMYCIN'
p5700
sa(dp5701
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p5702
sg5
S'http://bio2rdf.org/drugbank:DB00619'
p5703
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5704
sg23
Nsg24
Nsg25
S'Gleevec'
p5705
sg27
Nsg28
S'Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).| There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).| \r'
p5706
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p5707
sa(dp5708
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p5709
sg5
S'http://bio2rdf.org/drugbank:DB00619'
p5710
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5711
sg23
Nsg24
Nsg25
S'Gleevec'
p5712
sg27
Nsg28
S'Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).| There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).| \r'
p5713
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p5714
sa(dp5715
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01100'
p5716
sg5
S'http://bio2rdf.org/drugbank:DB00619'
p5717
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5718
sg23
Nsg24
Nsg25
S'Gleevec'
p5719
sg27
Nsg28
S'Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).| \r'
p5720
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PIMOZIDE'
p5721
sa(dp5722
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00641'
p5723
sg5
S'http://bio2rdf.org/drugbank:DB00619'
p5724
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5725
sg23
Nsg24
Nsg25
S'Gleevec'
p5726
sg27
Nsg28
S'Drugs that may have their plasma concentration altered by Gleevec Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec.| \r'
p5727
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SIMVASTATIN'
p5728
sa(dp5729
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p5730
sg5
S'http://bio2rdf.org/drugbank:DB00222'
p5731
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5732
sg23
Nsg24
Nsg25
S'GLIMEPIRIDE'
p5733
sg27
Nsg28
S'Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);| \r'
p5734
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p5735
sa(dp5736
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01294'
p5737
sg5
S'http://bio2rdf.org/drugbank:DB00222'
p5738
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5739
sg23
Nsg24
Nsg25
S'GLIMEPIRIDE'
p5740
sg27
Nsg28
S'Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);| \r'
p5741
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BISMUTH SUBSALICYLATE'
p5742
sa(dp5743
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01399'
p5744
sg5
S'http://bio2rdf.org/drugbank:DB00222'
p5745
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5746
sg23
Nsg24
Nsg25
S'GLIMEPIRIDE'
p5747
sg27
Nsg28
S'Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);| \r'
p5748
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Disalcid'
p5749
sa(dp5750
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01397'
p5751
sg5
S'http://bio2rdf.org/drugbank:DB00222'
p5752
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5753
sg23
Nsg24
Nsg25
S'GLIMEPIRIDE'
p5754
sg27
Nsg28
S'Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);| \r'
p5755
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MAGNESIUM SALICYLATE ANHYDROUS'
p5756
sa(dp5757
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01397'
p5758
sg5
S'http://bio2rdf.org/drugbank:DB00222'
p5759
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5760
sg23
Nsg24
Nsg25
S'GLIMEPIRIDE'
p5761
sg27
Nsg28
S'Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);| \r'
p5762
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MAGNESIUM SALICYLATE'
p5763
sa(dp5764
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01294'
p5765
sg5
S'http://bio2rdf.org/drugbank:DB00222'
p5766
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5767
sg23
Nsg24
Nsg25
S'GLIMEPIRIDE'
p5768
sg27
Nsg28
S'Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);| \r'
p5769
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Pepto-bismol'
p5770
sa(dp5771
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01399'
p5772
sg5
S'http://bio2rdf.org/drugbank:DB00222'
p5773
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5774
sg23
Nsg24
Nsg25
S'GLIMEPIRIDE'
p5775
sg27
Nsg28
S'Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);| \r'
p5776
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SALSALATE'
p5777
sa(dp5778
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p5779
sg5
S'http://bio2rdf.org/drugbank:DB01067'
p5780
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5781
sg23
Nsg24
Nsg25
S'GLIPIZIDE'
p5782
sg27
Nsg28
S'The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).| \r'
p5783
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p5784
sa(dp5785
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00328'
p5786
sg5
S'http://bio2rdf.org/drugbank:DB00130'
p5787
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5788
sg23
Nsg24
Nsg25
S'GLUTAMINE'
p5789
sg27
Nsg28
S'Indomethacin - Concomitant use of L-glutamine and indomethacin may ameliorate increased intestinal permeability caused by indomethacin.| \r'
p5790
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDOMETHACIN'
p5791
sa(dp5792
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01229'
p5793
sg5
S'http://bio2rdf.org/drugbank:DB00130'
p5794
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5795
sg23
Nsg24
Nsg25
S'GLUTAMINE'
p5796
sg27
Nsg28
S'Paclitaxel - In one report, L-glutamine at a dose of 10 grams three times daily, given 24 hours after receiving paclitaxel, appeared to prevent the development of myalgia and arthralgia, adverse reactions of paclitaxel.| \r'
p5797
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PACLITAXEL'
p5798
sa(dp5799
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00537'
p5800
sg5
S'http://bio2rdf.org/drugbank:DB01016'
p5801
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p5802
sg23
Nsg24
Nsg25
S'GLYBURIDE'
p5803
sg27
Nsg28
S'A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.| \r'
p5804
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIPROFLOXACIN'
p5805
sa(dp5806
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00580'
p5807
sg5
S'http://bio2rdf.org/drugbank:DB01016'
p5808
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5809
sg23
Nsg24
Nsg25
S'GLYBURIDE'
p5810
sg27
Nsg28
S'Because changes in glucose concentrations with valdecoxib coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for glyburide (5 mg QD and 10 mg BID) with valdecoxib coadministration (up to 40 mg QD) is not indicated.| \r'
p5811
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VALDECOXIB'
p5812
sa(dp5813
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00855'
p5814
sg5
S'http://bio2rdf.org/drugbank:DB00400'
p5815
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5816
sg23
Nsg24
Nsg25
S'GRISEOFULVIN'
p5817
sg27
Nsg28
S'It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.| \r'
p5818
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Levulan Kerastick'
p5819
sa(dp5820
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00350'
p5821
sg5
S'http://bio2rdf.org/drugbank:DB01170'
p5822
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5823
sg23
Nsg24
Nsg25
S'GUANETHIDINE'
p5824
sg27
Nsg28
S'If at all possible guanethidine should be discontinued well before minoxidil is begun. | \r'
p5825
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MINOXIDIL'
p5826
sa(dp5827
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00612'
p5828
sg5
S'http://bio2rdf.org/drugbank:DB01170'
p5829
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5830
sg23
Nsg24
Nsg25
S'GUANETHIDINE'
p5831
sg27
Nsg28
S'Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.| \r'
p5832
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Zebeta'
p5833
sa(dp5834
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p5835
sg5
S'http://bio2rdf.org/drugbank:DB01018'
p5836
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5837
sg23
Nsg24
Nsg25
S'GUANFACINE'
p5838
sg27
Nsg28
S'The administration of guanfacine concomitantly with known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.| \r'
p5839
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p5840
sa(dp5841
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p5842
sg5
S'http://bio2rdf.org/drugbank:DB01018'
p5843
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5844
sg23
Nsg24
Nsg25
S'GUANFACINE'
p5845
sg27
Nsg28
S'The administration of guanfacine concomitantly with known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.| \r'
p5846
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p5847
sa(dp5848
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p5849
sg5
S'http://bio2rdf.org/drugbank:DB00502'
p5850
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5851
sg23
Nsg24
Nsg25
S'Haldol'
p5852
sg27
Nsg28
S'As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.| \r'
p5853
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p5854
sa(dp5855
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00988'
p5856
sg5
S'http://bio2rdf.org/drugbank:DB00502'
p5857
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5858
sg23
Nsg24
Nsg25
S'HALOPERIDOL'
p5859
sg27
Nsg28
S'Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.| \r'
p5860
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOPAMINE'
p5861
sa(dp5862
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB03575'
p5863
sg5
S'http://bio2rdf.org/drugbank:DB00502'
p5864
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5865
sg23
Nsg24
Nsg25
S'HALOPERIDOL'
p5866
sg27
Nsg28
S'Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. | \r'
p5867
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PCP'
p5868
sa(dp5869
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p5870
sg5
S'http://bio2rdf.org/drugbank:DB00502'
p5871
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5872
sg23
Nsg24
Nsg25
S'HALOPERIDOL'
p5873
sg27
Nsg28
S'In a study of 12 schizophrenic patients coadministered oral haloperidol and rifampin, plasma haloperidol levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.| \r'
p5874
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFAMPIN'
p5875
sa(dp5876
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p5877
sg5
S'http://bio2rdf.org/drugbank:DB00999'
p5878
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5879
sg23
Nsg24
Nsg25
S'HCTZ'
p5880
sg27
Nsg28
S'In patients receiving HCTZ alone, dofetilide AUC increased by 27% and Cmax by 21%.| \r'
p5881
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOFETILIDE'
p5882
sa(dp5883
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01259'
p5884
sg5
S'http://bio2rdf.org/drugbank:DB00072'
p5885
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5886
sg23
Nsg24
Nsg25
S'Herceptin'
p5887
sg27
Nsg28
S'Furthermore, we present a case report in which a second Herceptin treatment following lapatinib resulted in the marked shrinkage of multiple metastatic tumors in HER2-positive breast cancer. | \r'
p5888
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LAPATINIB DITOSYLATE'
p5889
sa(dp5890
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01259'
p5891
sg5
S'http://bio2rdf.org/drugbank:DB00072'
p5892
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5893
sg23
Nsg24
Nsg25
S'Herceptin'
p5894
sg27
Nsg28
S'Furthermore, we present a case report in which a second Herceptin treatment following lapatinib resulted in the marked shrinkage of multiple metastatic tumors in HER2-positive breast cancer. | \r'
p5895
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LAPATINIB'
p5896
sa(dp5897
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00515'
p5898
sg5
S'http://bio2rdf.org/drugbank:DB00488'
p5899
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5900
sg23
Nsg24
Nsg25
S'Hexalen'
p5901
sg27
Nsg28
S'Data from a randomized trial of HEXALEN and cisplatin plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity;| \r'
p5902
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CISPLATIN'
p5903
sa(dp5904
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00603'
p5905
sg5
S'http://bio2rdf.org/drugbank:DB00117'
p5906
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5907
sg23
Nsg24
Nsg25
S'HISTIDINE'
p5908
sg27
Nsg28
S'Medroxyprogesterone Acetate - L-histidine was observed to enhance (in tissue culture) the effect of medroxyprogesterone acetate in reducing the number of human breast cancer cells that were in the S phase.| \r'
p5909
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MEDROXYPROGESTERONE ACETATE'
p5910
sa(dp5911
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p5912
sg5
S'http://bio2rdf.org/drugbank:DB00943'
p5913
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5914
sg23
Nsg24
Nsg25
S'HIVID'
p5915
sg27
Nsg28
S'Concomitant use of HIVID with didanosine is not recommended.| \r'
p5916
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIDANOSINE'
p5917
sa(dp5918
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00413'
p5919
sg5
S'http://bio2rdf.org/drugbank:DB00999'
p5920
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5921
sg23
Nsg24
Nsg25
S'HYDROCHLOROTHIAZIDE'
p5922
sg27
Nsg28
S'Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | \r'
p5923
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PRAMIPEXOLE'
p5924
sa(dp5925
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00996'
p5926
sg5
S'http://bio2rdf.org/drugbank:DB00956'
p5927
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5928
sg23
Nsg24
Nsg25
S'HYDROCODONE'
p5929
sg27
Nsg28
S'Hydrocodone increases gabapentin AUC values by 14%.| \r'
p5930
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GABAPENTIN'
p5931
sa(dp5932
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00419'
p5933
sg5
S'http://bio2rdf.org/drugbank:DB06720'
p5934
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5935
sg23
Nsg24
Nsg25
S'Imiglucerase'
p5936
sg27
Nsg28
S'Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.| \r'
p5937
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Zavesca'
p5938
sa(dp5939
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00404'
p5940
sg5
S'http://bio2rdf.org/drugbank:DB00458'
p5941
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5942
sg23
Nsg24
Nsg25
S'IMIPRAMINE'
p5943
sg27
Nsg28
S'The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.| \r'
p5944
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALPRAZOLAM'
p5945
sa(dp5946
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p5947
sg5
S'http://bio2rdf.org/drugbank:DB00458'
p5948
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5949
sg23
Nsg24
Nsg25
S'IMIPRAMINE'
p5950
sg27
Nsg28
S'The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.| \r'
p5951
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIMETIDINE'
p5952
sa(dp5953
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p5954
sg5
S'http://bio2rdf.org/drugbank:DB00458'
p5955
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5956
sg23
Nsg24
Nsg25
S'IMIPRAMINE'
p5957
sg27
Nsg28
S'The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.| \r'
p5958
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p5959
sa(dp5960
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00261'
p5961
sg5
S'http://bio2rdf.org/drugbank:DB01427'
p5962
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p5963
sg23
Nsg24
Nsg25
S'INAMRINONE'
p5964
sg27
Nsg28
S'The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.| \r'
p5965
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ANAGRELIDE'
p5966
sa(dp5967
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00701'
p5968
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p5969
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5970
sg23
Nsg24
Nsg25
S'INDINAVIR ANHYDROUS'
p5971
sg27
Nsg28
S'Indinavir steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant amprenavir.| \r'
p5972
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPRENAVIR'
p5973
sa(dp5974
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p5975
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p5976
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5977
sg23
Nsg24
Nsg25
S'INDINAVIR ANHYDROUS'
p5978
sg27
Nsg28
S'Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| \r'
p5979
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p5980
sa(dp5981
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p5982
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p5983
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p5984
sg23
Nsg24
Nsg25
S'INDINAVIR ANHYDROUS'
p5985
sg27
Nsg28
S'Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. | Indinavir may be taken with a light meal 1 h following the administration of 400 mg of didanosine.| Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.| Median gastric pH was significantly higher when indinavir was taken after didanosine administration; | \r'
p5986
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIDANOSINE'
p5987
sa(dp5988
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p5989
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p5990
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5991
sg23
Nsg24
Nsg25
S'INDINAVIR ANHYDROUS'
p5992
sg27
Nsg28
S'Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. | Indinavir may be taken with a light meal 1 h following the administration of 400 mg of didanosine.| Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.| Median gastric pH was significantly higher when indinavir was taken after didanosine administration; | \r'
p5993
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIDANOSINE'
p5994
sa(dp5995
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00625'
p5996
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p5997
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p5998
sg23
Nsg24
Nsg25
S'INDINAVIR ANHYDROUS'
p5999
sg27
Nsg28
S'Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to efavirenz.| \r'
p6000
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EFAVIRENZ'
p6001
sa(dp6002
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00351'
p6003
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6004
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p6005
sg23
Nsg24
Nsg25
S'INDINAVIR ANHYDROUS'
p6006
sg27
Nsg28
S'Administration of a higher dose of indinavir should be considered when coadministering with megestrol acetate. | \r'
p6007
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MEGESTROL ACETATE'
p6008
sa(dp6009
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00238'
p6010
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6011
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6012
sg23
Nsg24
Nsg25
S'INDINAVIR ANHYDROUS'
p6013
sg27
Nsg28
S'Indinavir concentrations may be decreased in the presence of nevirapine.| \r'
p6014
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NEVIRAPINE'
p6015
sa(dp6016
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p6017
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6018
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p6019
sg23
Nsg24
Nsg25
S'INDINAVIR ANHYDROUS'
p6020
sg27
Nsg28
S'Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving indinavir in combination with ritonavir than those receiving CRIXIVAN 800 mg q8h.| \r'
p6021
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p6022
sa(dp6023
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00625'
p6024
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6025
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6026
sg23
Nsg24
Nsg25
S'INDINAVIR ANHYDROUS'
p6027
sg27
Nsg28
S'When indinavir at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when indinavir (800 mg every 8 hours) was given alone.| Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to SUSTIVA.| \r'
p6028
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sustiva'
p6029
sa(dp6030
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00862'
p6031
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6032
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6033
sg23
Nsg24
Nsg25
S'INDINAVIR ANHYDROUS'
p6034
sg27
Nsg28
S'HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.| \r'
p6035
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VARDENAFIL'
p6036
sa(dp6037
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p6038
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6039
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p6040
sg23
Nsg24
Nsg25
S'INDINAVIR ANHYDROUS'
p6041
sg27
Nsg28
S'To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.| Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.| \r'
p6042
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Videx'
p6043
sa(dp6044
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p6045
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6046
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6047
sg23
Nsg24
Nsg25
S'INDINAVIR ANHYDROUS'
p6048
sg27
Nsg28
S'To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.| Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.| \r'
p6049
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Videx'
p6050
sa(dp6051
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p6052
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6053
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6054
sg23
Nsg24
Nsg25
S'INDINAVIR ANHYDROUS'
p6055
sg27
Nsg28
S'Indinavir: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.| \r'
p6056
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Viracept'
p6057
sa(dp6058
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00701'
p6059
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6060
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6061
sg23
Nsg24
Nsg25
S'INDINAVIR'
p6062
sg27
Nsg28
S'Indinavir steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant amprenavir.| \r'
p6063
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPRENAVIR'
p6064
sa(dp6065
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p6066
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6067
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6068
sg23
Nsg24
Nsg25
S'INDINAVIR'
p6069
sg27
Nsg28
S'Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| \r'
p6070
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p6071
sa(dp6072
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p6073
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6074
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p6075
sg23
Nsg24
Nsg25
S'INDINAVIR'
p6076
sg27
Nsg28
S'Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. | Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.| Median gastric pH was significantly higher when indinavir was taken after didanosine administration; | Indinavir may be taken with a light meal 1 h following the administration of 400 mg of didanosine.| \r'
p6077
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIDANOSINE'
p6078
sa(dp6079
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p6080
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6081
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6082
sg23
Nsg24
Nsg25
S'INDINAVIR'
p6083
sg27
Nsg28
S'Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. | Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.| Median gastric pH was significantly higher when indinavir was taken after didanosine administration; | Indinavir may be taken with a light meal 1 h following the administration of 400 mg of didanosine.| \r'
p6084
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIDANOSINE'
p6085
sa(dp6086
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00625'
p6087
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6088
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6089
sg23
Nsg24
Nsg25
S'INDINAVIR'
p6090
sg27
Nsg28
S'Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to efavirenz.| \r'
p6091
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EFAVIRENZ'
p6092
sa(dp6093
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00351'
p6094
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6095
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p6096
sg23
Nsg24
Nsg25
S'INDINAVIR'
p6097
sg27
Nsg28
S'Administration of a higher dose of indinavir should be considered when coadministering with megestrol acetate. | \r'
p6098
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MEGESTROL ACETATE'
p6099
sa(dp6100
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00238'
p6101
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6102
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6103
sg23
Nsg24
Nsg25
S'INDINAVIR'
p6104
sg27
Nsg28
S'Indinavir concentrations may be decreased in the presence of nevirapine.| \r'
p6105
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NEVIRAPINE'
p6106
sa(dp6107
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p6108
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6109
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p6110
sg23
Nsg24
Nsg25
S'INDINAVIR'
p6111
sg27
Nsg28
S'Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving indinavir in combination with ritonavir than those receiving CRIXIVAN 800 mg q8h.| \r'
p6112
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p6113
sa(dp6114
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00625'
p6115
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6116
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6117
sg23
Nsg24
Nsg25
S'INDINAVIR'
p6118
sg27
Nsg28
S'Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to SUSTIVA.| When indinavir at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when indinavir (800 mg every 8 hours) was given alone.| \r'
p6119
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sustiva'
p6120
sa(dp6121
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00862'
p6122
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6123
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6124
sg23
Nsg24
Nsg25
S'INDINAVIR'
p6125
sg27
Nsg28
S'HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.| \r'
p6126
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VARDENAFIL'
p6127
sa(dp6128
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p6129
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6130
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p6131
sg23
Nsg24
Nsg25
S'INDINAVIR'
p6132
sg27
Nsg28
S'To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.| Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.| \r'
p6133
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Videx'
p6134
sa(dp6135
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p6136
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6137
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6138
sg23
Nsg24
Nsg25
S'INDINAVIR'
p6139
sg27
Nsg28
S'To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.| Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.| \r'
p6140
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Videx'
p6141
sa(dp6142
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p6143
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6144
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6145
sg23
Nsg24
Nsg25
S'INDINAVIR'
p6146
sg27
Nsg28
S'Indinavir: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.| \r'
p6147
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Viracept'
p6148
sa(dp6149
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01197'
p6150
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6151
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p6152
sg23
Nsg24
Nsg25
S'Indocin'
p6153
sg27
Nsg28
S'INDOCIN can reduce the antihypertensive effects of captopril and losartan.| \r'
p6154
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CAPTOPRIL'
p6155
sa(dp6156
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00861'
p6157
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6158
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p6159
sg23
Nsg24
Nsg25
S'Indocin'
p6160
sg27
Nsg28
S'In some patients, combined use of INDOCIN and diflunisal has been associated with fatal gastrointestinal hemorrhage.| \r'
p6161
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIFLUNISAL'
p6162
sa(dp6163
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p6164
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6165
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p6166
sg23
Nsg24
Nsg25
S'Indocin'
p6167
sg27
Nsg28
S'Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored.| INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.| \r'
p6168
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p6169
sa(dp6170
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p6171
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6172
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6173
sg23
Nsg24
Nsg25
S'Indocin'
p6174
sg27
Nsg28
S'Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored.| INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.| \r'
p6175
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p6176
sa(dp6177
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p6178
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6179
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p6180
sg23
Nsg24
Nsg25
S'Indocin'
p6181
sg27
Nsg28
S'As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity.| Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.| \r'
p6182
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM CATION'
p6183
sa(dp6184
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p6185
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6186
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6187
sg23
Nsg24
Nsg25
S'Indocin'
p6188
sg27
Nsg28
S'As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity.| Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.| \r'
p6189
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM CATION'
p6190
sa(dp6191
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p6192
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6193
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p6194
sg23
Nsg24
Nsg25
S'Indocin'
p6195
sg27
Nsg28
S'As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity.| Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.| \r'
p6196
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM'
p6197
sa(dp6198
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p6199
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6200
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6201
sg23
Nsg24
Nsg25
S'Indocin'
p6202
sg27
Nsg28
S'As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity.| Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.| \r'
p6203
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM'
p6204
sa(dp6205
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00678'
p6206
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6207
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p6208
sg23
Nsg24
Nsg25
S'Indocin'
p6209
sg27
Nsg28
S'INDOCIN can reduce the antihypertensive effects of captopril and losartan.| \r'
p6210
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LOSARTAN'
p6211
sa(dp6212
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p6213
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6214
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p6215
sg23
Nsg24
Nsg25
S'Indocin'
p6216
sg27
Nsg28
S'INDOCIN has been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.| Caution should be used if INDOCIN is administered simultaneously with methotrexate.| \r'
p6217
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHOTREXATE'
p6218
sa(dp6219
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p6220
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6221
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6222
sg23
Nsg24
Nsg25
S'Indocin'
p6223
sg27
Nsg28
S'INDOCIN has been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.| Caution should be used if INDOCIN is administered simultaneously with methotrexate.| \r'
p6224
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHOTREXATE'
p6225
sa(dp6226
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p6227
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6228
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6229
sg23
Nsg24
Nsg25
S'Indocin'
p6230
sg27
Nsg28
S'When INDOCIN is given to patients receiving probenecid, the plasma levels of indomethacin are likely to be increased.| \r'
p6231
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROBENECID'
p6232
sa(dp6233
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00384'
p6234
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6235
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p6236
sg23
Nsg24
Nsg25
S'Indocin'
p6237
sg27
Nsg28
S'INDOCIN and triamterene should not be administered together.| \r'
p6238
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TRIAMTERENE'
p6239
sa(dp6240
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00887'
p6241
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6242
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p6243
sg23
Nsg24
Nsg25
S'INDOMETHACIN'
p6244
sg27
Nsg28
S'- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.| - Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.| \r'
p6245
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BUMETANIDE'
p6246
sa(dp6247
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00887'
p6248
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6249
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6250
sg23
Nsg24
Nsg25
S'INDOMETHACIN'
p6251
sg27
Nsg28
S'- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.| - Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.| \r'
p6252
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BUMETANIDE'
p6253
sa(dp6254
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01197'
p6255
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6256
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p6257
sg23
Nsg24
Nsg25
S'INDOMETHACIN'
p6258
sg27
Nsg28
S'Inhibitors Of Endogenous Prostaglandin Synthesis It has been reported that indomethacin may reduce the antihypertensive effect of captopril, especially in cases of low renin hypertension.| \r'
p6259
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CAPTOPRIL'
p6260
sa(dp6261
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00861'
p6262
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6263
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p6264
sg23
Nsg24
Nsg25
S'INDOMETHACIN'
p6265
sg27
Nsg28
S'In some patients the combined use of indomethacin and diflunisal has been associated with fatal gastrointestinal hemorrhage.| Therefore, indomethacin and diflunisal should not be used concomitantly.| \r'
p6266
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIFLUNISAL'
p6267
sa(dp6268
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00861'
p6269
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6270
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p6271
sg23
Nsg24
Nsg25
S'INDOMETHACIN'
p6272
sg27
Nsg28
S'In some patients the combined use of indomethacin and diflunisal has been associated with fatal gastrointestinal hemorrhage.| Therefore, indomethacin and diflunisal should not be used concomitantly.| \r'
p6273
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIFLUNISAL'
p6274
sa(dp6275
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p6276
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6277
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6278
sg23
Nsg24
Nsg25
S'INDOMETHACIN'
p6279
sg27
Nsg28
S'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| \r'
p6280
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p6281
sa(dp6282
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00695'
p6283
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6284
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p6285
sg23
Nsg24
Nsg25
S'INDOMETHACIN'
p6286
sg27
Nsg28
S'Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis.| Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.| \r'
p6287
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FUROSEMIDE'
p6288
sa(dp6289
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00695'
p6290
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6291
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p6292
sg23
Nsg24
Nsg25
S'INDOMETHACIN'
p6293
sg27
Nsg28
S'Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis.| Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.| \r'
p6294
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FUROSEMIDE'
p6295
sa(dp6296
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00594'
p6297
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6298
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p6299
sg23
Nsg24
Nsg25
S'INDOMETHACIN'
p6300
sg27
Nsg28
S'Since indomethacin and potassium-sparing diuretics, including MIDAMOR, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.| \r'
p6301
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Midamor'
p6302
sa(dp6303
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00413'
p6304
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6305
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6306
sg23
Nsg24
Nsg25
S'INDOMETHACIN'
p6307
sg27
Nsg28
S'Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | \r'
p6308
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PRAMIPEXOLE'
p6309
sa(dp6310
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00041'
p6311
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6312
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p6313
sg23
Nsg24
Nsg25
S'INDOMETHACIN'
p6314
sg27
Nsg28
S'Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.| \r'
p6315
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Proleukin'
p6316
sa(dp6317
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p6318
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p6319
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6320
sg23
Nsg24
Nsg25
S'INH'
p6321
sg27
Nsg28
S'INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.| \r'
p6322
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p6323
sa(dp6324
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00584'
p6325
sg5
S'http://bio2rdf.org/drugbank:DB00700'
p6326
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p6327
sg23
Nsg24
Nsg25
S'INSPRA'
p6328
sg27
Nsg28
S'In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the ACE inhibitor enalapril 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.| \r'
p6329
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ENALAPRIL'
p6330
sa(dp6331
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p6332
sg5
S'http://bio2rdf.org/drugbank:DB00700'
p6333
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6334
sg23
Nsg24
Nsg25
S'INSPRA'
p6335
sg27
Nsg28
S'A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone.| \r'
p6336
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p6337
sa(dp6338
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p6339
sg5
S'http://bio2rdf.org/drugbank:DB00700'
p6340
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p6341
sg23
Nsg24
Nsg25
S'INSPRA'
p6342
sg27
Nsg28
S'Serum lithium levels should be monitored frequently if INSPRA is administered concomitantly with lithium.| \r'
p6343
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM CATION'
p6344
sa(dp6345
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p6346
sg5
S'http://bio2rdf.org/drugbank:DB00700'
p6347
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p6348
sg23
Nsg24
Nsg25
S'INSPRA'
p6349
sg27
Nsg28
S'Serum lithium levels should be monitored frequently if INSPRA is administered concomitantly with lithium.| \r'
p6350
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM'
p6351
sa(dp6352
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p6353
sg5
S'http://bio2rdf.org/drugbank:DB01267'
p6354
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p6355
sg23
Nsg24
Nsg25
S'Invega'
p6356
sg27
Nsg28
S'Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. | \r'
p6357
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p6358
sa(dp6359
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p6360
sg5
S'http://bio2rdf.org/drugbank:DB01232'
p6361
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p6362
sg23
Nsg24
Nsg25
S'Invirase'
p6363
sg27
Nsg28
S'Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered.| \r'
p6364
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p6365
sa(dp6366
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00389'
p6367
sg5
S'http://bio2rdf.org/drugbank:DB05382'
p6368
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p6369
sg23
Nsg24
Nsg25
S'IODINE'
p6370
sg27
Nsg28
S'Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.| \r'
p6371
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CARBIMAZOLE'
p6372
sa(dp6373
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p6374
sg5
S'http://bio2rdf.org/drugbank:DB00964'
p6375
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p6376
sg23
Nsg24
Nsg25
S'Iopidine'
p6377
sg27
Nsg28
S'Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.| \r'
p6378
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p6379
sa(dp6380
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01258'
p6381
sg5
S'http://bio2rdf.org/drugbank:DB01029'
p6382
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6383
sg23
Nsg24
Nsg25
S'IRBESARTAN'
p6384
sg27
Nsg28
S'Co-administration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.| \r'
p6385
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALISKIREN'
p6386
sa(dp6387
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00361'
p6388
sg5
S'http://bio2rdf.org/drugbank:DB00317'
p6389
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p6390
sg23
Nsg24
Nsg25
S'Iressa'
p6391
sg27
Nsg28
S'Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine.| \r'
p6392
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VINORELBINE'
p6393
sa(dp6394
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00190'
p6395
sg5
S'http://bio2rdf.org/drugbank:DB01592'
p6396
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6397
sg23
Nsg24
Nsg25
S'IRON'
p6398
sg27
Nsg28
S'Iron salts may reduce the bioavailability of carbidopa and levodopa.| \r'
p6399
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CARBIDOPA'
p6400
sa(dp6401
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01155'
p6402
sg5
S'http://bio2rdf.org/drugbank:DB01592'
p6403
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p6404
sg23
Nsg24
Nsg25
S'IRON'
p6405
sg27
Nsg28
S'Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| \r'
p6406
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Factive'
p6407
sa(dp6408
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00710'
p6409
sg5
S'http://bio2rdf.org/drugbank:DB01592'
p6410
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6411
sg23
Nsg24
Nsg25
S'IRON'
p6412
sg27
Nsg28
S'Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.| \r'
p6413
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'IBANDRONIC ACID'
p6414
sa(dp6415
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01235'
p6416
sg5
S'http://bio2rdf.org/drugbank:DB01592'
p6417
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6418
sg23
Nsg24
Nsg25
S'IRON'
p6419
sg27
Nsg28
S'Iron salts may reduce the bioavailability of carbidopa and levodopa.| \r'
p6420
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LEVODOPA'
p6421
sa(dp6422
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01059'
p6423
sg5
S'http://bio2rdf.org/drugbank:DB01592'
p6424
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p6425
sg23
Nsg24
Nsg25
S'IRON'
p6426
sg27
Nsg28
S'Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.| \r'
p6427
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NORFLOXACIN'
p6428
sa(dp6429
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00822'
p6430
sg5
S'http://bio2rdf.org/drugbank:DB01247'
p6431
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p6432
sg23
Nsg24
Nsg25
S'ISOCARBOXAZID'
p6433
sg27
Nsg28
S'Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories).| \r'
p6434
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Antabuse'
p6435
sa(dp6436
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00822'
p6437
sg5
S'http://bio2rdf.org/drugbank:DB01247'
p6438
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p6439
sg23
Nsg24
Nsg25
S'ISOCARBOXAZID'
p6440
sg27
Nsg28
S'Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories).| \r'
p6441
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DISULFIRAM'
p6442
sa(dp6443
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00565'
p6444
sg5
S'http://bio2rdf.org/drugbank:DB00753'
p6445
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p6446
sg23
Nsg24
Nsg25
S'Isoflurane'
p6447
sg27
Nsg28
S'Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.| In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.| \r'
p6448
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nimbex'
p6449
sa(dp6450
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00565'
p6451
sg5
S'http://bio2rdf.org/drugbank:DB00753'
p6452
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p6453
sg23
Nsg24
Nsg25
S'Isoflurane'
p6454
sg27
Nsg28
S'Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.| In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.| \r'
p6455
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nimbex'
p6456
sa(dp6457
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01135'
p6458
sg5
S'http://bio2rdf.org/drugbank:DB00753'
p6459
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6460
sg23
Nsg24
Nsg25
S'Isoflurane'
p6461
sg27
Nsg28
S'Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.| \r'
p6462
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nuromax'
p6463
sa(dp6464
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p6465
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p6466
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p6467
sg23
Nsg24
Nsg25
S'ISONIAZID'
p6468
sg27
Nsg28
S'It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed.| Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites.| \r'
p6469
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACETAMINOPHEN'
p6470
sa(dp6471
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p6472
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p6473
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6474
sg23
Nsg24
Nsg25
S'ISONIAZID'
p6475
sg27
Nsg28
S'It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed.| Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites.| \r'
p6476
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACETAMINOPHEN'
p6477
sa(dp6478
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p6479
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p6480
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6481
sg23
Nsg24
Nsg25
S'ISONIAZID'
p6482
sg27
Nsg28
S'Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.| \r'
p6483
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CARBAMAZEPINE'
p6484
sa(dp6485
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00822'
p6486
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p6487
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p6488
sg23
Nsg24
Nsg25
S'ISONIAZID'
p6489
sg27
Nsg28
S'Patients taking isoniazid when disulfiram is given should be observed for the appearance of unsteady gait or marked changes in mental status;| \r'
p6490
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DISULFIRAM'
p6491
sa(dp6492
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p6493
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p6494
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6495
sg23
Nsg24
Nsg25
S'ISONIAZID'
p6496
sg27
Nsg28
S'INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.| \r'
p6497
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p6498
sa(dp6499
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01235'
p6500
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p6501
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p6502
sg23
Nsg24
Nsg25
S'ISONIAZID'
p6503
sg27
Nsg28
S'Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.| \r'
p6504
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LEVODOPA'
p6505
sa(dp6506
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p6507
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p6508
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6509
sg23
Nsg24
Nsg25
S'ISONIAZID'
p6510
sg27
Nsg28
S'Phenytoin: Isoniazid may increase serum levels of phenytoin.| \r'
p6511
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p6512
sa(dp6513
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p6514
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p6515
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6516
sg23
Nsg24
Nsg25
S'ISONIAZID'
p6517
sg27
Nsg28
S'Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid.| \r'
p6518
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p6519
sa(dp6520
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p6521
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p6522
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p6523
sg23
Nsg24
Nsg25
S'ISONIAZID'
p6524
sg27
Nsg28
S'Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.| \r'
p6525
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Valproate'
p6526
sa(dp6527
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p6528
sg5
S'http://bio2rdf.org/drugbank:DB01612'
p6529
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p6530
sg23
Nsg24
Nsg25
S'ISOPENTYL NITRITE'
p6531
sg27
Nsg28
S'Taking amyl nitrite after drinking alcohol may worsen side effects and may cause severe hypotension and cardiovascular collapse.| \r'
p6532
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p6533
sa(dp6534
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00870'
p6535
sg5
S'http://bio2rdf.org/drugbank:DB00411'
p6536
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p6537
sg23
Nsg24
Nsg25
S'Isopto Carbachol'
p6538
sg27
Nsg28
S'Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.| \r'
p6539
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Suprofen'
p6540
sa(dp6541
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p6542
sg5
S'http://bio2rdf.org/drugbank:DB01575'
p6543
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6544
sg23
Nsg24
Nsg25
S'KAOLIN'
p6545
sg27
Nsg28
S'Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.| \r'
p6546
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p6547
sa(dp6548
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01258'
p6549
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6550
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6551
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6552
sg27
Nsg28
S'Ketoconazole: Co-administration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.| \r'
p6553
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALISKIREN'
p6554
sa(dp6555
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00969'
p6556
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6557
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6558
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6559
sg27
Nsg28
S'Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%.| \r'
p6560
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALOSETRON'
p6561
sa(dp6562
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01238'
p6563
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6564
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p6565
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6566
sg27
Nsg28
S'When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.| Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.| Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.| \r'
p6567
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ARIPIPRAZOLE'
p6568
sa(dp6569
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01238'
p6570
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6571
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6572
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6573
sg27
Nsg28
S'When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.| Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.| Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.| \r'
p6574
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ARIPIPRAZOLE'
p6575
sa(dp6576
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p6577
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6578
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p6579
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6580
sg27
Nsg28
S'Another oral azole antifungal, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.| Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.| \r'
p6581
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASTEMIZOLE'
p6582
sa(dp6583
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p6584
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6585
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6586
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6587
sg27
Nsg28
S'Another oral azole antifungal, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.| Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.| \r'
p6588
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASTEMIZOLE'
p6589
sa(dp6590
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p6591
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6592
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6593
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6594
sg27
Nsg28
S'On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.| \r'
p6595
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BEXAROTENE'
p6596
sa(dp6597
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01410'
p6598
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6599
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p6600
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6601
sg27
Nsg28
S'Therefore, ketoconazole should be administered with caution with intranasal ciclesonide.| \r'
p6602
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CICLESONIDE'
p6603
sa(dp6604
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01012'
p6605
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6606
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6607
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6608
sg27
Nsg28
S'Co-administration of ketoconazole, a strong inhibitor of CYP3A4, increased cinacalcet exposure following a single 90 mg dose of Sensipar by 2.3 fold.| \r'
p6609
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CINACALCET'
p6610
sa(dp6611
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p6612
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6613
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p6614
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6615
sg27
Nsg28
S'Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.| Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.| Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.| Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.| Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.| \r'
p6616
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p6617
sa(dp6618
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p6619
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6620
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p6621
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6622
sg27
Nsg28
S'Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.| Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.| Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.| Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.| Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.| \r'
p6623
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p6624
sa(dp6625
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p6626
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6627
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6628
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6629
sg27
Nsg28
S'Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.| Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.| Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.| Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.| Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.| \r'
p6630
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p6631
sa(dp6632
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB04665'
p6633
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6634
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p6635
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6636
sg27
Nsg28
S'When taken orally , imidazole compounds like ketoconazole may enhance the anticoagulant effect of coumarin-like drugs.| \r'
p6637
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'COUMARIN'
p6638
sa(dp6639
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p6640
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6641
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6642
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6643
sg27
Nsg28
S'Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.| \r'
p6644
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSPORINE'
p6645
sa(dp6646
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00530'
p6647
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6648
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6649
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6650
sg27
Nsg28
S'Co-treatment with the potent CYP3A4 inhibitor ketoconazole increases erlotinib AUC by 2/3.| \r'
p6651
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERLOTINIB'
p6652
sa(dp6653
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00317'
p6654
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6655
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6656
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6657
sg27
Nsg28
S'Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.| \r'
p6658
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GEFITINIB'
p6659
sa(dp6660
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00951'
p6661
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6662
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p6663
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6664
sg27
Nsg28
S'Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist.| \r'
p6665
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ISONIAZID'
p6666
sa(dp6667
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01259'
p6668
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6669
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6670
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6671
sg27
Nsg28
S'Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.| \r'
p6672
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LAPATINIB DITOSYLATE'
p6673
sa(dp6674
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01259'
p6675
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6676
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6677
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6678
sg27
Nsg28
S'Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.| \r'
p6679
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LAPATINIB'
p6680
sa(dp6681
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00455'
p6682
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6683
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6684
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6685
sg27
Nsg28
S'After the coadministration of 200 mg oral ketoconazole twice daily and one 20 mg dose of loratadine to 11 subjects, the AUC and Cmax of loratadine averaged 302% (  142 S.D.) and 251% (  68 S.D.), respectively, of those obtained after co-treatment with placebo.| \r'
p6686
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LORATADINE'
p6687
sa(dp6688
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p6689
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6690
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6691
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6692
sg27
Nsg28
S'Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.| Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. | \r'
p6693
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHYLPREDNISOLONE'
p6694
sa(dp6695
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p6696
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6697
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6698
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6699
sg27
Nsg28
S'Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. | \r'
p6700
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIDAZOLAM'
p6701
sa(dp6702
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00834'
p6703
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6704
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6705
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6706
sg27
Nsg28
S'Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). | \r'
p6707
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIFEPRISTONE'
p6708
sa(dp6709
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00764'
p6710
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6711
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6712
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6713
sg27
Nsg28
S'However, ketoconazole, a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing.| \r'
p6714
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MOMETASONE FUROATE'
p6715
sa(dp6716
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00910'
p6717
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6718
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6719
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6720
sg27
Nsg28
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p6721
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PARICALCITOL'
p6722
sa(dp6723
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p6724
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6725
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p6726
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6727
sg27
Nsg28
S'It is suggested to monitor both ketoconazole and phenytoin.| Concomitant administration of ketoconazole tablets with phenytoin may alter the metabolism of one or both of the drugs.| \r'
p6728
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p6729
sa(dp6730
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p6731
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6732
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6733
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6734
sg27
Nsg28
S'It is suggested to monitor both ketoconazole and phenytoin.| Concomitant administration of ketoconazole tablets with phenytoin may alter the metabolism of one or both of the drugs.| \r'
p6735
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p6736
sa(dp6737
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01256'
p6738
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6739
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6740
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6741
sg27
Nsg28
S'Co-administration of oral ketoconazole 200 mg twice daily increased retapamulin geometric mean AUC(0-24) and Cmax by 81% after topical application of retapamulin ointment, 1% on the abraded skin of healthy adult males. | \r'
p6742
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RETAPAMULIN'
p6743
sa(dp6744
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00296'
p6745
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6746
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6747
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6748
sg27
Nsg28
S'Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.| \r'
p6749
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ROPIVACAINE'
p6750
sa(dp6751
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00864'
p6752
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6753
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6754
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6755
sg27
Nsg28
S'Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.| \r'
p6756
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TACROLIMUS ANHYDROUS'
p6757
sa(dp6758
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00864'
p6759
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6760
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6761
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6762
sg27
Nsg28
S'Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.| \r'
p6763
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TACROLIMUS'
p6764
sa(dp6765
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p6766
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6767
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6768
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6769
sg27
Nsg28
S'Ketoconazole at 400 mg daily (the maximum approved prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide Cmax by 53% in males and 97% in females, and AUC by 41% in males and 69% in females.| \r'
p6770
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tikosyn'
p6771
sa(dp6772
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01036'
p6773
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6774
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6775
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6776
sg27
Nsg28
S'CYP3A4 Inhibitors: Ketoconazole, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of tolterodine when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions). | \r'
p6777
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TOLTERODINE'
p6778
sa(dp6779
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01157'
p6780
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6781
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6782
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6783
sg27
Nsg28
S'Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. | \r'
p6784
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TRIMETREXATE'
p6785
sa(dp6786
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00862'
p6787
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6788
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6789
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6790
sg27
Nsg28
S'Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.| \r'
p6791
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VARDENAFIL'
p6792
sa(dp6793
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p6794
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6795
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p6796
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6797
sg27
Nsg28
S'Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least 2 hours prior to dosing with VIDEX.| \r'
p6798
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Videx'
p6799
sa(dp6800
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p6801
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6802
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6803
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6804
sg27
Nsg28
S'Ketoconazole: Coadministration of ketoconazole with VIRACEPT resulted in a 35% increase in nelfinavir plasma A.C.| \r'
p6805
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Viracept'
p6806
sa(dp6807
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00962'
p6808
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6809
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6810
sg23
Nsg24
Nsg25
S'Ketoconazole'
p6811
sg27
Nsg28
S'Other strong selective CYP3A4 inhibitors such as ketoconazole can also be expected to increase the exposure of zaleplon.| \r'
p6812
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZALEPLON'
p6813
sa(dp6814
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p6815
sg5
S'http://bio2rdf.org/drugbank:DB00709'
p6816
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p6817
sg23
Nsg24
Nsg25
S'LAMIVUDINE'
p6818
sg27
Nsg28
S'Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another.| Lamivudine: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited zalcitabine phosphorylation in a dose dependent manner.| Therefore, use of lamivudine in combination with zalcitabine is not recommended| \r'
p6819
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZALCITABINE'
p6820
sa(dp6821
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p6822
sg5
S'http://bio2rdf.org/drugbank:DB00709'
p6823
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p6824
sg23
Nsg24
Nsg25
S'LAMIVUDINE'
p6825
sg27
Nsg28
S'Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another.| Lamivudine: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited zalcitabine phosphorylation in a dose dependent manner.| Therefore, use of lamivudine in combination with zalcitabine is not recommended| \r'
p6826
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZALCITABINE'
p6827
sa(dp6828
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p6829
sg5
S'http://bio2rdf.org/drugbank:DB00448'
p6830
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6831
sg23
Nsg24
Nsg25
S'Lansoprazole'
p6832
sg27
Nsg28
S'therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).| \r'
p6833
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ADENOSINE PHOSPHATE'
p6834
sa(dp6835
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p6836
sg5
S'http://bio2rdf.org/drugbank:DB00448'
p6837
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6838
sg23
Nsg24
Nsg25
S'Lansoprazole'
p6839
sg27
Nsg28
S'therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).| \r'
p6840
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPICILLIN'
p6841
sa(dp6842
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p6843
sg5
S'http://bio2rdf.org/drugbank:DB00448'
p6844
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6845
sg23
Nsg24
Nsg25
S'Lansoprazole'
p6846
sg27
Nsg28
S'therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).| \r'
p6847
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p6848
sa(dp6849
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01592'
p6850
sg5
S'http://bio2rdf.org/drugbank:DB00448'
p6851
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6852
sg23
Nsg24
Nsg25
S'Lansoprazole'
p6853
sg27
Nsg28
S'therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).| \r'
p6854
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'IRON'
p6855
sa(dp6856
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p6857
sg5
S'http://bio2rdf.org/drugbank:DB00448'
p6858
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6859
sg23
Nsg24
Nsg25
S'Lansoprazole'
p6860
sg27
Nsg28
S'therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).| \r'
p6861
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p6862
sa(dp6863
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p6864
sg5
S'http://bio2rdf.org/drugbank:DB00448'
p6865
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6866
sg23
Nsg24
Nsg25
S'Lansoprazole'
p6867
sg27
Nsg28
S'When lansoprazole was administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen.| \r'
p6868
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p6869
sa(dp6870
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00072'
p6871
sg5
S'http://bio2rdf.org/drugbank:DB01259'
p6872
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p6873
sg23
Nsg24
Nsg25
S'LAPATINIB DITOSYLATE'
p6874
sg27
Nsg28
S'In an in vitro assay, lapatinib induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines, leading to the enhancement of Herceptin-mediated ADCC. | Lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.&#x0D;| Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.| \r'
p6875
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Herceptin'
p6876
sa(dp6877
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00072'
p6878
sg5
S'http://bio2rdf.org/drugbank:DB01259'
p6879
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p6880
sg23
Nsg24
Nsg25
S'LAPATINIB'
p6881
sg27
Nsg28
S'In an in vitro assay, lapatinib induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines, leading to the enhancement of Herceptin-mediated ADCC. | Lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.&#x0D;| Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.| \r'
p6882
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Herceptin'
p6883
sa(dp6884
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p6885
sg5
S'http://bio2rdf.org/drugbank:DB00020'
p6886
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p6887
sg23
Nsg24
Nsg25
S'Leukine'
p6888
sg27
Nsg28
S'Drugs which may potentiate the myeloproliferative effects of Leukine, such as lithium and corticosteroids, should be used with caution.| \r'
p6889
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM CATION'
p6890
sa(dp6891
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p6892
sg5
S'http://bio2rdf.org/drugbank:DB00020'
p6893
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p6894
sg23
Nsg24
Nsg25
S'Leukine'
p6895
sg27
Nsg28
S'Drugs which may potentiate the myeloproliferative effects of Leukine, such as lithium and corticosteroids, should be used with caution.| \r'
p6896
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM'
p6897
sa(dp6898
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p6899
sg5
S'http://bio2rdf.org/drugbank:DB01002'
p6900
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6901
sg23
Nsg24
Nsg25
S'LEVOBUPIVACAINE'
p6902
sg27
Nsg28
S'Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;| \r'
p6903
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p6904
sa(dp6905
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p6906
sg5
S'http://bio2rdf.org/drugbank:DB01002'
p6907
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6908
sg23
Nsg24
Nsg25
S'LEVOBUPIVACAINE'
p6909
sg27
Nsg28
S'Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;| \r'
p6910
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p6911
sa(dp6912
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p6913
sg5
S'http://bio2rdf.org/drugbank:DB01002'
p6914
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6915
sg23
Nsg24
Nsg25
S'LEVOBUPIVACAINE'
p6916
sg27
Nsg28
S'Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;| \r'
p6917
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p6918
sa(dp6919
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p6920
sg5
S'http://bio2rdf.org/drugbank:DB01002'
p6921
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6922
sg23
Nsg24
Nsg25
S'LEVOBUPIVACAINE'
p6923
sg27
Nsg28
S'Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;| \r'
p6924
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFAMPIN'
p6925
sa(dp6926
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01113'
p6927
sg5
S'http://bio2rdf.org/drugbank:DB01235'
p6928
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p6929
sg23
Nsg24
Nsg25
S'LEVODOPA'
p6930
sg27
Nsg28
S'In addition, the beneficial effects of levodopa in Parkinsons disease have been reported to be reversed by phenytoin and papaverine.| \r'
p6931
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PAPAVERINE'
p6932
sa(dp6933
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p6934
sg5
S'http://bio2rdf.org/drugbank:DB01235'
p6935
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p6936
sg23
Nsg24
Nsg25
S'LEVODOPA'
p6937
sg27
Nsg28
S'In addition, the beneficial effects of levodopa in Parkinsons disease have been reported to be reversed by phenytoin and papaverine.| \r'
p6938
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p6939
sa(dp6940
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p6941
sg5
S'http://bio2rdf.org/drugbank:DB00854'
p6942
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p6943
sg23
Nsg24
Nsg25
S'Levo-Dromoran'
p6944
sg27
Nsg28
S'Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.| \r'
p6945
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p6946
sa(dp6947
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00286'
p6948
sg5
S'http://bio2rdf.org/drugbank:DB00451'
p6949
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6950
sg23
Nsg24
Nsg25
S'LEVOTHYROXINE'
p6951
sg27
Nsg28
S'In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free levothyroxine may be decreased when estrogens are started thus increasing thyroid requirements.| \r'
p6952
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Estrogens'
p6953
sa(dp6954
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00915'
p6955
sg5
S'http://bio2rdf.org/drugbank:DB00424'
p6956
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p6957
sg23
Nsg24
Nsg25
S'Levsin'
p6958
sg27
Nsg28
S'Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.| \r'
p6959
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMANTADINE'
p6960
sa(dp6961
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00502'
p6962
sg5
S'http://bio2rdf.org/drugbank:DB00424'
p6963
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p6964
sg23
Nsg24
Nsg25
S'Levsin'
p6965
sg27
Nsg28
S'Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.| \r'
p6966
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HALOPERIDOL'
p6967
sa(dp6968
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p6969
sg5
S'http://bio2rdf.org/drugbank:DB01175'
p6970
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p6971
sg23
Nsg24
Nsg25
S'Lexapro'
p6972
sg27
Nsg28
S'Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.| \r'
p6973
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM CATION'
p6974
sa(dp6975
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p6976
sg5
S'http://bio2rdf.org/drugbank:DB01175'
p6977
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p6978
sg23
Nsg24
Nsg25
S'Lexapro'
p6979
sg27
Nsg28
S'Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.| \r'
p6980
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM'
p6981
sa(dp6982
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p6983
sg5
S'http://bio2rdf.org/drugbank:DB01627'
p6984
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p6985
sg23
Nsg24
Nsg25
S'LINCOMYCIN'
p6986
sg27
Nsg28
S'Antagonism between lincomycin and erythromycin in vitro has been demonstrated.| \r'
p6987
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERYTHROMYCIN'
p6988
sa(dp6989
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00796'
p6990
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p6991
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p6992
sg23
Nsg24
Nsg25
S'LITHIUM CATION'
p6993
sg27
Nsg28
S'An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND, so careful monitoring of serum lithium levels is recommended during concomitant use.| \r'
p6994
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Atacand'
p6995
sa(dp6996
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00887'
p6997
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p6998
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p6999
sg23
Nsg24
Nsg25
S'LITHIUM CATION'
p7000
sg27
Nsg28
S'- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.| \r'
p7001
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BUMETANIDE'
p7002
sa(dp7003
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00482'
p7004
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7005
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7006
sg23
Nsg24
Nsg25
S'LITHIUM CATION'
p7007
sg27
Nsg28
S'Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.| Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.| \r'
p7008
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Celebrex'
p7009
sa(dp7010
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00482'
p7011
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7012
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7013
sg23
Nsg24
Nsg25
S'LITHIUM CATION'
p7014
sg27
Nsg28
S'Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.| Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.| \r'
p7015
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Celebrex'
p7016
sa(dp7017
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00880'
p7018
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7019
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7020
sg23
Nsg24
Nsg25
S'LITHIUM CATION'
p7021
sg27
Nsg28
S'Refer to the package insert for lithium preparations before use of such preparations with chlorothiazide| \r'
p7022
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CHLOROTHIAZIDE'
p7023
sa(dp7024
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p7025
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7026
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7027
sg23
Nsg24
Nsg25
S'LITHIUM CATION'
p7028
sg27
Nsg28
S'Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.| \r'
p7029
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ESCITALOPRAM OXALATE'
p7030
sa(dp7031
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p7032
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7033
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7034
sg23
Nsg24
Nsg25
S'LITHIUM CATION'
p7035
sg27
Nsg28
S'Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.| \r'
p7036
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ESCITALOPRAM'
p7037
sa(dp7038
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00554'
p7039
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7040
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7041
sg23
Nsg24
Nsg25
S'LITHIUM CATION'
p7042
sg27
Nsg28
S'It is recommended that plasma lithium levels be monitored when initiating, adjusting and discontinuing FELDENE.| \r'
p7043
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Feldene'
p7044
sa(dp7045
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00502'
p7046
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7047
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7048
sg23
Nsg24
Nsg25
S'LITHIUM CATION'
p7049
sg27
Nsg28
S'An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with lithium plus HALDOL.| \r'
p7050
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Haldol'
p7051
sa(dp7052
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00999'
p7053
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7054
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7055
sg23
Nsg24
Nsg25
S'LITHIUM CATION'
p7056
sg27
Nsg28
S'Refer to the package insert for lithium preparations before use of such preparations with Hydrochlorothiazide.| \r'
p7057
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HYDROCHLOROTHIAZIDE'
p7058
sa(dp7059
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00814'
p7060
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7061
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7062
sg23
Nsg24
Nsg25
S'LITHIUM CATION'
p7063
sg27
Nsg28
S'In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. | \r'
p7064
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MELOXICAM'
p7065
sa(dp7066
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00814'
p7067
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7068
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7069
sg23
Nsg24
Nsg25
S'LITHIUM CATION'
p7070
sg27
Nsg28
S'Patients on lithium treatment should be closely monitored when MOBIC is introduced or withdrawn. | \r'
p7071
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Mobic'
p7072
sa(dp7073
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00019'
p7074
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7075
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7076
sg23
Nsg24
Nsg25
S'LITHIUM CATION'
p7077
sg27
Nsg28
S'patients receiving lithium and Neulasta should have more frequent monitoring of neutrophil counts.| \r'
p7078
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Neulasta'
p7079
sa(dp7080
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00465'
p7081
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7082
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7083
sg23
Nsg24
Nsg25
S'LITHIUM CATION'
p7084
sg27
Nsg28
S'The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.| \r'
p7085
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Toradol'
p7086
sa(dp7087
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00796'
p7088
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7089
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7090
sg23
Nsg24
Nsg25
S'LITHIUM'
p7091
sg27
Nsg28
S'An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND, so careful monitoring of serum lithium levels is recommended during concomitant use.| \r'
p7092
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Atacand'
p7093
sa(dp7094
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00887'
p7095
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7096
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7097
sg23
Nsg24
Nsg25
S'LITHIUM'
p7098
sg27
Nsg28
S'- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.| \r'
p7099
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BUMETANIDE'
p7100
sa(dp7101
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00482'
p7102
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7103
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7104
sg23
Nsg24
Nsg25
S'LITHIUM'
p7105
sg27
Nsg28
S'Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.| Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.| \r'
p7106
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Celebrex'
p7107
sa(dp7108
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00482'
p7109
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7110
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7111
sg23
Nsg24
Nsg25
S'LITHIUM'
p7112
sg27
Nsg28
S'Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.| Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.| \r'
p7113
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Celebrex'
p7114
sa(dp7115
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00880'
p7116
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7117
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7118
sg23
Nsg24
Nsg25
S'LITHIUM'
p7119
sg27
Nsg28
S'Refer to the package insert for lithium preparations before use of such preparations with chlorothiazide| \r'
p7120
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CHLOROTHIAZIDE'
p7121
sa(dp7122
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p7123
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7124
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7125
sg23
Nsg24
Nsg25
S'LITHIUM'
p7126
sg27
Nsg28
S'Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.| \r'
p7127
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ESCITALOPRAM OXALATE'
p7128
sa(dp7129
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p7130
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7131
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7132
sg23
Nsg24
Nsg25
S'LITHIUM'
p7133
sg27
Nsg28
S'Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.| \r'
p7134
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ESCITALOPRAM'
p7135
sa(dp7136
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00554'
p7137
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7138
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7139
sg23
Nsg24
Nsg25
S'LITHIUM'
p7140
sg27
Nsg28
S'It is recommended that plasma lithium levels be monitored when initiating, adjusting and discontinuing FELDENE.| \r'
p7141
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Feldene'
p7142
sa(dp7143
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00502'
p7144
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7145
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7146
sg23
Nsg24
Nsg25
S'LITHIUM'
p7147
sg27
Nsg28
S'An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with lithium plus HALDOL.| \r'
p7148
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Haldol'
p7149
sa(dp7150
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00999'
p7151
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7152
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7153
sg23
Nsg24
Nsg25
S'LITHIUM'
p7154
sg27
Nsg28
S'Refer to the package insert for lithium preparations before use of such preparations with Hydrochlorothiazide.| \r'
p7155
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HYDROCHLOROTHIAZIDE'
p7156
sa(dp7157
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00814'
p7158
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7159
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7160
sg23
Nsg24
Nsg25
S'LITHIUM'
p7161
sg27
Nsg28
S'In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. | \r'
p7162
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MELOXICAM'
p7163
sa(dp7164
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00814'
p7165
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7166
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7167
sg23
Nsg24
Nsg25
S'LITHIUM'
p7168
sg27
Nsg28
S'Patients on lithium treatment should be closely monitored when MOBIC is introduced or withdrawn. | \r'
p7169
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Mobic'
p7170
sa(dp7171
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00019'
p7172
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7173
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7174
sg23
Nsg24
Nsg25
S'LITHIUM'
p7175
sg27
Nsg28
S'patients receiving lithium and Neulasta should have more frequent monitoring of neutrophil counts.| \r'
p7176
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Neulasta'
p7177
sa(dp7178
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00465'
p7179
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7180
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7181
sg23
Nsg24
Nsg25
S'LITHIUM'
p7182
sg27
Nsg28
S'The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.| \r'
p7183
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Toradol'
p7184
sa(dp7185
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p7186
sg5
S'http://bio2rdf.org/drugbank:DB00749'
p7187
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7188
sg23
Nsg24
Nsg25
S'Lodine'
p7189
sg27
Nsg28
S'Aspirin: When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.| however, as with other NSAIDs, concomitant administration of Lodine and aspirin is not generally recommended because of the potential of increased adverse effects.| \r'
p7190
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p7191
sa(dp7192
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p7193
sg5
S'http://bio2rdf.org/drugbank:DB00749'
p7194
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7195
sg23
Nsg24
Nsg25
S'Lodine'
p7196
sg27
Nsg28
S'Aspirin: When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.| however, as with other NSAIDs, concomitant administration of Lodine and aspirin is not generally recommended because of the potential of increased adverse effects.| \r'
p7197
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p7198
sa(dp7199
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p7200
sg5
S'http://bio2rdf.org/drugbank:DB00749'
p7201
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7202
sg23
Nsg24
Nsg25
S'Lodine'
p7203
sg27
Nsg28
S'Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.| \r'
p7204
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSPORINE'
p7205
sa(dp7206
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p7207
sg5
S'http://bio2rdf.org/drugbank:DB00749'
p7208
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7209
sg23
Nsg24
Nsg25
S'Lodine'
p7210
sg27
Nsg28
S'Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.| \r'
p7211
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p7212
sa(dp7213
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00695'
p7214
sg5
S'http://bio2rdf.org/drugbank:DB00749'
p7215
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7216
sg23
Nsg24
Nsg25
S'Lodine'
p7217
sg27
Nsg28
S'Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of furosemide and thiazides in some patients.| \r'
p7218
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FUROSEMIDE'
p7219
sa(dp7220
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p7221
sg5
S'http://bio2rdf.org/drugbank:DB00749'
p7222
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7223
sg23
Nsg24
Nsg25
S'Lodine'
p7224
sg27
Nsg28
S'Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.| \r'
p7225
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHOTREXATE'
p7226
sa(dp7227
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00238'
p7228
sg5
S'http://bio2rdf.org/drugbank:DB01601'
p7229
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7230
sg23
Nsg24
Nsg25
S'LOPINAVIR'
p7231
sg27
Nsg28
S'A dose increase of lopinavir/ritonavir to 533/133 mg twice daily with food isrecommended in combination with nevirapine.| \r'
p7232
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NEVIRAPINE'
p7233
sa(dp7234
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00625'
p7235
sg5
S'http://bio2rdf.org/drugbank:DB01601'
p7236
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7237
sg23
Nsg24
Nsg25
S'LOPINAVIR'
p7238
sg27
Nsg28
S'A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.| \r'
p7239
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sustiva'
p7240
sa(dp7241
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p7242
sg5
S'http://bio2rdf.org/drugbank:DB00447'
p7243
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7244
sg23
Nsg24
Nsg25
S'LORACARBEF ANHYDROUS'
p7245
sg27
Nsg28
S'Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.| \r'
p7246
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROBENECID'
p7247
sa(dp7248
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p7249
sg5
S'http://bio2rdf.org/drugbank:DB00447'
p7250
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7251
sg23
Nsg24
Nsg25
S'LORACARBEF'
p7252
sg27
Nsg28
S'Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.| \r'
p7253
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROBENECID'
p7254
sa(dp7255
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00328'
p7256
sg5
S'http://bio2rdf.org/drugbank:DB00678'
p7257
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7258
sg23
Nsg24
Nsg25
S'LOSARTAN'
p7259
sg27
Nsg28
S'As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin| \r'
p7260
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDOMETHACIN'
p7261
sa(dp7262
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p7263
sg5
S'http://bio2rdf.org/drugbank:DB00227'
p7264
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7265
sg23
Nsg24
Nsg25
S'LOVASTATIN'
p7266
sg27
Nsg28
S'Patients receiving concomitant lovastatin and erythromycin should be carefully monitored;| \r'
p7267
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERYTHROMYCIN'
p7268
sa(dp7269
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01592'
p7270
sg5
S'http://bio2rdf.org/drugbank:DB00256'
p7271
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7272
sg23
Nsg24
Nsg25
S'LYMECYCLINE'
p7273
sg27
Nsg28
S'The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements.| \r'
p7274
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'IRON'
p7275
sa(dp7276
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01593'
p7277
sg5
S'http://bio2rdf.org/drugbank:DB00256'
p7278
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7279
sg23
Nsg24
Nsg25
S'LYMECYCLINE'
p7280
sg27
Nsg28
S'The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements.| \r'
p7281
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZINC'
p7282
sa(dp7283
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01155'
p7284
sg5
S'http://bio2rdf.org/drugbank:DB01378'
p7285
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7286
sg23
Nsg24
Nsg25
S'MAGNESIUM CATION'
p7287
sg27
Nsg28
S'Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| \r'
p7288
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Factive'
p7289
sa(dp7290
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00710'
p7291
sg5
S'http://bio2rdf.org/drugbank:DB01378'
p7292
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7293
sg23
Nsg24
Nsg25
S'MAGNESIUM CATION'
p7294
sg27
Nsg28
S'Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.| \r'
p7295
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'IBANDRONIC ACID'
p7296
sa(dp7297
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01133'
p7298
sg5
S'http://bio2rdf.org/drugbank:DB01378'
p7299
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7300
sg23
Nsg24
Nsg25
S'MAGNESIUM CATION'
p7301
sg27
Nsg28
S'The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. | \r'
p7302
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Skelid'
p7303
sa(dp7304
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p7305
sg5
S'http://bio2rdf.org/drugbank:DB01378'
p7306
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7307
sg23
Nsg24
Nsg25
S'MAGNESIUM CATION'
p7308
sg27
Nsg28
S'Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.| \r'
p7309
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Videx'
p7310
sa(dp7311
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01155'
p7312
sg5
S'http://bio2rdf.org/drugbank:DB01378'
p7313
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7314
sg23
Nsg24
Nsg25
S'MAGNESIUM'
p7315
sg27
Nsg28
S'Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| \r'
p7316
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Factive'
p7317
sa(dp7318
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00710'
p7319
sg5
S'http://bio2rdf.org/drugbank:DB01378'
p7320
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7321
sg23
Nsg24
Nsg25
S'MAGNESIUM'
p7322
sg27
Nsg28
S'Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.| \r'
p7323
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'IBANDRONIC ACID'
p7324
sa(dp7325
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01133'
p7326
sg5
S'http://bio2rdf.org/drugbank:DB01378'
p7327
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7328
sg23
Nsg24
Nsg25
S'MAGNESIUM'
p7329
sg27
Nsg28
S'The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. | \r'
p7330
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Skelid'
p7331
sa(dp7332
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p7333
sg5
S'http://bio2rdf.org/drugbank:DB01378'
p7334
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7335
sg23
Nsg24
Nsg25
S'MAGNESIUM'
p7336
sg27
Nsg28
S'Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.| \r'
p7337
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Videx'
p7338
sa(dp7339
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01170'
p7340
sg5
S'http://bio2rdf.org/drugbank:DB00579'
p7341
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7342
sg23
Nsg24
Nsg25
S'Mazindol'
p7343
sg27
Nsg28
S'Mazindol may reduce the effects of guanethidine (Ismelin). | \r'
p7344
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GUANETHIDINE'
p7345
sa(dp7346
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01170'
p7347
sg5
S'http://bio2rdf.org/drugbank:DB00579'
p7348
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7349
sg23
Nsg24
Nsg25
S'Mazindol'
p7350
sg27
Nsg28
S'Mazindol may reduce the effects of guanethidine (Ismelin). | \r'
p7351
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ismelin'
p7352
sa(dp7353
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01247'
p7354
sg5
S'http://bio2rdf.org/drugbank:DB00579'
p7355
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7356
sg23
Nsg24
Nsg25
S'Mazindol'
p7357
sg27
Nsg28
S'You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | \r'
p7358
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ISOCARBOXAZID'
p7359
sa(dp7360
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01247'
p7361
sg5
S'http://bio2rdf.org/drugbank:DB00579'
p7362
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7363
sg23
Nsg24
Nsg25
S'Mazindol'
p7364
sg27
Nsg28
S'You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | \r'
p7365
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Marplan'
p7366
sa(dp7367
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00780'
p7368
sg5
S'http://bio2rdf.org/drugbank:DB00579'
p7369
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7370
sg23
Nsg24
Nsg25
S'Mazindol'
p7371
sg27
Nsg28
S'You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | \r'
p7372
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nardil'
p7373
sa(dp7374
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00752'
p7375
sg5
S'http://bio2rdf.org/drugbank:DB00579'
p7376
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7377
sg23
Nsg24
Nsg25
S'Mazindol'
p7378
sg27
Nsg28
S'You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | \r'
p7379
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Parnate'
p7380
sa(dp7381
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00780'
p7382
sg5
S'http://bio2rdf.org/drugbank:DB00579'
p7383
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7384
sg23
Nsg24
Nsg25
S'Mazindol'
p7385
sg27
Nsg28
S'You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | \r'
p7386
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENELZINE'
p7387
sa(dp7388
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00752'
p7389
sg5
S'http://bio2rdf.org/drugbank:DB00579'
p7390
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7391
sg23
Nsg24
Nsg25
S'Mazindol'
p7392
sg27
Nsg28
S'You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | \r'
p7393
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tranylcypromine'
p7394
sa(dp7395
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p7396
sg5
S'http://bio2rdf.org/drugbank:DB00351'
p7397
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7398
sg23
Nsg24
Nsg25
S'MEGESTROL ACETATE'
p7399
sg27
Nsg28
S'A pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir. | \r'
p7400
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDINAVIR ANHYDROUS'
p7401
sa(dp7402
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p7403
sg5
S'http://bio2rdf.org/drugbank:DB00351'
p7404
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7405
sg23
Nsg24
Nsg25
S'MEGESTROL ACETATE'
p7406
sg27
Nsg28
S'A pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir. | \r'
p7407
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDINAVIR'
p7408
sa(dp7409
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p7410
sg5
S'http://bio2rdf.org/drugbank:DB01065'
p7411
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p7412
sg23
Nsg24
Nsg25
S'MELATONIN'
p7413
sg27
Nsg28
S'Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).| \r'
p7414
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p7415
sa(dp7416
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p7417
sg5
S'http://bio2rdf.org/drugbank:DB01065'
p7418
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p7419
sg23
Nsg24
Nsg25
S'MELATONIN'
p7420
sg27
Nsg28
S'Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).| \r'
p7421
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p7422
sa(dp7423
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p7424
sg5
S'http://bio2rdf.org/drugbank:DB00814'
p7425
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7426
sg23
Nsg24
Nsg25
S'MELOXICAM'
p7427
sg27
Nsg28
S'however, as with other NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects. | \r'
p7428
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p7429
sa(dp7430
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p7431
sg5
S'http://bio2rdf.org/drugbank:DB00454'
p7432
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7433
sg23
Nsg24
Nsg25
S'MEPERIDINE'
p7434
sg27
Nsg28
S'Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). | \r'
p7435
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p7436
sa(dp7437
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00352'
p7438
sg5
S'http://bio2rdf.org/drugbank:DB01033'
p7439
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7440
sg23
Nsg24
Nsg25
S'MERCAPTOPURINE'
p7441
sg27
Nsg28
S'There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. | \r'
p7442
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tabloid'
p7443
sa(dp7444
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p7445
sg5
S'http://bio2rdf.org/drugbank:DB00760'
p7446
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7447
sg23
Nsg24
Nsg25
S'MEROPENEM ANHYDROUS'
p7448
sg27
Nsg28
S'There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).| \r'
p7449
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIPHENOLIC ACID'
p7450
sa(dp7451
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p7452
sg5
S'http://bio2rdf.org/drugbank:DB00760'
p7453
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7454
sg23
Nsg24
Nsg25
S'MEROPENEM ANHYDROUS'
p7455
sg27
Nsg28
S'There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).| \r'
p7456
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VALPROIC ACID'
p7457
sa(dp7458
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p7459
sg5
S'http://bio2rdf.org/drugbank:DB00760'
p7460
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7461
sg23
Nsg24
Nsg25
S'MEROPENEM'
p7462
sg27
Nsg28
S'There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).| \r'
p7463
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIPHENOLIC ACID'
p7464
sa(dp7465
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p7466
sg5
S'http://bio2rdf.org/drugbank:DB00760'
p7467
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7468
sg23
Nsg24
Nsg25
S'MEROPENEM'
p7469
sg27
Nsg28
S'There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).| \r'
p7470
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VALPROIC ACID'
p7471
sa(dp7472
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p7473
sg5
S'http://bio2rdf.org/drugbank:DB00331'
p7474
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7475
sg23
Nsg24
Nsg25
S'METFORMIN'
p7476
sg27
Nsg28
S'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.| \r'
p7477
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOFETILIDE'
p7478
sa(dp7479
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01626'
p7480
sg5
S'http://bio2rdf.org/drugbank:DB01577'
p7481
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7482
sg23
Nsg24
Nsg25
S'METHAMPHETAMINE'
p7483
sg27
Nsg28
S'Methamphetamine, like MPTP, produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment. | \r'
p7484
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PARGYLINE'
p7485
sa(dp7486
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p7487
sg5
S'http://bio2rdf.org/drugbank:DB00134'
p7488
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7489
sg23
Nsg24
Nsg25
S'METHIONINE'
p7490
sg27
Nsg28
S'Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.| \r'
p7491
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACETAMINOPHEN'
p7492
sa(dp7493
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p7494
sg5
S'http://bio2rdf.org/drugbank:DB00134'
p7495
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7496
sg23
Nsg24
Nsg25
S'METHIONINE'
p7497
sg27
Nsg28
S'Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.| \r'
p7498
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHOTREXATE'
p7499
sa(dp7500
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00459'
p7501
sg5
S'http://bio2rdf.org/drugbank:DB00563'
p7502
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7503
sg23
Nsg24
Nsg25
S'METHOTREXATE'
p7504
sg27
Nsg28
S'Consequently, the combination of methotrexate with acitretin is also contraindicated.| \r'
p7505
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACITRETIN'
p7506
sa(dp7507
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00537'
p7508
sg5
S'http://bio2rdf.org/drugbank:DB00563'
p7509
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7510
sg23
Nsg24
Nsg25
S'METHOTREXATE'
p7511
sg27
Nsg28
S'Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate.| Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.| \r'
p7512
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIPROFLOXACIN'
p7513
sa(dp7514
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00537'
p7515
sg5
S'http://bio2rdf.org/drugbank:DB00563'
p7516
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7517
sg23
Nsg24
Nsg25
S'METHOTREXATE'
p7518
sg27
Nsg28
S'Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate.| Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.| \r'
p7519
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIPROFLOXACIN'
p7520
sa(dp7521
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00023'
p7522
sg5
S'http://bio2rdf.org/drugbank:DB00563'
p7523
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7524
sg23
Nsg24
Nsg25
S'METHOTREXATE'
p7525
sg27
Nsg28
S'These results would seem to dictate against the clinical use of methotrexate with ELSPAR, or during the period following ELSPAR therapy when plasma asparagine levels are below normal.| \r'
p7526
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Elspar'
p7527
sa(dp7528
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00926'
p7529
sg5
S'http://bio2rdf.org/drugbank:DB00563'
p7530
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7531
sg23
Nsg24
Nsg25
S'METHOTREXATE'
p7532
sg27
Nsg28
S'Methotrexate: An increased risk of hepatitis has been reported to result from combined use of methotrexate and etretinate.| \r'
p7533
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ETRETINATE'
p7534
sa(dp7535
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00130'
p7536
sg5
S'http://bio2rdf.org/drugbank:DB00563'
p7537
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7538
sg23
Nsg24
Nsg25
S'METHOTREXATE'
p7539
sg27
Nsg28
S'In another report, nine patients with breast cancer were reported to have decreased symptoms of methotrexate-related toxicity when given supplemental L-glutamine at a dose of 0.5 gram/kilogram/day.| Methotrexate - There is one report that methotrexate may decrease the possible effectiveness of supplemental L-glutamine for chemotherapy-induced mucositis.| \r'
p7540
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GLUTAMINE'
p7541
sa(dp7542
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00041'
p7543
sg5
S'http://bio2rdf.org/drugbank:DB00563'
p7544
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7545
sg23
Nsg24
Nsg25
S'METHOTREXATE'
p7546
sg27
Nsg28
S'Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.| \r'
p7547
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Proleukin'
p7548
sa(dp7549
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00533'
p7550
sg5
S'http://bio2rdf.org/drugbank:DB00563'
p7551
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7552
sg23
Nsg24
Nsg25
S'METHOTREXATE'
p7553
sg27
Nsg28
S'At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).| \r'
p7554
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ROFECOXIB'
p7555
sa(dp7556
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00891'
p7557
sg5
S'http://bio2rdf.org/drugbank:DB00563'
p7558
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7559
sg23
Nsg24
Nsg25
S'METHOTREXATE'
p7560
sg27
Nsg28
S'- Methotrexate (e.g., Mexate) Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate| \r'
p7561
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SULFAPYRIDINE'
p7562
sa(dp7563
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00444'
p7564
sg5
S'http://bio2rdf.org/drugbank:DB00563'
p7565
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7566
sg23
Nsg24
Nsg25
S'METHOTREXATE'
p7567
sg27
Nsg28
S'An increase in intracellular levels of methotrexate was observed in vitro in the presence of teniposide.| \r'
p7568
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TENIPOSIDE'
p7569
sa(dp7570
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p7571
sg5
S'http://bio2rdf.org/drugbank:DB00968'
p7572
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7573
sg23
Nsg24
Nsg25
S'METHYLDOPA'
p7574
sg27
Nsg28
S'When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity. | \r'
p7575
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM CATION'
p7576
sa(dp7577
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p7578
sg5
S'http://bio2rdf.org/drugbank:DB00968'
p7579
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7580
sg23
Nsg24
Nsg25
S'METHYLDOPA'
p7581
sg27
Nsg28
S'When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity. | \r'
p7582
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM'
p7583
sa(dp7584
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00891'
p7585
sg5
S'http://bio2rdf.org/drugbank:DB00968'
p7586
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7587
sg23
Nsg24
Nsg25
S'METHYLDOPA'
p7588
sg27
Nsg28
S'- Methyldopa (e.g., Aldomet) Use of methyldopa with sulfapyridine may increase the chance of side effects affecting the liver and/or the blood| \r'
p7589
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SULFAPYRIDINE'
p7590
sa(dp7591
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p7592
sg5
S'http://bio2rdf.org/drugbank:DB00959'
p7593
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7594
sg23
Nsg24
Nsg25
S'METHYLPREDNISOLONE'
p7595
sg27
Nsg28
S'The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.| \r'
p7596
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'APREPITANT'
p7597
sa(dp7598
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p7599
sg5
S'http://bio2rdf.org/drugbank:DB00959'
p7600
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7601
sg23
Nsg24
Nsg25
S'METHYLPREDNISOLONE'
p7602
sg27
Nsg28
S'Methylprednisolone may increase the clearance of chronic high dose aspirin. | \r'
p7603
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p7604
sa(dp7605
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00918'
p7606
sg5
S'http://bio2rdf.org/drugbank:DB00247'
p7607
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7608
sg23
Nsg24
Nsg25
S'METHYSERGIDE'
p7609
sg27
Nsg28
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.| \r'
p7610
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Axert'
p7611
sa(dp7612
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00998'
p7613
sg5
S'http://bio2rdf.org/drugbank:DB00247'
p7614
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7615
sg23
Nsg24
Nsg25
S'METHYSERGIDE'
p7616
sg27
Nsg28
S'Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).| \r'
p7617
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Frova'
p7618
sa(dp7619
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00952'
p7620
sg5
S'http://bio2rdf.org/drugbank:DB00247'
p7621
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7622
sg23
Nsg24
Nsg25
S'METHYSERGIDE'
p7623
sg27
Nsg28
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.| \r'
p7624
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NARATRIPTAN'
p7625
sa(dp7626
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p7627
sg5
S'http://bio2rdf.org/drugbank:DB00247'
p7628
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7629
sg23
Nsg24
Nsg25
S'METHYSERGIDE'
p7630
sg27
Nsg28
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. | \r'
p7631
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUMATRIPTAN SUCCINATE'
p7632
sa(dp7633
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p7634
sg5
S'http://bio2rdf.org/drugbank:DB00247'
p7635
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7636
sg23
Nsg24
Nsg25
S'METHYSERGIDE'
p7637
sg27
Nsg28
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. | \r'
p7638
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUMATRIPTAN'
p7639
sa(dp7640
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p7641
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p7642
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7643
sg23
Nsg24
Nsg25
S'METOCLOPRAMIDE'
p7644
sg27
Nsg28
S'Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). | \r'
p7645
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACETAMINOPHEN'
p7646
sa(dp7647
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p7648
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p7649
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7650
sg23
Nsg24
Nsg25
S'METOCLOPRAMIDE'
p7651
sg27
Nsg28
S'Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. | \r'
p7652
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p7653
sa(dp7654
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00714'
p7655
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p7656
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7657
sg23
Nsg24
Nsg25
S'METOCLOPRAMIDE'
p7658
sg27
Nsg28
S'Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.| \r'
p7659
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Apokyn'
p7660
sa(dp7661
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p7662
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p7663
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7664
sg23
Nsg24
Nsg25
S'METOCLOPRAMIDE'
p7665
sg27
Nsg28
S'Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.| \r'
p7666
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p7667
sa(dp7668
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01235'
p7669
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p7670
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7671
sg23
Nsg24
Nsg25
S'METOCLOPRAMIDE'
p7672
sg27
Nsg28
S'Although metoclopramide may increase the bioavailability of levodopa by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties.| \r'
p7673
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LEVODOPA'
p7674
sa(dp7675
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01186'
p7676
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p7677
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7678
sg23
Nsg24
Nsg25
S'METOCLOPRAMIDE'
p7679
sg27
Nsg28
S'Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); | \r'
p7680
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Permax'
p7681
sa(dp7682
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00413'
p7683
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p7684
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7685
sg23
Nsg24
Nsg25
S'METOCLOPRAMIDE'
p7686
sg27
Nsg28
S'Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. | \r'
p7687
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Mirapex'
p7688
sa(dp7689
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00368'
p7690
sg5
S'http://bio2rdf.org/drugbank:DB00524'
p7691
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7692
sg23
Nsg24
Nsg25
S'Metolazone'
p7693
sg27
Nsg28
S'Sympathomimetics: Metolazone may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. | \r'
p7694
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NOREPINEPHRINE'
p7695
sa(dp7696
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p7697
sg5
S'http://bio2rdf.org/drugbank:DB01011'
p7698
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7699
sg23
Nsg24
Nsg25
S'Metopirone'
p7700
sg27
Nsg28
S'Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.| Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.| \r'
p7701
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACETAMINOPHEN'
p7702
sa(dp7703
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p7704
sg5
S'http://bio2rdf.org/drugbank:DB01011'
p7705
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7706
sg23
Nsg24
Nsg25
S'Metopirone'
p7707
sg27
Nsg28
S'Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.| Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.| \r'
p7708
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACETAMINOPHEN'
p7709
sa(dp7710
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p7711
sg5
S'http://bio2rdf.org/drugbank:DB01011'
p7712
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7713
sg23
Nsg24
Nsg25
S'Metopirone'
p7714
sg27
Nsg28
S'The metabolism of Metopirone is accelerated by phenytoin; | \r'
p7715
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p7716
sa(dp7717
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB04665'
p7718
sg5
S'http://bio2rdf.org/drugbank:DB00916'
p7719
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7720
sg23
Nsg24
Nsg25
S'METRONIDAZOLE'
p7721
sg27
Nsg28
S'Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. | \r'
p7722
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'COUMARIN'
p7723
sa(dp7724
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p7725
sg5
S'http://bio2rdf.org/drugbank:DB00379'
p7726
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7727
sg23
Nsg24
Nsg25
S'Mexitil'
p7728
sg27
Nsg28
S'This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. | Concurrent use of Mexitil    and theophylline may lead to increased plasma theophylline levels. | \r'
p7729
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p7730
sa(dp7731
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p7732
sg5
S'http://bio2rdf.org/drugbank:DB00379'
p7733
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7734
sg23
Nsg24
Nsg25
S'Mexitil'
p7735
sg27
Nsg28
S'This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. | Concurrent use of Mexitil    and theophylline may lead to increased plasma theophylline levels. | \r'
p7736
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p7737
sa(dp7738
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p7739
sg5
S'http://bio2rdf.org/drugbank:DB00683'
p7740
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7741
sg23
Nsg24
Nsg25
S'MIDAZOLAM'
p7742
sg27
Nsg28
S'The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.| \r'
p7743
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'APREPITANT'
p7744
sa(dp7745
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p7746
sg5
S'http://bio2rdf.org/drugbank:DB00683'
p7747
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7748
sg23
Nsg24
Nsg25
S'MIDAZOLAM'
p7749
sg27
Nsg28
S'Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20). | \r'
p7750
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSPORINE'
p7751
sa(dp7752
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p7753
sg5
S'http://bio2rdf.org/drugbank:DB00683'
p7754
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7755
sg23
Nsg24
Nsg25
S'MIDAZOLAM'
p7756
sg27
Nsg28
S'The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.| \r'
p7757
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DILTIAZEM'
p7758
sa(dp7759
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p7760
sg5
S'http://bio2rdf.org/drugbank:DB00683'
p7761
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7762
sg23
Nsg24
Nsg25
S'MIDAZOLAM'
p7763
sg27
Nsg28
S'This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously. | Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. | \r'
p7764
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p7765
sa(dp7766
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p7767
sg5
S'http://bio2rdf.org/drugbank:DB00683'
p7768
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7769
sg23
Nsg24
Nsg25
S'MIDAZOLAM'
p7770
sg27
Nsg28
S'This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously. | Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. | \r'
p7771
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p7772
sa(dp7773
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p7774
sg5
S'http://bio2rdf.org/drugbank:DB00683'
p7775
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7776
sg23
Nsg24
Nsg25
S'MIDAZOLAM'
p7777
sg27
Nsg28
S'Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| \r'
p7778
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p7779
sa(dp7780
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00328'
p7781
sg5
S'http://bio2rdf.org/drugbank:DB00683'
p7782
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7783
sg23
Nsg24
Nsg25
S'MIDAZOLAM'
p7784
sg27
Nsg28
S'Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.| \r'
p7785
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDOMETHACIN'
p7786
sa(dp7787
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p7788
sg5
S'http://bio2rdf.org/drugbank:DB00683'
p7789
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7790
sg23
Nsg24
Nsg25
S'MIDAZOLAM'
p7791
sg27
Nsg28
S'Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.| \r'
p7792
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MORPHINE'
p7793
sa(dp7794
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00261'
p7795
sg5
S'http://bio2rdf.org/drugbank:DB00235'
p7796
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7797
sg23
Nsg24
Nsg25
S'MILRINONE'
p7798
sg27
Nsg28
S'The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.| \r'
p7799
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ANAGRELIDE'
p7800
sa(dp7801
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00828'
p7802
sg5
S'http://bio2rdf.org/drugbank:DB01017'
p7803
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7804
sg23
Nsg24
Nsg25
S'MINOCYCLINE'
p7805
sg27
Nsg28
S'The combination of minocycline and fosfomycin can be synergistic against MRSA. | \r'
p7806
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FOSFOMYCIN'
p7807
sa(dp7808
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01170'
p7809
sg5
S'http://bio2rdf.org/drugbank:DB00350'
p7810
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7811
sg23
Nsg24
Nsg25
S'MINOXIDIL'
p7812
sg27
Nsg28
S'Interaction with Guanethidine: Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects. | \r'
p7813
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GUANETHIDINE'
p7814
sa(dp7815
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00626'
p7816
sg5
S'http://bio2rdf.org/drugbank:DB01226'
p7817
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p7818
sg23
Nsg24
Nsg25
S'Mivacron'
p7819
sg27
Nsg28
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. | \r'
p7820
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BACITRACIN A'
p7821
sa(dp7822
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01190'
p7823
sg5
S'http://bio2rdf.org/drugbank:DB01226'
p7824
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p7825
sg23
Nsg24
Nsg25
S'Mivacron'
p7826
sg27
Nsg28
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. | \r'
p7827
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLINDAMYCIN'
p7828
sa(dp7829
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00803'
p7830
sg5
S'http://bio2rdf.org/drugbank:DB01226'
p7831
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p7832
sg23
Nsg24
Nsg25
S'Mivacron'
p7833
sg27
Nsg28
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. | \r'
p7834
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Colistin'
p7835
sa(dp7836
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01627'
p7837
sg5
S'http://bio2rdf.org/drugbank:DB01226'
p7838
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p7839
sg23
Nsg24
Nsg25
S'Mivacron'
p7840
sg27
Nsg28
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. | \r'
p7841
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LINCOMYCIN'
p7842
sa(dp7843
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p7844
sg5
S'http://bio2rdf.org/drugbank:DB01226'
p7845
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p7846
sg23
Nsg24
Nsg25
S'Mivacron'
p7847
sg27
Nsg28
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. | \r'
p7848
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM CATION'
p7849
sa(dp7850
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p7851
sg5
S'http://bio2rdf.org/drugbank:DB01226'
p7852
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p7853
sg23
Nsg24
Nsg25
S'Mivacron'
p7854
sg27
Nsg28
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. | \r'
p7855
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM'
p7856
sa(dp7857
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01378'
p7858
sg5
S'http://bio2rdf.org/drugbank:DB01226'
p7859
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p7860
sg23
Nsg24
Nsg25
S'Mivacron'
p7861
sg27
Nsg28
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. | \r'
p7862
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MAGNESIUM CATION'
p7863
sa(dp7864
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01378'
p7865
sg5
S'http://bio2rdf.org/drugbank:DB01226'
p7866
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p7867
sg23
Nsg24
Nsg25
S'Mivacron'
p7868
sg27
Nsg28
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. | \r'
p7869
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MAGNESIUM'
p7870
sa(dp7871
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01035'
p7872
sg5
S'http://bio2rdf.org/drugbank:DB01226'
p7873
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p7874
sg23
Nsg24
Nsg25
S'Mivacron'
p7875
sg27
Nsg28
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. | \r'
p7876
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROCAINAMIDE'
p7877
sa(dp7878
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00908'
p7879
sg5
S'http://bio2rdf.org/drugbank:DB01226'
p7880
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p7881
sg23
Nsg24
Nsg25
S'Mivacron'
p7882
sg27
Nsg28
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. | \r'
p7883
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'QUINIDINE'
p7884
sa(dp7885
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00918'
p7886
sg5
S'http://bio2rdf.org/drugbank:DB01171'
p7887
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7888
sg23
Nsg24
Nsg25
S'MOCLOBEMIDE'
p7889
sg27
Nsg28
S'Monoamine Oxidase Inhibitors: Coadministration of moclobemide resulted in a 27% decrease in almotriptan clearance and an increase in Cmax of approximately 6%.| \r'
p7890
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALMOTRIPTAN'
p7891
sa(dp7892
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01233'
p7893
sg5
S'http://bio2rdf.org/drugbank:DB00828'
p7894
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7895
sg23
Nsg24
Nsg25
S'Monurol'
p7896
sg27
Nsg28
S'Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.| \r'
p7897
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METOCLOPRAMIDE'
p7898
sa(dp7899
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB06274'
p7900
sg5
S'http://bio2rdf.org/drugbank:DB00295'
p7901
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7902
sg23
Nsg24
Nsg25
S'MORPHINE'
p7903
sg27
Nsg28
S'Morphine prolonged gastrointestinal transit time from 69 to 103 minutes (P = .005); this was prevented by ADL 8-2698 (P = .004). | \r'
p7904
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ADL 8-2698'
p7905
sa(dp7906
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p7907
sg5
S'http://bio2rdf.org/drugbank:DB00295'
p7908
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7909
sg23
Nsg24
Nsg25
S'MORPHINE'
p7910
sg27
Nsg28
S'Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. | \r'
p7911
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p7912
sa(dp7913
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00996'
p7914
sg5
S'http://bio2rdf.org/drugbank:DB00295'
p7915
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7916
sg23
Nsg24
Nsg25
S'MORPHINE'
p7917
sg27
Nsg28
S'Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.| \r'
p7918
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Neurontin'
p7919
sa(dp7920
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p7921
sg5
S'http://bio2rdf.org/drugbank:DB00218'
p7922
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7923
sg23
Nsg24
Nsg25
S'MOXIFLOXACIN'
p7924
sg27
Nsg28
S'Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. | \r'
p7925
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERYTHROMYCIN'
p7926
sa(dp7927
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01370'
p7928
sg5
S'http://bio2rdf.org/drugbank:DB01024'
p7929
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7930
sg23
Nsg24
Nsg25
S'Myfortic'
p7931
sg27
Nsg28
S'Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. | \r'
p7932
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALUMINUM'
p7933
sa(dp7934
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00993'
p7935
sg5
S'http://bio2rdf.org/drugbank:DB01024'
p7936
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7937
sg23
Nsg24
Nsg25
S'Myfortic'
p7938
sg27
Nsg28
S'Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. | \r'
p7939
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AZATHIOPRINE'
p7940
sa(dp7941
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01378'
p7942
sg5
S'http://bio2rdf.org/drugbank:DB01024'
p7943
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7944
sg23
Nsg24
Nsg25
S'Myfortic'
p7945
sg27
Nsg28
S'Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. | \r'
p7946
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MAGNESIUM CATION'
p7947
sa(dp7948
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01378'
p7949
sg5
S'http://bio2rdf.org/drugbank:DB01024'
p7950
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p7951
sg23
Nsg24
Nsg25
S'Myfortic'
p7952
sg27
Nsg28
S'Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. | \r'
p7953
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MAGNESIUM'
p7954
sa(dp7955
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00688'
p7956
sg5
S'http://bio2rdf.org/drugbank:DB01024'
p7957
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7958
sg23
Nsg24
Nsg25
S'Myfortic'
p7959
sg27
Nsg28
S'Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. | \r'
p7960
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MYCOPHENOLATE MOFETIL'
p7961
sa(dp7962
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p7963
sg5
S'http://bio2rdf.org/drugbank:DB00486'
p7964
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7965
sg23
Nsg24
Nsg25
S'Nabilone'
p7966
sg27
Nsg28
S'Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.| Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).| \r'
p7967
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p7968
sa(dp7969
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p7970
sg5
S'http://bio2rdf.org/drugbank:DB00486'
p7971
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7972
sg23
Nsg24
Nsg25
S'Nabilone'
p7973
sg27
Nsg28
S'Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.| Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).| \r'
p7974
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p7975
sa(dp7976
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00318'
p7977
sg5
S'http://bio2rdf.org/drugbank:DB00486'
p7978
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7979
sg23
Nsg24
Nsg25
S'Nabilone'
p7980
sg27
Nsg28
S'Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.| \r'
p7981
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CODEINE'
p7982
sa(dp7983
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p7984
sg5
S'http://bio2rdf.org/drugbank:DB00486'
p7985
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p7986
sg23
Nsg24
Nsg25
S'Nabilone'
p7987
sg27
Nsg28
S'Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.| \r'
p7988
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIAZEPAM'
p7989
sa(dp7990
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00854'
p7991
sg5
S'http://bio2rdf.org/drugbank:DB00844'
p7992
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p7993
sg23
Nsg24
Nsg25
S'NALBUPHINE'
p7994
sg27
Nsg28
S'Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| \r'
p7995
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Levo-Dromoran'
p7996
sa(dp7997
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01042'
p7998
sg5
S'http://bio2rdf.org/drugbank:DB00779'
p7999
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8000
sg23
Nsg24
Nsg25
S'NALIDIXIC ACID'
p8001
sg27
Nsg28
S'DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  | \r'
p8002
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MELPHALAN'
p8003
sa(dp8004
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p8005
sg5
S'http://bio2rdf.org/drugbank:DB01183'
p8006
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8007
sg23
Nsg24
Nsg25
S'NALOXONE'
p8008
sg27
Nsg28
S'Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine. | the doses of naloxone required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of morphine. | On the other hand, intrathecal naloxone (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular morphine (40 micrograms). | \r'
p8009
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MORPHINE'
p8010
sa(dp8011
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00659'
p8012
sg5
S'http://bio2rdf.org/drugbank:DB00704'
p8013
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8014
sg23
Nsg24
Nsg25
S'NALTREXONE'
p8015
sg27
Nsg28
S'Co-administration of naltrexone with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.| \r'
p8016
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACAMPROSATE'
p8017
sa(dp8018
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p8019
sg5
S'http://bio2rdf.org/drugbank:DB00788'
p8020
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p8021
sg23
Nsg24
Nsg25
S'NAPROXEN'
p8022
sg27
Nsg28
S'Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.| \r'
p8023
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p8024
sa(dp8025
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p8026
sg5
S'http://bio2rdf.org/drugbank:DB00788'
p8027
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p8028
sg23
Nsg24
Nsg25
S'NAPROXEN'
p8029
sg27
Nsg28
S'Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.| Caution should be used if naproxen is administered concomitantly with methotrexate.| \r'
p8030
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHOTREXATE'
p8031
sa(dp8032
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p8033
sg5
S'http://bio2rdf.org/drugbank:DB00788'
p8034
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8035
sg23
Nsg24
Nsg25
S'NAPROXEN'
p8036
sg27
Nsg28
S'Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.| Caution should be used if naproxen is administered concomitantly with methotrexate.| \r'
p8037
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHOTREXATE'
p8038
sa(dp8039
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p8040
sg5
S'http://bio2rdf.org/drugbank:DB01149'
p8041
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8042
sg23
Nsg24
Nsg25
S'NEFAZODONE'
p8043
sg27
Nsg28
S'Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| \r'
p8044
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p8045
sa(dp8046
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00701'
p8047
sg5
S'http://bio2rdf.org/drugbank:DB05251'
p8048
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8049
sg23
Nsg24
Nsg25
S'NELFINAVIR'
p8050
sg27
Nsg28
S'Nelfinavir steady-state Cmax, A.C. and Cmin were increased by 12%, 15%, and 14%, respectively, by concomitant amprenavir.| \r'
p8051
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPRENAVIR'
p8052
sa(dp8053
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p8054
sg5
S'http://bio2rdf.org/drugbank:DB05251'
p8055
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p8056
sg23
Nsg24
Nsg25
S'NELFINAVIR'
p8057
sg27
Nsg28
S'therefore, nelfinavir should be administered (with food) one hour after or more than two hours before didanosine.| \r'
p8058
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIDANOSINE'
p8059
sa(dp8060
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p8061
sg5
S'http://bio2rdf.org/drugbank:DB05251'
p8062
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8063
sg23
Nsg24
Nsg25
S'NELFINAVIR'
p8064
sg27
Nsg28
S'Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. | \r'
p8065
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIDAZOLAM'
p8066
sa(dp8067
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00903'
p8068
sg5
S'http://bio2rdf.org/drugbank:DB00955'
p8069
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p8070
sg23
Nsg24
Nsg25
S'NETILMICIN'
p8071
sg27
Nsg28
S'Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.| \r'
p8072
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ETHACRYNIC ACID'
p8073
sa(dp8074
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00695'
p8075
sg5
S'http://bio2rdf.org/drugbank:DB00955'
p8076
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p8077
sg23
Nsg24
Nsg25
S'NETILMICIN'
p8078
sg27
Nsg28
S'Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.| \r'
p8079
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FUROSEMIDE'
p8080
sa(dp8081
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00520'
p8082
sg5
S'http://bio2rdf.org/drugbank:DB00238'
p8083
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8084
sg23
Nsg24
Nsg25
S'NEVIRAPINE'
p8085
sg27
Nsg28
S'In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.| \r'
p8086
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cancidas'
p8087
sa(dp8088
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p8089
sg5
S'http://bio2rdf.org/drugbank:DB00238'
p8090
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p8091
sg23
Nsg24
Nsg25
S'NEVIRAPINE'
p8092
sg27
Nsg28
S'Nevirapine and ketoconazole should not beadministered concomitantly becausedecreases in ketoconazole plasmaconcentrations may reduce the efficacy of the drug.| \r'
p8093
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p8094
sa(dp8095
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p8096
sg5
S'http://bio2rdf.org/drugbank:DB00238'
p8097
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p8098
sg23
Nsg24
Nsg25
S'NEVIRAPINE'
p8099
sg27
Nsg28
S'Nevirapine and rifampin should not beadministered concomitantly becausedecreases in nevirapine plasmaconcentrations may reduce the efficacy ofthe drug.| \r'
p8100
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFAMPIN'
p8101
sa(dp8102
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00997'
p8103
sg5
S'http://bio2rdf.org/drugbank:DB00398'
p8104
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8105
sg23
Nsg24
Nsg25
S'Nexavar'
p8106
sg27
Nsg28
S'Concomitant treatment with NEXAVAR resulted in a 21% increase in the AUC of doxorubicin. | \r'
p8107
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOXORUBICIN'
p8108
sa(dp8109
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00762'
p8110
sg5
S'http://bio2rdf.org/drugbank:DB00398'
p8111
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p8112
sg23
Nsg24
Nsg25
S'Nexavar'
p8113
sg27
Nsg28
S'Caution is recommended when administering NEXAVAR with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e.g. irinotecan). | \r'
p8114
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'IRINOTECAN'
p8115
sa(dp8116
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00363'
p8117
sg5
S'http://bio2rdf.org/drugbank:DB00184'
p8118
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8119
sg23
Nsg24
Nsg25
S'NICOTINE'
p8120
sg27
Nsg28
S'Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.| \r'
p8121
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLOZAPINE'
p8122
sa(dp8123
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p8124
sg5
S'http://bio2rdf.org/drugbank:DB01115'
p8125
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p8126
sg23
Nsg24
Nsg25
S'NIFEDIPINE'
p8127
sg27
Nsg28
S'If nifedipine therapy is initiated in a patient currently receiving cimetidine, cautious titration is advised.| \r'
p8128
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIMETIDINE'
p8129
sa(dp8130
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01141'
p8131
sg5
S'http://bio2rdf.org/drugbank:DB01115'
p8132
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p8133
sg23
Nsg24
Nsg25
S'NIFEDIPINE'
p8134
sg27
Nsg28
S'Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. | Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state MYCAMINE compared with nifedipine alone. | \r'
p8135
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Mycamine'
p8136
sa(dp8137
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01141'
p8138
sg5
S'http://bio2rdf.org/drugbank:DB01115'
p8139
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8140
sg23
Nsg24
Nsg25
S'NIFEDIPINE'
p8141
sg27
Nsg28
S'Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. | Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state MYCAMINE compared with nifedipine alone. | \r'
p8142
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Mycamine'
p8143
sa(dp8144
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00862'
p8145
sg5
S'http://bio2rdf.org/drugbank:DB01115'
p8146
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8147
sg23
Nsg24
Nsg25
S'NIFEDIPINE'
p8148
sg27
Nsg28
S'In these patients whose hypertension was controlled with nifedipine, Vardenafil 20 mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm Hg compared to placebo.| \r'
p8149
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VARDENAFIL'
p8150
sa(dp8151
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00626'
p8152
sg5
S'http://bio2rdf.org/drugbank:DB00565'
p8153
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8154
sg23
Nsg24
Nsg25
S'Nimbex'
p8155
sg27
Nsg28
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8156
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BACITRACIN A'
p8157
sa(dp8158
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01190'
p8159
sg5
S'http://bio2rdf.org/drugbank:DB00565'
p8160
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8161
sg23
Nsg24
Nsg25
S'Nimbex'
p8162
sg27
Nsg28
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8163
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLINDAMYCIN'
p8164
sa(dp8165
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00803'
p8166
sg5
S'http://bio2rdf.org/drugbank:DB00565'
p8167
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8168
sg23
Nsg24
Nsg25
S'Nimbex'
p8169
sg27
Nsg28
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8170
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Colistin'
p8171
sa(dp8172
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01627'
p8173
sg5
S'http://bio2rdf.org/drugbank:DB00565'
p8174
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8175
sg23
Nsg24
Nsg25
S'Nimbex'
p8176
sg27
Nsg28
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8177
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LINCOMYCIN'
p8178
sa(dp8179
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p8180
sg5
S'http://bio2rdf.org/drugbank:DB00565'
p8181
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8182
sg23
Nsg24
Nsg25
S'Nimbex'
p8183
sg27
Nsg28
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8184
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM CATION'
p8185
sa(dp8186
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p8187
sg5
S'http://bio2rdf.org/drugbank:DB00565'
p8188
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8189
sg23
Nsg24
Nsg25
S'Nimbex'
p8190
sg27
Nsg28
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8191
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM'
p8192
sa(dp8193
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01378'
p8194
sg5
S'http://bio2rdf.org/drugbank:DB00565'
p8195
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8196
sg23
Nsg24
Nsg25
S'Nimbex'
p8197
sg27
Nsg28
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8198
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MAGNESIUM CATION'
p8199
sa(dp8200
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01378'
p8201
sg5
S'http://bio2rdf.org/drugbank:DB00565'
p8202
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8203
sg23
Nsg24
Nsg25
S'Nimbex'
p8204
sg27
Nsg28
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8205
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MAGNESIUM'
p8206
sa(dp8207
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01035'
p8208
sg5
S'http://bio2rdf.org/drugbank:DB00565'
p8209
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8210
sg23
Nsg24
Nsg25
S'Nimbex'
p8211
sg27
Nsg28
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8212
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROCAINAMIDE'
p8213
sa(dp8214
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00908'
p8215
sg5
S'http://bio2rdf.org/drugbank:DB00565'
p8216
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8217
sg23
Nsg24
Nsg25
S'Nimbex'
p8218
sg27
Nsg28
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8219
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'QUINIDINE'
p8220
sa(dp8221
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00202'
p8222
sg5
S'http://bio2rdf.org/drugbank:DB00565'
p8223
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8224
sg23
Nsg24
Nsg25
S'Nimbex'
p8225
sg27
Nsg28
S'Administration of 0.1-mg/kg (2 x ED95) NIMBEX at 10% or 95% recovery following an intubating dose of succinylcholine (1 mg/kg) produced  95% neuromuscular block.| The time to onset of maximum block following NIMBEX is approximately 2 minutes faster with prior administration of succinylcholine.| \r'
p8226
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUCCINYLCHOLINE'
p8227
sa(dp8228
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00779'
p8229
sg5
S'http://bio2rdf.org/drugbank:DB00698'
p8230
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8231
sg23
Nsg24
Nsg25
S'NITROFURANTOIN'
p8232
sg27
Nsg28
S'Nitrofurantoin interferes with the therapeutic action of nalidixic acid.| \r'
p8233
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NALIDIXIC ACID'
p8234
sa(dp8235
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01059'
p8236
sg5
S'http://bio2rdf.org/drugbank:DB00698'
p8237
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8238
sg23
Nsg24
Nsg25
S'NITROFURANTOIN'
p8239
sg27
Nsg28
S'The concomitant use of nitrofurantoin is not recommended since nitrofurantoin may antagonize the antibacterial effect of Norfloxacin in the urinary tract.| \r'
p8240
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NORFLOXACIN'
p8241
sa(dp8242
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01197'
p8243
sg5
S'http://bio2rdf.org/drugbank:DB00727'
p8244
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p8245
sg23
Nsg24
Nsg25
S'NITROGLYCERIN'
p8246
sg27
Nsg28
S'therefore, nitroglycerin or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting captopril.| \r'
p8247
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CAPTOPRIL'
p8248
sa(dp8249
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00435'
p8250
sg5
S'http://bio2rdf.org/drugbank:DB00727'
p8251
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8252
sg23
Nsg24
Nsg25
S'NITROGLYCERIN'
p8253
sg27
Nsg28
S'Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.| \r'
p8254
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INOmax'
p8255
sa(dp8256
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p8257
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p8258
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8259
sg23
Nsg24
Nsg25
S'Nizoral'
p8260
sg27
Nsg28
S'Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.| \r'
p8261
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIDAZOLAM'
p8262
sa(dp8263
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00897'
p8264
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p8265
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8266
sg23
Nsg24
Nsg25
S'Nizoral'
p8267
sg27
Nsg28
S'Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.| \r'
p8268
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TRIAZOLAM'
p8269
sa(dp8270
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01158'
p8271
sg5
S'http://bio2rdf.org/drugbank:DB00368'
p8272
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8273
sg23
Nsg24
Nsg25
S'NOREPINEPHRINE'
p8274
sg27
Nsg28
S'The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.| \r'
p8275
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Bretylium tosylate'
p8276
sa(dp8277
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01390'
p8278
sg5
S'http://bio2rdf.org/drugbank:DB00368'
p8279
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p8280
sg23
Nsg24
Nsg25
S'NOREPINEPHRINE'
p8281
sg27
Nsg28
S'norepinephrine and dobutamine are incompatible with sodium bicarbonate solution. | \r'
p8282
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SODIUM BICARBONATE'
p8283
sa(dp8284
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00996'
p8285
sg5
S'http://bio2rdf.org/drugbank:DB00717'
p8286
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8287
sg23
Nsg24
Nsg25
S'NORETHINDRONE'
p8288
sg27
Nsg28
S'The Cmax of norethindrone was 13% higher when it was coadministered with gabapentin;| \r'
p8289
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GABAPENTIN'
p8290
sa(dp8291
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01016'
p8292
sg5
S'http://bio2rdf.org/drugbank:DB01059'
p8293
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8294
sg23
Nsg24
Nsg25
S'NORFLOXACIN'
p8295
sg27
Nsg28
S'The concomitant administration of quinolones including norfloxacin with glyburide (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.| \r'
p8296
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GLYBURIDE'
p8297
sa(dp8298
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p8299
sg5
S'http://bio2rdf.org/drugbank:DB01059'
p8300
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8301
sg23
Nsg24
Nsg25
S'NORFLOXACIN'
p8302
sg27
Nsg28
S'There have been reports of theophylline-related side effects in patients on concomitant therapy with norfloxacin and theophylline.| \r'
p8303
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p8304
sa(dp8305
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p8306
sg5
S'http://bio2rdf.org/drugbank:DB01059'
p8307
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p8308
sg23
Nsg24
Nsg25
S'NORFLOXACIN'
p8309
sg27
Nsg28
S'Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| \r'
p8310
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tikosyn'
p8311
sa(dp8312
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00908'
p8313
sg5
S'http://bio2rdf.org/drugbank:DB00280'
p8314
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8315
sg23
Nsg24
Nsg25
S'Norpace'
p8316
sg27
Nsg28
S'Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.| \r'
p8317
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'QUINIDINE'
p8318
sa(dp8319
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00626'
p8320
sg5
S'http://bio2rdf.org/drugbank:DB01135'
p8321
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8322
sg23
Nsg24
Nsg25
S'Nuromax'
p8323
sg27
Nsg28
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8324
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BACITRACIN A'
p8325
sa(dp8326
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p8327
sg5
S'http://bio2rdf.org/drugbank:DB01135'
p8328
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8329
sg23
Nsg24
Nsg25
S'Nuromax'
p8330
sg27
Nsg28
S'As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.| \r'
p8331
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CARBAMAZEPINE'
p8332
sa(dp8333
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01190'
p8334
sg5
S'http://bio2rdf.org/drugbank:DB01135'
p8335
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8336
sg23
Nsg24
Nsg25
S'Nuromax'
p8337
sg27
Nsg28
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8338
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLINDAMYCIN'
p8339
sa(dp8340
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00803'
p8341
sg5
S'http://bio2rdf.org/drugbank:DB01135'
p8342
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8343
sg23
Nsg24
Nsg25
S'Nuromax'
p8344
sg27
Nsg28
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8345
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Colistin'
p8346
sa(dp8347
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01627'
p8348
sg5
S'http://bio2rdf.org/drugbank:DB01135'
p8349
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8350
sg23
Nsg24
Nsg25
S'Nuromax'
p8351
sg27
Nsg28
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8352
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LINCOMYCIN'
p8353
sa(dp8354
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p8355
sg5
S'http://bio2rdf.org/drugbank:DB01135'
p8356
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8357
sg23
Nsg24
Nsg25
S'Nuromax'
p8358
sg27
Nsg28
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8359
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM CATION'
p8360
sa(dp8361
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p8362
sg5
S'http://bio2rdf.org/drugbank:DB01135'
p8363
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8364
sg23
Nsg24
Nsg25
S'Nuromax'
p8365
sg27
Nsg28
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8366
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM'
p8367
sa(dp8368
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01378'
p8369
sg5
S'http://bio2rdf.org/drugbank:DB01135'
p8370
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8371
sg23
Nsg24
Nsg25
S'Nuromax'
p8372
sg27
Nsg28
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8373
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MAGNESIUM CATION'
p8374
sa(dp8375
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01378'
p8376
sg5
S'http://bio2rdf.org/drugbank:DB01135'
p8377
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8378
sg23
Nsg24
Nsg25
S'Nuromax'
p8379
sg27
Nsg28
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8380
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MAGNESIUM'
p8381
sa(dp8382
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p8383
sg5
S'http://bio2rdf.org/drugbank:DB01135'
p8384
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8385
sg23
Nsg24
Nsg25
S'Nuromax'
p8386
sg27
Nsg28
S'As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.| \r'
p8387
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p8388
sa(dp8389
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01035'
p8390
sg5
S'http://bio2rdf.org/drugbank:DB01135'
p8391
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8392
sg23
Nsg24
Nsg25
S'Nuromax'
p8393
sg27
Nsg28
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8394
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROCAINAMIDE'
p8395
sa(dp8396
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00908'
p8397
sg5
S'http://bio2rdf.org/drugbank:DB01135'
p8398
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8399
sg23
Nsg24
Nsg25
S'Nuromax'
p8400
sg27
Nsg28
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8401
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'QUINIDINE'
p8402
sa(dp8403
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00450'
p8404
sg5
S'http://bio2rdf.org/drugbank:DB01092'
p8405
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8406
sg23
Nsg24
Nsg25
S'OUABAIN'
p8407
sg27
Nsg28
S'Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.| \r'
p8408
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DROPERIDOL'
p8409
sa(dp8410
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00692'
p8411
sg5
S'http://bio2rdf.org/drugbank:DB01092'
p8412
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8413
sg23
Nsg24
Nsg25
S'OUABAIN'
p8414
sg27
Nsg28
S'When ouabain was applied to the muscle in the presence of phentolamine, both first and second contractile responses to PTX were abolished. | \r'
p8415
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENTOLAMINE'
p8416
sa(dp8417
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00818'
p8418
sg5
S'http://bio2rdf.org/drugbank:DB01192'
p8419
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8420
sg23
Nsg24
Nsg25
S'OXYMORPHONE'
p8421
sg27
Nsg28
S'It has been reported that the incidence of bradycardia was increased when oxymorphone was combined with propofol for induction of anesthesia. | \r'
p8422
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROPOFOL'
p8423
sa(dp8424
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p8425
sg5
S'http://bio2rdf.org/drugbank:DB03585'
p8426
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8427
sg23
Nsg24
Nsg25
S'Oxyphenbutazone'
p8428
sg27
Nsg28
S'Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.| \r'
p8429
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p8430
sa(dp8431
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00997'
p8432
sg5
S'http://bio2rdf.org/drugbank:DB01229'
p8433
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8434
sg23
Nsg24
Nsg25
S'PACLITAXEL'
p8435
sg27
Nsg28
S'Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination.| \r'
p8436
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOXORUBICIN'
p8437
sa(dp8438
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00072'
p8439
sg5
S'http://bio2rdf.org/drugbank:DB01229'
p8440
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8441
sg23
Nsg24
Nsg25
S'PACLITAXEL'
p8442
sg27
Nsg28
S'Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.| \r'
p8443
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Herceptin'
p8444
sa(dp8445
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00721'
p8446
sg5
S'http://bio2rdf.org/drugbank:DB00345'
p8447
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8448
sg23
Nsg24
Nsg25
S'PAH'
p8449
sg27
Nsg28
S'Renal clearance measurements of PAH cannot be made with any significant accuracy in patients receiving sulfonamides, procaine, or thiazolesulfone.| \r'
p8450
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROCAINE'
p8451
sa(dp8452
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00115'
p8453
sg5
S'http://bio2rdf.org/drugbank:DB00233'
p8454
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8455
sg23
Nsg24
Nsg25
S'para-aminosalicylic acid'
p8456
sg27
Nsg28
S'Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.| \r'
p8457
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Vitamin B12'
p8458
sa(dp8459
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01072'
p8460
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p8461
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p8462
sg23
Nsg24
Nsg25
S'PARICALCITOL'
p8463
sg27
Nsg28
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p8464
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ATAZANAVIR'
p8465
sa(dp8466
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01211'
p8467
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p8468
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p8469
sg23
Nsg24
Nsg25
S'PARICALCITOL'
p8470
sg27
Nsg28
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p8471
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLARITHROMYCIN'
p8472
sa(dp8473
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p8474
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p8475
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p8476
sg23
Nsg24
Nsg25
S'PARICALCITOL'
p8477
sg27
Nsg28
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p8478
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDINAVIR ANHYDROUS'
p8479
sa(dp8480
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p8481
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p8482
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p8483
sg23
Nsg24
Nsg25
S'PARICALCITOL'
p8484
sg27
Nsg28
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p8485
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDINAVIR'
p8486
sa(dp8487
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p8488
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p8489
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p8490
sg23
Nsg24
Nsg25
S'PARICALCITOL'
p8491
sg27
Nsg28
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p8492
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p8493
sa(dp8494
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01149'
p8495
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p8496
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p8497
sg23
Nsg24
Nsg25
S'PARICALCITOL'
p8498
sg27
Nsg28
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p8499
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NEFAZODONE'
p8500
sa(dp8501
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB05251'
p8502
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p8503
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p8504
sg23
Nsg24
Nsg25
S'PARICALCITOL'
p8505
sg27
Nsg28
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p8506
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NELFINAVIR'
p8507
sa(dp8508
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p8509
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p8510
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p8511
sg23
Nsg24
Nsg25
S'PARICALCITOL'
p8512
sg27
Nsg28
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p8513
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p8514
sa(dp8515
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p8516
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p8517
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p8518
sg23
Nsg24
Nsg25
S'PARICALCITOL'
p8519
sg27
Nsg28
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p8520
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p8521
sa(dp8522
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p8523
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p8524
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p8525
sg23
Nsg24
Nsg25
S'PARICALCITOL'
p8526
sg27
Nsg28
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p8527
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p8528
sa(dp8529
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00976'
p8530
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p8531
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p8532
sg23
Nsg24
Nsg25
S'PARICALCITOL'
p8533
sg27
Nsg28
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p8534
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TELITHROMYCIN'
p8535
sa(dp8536
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00582'
p8537
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p8538
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p8539
sg23
Nsg24
Nsg25
S'PARICALCITOL'
p8540
sg27
Nsg28
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p8541
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VORICONAZOLE'
p8542
sa(dp8543
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01238'
p8544
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p8545
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8546
sg23
Nsg24
Nsg25
S'PAROXETINE'
p8547
sg27
Nsg28
S'Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.| \r'
p8548
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ARIPIPRAZOLE'
p8549
sa(dp8550
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00289'
p8551
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p8552
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8553
sg23
Nsg24
Nsg25
S'PAROXETINE'
p8554
sg27
Nsg28
S'In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.| \r'
p8555
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ATOMOXETINE'
p8556
sa(dp8557
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00363'
p8558
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p8559
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8560
sg23
Nsg24
Nsg25
S'PAROXETINE'
p8561
sg27
Nsg28
S'Paroxetine produced only minor changes in the levels of clozapine and its metabolites.| \r'
p8562
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLOZAPINE'
p8563
sa(dp8564
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00476'
p8565
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p8566
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8567
sg23
Nsg24
Nsg25
S'PAROXETINE'
p8568
sg27
Nsg28
S'Paroxetine (20 mg QD) increased the concentration of duloxetine (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine.| \r'
p8569
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DULOXETINE'
p8570
sa(dp8571
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p8572
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p8573
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8574
sg23
Nsg24
Nsg25
S'PAROXETINE'
p8575
sg27
Nsg28
S'Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | \r'
p8576
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUMATRIPTAN SUCCINATE'
p8577
sa(dp8578
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p8579
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p8580
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8581
sg23
Nsg24
Nsg25
S'PAROXETINE'
p8582
sg27
Nsg28
S'Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | \r'
p8583
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUMATRIPTAN'
p8584
sa(dp8585
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01121'
p8586
sg5
S'http://bio2rdf.org/drugbank:DB00754'
p8587
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p8588
sg23
Nsg24
Nsg25
S'Peganone'
p8589
sg27
Nsg28
S'Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.| \r'
p8590
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENACEMIDE'
p8591
sa(dp8592
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01121'
p8593
sg5
S'http://bio2rdf.org/drugbank:DB00754'
p8594
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p8595
sg23
Nsg24
Nsg25
S'Peganone'
p8596
sg27
Nsg28
S'Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.| \r'
p8597
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Phenurone'
p8598
sa(dp8599
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p8600
sg5
S'http://bio2rdf.org/drugbank:DB00008'
p8601
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8602
sg23
Nsg24
Nsg25
S'Pegasys'
p8603
sg27
Nsg28
S'Treatment with PEGASYS once weekly for 4 weeks in healthy subjects was associated with an inhibition of P450 1A2 and a 25% increase in theophylline AUC.| \r'
p8604
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p8605
sa(dp8606
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p8607
sg5
S'http://bio2rdf.org/drugbank:DB00738'
p8608
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p8609
sg23
Nsg24
Nsg25
S'PENTAMIDINE'
p8610
sg27
Nsg28
S'Death due to fulminant pancreatitis possibly related to intravenous pentamidine and HIVID has been reported.| If intravenous pentamidine is required to treat Pneumocystis carinii pneumonia, treatment with HIVID should be interrupted.| \r'
p8611
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HIVID'
p8612
sa(dp8613
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p8614
sg5
S'http://bio2rdf.org/drugbank:DB00738'
p8615
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8616
sg23
Nsg24
Nsg25
S'PENTAMIDINE'
p8617
sg27
Nsg28
S'Death due to fulminant pancreatitis possibly related to intravenous pentamidine and HIVID has been reported.| If intravenous pentamidine is required to treat Pneumocystis carinii pneumonia, treatment with HIVID should be interrupted.| \r'
p8618
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HIVID'
p8619
sa(dp8620
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00854'
p8621
sg5
S'http://bio2rdf.org/drugbank:DB00652'
p8622
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p8623
sg23
Nsg24
Nsg25
S'PENTAZOCINE, (-)-'
p8624
sg27
Nsg28
S'Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| \r'
p8625
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Levo-Dromoran'
p8626
sa(dp8627
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00792'
p8628
sg5
S'http://bio2rdf.org/drugbank:DB00652'
p8629
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8630
sg23
Nsg24
Nsg25
S'PENTAZOCINE, (-)-'
p8631
sg27
Nsg28
S'Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in pentazocine and tripelennamine, addicts) were completely inhibited by the drug combination. | \r'
p8632
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TRIPELENNAMINE'
p8633
sa(dp8634
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00580'
p8635
sg5
S'http://bio2rdf.org/drugbank:DB00514'
p8636
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8637
sg23
Nsg24
Nsg25
S'PHENARSAZINE CHLORIDE'
p8638
sg27
Nsg28
S'Even so dextromethorphan plasma concentrations in the presence of high doses of valdecoxib were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.| \r'
p8639
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VALDECOXIB'
p8640
sa(dp8641
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p8642
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8643
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8644
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p8645
sg27
Nsg28
S'Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. | \r'
p8646
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACETAMINOPHEN'
p8647
sa(dp8648
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p8649
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8650
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8651
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p8652
sg27
Nsg28
S'Phenobarbital: Decreases aspirin effectiveness by enzyme induction.| \r'
p8653
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p8654
sa(dp8655
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p8656
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8657
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8658
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p8659
sg27
Nsg28
S'Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.| \r'
p8660
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BEXAROTENE'
p8661
sa(dp8662
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00136'
p8663
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8664
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8665
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p8666
sg27
Nsg28
S'Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.| \r'
p8667
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CALCITRIOL'
p8668
sa(dp8669
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01068'
p8670
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8671
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8672
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p8673
sg27
Nsg28
S'Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.| \r'
p8674
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLONAZEPAM'
p8675
sa(dp8676
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00586'
p8677
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8678
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8679
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p8680
sg27
Nsg28
S'Phenobarbital toxicity has been reported to have occurred in a patient on chronic phenobarbital treatment following the initiation of diclofenac therapy.| \r'
p8681
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DICLOFENAC'
p8682
sa(dp8683
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00625'
p8684
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8685
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8686
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p8687
sg27
Nsg28
S'Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.| \r'
p8688
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EFAVIRENZ'
p8689
sa(dp8690
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00977'
p8691
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8692
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8693
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p8694
sg27
Nsg28
S'Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.| \r'
p8695
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ETHINYL ESTRADIOL'
p8696
sa(dp8697
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00990'
p8698
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8699
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8700
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p8701
sg27
Nsg28
S'Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.| \r'
p8702
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EXEMESTANE'
p8703
sa(dp8704
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00949'
p8705
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8706
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8707
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p8708
sg27
Nsg28
S'Phenobarbital: It appears that phenobarbital may reduce plasma felbamate concentrations.| \r'
p8709
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FELBAMATE'
p8710
sa(dp8711
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00573'
p8712
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8713
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8714
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p8715
sg27
Nsg28
S'Chronic administration of phenobarbital, a known enzyme inducer, may be associated with a decrease in the plasma half-life of fenoprofen.| \r'
p8716
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Fenoprofen'
p8717
sa(dp8718
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p8719
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8720
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p8721
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p8722
sg27
Nsg28
S'Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | \r'
p8723
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHYLPREDNISOLONE'
p8724
sa(dp8725
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p8726
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8727
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8728
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p8729
sg27
Nsg28
S'Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | \r'
p8730
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHYLPREDNISOLONE'
p8731
sa(dp8732
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00379'
p8733
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8734
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8735
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p8736
sg27
Nsg28
S'When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. | \r'
p8737
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Mexitil'
p8738
sa(dp8739
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00834'
p8740
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8741
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8742
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p8743
sg27
Nsg28
S'John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). | \r'
p8744
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIFEPRISTONE'
p8745
sa(dp8746
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00471'
p8747
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8748
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p8749
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p8750
sg27
Nsg28
S'It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.| \r'
p8751
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MONTELUKAST'
p8752
sa(dp8753
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00573'
p8754
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8755
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p8756
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p8757
sg27
Nsg28
S'When phenobarbital is added to or withdrawn from treatment, dosage adjustment of Nalfon may be required.| \r'
p8758
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nalfon'
p8759
sa(dp8760
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p8761
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8762
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8763
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p8764
sg27
Nsg28
S'Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| \r'
p8765
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p8766
sa(dp8767
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p8768
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8769
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8770
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p8771
sg27
Nsg28
S'Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| \r'
p8772
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p8773
sa(dp8774
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00776'
p8775
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8776
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8777
sg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p8778
sg27
Nsg28
S'The increase of phenobarbital level, however, is small (15%) when given with Trileptal.| \r'
p8779
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Trileptal'
p8780
sa(dp8781
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01037'
p8782
sg5
S'http://bio2rdf.org/drugbank:DB00120'
p8783
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8784
sg23
Nsg24
Nsg25
S'PHENYLALANINE'
p8785
sg27
Nsg28
S'Selegiline - L-phenylalanine and the selective MAO inhibitor selegiline may have synergistic antidepressant activity if used concomitantly.| \r'
p8786
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SELEGILINE'
p8787
sa(dp8788
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p8789
sg5
S'http://bio2rdf.org/drugbank:DB00812'
p8790
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8791
sg23
Nsg24
Nsg25
S'PHENYLBUTAZONE'
p8792
sg27
Nsg28
S'Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.| \r'
p8793
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p8794
sa(dp8795
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00749'
p8796
sg5
S'http://bio2rdf.org/drugbank:DB00812'
p8797
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8798
sg23
Nsg24
Nsg25
S'PHENYLBUTAZONE'
p8799
sg27
Nsg28
S'Phenylbutazone: Phenylbutazone causes increase (by about 80%) in the free fraction of etodolac.| \r'
p8800
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Etodolac'
p8801
sa(dp8802
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00211'
p8803
sg5
S'http://bio2rdf.org/drugbank:DB00388'
p8804
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8805
sg23
Nsg24
Nsg25
S'PHENYLEPHRINE'
p8806
sg27
Nsg28
S'The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. | \r'
p8807
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ProAmatine'
p8808
sa(dp8809
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p8810
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8811
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8812
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p8813
sg27
Nsg28
S'- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine, chronic alcohol abuse, reserpine| The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| \r'
p8814
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p8815
sa(dp8816
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01118'
p8817
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8818
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8819
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p8820
sg27
Nsg28
S'The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| \r'
p8821
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMIODARONE'
p8822
sa(dp8823
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p8824
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8825
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8826
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p8827
sg27
Nsg28
S'Phenytoin: Serum phenytoin levels may be increased by aspirin.| \r'
p8828
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p8829
sa(dp8830
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p8831
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8832
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8833
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p8834
sg27
Nsg28
S'Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.| \r'
p8835
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BEXAROTENE'
p8836
sa(dp8837
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01008'
p8838
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8839
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8840
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p8841
sg27
Nsg28
S'Phenytoin increases the clearance of busulfan by 15% or more, possibly due to the induction of glutathione-S-transferase.| \r'
p8842
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BUSULFAN'
p8843
sa(dp8844
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00136'
p8845
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8846
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8847
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p8848
sg27
Nsg28
S'Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.| \r'
p8849
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CALCITRIOL'
p8850
sa(dp8851
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00520'
p8852
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8853
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8854
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p8855
sg27
Nsg28
S'In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.| \r'
p8856
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cancidas'
p8857
sa(dp8858
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p8859
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8860
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8861
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p8862
sg27
Nsg28
S'- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine, chronic alcohol abuse, reserpine| \r'
p8863
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CARBAMAZEPINE'
p8864
sa(dp8865
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00475'
p8866
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8867
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8868
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p8869
sg27
Nsg28
S'The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| \r'
p8870
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CHLORDIAZEPOXIDE'
p8871
sa(dp8872
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p8873
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8874
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8875
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p8876
sg27
Nsg28
S'The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| \r'
p8877
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIMETIDINE'
p8878
sa(dp8879
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00537'
p8880
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8881
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8882
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p8883
sg27
Nsg28
S'Phenytoin: Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin.| \r'
p8884
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIPROFLOXACIN'
p8885
sa(dp8886
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01068'
p8887
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8888
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8889
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p8890
sg27
Nsg28
S'Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.| \r'
p8891
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLONAZEPAM'
p8892
sa(dp8893
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00363'
p8894
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8895
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8896
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p8897
sg27
Nsg28
S'Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.| \r'
p8898
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLOZAPINE'
p8899
sa(dp8900
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB04665'
p8901
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8902
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8903
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p8904
sg27
Nsg28
S'Presumably, phenytoin acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations.| - Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.| \r'
p8905
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'COUMARIN'
p8906
sa(dp8907
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB04665'
p8908
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8909
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8910
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p8911
sg27
Nsg28
S'Presumably, phenytoin acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations.| - Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.| \r'
p8912
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'COUMARIN'
p8913
sa(dp8914
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01234'
p8915
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8916
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8917
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p8918
sg27
Nsg28
S'Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control.| \r'
p8919
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DEXAMETHASONE'
p8920
sa(dp8921
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p8922
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8923
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8924
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p8925
sg27
Nsg28
S'The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| \r'
p8926
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIAZEPAM'
p8927
sa(dp8928
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00266'
p8929
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8930
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8931
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p8932
sg27
Nsg28
S'The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| \r'
p8933
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DICUMAROL'
p8934
sa(dp8935
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01396'
p8936
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8937
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8938
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p8939
sg27
Nsg28
S'- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.| \r'
p8940
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGITOXIN'
p8941
sa(dp8942
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p8943
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8944
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8945
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p8946
sg27
Nsg28
S'Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable| \r'
p8947
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIPHENOLIC ACID'
p8948
sa(dp8949
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00822'
p8950
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8951
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8952
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p8953
sg27
Nsg28
S'The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| \r'
p8954
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DISULFIRAM'
p8955
sa(dp8956
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00254'
p8957
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8958
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8959
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p8960
sg27
Nsg28
S'Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.| - Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.| \r'
p8961
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOXYCYCLINE'
p8962
sa(dp8963
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00254'
p8964
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8965
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8966
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p8967
sg27
Nsg28
S'Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.| - Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.| \r'
p8968
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOXYCYCLINE'
p8969
sa(dp8970
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00286'
p8971
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8972
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p8973
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p8974
sg27
Nsg28
S'The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| - Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.| \r'
p8975
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Estrogens'
p8976
sa(dp8977
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00286'
p8978
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8979
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8980
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p8981
sg27
Nsg28
S'The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| - Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.| \r'
p8982
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Estrogens'
p8983
sa(dp8984
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00977'
p8985
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8986
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8987
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p8988
sg27
Nsg28
S'Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.| \r'
p8989
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ETHINYL ESTRADIOL'
p8990
sa(dp8991
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00990'
p8992
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8993
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p8994
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p8995
sg27
Nsg28
S'Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.| \r'
p8996
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EXEMESTANE'
p8997
sa(dp8998
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00949'
p8999
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9000
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9001
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p9002
sg27
Nsg28
S'Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.| \r'
p9003
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FELBAMATE'
p9004
sa(dp9005
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00949'
p9006
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9007
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9008
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p9009
sg27
Nsg28
S'Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.| \r'
p9010
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Felbatol'
p9011
sa(dp9012
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00695'
p9013
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9014
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9015
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p9016
sg27
Nsg28
S'- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.| \r'
p9017
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FUROSEMIDE'
p9018
sa(dp9019
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00951'
p9020
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9021
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9022
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p9023
sg27
Nsg28
S'The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| \r'
p9024
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ISONIAZID'
p9025
sa(dp9026
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p9027
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9028
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p9029
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p9030
sg27
Nsg28
S'Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | \r'
p9031
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHYLPREDNISOLONE'
p9032
sa(dp9033
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p9034
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9035
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9036
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p9037
sg27
Nsg28
S'Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | \r'
p9038
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHYLPREDNISOLONE'
p9039
sa(dp9040
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00379'
p9041
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9042
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9043
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p9044
sg27
Nsg28
S'When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. | \r'
p9045
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Mexitil'
p9046
sa(dp9047
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p9048
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9049
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9050
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p9051
sg27
Nsg28
S'Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. | \r'
p9052
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIDAZOLAM'
p9053
sa(dp9054
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00834'
p9055
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9056
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9057
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p9058
sg27
Nsg28
S'John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). | \r'
p9059
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIFEPRISTONE'
p9060
sa(dp9061
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01226'
p9062
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9063
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9064
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p9065
sg27
Nsg28
S'While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. | \r'
p9066
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Mivacron'
p9067
sa(dp9068
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00565'
p9069
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9070
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9071
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p9072
sg27
Nsg28
S'While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.| \r'
p9073
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nimbex'
p9074
sa(dp9075
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00280'
p9076
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9077
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9078
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p9079
sg27
Nsg28
S'If phenytoin or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR, lower plasma levels of disopyramide may occur.| \r'
p9080
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Norpace'
p9081
sa(dp9082
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p9083
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9084
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9085
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p9086
sg27
Nsg28
S'- Drugs that may either increase or decrease plasma phenytoin concentrations include: phenobarbital, vaiproic acid, and sodium valproate.| Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable| \r'
p9087
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p9088
sa(dp9089
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p9090
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9091
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9092
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p9093
sg27
Nsg28
S'- Drugs that may either increase or decrease plasma phenytoin concentrations include: phenobarbital, vaiproic acid, and sodium valproate.| Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable| \r'
p9094
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p9095
sa(dp9096
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00812'
p9097
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9098
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9099
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p9100
sg27
Nsg28
S'The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| \r'
p9101
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYLBUTAZONE'
p9102
sa(dp9103
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01224'
p9104
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9105
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9106
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p9107
sg27
Nsg28
S'This study demonstrated that the potent cytochrome P450 enzyme-inducer phenytoin did indeed have a marked effect on the metabolism of quetiapine, resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder. | \r'
p9108
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'QUETIAPINE FUMARATE'
p9109
sa(dp9110
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01224'
p9111
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9112
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9113
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p9114
sg27
Nsg28
S'This study demonstrated that the potent cytochrome P450 enzyme-inducer phenytoin did indeed have a marked effect on the metabolism of quetiapine, resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder. | \r'
p9115
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'QUETIAPINE'
p9116
sa(dp9117
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00908'
p9118
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9119
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9120
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p9121
sg27
Nsg28
S'- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.| \r'
p9122
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'QUINIDINE'
p9123
sa(dp9124
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00206'
p9125
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9126
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9127
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p9128
sg27
Nsg28
S'- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine, chronic alcohol abuse, reserpine| \r'
p9129
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RESERPINE'
p9130
sa(dp9131
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p9132
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9133
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9134
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p9135
sg27
Nsg28
S'- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.| \r'
p9136
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFAMPIN'
p9137
sa(dp9138
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p9139
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9140
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9141
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p9142
sg27
Nsg28
S'Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| \r'
p9143
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p9144
sa(dp9145
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p9146
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9147
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9148
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p9149
sg27
Nsg28
S'Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| \r'
p9150
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p9151
sa(dp9152
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00401'
p9153
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9154
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9155
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p9156
sg27
Nsg28
S'Coadministration of phenytoin with 40 mg SULAR tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.| \r'
p9157
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sular'
p9158
sa(dp9159
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00891'
p9160
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9161
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9162
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p9163
sg27
Nsg28
S'- Phenytoin (e.g., Dilantin) Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin| \r'
p9164
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SULFAPYRIDINE'
p9165
sa(dp9166
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p9167
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9168
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9169
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p9170
sg27
Nsg28
S'- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.| With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.| \r'
p9171
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p9172
sa(dp9173
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p9174
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9175
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9176
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p9177
sg27
Nsg28
S'The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| \r'
p9178
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TOLBUTAMIDE'
p9179
sa(dp9180
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00656'
p9181
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9182
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9183
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p9184
sg27
Nsg28
S'The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| \r'
p9185
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TRAZODONE'
p9186
sa(dp9187
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00776'
p9188
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9189
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9190
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p9191
sg27
Nsg28
S'1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high Trileptal doses In vivo, the plasma levels of phenytoin increased by up to 40%, when Trileptal was given at doses above 1200 mg/day.| \r'
p9192
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Trileptal'
p9193
sa(dp9194
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p9195
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9196
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9197
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p9198
sg27
Nsg28
S'Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable| \r'
p9199
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Valproate'
p9200
sa(dp9201
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p9202
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9203
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9204
sg23
Nsg24
Nsg25
S'PHENYTOIN'
p9205
sg27
Nsg28
S'Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable| \r'
p9206
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VALPROIC ACID'
p9207
sa(dp9208
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00202'
p9209
sg5
S'http://bio2rdf.org/drugbank:DB01057'
p9210
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9211
sg23
Nsg24
Nsg25
S'Phospholine Iodide'
p9212
sg27
Nsg28
S'Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticides.| \r'
p9213
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUCCINYLCHOLINE'
p9214
sa(dp9215
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p9216
sg5
S'http://bio2rdf.org/drugbank:DB00981'
p9217
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9218
sg23
Nsg24
Nsg25
S'PHYSOSTIGMINE'
p9219
sg27
Nsg28
S"Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3. | \r"
p9220
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p9221
sa(dp9222
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p9223
sg5
S'http://bio2rdf.org/drugbank:DB01100'
p9224
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9225
sg23
Nsg24
Nsg25
S'PIMOZIDE'
p9226
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p9227
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p9228
sa(dp9229
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p9230
sg5
S'http://bio2rdf.org/drugbank:DB01100'
p9231
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9232
sg23
Nsg24
Nsg25
S'PIMOZIDE'
p9233
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p9234
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p9235
sa(dp9236
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p9237
sg5
S'http://bio2rdf.org/drugbank:DB01100'
p9238
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p9239
sg23
Nsg24
Nsg25
S'PIMOZIDE'
p9240
sg27
Nsg28
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p9241
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sprycel'
p9242
sa(dp9243
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01339'
p9244
sg5
S'http://bio2rdf.org/drugbank:DB00319'
p9245
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9246
sg23
Nsg24
Nsg25
S'PIPERACILLIN ANHYDROUS'
p9247
sg27
Nsg28
S'Vecuronium: When used in the perioperative period, piperacillin has been implicated in the prolongation of the neuromuscular blockade of vecuronium.| In one controlled clinical study, the ureidopenicillins, including piperacillin, were reported to prolong the action of vecuronium.| \r'
p9248
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VECURONIUM'
p9249
sa(dp9250
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01339'
p9251
sg5
S'http://bio2rdf.org/drugbank:DB00319'
p9252
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9253
sg23
Nsg24
Nsg25
S'PIPERACILLIN'
p9254
sg27
Nsg28
S'In one controlled clinical study, the ureidopenicillins, including piperacillin, were reported to prolong the action of vecuronium.| Vecuronium: When used in the perioperative period, piperacillin has been implicated in the prolongation of the neuromuscular blockade of vecuronium.| \r'
p9255
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VECURONIUM'
p9256
sa(dp9257
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p9258
sg5
S'http://bio2rdf.org/drugbank:DB01166'
p9259
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p9260
sg23
Nsg24
Nsg25
S'Pletal'
p9261
sg27
Nsg28
S'Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.| \r'
p9262
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERYTHROMYCIN'
p9263
sa(dp9264
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p9265
sg5
S'http://bio2rdf.org/drugbank:DB01166'
p9266
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p9267
sg23
Nsg24
Nsg25
S'Pletal'
p9268
sg27
Nsg28
S'Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.| \r'
p9269
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p9270
sa(dp9271
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p9272
sg5
S'http://bio2rdf.org/drugbank:DB00784'
p9273
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p9274
sg23
Nsg24
Nsg25
S'Ponstel'
p9275
sg27
Nsg28
S'Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.| \r'
p9276
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p9277
sa(dp9278
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00695'
p9279
sg5
S'http://bio2rdf.org/drugbank:DB00784'
p9280
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p9281
sg23
Nsg24
Nsg25
S'Ponstel'
p9282
sg27
Nsg28
S'During concomitant therapy of Ponstel with furosemide, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.| \r'
p9283
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FUROSEMIDE'
p9284
sa(dp9285
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p9286
sg5
S'http://bio2rdf.org/drugbank:DB01388'
p9287
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9288
sg23
Nsg24
Nsg25
S'Posicor'
p9289
sg27
Nsg28
S"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. | \r"
p9290
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASTEMIZOLE'
p9291
sa(dp9292
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p9293
sg5
S'http://bio2rdf.org/drugbank:DB01388'
p9294
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9295
sg23
Nsg24
Nsg25
S'Posicor'
p9296
sg27
Nsg28
S"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. | \r"
p9297
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p9298
sa(dp9299
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p9300
sg5
S'http://bio2rdf.org/drugbank:DB01388'
p9301
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9302
sg23
Nsg24
Nsg25
S'Posicor'
p9303
sg27
Nsg28
S"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. | \r"
p9304
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSPORINE'
p9305
sa(dp9306
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00572'
p9307
sg5
S'http://bio2rdf.org/drugbank:DB00733'
p9308
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9309
sg23
Nsg24
Nsg25
S'PRALIDOXIME'
p9310
sg27
Nsg28
S'When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.| \r'
p9311
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Atropine'
p9312
sa(dp9313
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00211'
p9314
sg5
S'http://bio2rdf.org/drugbank:DB00457'
p9315
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9316
sg23
Nsg24
Nsg25
S'PRAZOSIN'
p9317
sg27
Nsg28
S'ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. | \r'
p9318
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ProAmatine'
p9319
sa(dp9320
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00594'
p9321
sg5
S'http://bio2rdf.org/drugbank:DB00722'
p9322
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9323
sg23
Nsg24
Nsg25
S'Prinivil'
p9324
sg27
Nsg28
S'Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.| \r'
p9325
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMILORIDE'
p9326
sa(dp9327
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p9328
sg5
S'http://bio2rdf.org/drugbank:DB00722'
p9329
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p9330
sg23
Nsg24
Nsg25
S'Prinivil'
p9331
sg27
Nsg28
S'It is recommended that serum lithium levels be monitored frequently if PRINIVIL is administered concomitantly with lithium.| \r'
p9332
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM CATION'
p9333
sa(dp9334
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p9335
sg5
S'http://bio2rdf.org/drugbank:DB00722'
p9336
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p9337
sg23
Nsg24
Nsg25
S'Prinivil'
p9338
sg27
Nsg28
S'It is recommended that serum lithium levels be monitored frequently if PRINIVIL is administered concomitantly with lithium.| \r'
p9339
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM'
p9340
sa(dp9341
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01345'
p9342
sg5
S'http://bio2rdf.org/drugbank:DB00722'
p9343
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9344
sg23
Nsg24
Nsg25
S'Prinivil'
p9345
sg27
Nsg28
S'Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.| \r'
p9346
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'POTASSIUM'
p9347
sa(dp9348
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00421'
p9349
sg5
S'http://bio2rdf.org/drugbank:DB00722'
p9350
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9351
sg23
Nsg24
Nsg25
S'Prinivil'
p9352
sg27
Nsg28
S'Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.| \r'
p9353
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SPIRONOLACTONE'
p9354
sa(dp9355
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00384'
p9356
sg5
S'http://bio2rdf.org/drugbank:DB00722'
p9357
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9358
sg23
Nsg24
Nsg25
S'Prinivil'
p9359
sg27
Nsg28
S'Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.| \r'
p9360
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TRIAMTERENE'
p9361
sa(dp9362
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p9363
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9364
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9365
sg23
Nsg24
Nsg25
S'PROBENECID'
p9366
sg27
Nsg28
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p9367
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACETAMINOPHEN'
p9368
sa(dp9369
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00787'
p9370
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9371
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9372
sg23
Nsg24
Nsg25
S'PROBENECID'
p9373
sg27
Nsg28
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| Co-administration of probenecid with acyclovir has been shown to increase the mean half-life and the area under the concentration-time curve.| \r'
p9374
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACYCLOVIR'
p9375
sa(dp9376
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p9377
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9378
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9379
sg23
Nsg24
Nsg25
S'PROBENECID'
p9380
sg27
Nsg28
S'Probenecid: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.| \r'
p9381
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ADENOSINE PHOSPHATE'
p9382
sa(dp9383
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00642'
p9384
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9385
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9386
sg23
Nsg24
Nsg25
S'PROBENECID'
p9387
sg27
Nsg28
S'Concomitant administration of substances that are also tubularly secreted (e.g., probenecid) could potentially result in delayed clearance of ALIMTA. | \r'
p9388
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alimta'
p9389
sa(dp9390
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00233'
p9391
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9392
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9393
sg23
Nsg24
Nsg25
S'PROBENECID'
p9394
sg27
Nsg28
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p9395
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMINOSALICYLIC ACID'
p9396
sa(dp9397
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p9398
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9399
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9400
sg23
Nsg24
Nsg25
S'PROBENECID'
p9401
sg27
Nsg28
S'Probenecid: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.| \r'
p9402
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPICILLIN'
p9403
sa(dp9404
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00887'
p9405
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9406
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p9407
sg23
Nsg24
Nsg25
S'PROBENECID'
p9408
sg27
Nsg28
S'Thus, probenecid should not be administered concurrently with bumetanide.| - Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.| This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.| Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p9409
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BUMETANIDE'
p9410
sa(dp9411
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00887'
p9412
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9413
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9414
sg23
Nsg24
Nsg25
S'PROBENECID'
p9415
sg27
Nsg28
S'Thus, probenecid should not be administered concurrently with bumetanide.| - Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.| This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.| Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p9416
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BUMETANIDE'
p9417
sa(dp9418
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00887'
p9419
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9420
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9421
sg23
Nsg24
Nsg25
S'PROBENECID'
p9422
sg27
Nsg28
S'Thus, probenecid should not be administered concurrently with bumetanide.| - Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.| This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.| Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p9423
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BUMETANIDE'
p9424
sa(dp9425
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00535'
p9426
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9427
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9428
sg23
Nsg24
Nsg25
S'PROBENECID'
p9429
sg27
Nsg28
S'Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.| \r'
p9430
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CEFDINIR'
p9431
sa(dp9432
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01066'
p9433
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9434
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9435
sg23
Nsg24
Nsg25
S'PROBENECID'
p9436
sg27
Nsg28
S'Probenecid: As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.| \r'
p9437
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CEFDITOREN PIVOXIL'
p9438
sa(dp9439
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01150'
p9440
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9441
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9442
sg23
Nsg24
Nsg25
S'PROBENECID'
p9443
sg27
Nsg28
S'Concomitant administration of probenecid doubled the AUC for cefprozil.| \r'
p9444
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CEFPROZIL ANHYDROUS, (E)-'
p9445
sa(dp9446
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00537'
p9447
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9448
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9449
sg23
Nsg24
Nsg25
S'PROBENECID'
p9450
sg27
Nsg28
S'Probenecid: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.| \r'
p9451
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIPROFLOXACIN'
p9452
sa(dp9453
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00636'
p9454
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9455
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9456
sg23
Nsg24
Nsg25
S'PROBENECID'
p9457
sg27
Nsg28
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p9458
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLOFIBRATE'
p9459
sa(dp9460
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01147'
p9461
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9462
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9463
sg23
Nsg24
Nsg25
S'PROBENECID'
p9464
sg27
Nsg28
S'This might be explained by a blockade by probenecid of the elimination of cloxacillin by the liver.| \r'
p9465
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLOXACILLIN'
p9466
sa(dp9467
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00303'
p9468
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9469
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p9470
sg23
Nsg24
Nsg25
S'PROBENECID'
p9471
sg27
Nsg28
S'When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem.| Because of the small effect on half-life, the coadministration with probenecid to extend the half-life of ertapenem is not recommended.| \r'
p9472
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERTAPENEM'
p9473
sa(dp9474
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00303'
p9475
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9476
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9477
sg23
Nsg24
Nsg25
S'PROBENECID'
p9478
sg27
Nsg28
S'When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem.| Because of the small effect on half-life, the coadministration with probenecid to extend the half-life of ertapenem is not recommended.| \r'
p9479
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERTAPENEM'
p9480
sa(dp9481
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00927'
p9482
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9483
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9484
sg23
Nsg24
Nsg25
S'PROBENECID'
p9485
sg27
Nsg28
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p9486
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FAMOTIDINE'
p9487
sa(dp9488
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00695'
p9489
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9490
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9491
sg23
Nsg24
Nsg25
S'PROBENECID'
p9492
sg27
Nsg28
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p9493
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FUROSEMIDE'
p9494
sa(dp9495
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00760'
p9496
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9497
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p9498
sg23
Nsg24
Nsg25
S'PROBENECID'
p9499
sg27
Nsg28
S'Therefore, the coadministration of probenecid with meropenem is not recommended. | Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem. | \r'
p9500
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MEROPENEM ANHYDROUS'
p9501
sa(dp9502
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00760'
p9503
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9504
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9505
sg23
Nsg24
Nsg25
S'PROBENECID'
p9506
sg27
Nsg28
S'Therefore, the coadministration of probenecid with meropenem is not recommended. | Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem. | \r'
p9507
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MEROPENEM ANHYDROUS'
p9508
sa(dp9509
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00760'
p9510
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9511
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p9512
sg23
Nsg24
Nsg25
S'PROBENECID'
p9513
sg27
Nsg28
S'Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem. | Therefore, the coadministration of probenecid with meropenem is not recommended. | \r'
p9514
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MEROPENEM'
p9515
sa(dp9516
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00760'
p9517
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9518
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9519
sg23
Nsg24
Nsg25
S'PROBENECID'
p9520
sg27
Nsg28
S'Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem. | Therefore, the coadministration of probenecid with meropenem is not recommended. | \r'
p9521
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MEROPENEM'
p9522
sa(dp9523
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p9524
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9525
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9526
sg23
Nsg24
Nsg25
S'PROBENECID'
p9527
sg27
Nsg28
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p9528
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHOTREXATE'
p9529
sa(dp9530
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00788'
p9531
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9532
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9533
sg23
Nsg24
Nsg25
S'PROBENECID'
p9534
sg27
Nsg28
S'Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly.| \r'
p9535
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NAPROXEN'
p9536
sa(dp9537
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00698'
p9538
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9539
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9540
sg23
Nsg24
Nsg25
S'PROBENECID'
p9541
sg27
Nsg28
S'Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.| \r'
p9542
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NITROFURANTOIN'
p9543
sa(dp9544
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01059'
p9545
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9546
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9547
sg23
Nsg24
Nsg25
S'PROBENECID'
p9548
sg27
Nsg28
S'Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of probenecid and norfloxacin.| \r'
p9549
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NORFLOXACIN'
p9550
sa(dp9551
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00345'
p9552
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9553
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9554
sg23
Nsg24
Nsg25
S'PROBENECID'
p9555
sg27
Nsg28
S'Probenecid depresses tubular secretion of certain weak acids such as PAH.| Therefore, patients receiving probenecid will have erroneously low ERPF and Tm PAH values.| \r'
p9556
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PAH'
p9557
sa(dp9558
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00345'
p9559
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9560
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9561
sg23
Nsg24
Nsg25
S'PROBENECID'
p9562
sg27
Nsg28
S'Probenecid depresses tubular secretion of certain weak acids such as PAH.| Therefore, patients receiving probenecid will have erroneously low ERPF and Tm PAH values.| \r'
p9563
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PAH'
p9564
sa(dp9565
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00299'
p9566
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9567
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9568
sg23
Nsg24
Nsg25
S'PROBENECID'
p9569
sg27
Nsg28
S'Concurrent use with probenecid or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of penciclovir.| \r'
p9570
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PENCICLOVIR'
p9571
sa(dp9572
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00319'
p9573
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9574
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9575
sg23
Nsg24
Nsg25
S'PROBENECID'
p9576
sg27
Nsg28
S'Probenecid: The oral combination of probenecid before intramuscular injection of PIPRACIL produces an increase in piperacillin peak serum level of about 30%.| \r'
p9577
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Pipracil'
p9578
sa(dp9579
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00140'
p9580
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9581
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9582
sg23
Nsg24
Nsg25
S'PROBENECID'
p9583
sg27
Nsg28
S'Probenecid - concurrent use decreases gastrointestinal absorption of riboflavin; | \r'
p9584
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIBOFLAVIN'
p9585
sa(dp9586
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p9587
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9588
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9589
sg23
Nsg24
Nsg25
S'PROBENECID'
p9590
sg27
Nsg28
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p9591
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p9592
sa(dp9593
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p9594
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9595
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9596
sg23
Nsg24
Nsg25
S'PROBENECID'
p9597
sg27
Nsg28
S'Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.| \r'
p9598
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZALCITABINE'
p9599
sa(dp9600
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00495'
p9601
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9602
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9603
sg23
Nsg24
Nsg25
S'PROBENECID'
p9604
sg27
Nsg28
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p9605
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZIDOVUDINE'
p9606
sa(dp9607
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00762'
p9608
sg5
S'http://bio2rdf.org/drugbank:DB00433'
p9609
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9610
sg23
Nsg24
Nsg25
S'PROCHLORPERAZINE'
p9611
sg27
Nsg28
S'The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when prochlorperazine was administered on the same day as CAMPTOSAR than when these drugs were given on separate days (1.3%, 1/80 patients).| \r'
p9612
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Camptosar'
p9613
sa(dp9614
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00851'
p9615
sg5
S'http://bio2rdf.org/drugbank:DB00041'
p9616
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9617
sg23
Nsg24
Nsg25
S'Proleukin'
p9618
sg27
Nsg28
S'Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.| \r'
p9619
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DACARBAZINE'
p9620
sa(dp9621
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00675'
p9622
sg5
S'http://bio2rdf.org/drugbank:DB00041'
p9623
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9624
sg23
Nsg24
Nsg25
S'Proleukin'
p9625
sg27
Nsg28
S'Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.| \r'
p9626
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TAMOXIFEN'
p9627
sa(dp9628
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p9629
sg5
S'http://bio2rdf.org/drugbank:DB00782'
p9630
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9631
sg23
Nsg24
Nsg25
S'PROPANTHELINE'
p9632
sg27
Nsg28
S'Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.| \r'
p9633
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p9634
sa(dp9635
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p9636
sg5
S'http://bio2rdf.org/drugbank:DB00647'
p9637
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9638
sg23
Nsg24
Nsg25
S'PROPOXYPHENE'
p9639
sg27
Nsg28
S'The CNS-depressant effect of propoxyphene is additive with that of other CNS depressants, including alcohol. | \r'
p9640
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p9641
sa(dp9642
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00404'
p9643
sg5
S'http://bio2rdf.org/drugbank:DB00647'
p9644
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9645
sg23
Nsg24
Nsg25
S'PROPOXYPHENE'
p9646
sg27
Nsg28
S'Coadministration of propoxyphene decreased the maximum plasma concentration of alprazolam by 6%, decreased clearance by 38%, and increased half-life by 58%.| \r'
p9647
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALPRAZOLAM'
p9648
sa(dp9649
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01575'
p9650
sg5
S'http://bio2rdf.org/drugbank:DB00852'
p9651
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9652
sg23
Nsg24
Nsg25
S'PSEUDOEPHEDRINE'
p9653
sg27
Nsg28
S'Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it.| \r'
p9654
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'KAOLIN'
p9655
sa(dp9656
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00211'
p9657
sg5
S'http://bio2rdf.org/drugbank:DB00852'
p9658
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9659
sg23
Nsg24
Nsg25
S'PSEUDOEPHEDRINE'
p9660
sg27
Nsg28
S'The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. | \r'
p9661
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ProAmatine'
p9662
sa(dp9663
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00352'
p9664
sg5
S'http://bio2rdf.org/drugbank:DB01033'
p9665
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9666
sg23
Nsg24
Nsg25
S'Purinethol'
p9667
sg27
Nsg28
S'There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. | \r'
p9668
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tabloid'
p9669
sa(dp9670
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00515'
p9671
sg5
S'http://bio2rdf.org/drugbank:DB00165'
p9672
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p9673
sg23
Nsg24
Nsg25
S'PYRIDOXINE'
p9674
sg27
Nsg28
S'however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN and/or cisplatin.1| \r'
p9675
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CISPLATIN'
p9676
sa(dp9677
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00488'
p9678
sg5
S'http://bio2rdf.org/drugbank:DB00165'
p9679
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p9680
sg23
Nsg24
Nsg25
S'PYRIDOXINE'
p9681
sg27
Nsg28
S'however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN and/or cisplatin.1| \r'
p9682
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Hexalen'
p9683
sa(dp9684
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01238'
p9685
sg5
S'http://bio2rdf.org/drugbank:DB00908'
p9686
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p9687
sg23
Nsg24
Nsg25
S'QUINIDINE'
p9688
sg27
Nsg28
S'Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs.| Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.| \r'
p9689
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ARIPIPRAZOLE'
p9690
sa(dp9691
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01238'
p9692
sg5
S'http://bio2rdf.org/drugbank:DB00908'
p9693
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9694
sg23
Nsg24
Nsg25
S'QUINIDINE'
p9695
sg27
Nsg28
S'Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs.| Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.| \r'
p9696
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ARIPIPRAZOLE'
p9697
sa(dp9698
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p9699
sg5
S'http://bio2rdf.org/drugbank:DB00908'
p9700
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9701
sg23
Nsg24
Nsg25
S'QUINIDINE'
p9702
sg27
Nsg28
S'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| \r'
p9703
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p9704
sa(dp9705
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01115'
p9706
sg5
S'http://bio2rdf.org/drugbank:DB00908'
p9707
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9708
sg23
Nsg24
Nsg25
S'QUINIDINE'
p9709
sg27
Nsg28
S'Quinidine: Immediate Release Capsules: There have been rare reports of an interaction between quinidine and nifedipine (with a decreased plasma level of quinidine).| \r'
p9710
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NIFEDIPINE'
p9711
sa(dp9712
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00413'
p9713
sg5
S'http://bio2rdf.org/drugbank:DB00908'
p9714
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9715
sg23
Nsg24
Nsg25
S'QUINIDINE'
p9716
sg27
Nsg28
S'Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | \r'
p9717
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PRAMIPEXOLE'
p9718
sa(dp9719
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p9720
sg5
S'http://bio2rdf.org/drugbank:DB00908'
p9721
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9722
sg23
Nsg24
Nsg25
S'QUINIDINE'
p9723
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p9724
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p9725
sa(dp9726
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p9727
sg5
S'http://bio2rdf.org/drugbank:DB00908'
p9728
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9729
sg23
Nsg24
Nsg25
S'QUINIDINE'
p9730
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p9731
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p9732
sa(dp9733
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p9734
sg5
S'http://bio2rdf.org/drugbank:DB00908'
p9735
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p9736
sg23
Nsg24
Nsg25
S'QUINIDINE'
p9737
sg27
Nsg28
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p9738
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sprycel'
p9739
sa(dp9740
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00413'
p9741
sg5
S'http://bio2rdf.org/drugbank:DB00468'
p9742
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9743
sg23
Nsg24
Nsg25
S'QUININE'
p9744
sg27
Nsg28
S'Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | \r'
p9745
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PRAMIPEXOLE'
p9746
sa(dp9747
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p9748
sg5
S'http://bio2rdf.org/drugbank:DB00468'
p9749
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9750
sg23
Nsg24
Nsg25
S'QUININE'
p9751
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p9752
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p9753
sa(dp9754
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p9755
sg5
S'http://bio2rdf.org/drugbank:DB00468'
p9756
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9757
sg23
Nsg24
Nsg25
S'QUININE'
p9758
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p9759
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p9760
sa(dp9761
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p9762
sg5
S'http://bio2rdf.org/drugbank:DB00468'
p9763
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p9764
sg23
Nsg24
Nsg25
S'QUININE'
p9765
sg27
Nsg28
S'Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| \r'
p9766
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tikosyn'
p9767
sa(dp9768
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00630'
p9769
sg5
S'http://bio2rdf.org/drugbank:DB00863'
p9770
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9771
sg23
Nsg24
Nsg25
S'RANITIDINE'
p9772
sg27
Nsg28
S'Intravenous ranitidine was shown to double the bioavailability of oral alendronate.| \r'
p9773
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALENDRONIC ACID'
p9774
sa(dp9775
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01415'
p9776
sg5
S'http://bio2rdf.org/drugbank:DB00863'
p9777
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9778
sg23
Nsg24
Nsg25
S'RANITIDINE'
p9779
sg27
Nsg28
S'however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.| \r'
p9780
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CEFTIBUTEN'
p9781
sa(dp9782
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p9783
sg5
S'http://bio2rdf.org/drugbank:DB00863'
p9784
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9785
sg23
Nsg24
Nsg25
S'RANITIDINE'
p9786
sg27
Nsg28
S'The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.| \r'
p9787
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p9788
sa(dp9789
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00317'
p9790
sg5
S'http://bio2rdf.org/drugbank:DB00863'
p9791
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9792
sg23
Nsg24
Nsg25
S'RANITIDINE'
p9793
sg27
Nsg28
S'Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.| \r'
p9794
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Iressa'
p9795
sa(dp9796
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00413'
p9797
sg5
S'http://bio2rdf.org/drugbank:DB00863'
p9798
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9799
sg23
Nsg24
Nsg25
S'RANITIDINE'
p9800
sg27
Nsg28
S'Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | \r'
p9801
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PRAMIPEXOLE'
p9802
sa(dp9803
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p9804
sg5
S'http://bio2rdf.org/drugbank:DB00370'
p9805
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9806
sg23
Nsg24
Nsg25
S'Remeron'
p9807
sg27
Nsg28
S'However, the impairment of cognitive and motor skills produced by REMERON    were shown to be additive with those produced by alcohol. | \r'
p9808
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p9809
sa(dp9810
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p9811
sg5
S'http://bio2rdf.org/drugbank:DB00370'
p9812
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9813
sg23
Nsg24
Nsg25
S'Remeron'
p9814
sg27
Nsg28
S'However, the impairment of motor skills produced by REMERON has been shown to be additive with those caused by diazepam. | \r'
p9815
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIAZEPAM'
p9816
sa(dp9817
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00612'
p9818
sg5
S'http://bio2rdf.org/drugbank:DB00206'
p9819
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9820
sg23
Nsg24
Nsg25
S'RESERPINE'
p9821
sg27
Nsg28
S'Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.| \r'
p9822
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Zebeta'
p9823
sa(dp9824
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00459'
p9825
sg5
S'http://bio2rdf.org/drugbank:DB00162'
p9826
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p9827
sg23
Nsg24
Nsg25
S'RETINOL'
p9828
sg27
Nsg28
S'Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.| \r'
p9829
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACITRETIN'
p9830
sa(dp9831
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00822'
p9832
sg5
S'http://bio2rdf.org/drugbank:DB00704'
p9833
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9834
sg23
Nsg24
Nsg25
S'Revia'
p9835
sg27
Nsg28
S'The safety and efficacy of concomitant use of REVIA and disulfiram is unknown, and the concomitant use of two potentially hepatotoxic medications is not ordinarily recommended unless the probable benefits outweigh the known risks.| \r'
p9836
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DISULFIRAM'
p9837
sa(dp9838
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00649'
p9839
sg5
S'http://bio2rdf.org/drugbank:DB00811'
p9840
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9841
sg23
Nsg24
Nsg25
S'RIBAVIRIN'
p9842
sg27
Nsg28
S'Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.| \r'
p9843
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'STAVUDINE'
p9844
sa(dp9845
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00495'
p9846
sg5
S'http://bio2rdf.org/drugbank:DB00811'
p9847
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9848
sg23
Nsg24
Nsg25
S'RIBAVIRIN'
p9849
sg27
Nsg28
S'Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.| \r'
p9850
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZIDOVUDINE'
p9851
sa(dp9852
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p9853
sg5
S'http://bio2rdf.org/drugbank:DB00140'
p9854
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p9855
sg23
Nsg24
Nsg25
S'RIBOFLAVIN'
p9856
sg27
Nsg28
S'requirements for riboflavin may be increased in patients receiving probenecid.| \r'
p9857
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROBENECID'
p9858
sa(dp9859
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p9860
sg5
S'http://bio2rdf.org/drugbank:DB00615'
p9861
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p9862
sg23
Nsg24
Nsg25
S'RIFABUTIN'
p9863
sg27
Nsg28
S'Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.| \r'
p9864
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Crixivan'
p9865
sa(dp9866
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00625'
p9867
sg5
S'http://bio2rdf.org/drugbank:DB00615'
p9868
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9869
sg23
Nsg24
Nsg25
S'RIFABUTIN'
p9870
sg27
Nsg28
S'Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.| \r'
p9871
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EFAVIRENZ'
p9872
sa(dp9873
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p9874
sg5
S'http://bio2rdf.org/drugbank:DB00615'
p9875
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p9876
sg23
Nsg24
Nsg25
S'RIFABUTIN'
p9877
sg27
Nsg28
S'Patients receiving rifabutin and fluconazole concomitantly should be carefully monitored. | \r'
p9878
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p9879
sa(dp9880
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p9881
sg5
S'http://bio2rdf.org/drugbank:DB00615'
p9882
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p9883
sg23
Nsg24
Nsg25
S'RIFABUTIN'
p9884
sg27
Nsg28
S'It is recommended that the dose of rifabutin be reduced to one-half the usual dose when administered with VIRACEPT.| Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.| \r'
p9885
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Viracept'
p9886
sa(dp9887
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p9888
sg5
S'http://bio2rdf.org/drugbank:DB00615'
p9889
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9890
sg23
Nsg24
Nsg25
S'RIFABUTIN'
p9891
sg27
Nsg28
S'It is recommended that the dose of rifabutin be reduced to one-half the usual dose when administered with VIRACEPT.| Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.| \r'
p9892
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Viracept'
p9893
sa(dp9894
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00701'
p9895
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p9896
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9897
sg23
Nsg24
Nsg25
S'RIFAMPIN'
p9898
sg27
Nsg28
S'Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated. | Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. | \r'
p9899
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPRENAVIR'
p9900
sa(dp9901
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p9902
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p9903
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9904
sg23
Nsg24
Nsg25
S'RIFAMPIN'
p9905
sg27
Nsg28
S'Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.| \r'
p9906
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BEXAROTENE'
p9907
sa(dp9908
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00520'
p9909
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p9910
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p9911
sg23
Nsg24
Nsg25
S'RIFAMPIN'
p9912
sg27
Nsg28
S'Patients on rifampin should receive 70 mg of CANCIDAS daily.| \r'
p9913
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cancidas'
p9914
sa(dp9915
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00363'
p9916
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p9917
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9918
sg23
Nsg24
Nsg25
S'RIFAMPIN'
p9919
sg27
Nsg28
S'Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.| \r'
p9920
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLOZAPINE'
p9921
sa(dp9922
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p9923
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p9924
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9925
sg23
Nsg24
Nsg25
S'RIFAMPIN'
p9926
sg27
Nsg28
S'Rifampin: Rifampin enhances the metabolism of concurrently administered DIFLUCAN. | \r'
p9927
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Diflucan'
p9928
sa(dp9929
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p9930
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p9931
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9932
sg23
Nsg24
Nsg25
S'RIFAMPIN'
p9933
sg27
Nsg28
S'Rifampin may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin.| \r'
p9934
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p9935
sa(dp9936
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p9937
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p9938
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9939
sg23
Nsg24
Nsg25
S'RIFAMPIN'
p9940
sg27
Nsg28
S'Coadministration of rifampin with diltiazem lowered the diltiazem plasma concentrations to undetectable levels.| \r'
p9941
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DILTIAZEM'
p9942
sa(dp9943
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00625'
p9944
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p9945
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9946
sg23
Nsg24
Nsg25
S'RIFAMPIN'
p9947
sg27
Nsg28
S'Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.| \r'
p9948
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EFAVIRENZ'
p9949
sa(dp9950
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00530'
p9951
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p9952
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9953
sg23
Nsg24
Nsg25
S'RIFAMPIN'
p9954
sg27
Nsg28
S'Pre-treatment with the CYP3A4 inducer rifampicin decreased erlotinib AUC by about 2/3.| \r'
p9955
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERLOTINIB'
p9956
sa(dp9957
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00977'
p9958
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p9959
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9960
sg23
Nsg24
Nsg25
S'RIFAMPIN'
p9961
sg27
Nsg28
S'Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.| \r'
p9962
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ETHINYL ESTRADIOL'
p9963
sa(dp9964
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00990'
p9965
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p9966
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9967
sg23
Nsg24
Nsg25
S'RIFAMPIN'
p9968
sg27
Nsg28
S'Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.| \r'
p9969
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EXEMESTANE'
p9970
sa(dp9971
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00619'
p9972
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p9973
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9974
sg23
Nsg24
Nsg25
S'RIFAMPIN'
p9975
sg27
Nsg28
S'Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).| \r'
p9976
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Gleevec'
p9977
sa(dp9978
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00502'
p9979
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p9980
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p9981
sg23
Nsg24
Nsg25
S'RIFAMPIN'
p9982
sg27
Nsg28
S'Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol-treated patients.| In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.| \r'
p9983
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HALOPERIDOL'
p9984
sa(dp9985
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00502'
p9986
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p9987
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9988
sg23
Nsg24
Nsg25
S'RIFAMPIN'
p9989
sg27
Nsg28
S'Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol-treated patients.| In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.| \r'
p9990
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HALOPERIDOL'
p9991
sa(dp9992
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p9993
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p9994
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p9995
sg23
Nsg24
Nsg25
S'RIFAMPIN'
p9996
sg27
Nsg28
S'Concomitant administration of rifampin with ketoconazole tablets reduces the blood levels of the latter.| \r'
p9997
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p9998
sa(dp9999
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00678'
p10000
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p10001
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10002
sg23
Nsg24
Nsg25
S'RIFAMPIN'
p10003
sg27
Nsg28
S'Rifampin, an inducer of drug metabolism, decreased the concentrations of losartan and its active metabolite.| \r'
p10004
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LOSARTAN'
p10005
sa(dp10006
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p10007
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p10008
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10009
sg23
Nsg24
Nsg25
S'RIFAMPIN'
p10010
sg27
Nsg28
S'Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | \r'
p10011
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHYLPREDNISOLONE'
p10012
sa(dp10013
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p10014
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p10015
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10016
sg23
Nsg24
Nsg25
S'RIFAMPIN'
p10017
sg27
Nsg28
S'Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | \r'
p10018
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHYLPREDNISOLONE'
p10019
sa(dp10020
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00379'
p10021
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p10022
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10023
sg23
Nsg24
Nsg25
S'RIFAMPIN'
p10024
sg27
Nsg28
S'When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. | \r'
p10025
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Mexitil'
p10026
sa(dp10027
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p10028
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p10029
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10030
sg23
Nsg24
Nsg25
S'RIFAMPIN'
p10031
sg27
Nsg28
S'Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. | \r'
p10032
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIDAZOLAM'
p10033
sa(dp10034
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00471'
p10035
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p10036
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10037
sg23
Nsg24
Nsg25
S'RIFAMPIN'
p10038
sg27
Nsg28
S'It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.| \r'
p10039
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MONTELUKAST'
p10040
sa(dp10041
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00717'
p10042
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p10043
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10044
sg23
Nsg24
Nsg25
S'RIFAMPIN'
p10045
sg27
Nsg28
S'Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.| \r'
p10046
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NORETHINDRONE'
p10047
sa(dp10048
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p10049
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p10050
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10051
sg23
Nsg24
Nsg25
S'RIFAMPIN'
p10052
sg27
Nsg28
S'Rifampin: Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A.C.| \r'
p10053
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Viracept'
p10054
sa(dp10055
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00962'
p10056
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p10057
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10058
sg23
Nsg24
Nsg25
S'RIFAMPIN'
p10059
sg27
Nsg28
S'Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon Cmax and AUC by approximately 80%.| \r'
p10060
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZALEPLON'
p10061
sa(dp10062
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00612'
p10063
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p10064
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10065
sg23
Nsg24
Nsg25
S'RIFAMPIN'
p10066
sg27
Nsg28
S'Concurrent use of rifampin increases the metabolic clearance of ZEBETA, resulting in a shortened elimination half-life of ZEBETA.| \r'
p10067
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Zebeta'
p10068
sa(dp10069
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01235'
p10070
sg5
S'http://bio2rdf.org/drugbank:DB00734'
p10071
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p10072
sg23
Nsg24
Nsg25
S'RISPERIDONE'
p10073
sg27
Nsg28
S'Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.| \r'
p10074
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LEVODOPA'
p10075
sa(dp10076
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01242'
p10077
sg5
S'http://bio2rdf.org/drugbank:DB00422'
p10078
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10079
sg23
Nsg24
Nsg25
S'Ritalin'
p10080
sg27
Nsg28
S'Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). | \r'
p10081
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLOMIPRAMINE'
p10082
sa(dp10083
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01151'
p10084
sg5
S'http://bio2rdf.org/drugbank:DB00422'
p10085
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10086
sg23
Nsg24
Nsg25
S'Ritalin'
p10087
sg27
Nsg28
S'Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). | \r'
p10088
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DESIPRAMINE'
p10089
sa(dp10090
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01170'
p10091
sg5
S'http://bio2rdf.org/drugbank:DB00422'
p10092
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p10093
sg23
Nsg24
Nsg25
S'Ritalin'
p10094
sg27
Nsg28
S'Ritalin may decrease the hypotensive effect of guanethidine. | \r'
p10095
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GUANETHIDINE'
p10096
sa(dp10097
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00458'
p10098
sg5
S'http://bio2rdf.org/drugbank:DB00422'
p10099
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10100
sg23
Nsg24
Nsg25
S'Ritalin'
p10101
sg27
Nsg28
S'Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). | \r'
p10102
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'IMIPRAMINE'
p10103
sa(dp10104
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p10105
sg5
S'http://bio2rdf.org/drugbank:DB00422'
p10106
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10107
sg23
Nsg24
Nsg25
S'Ritalin'
p10108
sg27
Nsg28
S'Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). | \r'
p10109
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p10110
sa(dp10111
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00812'
p10112
sg5
S'http://bio2rdf.org/drugbank:DB00422'
p10113
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10114
sg23
Nsg24
Nsg25
S'Ritalin'
p10115
sg27
Nsg28
S'Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). | \r'
p10116
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYLBUTAZONE'
p10117
sa(dp10118
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00794'
p10119
sg5
S'http://bio2rdf.org/drugbank:DB00422'
p10120
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10121
sg23
Nsg24
Nsg25
S'Ritalin'
p10122
sg27
Nsg28
S'Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). | \r'
p10123
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PRIMIDONE'
p10124
sa(dp10125
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00918'
p10126
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p10127
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10128
sg23
Nsg24
Nsg25
S'RITONAVIR'
p10129
sg27
Nsg28
S'Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.| \r'
p10130
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALMOTRIPTAN'
p10131
sa(dp10132
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p10133
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p10134
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10135
sg23
Nsg24
Nsg25
S'RITONAVIR'
p10136
sg27
Nsg28
S'Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| \r'
p10137
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p10138
sa(dp10139
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p10140
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p10141
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10142
sg23
Nsg24
Nsg25
S'RITONAVIR'
p10143
sg27
Nsg28
S'Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. | \r'
p10144
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIDAZOLAM'
p10145
sa(dp10146
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00238'
p10147
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p10148
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10149
sg23
Nsg24
Nsg25
S'RITONAVIR'
p10150
sg27
Nsg28
S'A dose increase of lopinavir/ritonavir to 533/133 mg twice daily with food isrecommended in combination with nevirapine.| \r'
p10151
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NEVIRAPINE'
p10152
sa(dp10153
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00625'
p10154
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p10155
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10156
sg23
Nsg24
Nsg25
S'RITONAVIR'
p10157
sg27
Nsg28
S'A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.| \r'
p10158
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sustiva'
p10159
sa(dp10160
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00862'
p10161
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p10162
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10163
sg23
Nsg24
Nsg25
S'RITONAVIR'
p10164
sg27
Nsg28
S'Ritonavir significantly prolonged the half-life of vardenafil to 26 hours.| Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.| \r'
p10165
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VARDENAFIL'
p10166
sa(dp10167
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p10168
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p10169
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10170
sg23
Nsg24
Nsg25
S'RITONAVIR'
p10171
sg27
Nsg28
S'Ritonavir: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.| \r'
p10172
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Viracept'
p10173
sa(dp10174
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00761'
p10175
sg5
S'http://bio2rdf.org/drugbank:DB00986'
p10176
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10177
sg23
Nsg24
Nsg25
S'Robinul'
p10178
sg27
Nsg28
S'Concomitant administration of Robinul Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.| \r'
p10179
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'POTASSIUM CHLORIDE'
p10180
sa(dp10181
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p10182
sg5
S'http://bio2rdf.org/drugbank:DB00296'
p10183
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10184
sg23
Nsg24
Nsg25
S'ROPIVACAINE'
p10185
sg27
Nsg28
S'In vivo, the plasma clearance of ropivacaine was reduced by 70% during coadministration of fluvoxamine (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor. | \r'
p10186
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p10187
sa(dp10188
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p10189
sg5
S'http://bio2rdf.org/drugbank:DB00778'
p10190
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10191
sg23
Nsg24
Nsg25
S'ROXITHROMYCIN'
p10192
sg27
Nsg28
S'Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. | \r'
p10193
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASTEMIZOLE'
p10194
sa(dp10195
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p10196
sg5
S'http://bio2rdf.org/drugbank:DB00209'
p10197
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10198
sg23
Nsg24
Nsg25
S'Sanctura'
p10199
sg27
Nsg28
S'Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). | \r'
p10200
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p10201
sa(dp10202
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00331'
p10203
sg5
S'http://bio2rdf.org/drugbank:DB00209'
p10204
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10205
sg23
Nsg24
Nsg25
S'Sanctura'
p10206
sg27
Nsg28
S'Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). | \r'
p10207
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METFORMIN'
p10208
sa(dp10209
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p10210
sg5
S'http://bio2rdf.org/drugbank:DB00209'
p10211
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10212
sg23
Nsg24
Nsg25
S'Sanctura'
p10213
sg27
Nsg28
S'Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). | \r'
p10214
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MORPHINE'
p10215
sa(dp10216
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01337'
p10217
sg5
S'http://bio2rdf.org/drugbank:DB00209'
p10218
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10219
sg23
Nsg24
Nsg25
S'Sanctura'
p10220
sg27
Nsg28
S'Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). | \r'
p10221
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PANCURONIUM'
p10222
sa(dp10223
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01035'
p10224
sg5
S'http://bio2rdf.org/drugbank:DB00209'
p10225
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10226
sg23
Nsg24
Nsg25
S'Sanctura'
p10227
sg27
Nsg28
S'Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). | \r'
p10228
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROCAINAMIDE'
p10229
sa(dp10230
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00300'
p10231
sg5
S'http://bio2rdf.org/drugbank:DB00209'
p10232
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10233
sg23
Nsg24
Nsg25
S'Sanctura'
p10234
sg27
Nsg28
S'Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). | \r'
p10235
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TENOFOVIR'
p10236
sa(dp10237
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00512'
p10238
sg5
S'http://bio2rdf.org/drugbank:DB00209'
p10239
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10240
sg23
Nsg24
Nsg25
S'Sanctura'
p10241
sg27
Nsg28
S'Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). | \r'
p10242
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VANCOMYCIN'
p10243
sa(dp10244
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00701'
p10245
sg5
S'http://bio2rdf.org/drugbank:DB01232'
p10246
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10247
sg23
Nsg24
Nsg25
S'SAQUINAVIR MESYLATE'
p10248
sg27
Nsg28
S'Saquinavir steady-state Cmax, A.C. and Cmin were increased 21%, decreased 19%, and decreased 48%, respectively, by concomitant amprenavir.| \r'
p10249
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPRENAVIR'
p10250
sa(dp10251
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p10252
sg5
S'http://bio2rdf.org/drugbank:DB01232'
p10253
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10254
sg23
Nsg24
Nsg25
S'SAQUINAVIR MESYLATE'
p10255
sg27
Nsg28
S'Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.| \r'
p10256
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Viracept'
p10257
sa(dp10258
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00701'
p10259
sg5
S'http://bio2rdf.org/drugbank:DB01232'
p10260
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10261
sg23
Nsg24
Nsg25
S'SAQUINAVIR'
p10262
sg27
Nsg28
S'Saquinavir steady-state Cmax, A.C. and Cmin were increased 21%, decreased 19%, and decreased 48%, respectively, by concomitant amprenavir.| \r'
p10263
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPRENAVIR'
p10264
sa(dp10265
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p10266
sg5
S'http://bio2rdf.org/drugbank:DB01232'
p10267
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10268
sg23
Nsg24
Nsg25
S'SAQUINAVIR'
p10269
sg27
Nsg28
S'Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.| \r'
p10270
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Viracept'
p10271
sa(dp10272
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p10273
sg5
S'http://bio2rdf.org/drugbank:DB00747'
p10274
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10275
sg23
Nsg24
Nsg25
S'SCOPOLAMINE'
p10276
sg27
Nsg28
S'Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol. | \r'
p10277
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p10278
sa(dp10279
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01364'
p10280
sg5
S'http://bio2rdf.org/drugbank:DB01037'
p10281
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p10282
sg23
Nsg24
Nsg25
S'SELEGILINE'
p10283
sg27
Nsg28
S'One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication (ephedrine).| \r'
p10284
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EPHEDRINE'
p10285
sa(dp10286
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00454'
p10287
sg5
S'http://bio2rdf.org/drugbank:DB01037'
p10288
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p10289
sg23
Nsg24
Nsg25
S'SELEGILINE'
p10290
sg27
Nsg28
S'The occurrence of stupor, muscular rigidity, severe agitation, and elevated temperature has been reported in some patients receiving the combination of selegiline and meperidine. | \r'
p10291
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MEPERIDINE'
p10292
sa(dp10293
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p10294
sg5
S'http://bio2rdf.org/drugbank:DB01012'
p10295
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10296
sg23
Nsg24
Nsg25
S'Sensipar'
p10297
sg27
Nsg28
S'Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;| \r'
p10298
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERYTHROMYCIN'
p10299
sa(dp10300
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p10301
sg5
S'http://bio2rdf.org/drugbank:DB01012'
p10302
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10303
sg23
Nsg24
Nsg25
S'Sensipar'
p10304
sg27
Nsg28
S'Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;| \r'
p10305
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p10306
sa(dp10307
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p10308
sg5
S'http://bio2rdf.org/drugbank:DB01104'
p10309
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p10310
sg23
Nsg24
Nsg25
S'SERTRALINE'
p10311
sg27
Nsg28
S'Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | \r'
p10312
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUMATRIPTAN SUCCINATE'
p10313
sa(dp10314
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p10315
sg5
S'http://bio2rdf.org/drugbank:DB01104'
p10316
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p10317
sg23
Nsg24
Nsg25
S'SERTRALINE'
p10318
sg27
Nsg28
S'Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | \r'
p10319
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUMATRIPTAN'
p10320
sa(dp10321
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p10322
sg5
S'http://bio2rdf.org/drugbank:DB00203'
p10323
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10324
sg23
Nsg24
Nsg25
S'SILDENAFIL'
p10325
sg27
Nsg28
S'Sildenafil dose should not exceed a maximum of 25 mg in a 48- hour period in patients receiving concomitant indinavir therapy.| \r'
p10326
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDINAVIR ANHYDROUS'
p10327
sa(dp10328
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p10329
sg5
S'http://bio2rdf.org/drugbank:DB00203'
p10330
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10331
sg23
Nsg24
Nsg25
S'SILDENAFIL'
p10332
sg27
Nsg28
S'Sildenafil dose should not exceed a maximum of 25 mg in a 48- hour period in patients receiving concomitant indinavir therapy.| \r'
p10333
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDINAVIR'
p10334
sa(dp10335
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00993'
p10336
sg5
S'http://bio2rdf.org/drugbank:DB00074'
p10337
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10338
sg23
Nsg24
Nsg25
S'Simulect'
p10339
sg27
Nsg28
S'Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.| \r'
p10340
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AZATHIOPRINE'
p10341
sa(dp10342
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00688'
p10343
sg5
S'http://bio2rdf.org/drugbank:DB00074'
p10344
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10345
sg23
Nsg24
Nsg25
S'Simulect'
p10346
sg27
Nsg28
S'Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.| \r'
p10347
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MYCOPHENOLATE MOFETIL'
p10348
sa(dp10349
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01211'
p10350
sg5
S'http://bio2rdf.org/drugbank:DB00641'
p10351
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p10352
sg23
Nsg24
Nsg25
S'SIMVASTATIN'
p10353
sg27
Nsg28
S'Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.&#x0D;| \r'
p10354
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLARITHROMYCIN'
p10355
sa(dp10356
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p10357
sg5
S'http://bio2rdf.org/drugbank:DB00877'
p10358
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10359
sg23
Nsg24
Nsg25
S'SIROLIMUS'
p10360
sg27
Nsg28
S'RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours. | Because of the pronounced intersubject variability in the extent of the sirolimus-diltiazem interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.| Apparent oral clearance and volume of distribution of sirolimus decreased with 38% and 45%, respectively, when sirolimus was given with diltiazem. | \r'
p10361
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DILTIAZEM'
p10362
sa(dp10363
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p10364
sg5
S'http://bio2rdf.org/drugbank:DB00877'
p10365
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10366
sg23
Nsg24
Nsg25
S'SIROLIMUS'
p10367
sg27
Nsg28
S'RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours. | Because of the pronounced intersubject variability in the extent of the sirolimus-diltiazem interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.| Apparent oral clearance and volume of distribution of sirolimus decreased with 38% and 45%, respectively, when sirolimus was given with diltiazem. | \r'
p10368
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DILTIAZEM'
p10369
sa(dp10370
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01141'
p10371
sg5
S'http://bio2rdf.org/drugbank:DB00877'
p10372
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10373
sg23
Nsg24
Nsg25
S'SIROLIMUS'
p10374
sg27
Nsg28
S'Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state MYCAMINE compared with sirolimus alone. | Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. | \r'
p10375
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Mycamine'
p10376
sa(dp10377
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01141'
p10378
sg5
S'http://bio2rdf.org/drugbank:DB00877'
p10379
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10380
sg23
Nsg24
Nsg25
S'SIROLIMUS'
p10381
sg27
Nsg28
S'Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state MYCAMINE compared with sirolimus alone. | Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. | \r'
p10382
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Mycamine'
p10383
sa(dp10384
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p10385
sg5
S'http://bio2rdf.org/drugbank:DB00877'
p10386
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10387
sg23
Nsg24
Nsg25
S'SIROLIMUS'
p10388
sg27
Nsg28
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p10389
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sprycel'
p10390
sa(dp10391
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p10392
sg5
S'http://bio2rdf.org/drugbank:DB00660'
p10393
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p10394
sg23
Nsg24
Nsg25
S'Skelaxin'
p10395
sg27
Nsg28
S'SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.| \r'
p10396
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p10397
sa(dp10398
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01373'
p10399
sg5
S'http://bio2rdf.org/drugbank:DB01133'
p10400
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10401
sg23
Nsg24
Nsg25
S'Skelid'
p10402
sg27
Nsg28
S'The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. | \r'
p10403
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CALCIUM'
p10404
sa(dp10405
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00328'
p10406
sg5
S'http://bio2rdf.org/drugbank:DB01133'
p10407
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10408
sg23
Nsg24
Nsg25
S'Skelid'
p10409
sg27
Nsg28
S'The bioavailability of SKELID is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of diclofenac. | \r'
p10410
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDOMETHACIN'
p10411
sa(dp10412
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00444'
p10413
sg5
S'http://bio2rdf.org/drugbank:DB01398'
p10414
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10415
sg23
Nsg24
Nsg25
S'SODIUM SALICYLATE'
p10416
sg27
Nsg28
S'In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. | \r'
p10417
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TENIPOSIDE'
p10418
sa(dp10419
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p10420
sg5
S'http://bio2rdf.org/drugbank:DB00962'
p10421
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p10422
sg23
Nsg24
Nsg25
S'Sonata'
p10423
sg27
Nsg28
S'CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.| \r'
p10424
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p10425
sa(dp10426
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p10427
sg5
S'http://bio2rdf.org/drugbank:DB00962'
p10428
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10429
sg23
Nsg24
Nsg25
S'Sonata'
p10430
sg27
Nsg28
S'Concomitant administration of Sonata (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon.| \r'
p10431
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIMETIDINE'
p10432
sa(dp10433
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00458'
p10434
sg5
S'http://bio2rdf.org/drugbank:DB00962'
p10435
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p10436
sg23
Nsg24
Nsg25
S'Sonata'
p10437
sg27
Nsg28
S'Imipramine: Coadministration of single doses of Sonata 20 mg and imipramine 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.| \r'
p10438
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'IMIPRAMINE'
p10439
sa(dp10440
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p10441
sg5
S'http://bio2rdf.org/drugbank:DB00421'
p10442
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10443
sg23
Nsg24
Nsg25
S'SPIRONOLACTONE'
p10444
sg27
Nsg28
S'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| \r'
p10445
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p10446
sa(dp10447
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01072'
p10448
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p10449
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10450
sg23
Nsg24
Nsg25
S'Sprycel'
p10451
sg27
Nsg28
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p10452
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ATAZANAVIR'
p10453
sa(dp10454
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01211'
p10455
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p10456
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10457
sg23
Nsg24
Nsg25
S'Sprycel'
p10458
sg27
Nsg28
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p10459
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLARITHROMYCIN'
p10460
sa(dp10461
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p10462
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p10463
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10464
sg23
Nsg24
Nsg25
S'Sprycel'
p10465
sg27
Nsg28
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p10466
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERYTHROMYCIN'
p10467
sa(dp10468
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p10469
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p10470
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10471
sg23
Nsg24
Nsg25
S'Sprycel'
p10472
sg27
Nsg28
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p10473
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDINAVIR ANHYDROUS'
p10474
sa(dp10475
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p10476
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p10477
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10478
sg23
Nsg24
Nsg25
S'Sprycel'
p10479
sg27
Nsg28
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p10480
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDINAVIR'
p10481
sa(dp10482
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p10483
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p10484
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10485
sg23
Nsg24
Nsg25
S'Sprycel'
p10486
sg27
Nsg28
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p10487
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p10488
sa(dp10489
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01149'
p10490
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p10491
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10492
sg23
Nsg24
Nsg25
S'Sprycel'
p10493
sg27
Nsg28
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p10494
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NEFAZODONE'
p10495
sa(dp10496
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB05251'
p10497
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p10498
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10499
sg23
Nsg24
Nsg25
S'Sprycel'
p10500
sg27
Nsg28
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p10501
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NELFINAVIR'
p10502
sa(dp10503
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p10504
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p10505
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10506
sg23
Nsg24
Nsg25
S'Sprycel'
p10507
sg27
Nsg28
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p10508
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p10509
sa(dp10510
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p10511
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p10512
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10513
sg23
Nsg24
Nsg25
S'Sprycel'
p10514
sg27
Nsg28
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p10515
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p10516
sa(dp10517
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p10518
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p10519
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10520
sg23
Nsg24
Nsg25
S'Sprycel'
p10521
sg27
Nsg28
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p10522
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p10523
sa(dp10524
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00976'
p10525
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p10526
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10527
sg23
Nsg24
Nsg25
S'Sprycel'
p10528
sg27
Nsg28
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p10529
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TELITHROMYCIN'
p10530
sa(dp10531
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p10532
sg5
S'http://bio2rdf.org/drugbank:DB00611'
p10533
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p10534
sg23
Nsg24
Nsg25
S'Stadol NS'
p10535
sg27
Nsg28
S'However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.| These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.| When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.| \r'
p10536
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUMATRIPTAN SUCCINATE'
p10537
sa(dp10538
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p10539
sg5
S'http://bio2rdf.org/drugbank:DB00611'
p10540
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10541
sg23
Nsg24
Nsg25
S'Stadol NS'
p10542
sg27
Nsg28
S'However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.| These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.| When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.| \r'
p10543
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUMATRIPTAN SUCCINATE'
p10544
sa(dp10545
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p10546
sg5
S'http://bio2rdf.org/drugbank:DB00611'
p10547
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p10548
sg23
Nsg24
Nsg25
S'Stadol NS'
p10549
sg27
Nsg28
S'When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.| However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.| These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.| \r'
p10550
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUMATRIPTAN'
p10551
sa(dp10552
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p10553
sg5
S'http://bio2rdf.org/drugbank:DB00611'
p10554
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10555
sg23
Nsg24
Nsg25
S'Stadol NS'
p10556
sg27
Nsg28
S'When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.| However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.| These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.| \r'
p10557
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUMATRIPTAN'
p10558
sa(dp10559
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p10560
sg5
S'http://bio2rdf.org/drugbank:DB00731'
p10561
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10562
sg23
Nsg24
Nsg25
S'Starlix'
p10563
sg27
Nsg28
S'Starlix is a potential inhibitor of the CYP2C9 isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of tolbutamide.| \r'
p10564
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TOLBUTAMIDE'
p10565
sa(dp10566
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00997'
p10567
sg5
S'http://bio2rdf.org/drugbank:DB00649'
p10568
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p10569
sg23
Nsg24
Nsg25
S'STAVUDINE'
p10570
sg27
Nsg28
S'In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin. | \r'
p10571
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOXORUBICIN'
p10572
sa(dp10573
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00811'
p10574
sg5
S'http://bio2rdf.org/drugbank:DB00649'
p10575
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p10576
sg23
Nsg24
Nsg25
S'STAVUDINE'
p10577
sg27
Nsg28
S'In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin. | \r'
p10578
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIBAVIRIN'
p10579
sa(dp10580
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01001'
p10581
sg5
S'http://bio2rdf.org/drugbank:DB00289'
p10582
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10583
sg23
Nsg24
Nsg25
S'Strattera'
p10584
sg27
Nsg28
S'Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.| \r'
p10585
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Albuterol'
p10586
sa(dp10587
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p10588
sg5
S'http://bio2rdf.org/drugbank:DB00289'
p10589
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10590
sg23
Nsg24
Nsg25
S'Strattera'
p10591
sg27
Nsg28
S'Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and quinidine.| \r'
p10592
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PAROXETINE'
p10593
sa(dp10594
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00908'
p10595
sg5
S'http://bio2rdf.org/drugbank:DB00289'
p10596
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10597
sg23
Nsg24
Nsg25
S'Strattera'
p10598
sg27
Nsg28
S'Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and quinidine.| \r'
p10599
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'QUINIDINE'
p10600
sa(dp10601
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00997'
p10602
sg5
S'http://bio2rdf.org/drugbank:DB00428'
p10603
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10604
sg23
Nsg24
Nsg25
S'STREPTOZOCIN'
p10605
sg27
Nsg28
S'Streptozocin has been reported to prolong the elimination half-life of doxorubicin and may lead to severe bone marrow suppression; | \r'
p10606
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOXORUBICIN'
p10607
sa(dp10608
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p10609
sg5
S'http://bio2rdf.org/drugbank:DB00428'
p10610
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p10611
sg23
Nsg24
Nsg25
S'STREPTOZOCIN'
p10612
sg27
Nsg28
S'The concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity.    | \r'
p10613
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p10614
sa(dp10615
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00187'
p10616
sg5
S'http://bio2rdf.org/drugbank:DB00202'
p10617
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p10618
sg23
Nsg24
Nsg25
S'SUCCINYLCHOLINE'
p10619
sg27
Nsg28
S'The onset of neuromuscular blockade by succinylcholine was unaffected by BREVIBLOC, but the duration of neuromuscular blockade was prolonged from 5 minutes to 8 minutes.| \r'
p10620
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Brevibloc'
p10621
sa(dp10622
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01111'
p10623
sg5
S'http://bio2rdf.org/drugbank:DB00202'
p10624
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p10625
sg23
Nsg24
Nsg25
S'SUCCINYLCHOLINE'
p10626
sg27
Nsg28
S'Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.| \r'
p10627
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Coly-Mycin M'
p10628
sa(dp10629
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01226'
p10630
sg5
S'http://bio2rdf.org/drugbank:DB00202'
p10631
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10632
sg23
Nsg24
Nsg25
S'SUCCINYLCHOLINE'
p10633
sg27
Nsg28
S'Evidence of spontaneous recovery from succinylcholine should be observed before the administration of MIVACRON. | \r'
p10634
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Mivacron'
p10635
sa(dp10636
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00565'
p10637
sg5
S'http://bio2rdf.org/drugbank:DB00202'
p10638
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p10639
sg23
Nsg24
Nsg25
S'SUCCINYLCHOLINE'
p10640
sg27
Nsg28
S'Infusion requirements of NIMBEX in patients administered succinylcholine prior to infusions of NIMBEX were comparable to or slightly greater than when succinylcholine was not administered.| \r'
p10641
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nimbex'
p10642
sa(dp10643
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p10644
sg5
S'http://bio2rdf.org/drugbank:DB00401'
p10645
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10646
sg23
Nsg24
Nsg25
S'Sular'
p10647
sg27
Nsg28
S'Coadministration of SULAR with phenytoin or any known CYP3A4 inducer should be avoided and alternative antihypertensive therapy should be considered.| \r'
p10648
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p10649
sa(dp10650
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00444'
p10651
sg5
S'http://bio2rdf.org/drugbank:DB00576'
p10652
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10653
sg23
Nsg24
Nsg25
S'SULFAMETHIZOLE'
p10654
sg27
Nsg28
S'In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. | \r'
p10655
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TENIPOSIDE'
p10656
sa(dp10657
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p10658
sg5
S'http://bio2rdf.org/drugbank:DB00576'
p10659
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p10660
sg23
Nsg24
Nsg25
S'SULFAMETHIZOLE'
p10661
sg27
Nsg28
S'Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. | \r'
p10662
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TOLBUTAMIDE'
p10663
sa(dp10664
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p10665
sg5
S'http://bio2rdf.org/drugbank:DB01015'
p10666
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10667
sg23
Nsg24
Nsg25
S'SULFAMETHOXAZOLE'
p10668
sg27
Nsg28
S'At a 1.6-g dose, sulfamethoxazole produced a slight but significant increase in the half-life of phenytoin but did not produce a corresponding decrease in the metabolic clearance rate. | Sulfamethoxazole may inhibit the hepatic metabolism of phenytoin. | \r'
p10669
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p10670
sa(dp10671
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p10672
sg5
S'http://bio2rdf.org/drugbank:DB00891'
p10673
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p10674
sg23
Nsg24
Nsg25
S'SULFAPYRIDINE'
p10675
sg27
Nsg28
S'Sulfapyridine may interact with any of the following: - Acetaminophen (e.g., Tylenol) (with long-term, high-dose use) or| \r'
p10676
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACETAMINOPHEN'
p10677
sa(dp10678
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p10679
sg5
S'http://bio2rdf.org/drugbank:DB00891'
p10680
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p10681
sg23
Nsg24
Nsg25
S'SULFAPYRIDINE'
p10682
sg27
Nsg28
S'Sulfapyridine may interact with any of the following: - Acetaminophen (e.g., Tylenol) (with long-term, high-dose use) or| \r'
p10683
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tylenol'
p10684
sa(dp10685
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p10686
sg5
S'http://bio2rdf.org/drugbank:DB00795'
p10687
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10688
sg23
Nsg24
Nsg25
S'SULFASALAZINE'
p10689
sg27
Nsg28
S'Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.| \r'
p10690
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p10691
sa(dp10692
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00005'
p10693
sg5
S'http://bio2rdf.org/drugbank:DB00795'
p10694
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p10695
sg23
Nsg24
Nsg25
S'SULFASALAZINE'
p10696
sg27
Nsg28
S'Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.| \r'
p10697
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Enbrel'
p10698
sa(dp10699
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p10700
sg5
S'http://bio2rdf.org/drugbank:DB01145'
p10701
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p10702
sg23
Nsg24
Nsg25
S'SULFOXONE'
p10703
sg27
Nsg28
S'Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. | \r'
p10704
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TOLBUTAMIDE'
p10705
sa(dp10706
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00320'
p10707
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p10708
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10709
sg23
Nsg24
Nsg25
S'SUMATRIPTAN SUCCINATE'
p10710
sg27
Nsg28
S'Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..| Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.| \r'
p10711
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'D.H.E. 45'
p10712
sa(dp10713
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00320'
p10714
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p10715
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p10716
sg23
Nsg24
Nsg25
S'SUMATRIPTAN SUCCINATE'
p10717
sg27
Nsg28
S'Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..| Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.| \r'
p10718
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'D.H.E. 45'
p10719
sa(dp10720
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p10721
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p10722
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10723
sg23
Nsg24
Nsg25
S'SUMATRIPTAN SUCCINATE'
p10724
sg27
Nsg28
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p10725
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ESCITALOPRAM OXALATE'
p10726
sa(dp10727
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p10728
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p10729
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10730
sg23
Nsg24
Nsg25
S'SUMATRIPTAN SUCCINATE'
p10731
sg27
Nsg28
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p10732
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ESCITALOPRAM'
p10733
sa(dp10734
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p10735
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p10736
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10737
sg23
Nsg24
Nsg25
S'SUMATRIPTAN SUCCINATE'
p10738
sg27
Nsg28
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p10739
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p10740
sa(dp10741
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p10742
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p10743
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10744
sg23
Nsg24
Nsg25
S'SUMATRIPTAN SUCCINATE'
p10745
sg27
Nsg28
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p10746
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PAROXETINE'
p10747
sa(dp10748
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01104'
p10749
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p10750
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10751
sg23
Nsg24
Nsg25
S'SUMATRIPTAN SUCCINATE'
p10752
sg27
Nsg28
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p10753
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SERTRALINE'
p10754
sa(dp10755
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00320'
p10756
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p10757
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10758
sg23
Nsg24
Nsg25
S'SUMATRIPTAN'
p10759
sg27
Nsg28
S'Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.| Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..| \r'
p10760
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'D.H.E. 45'
p10761
sa(dp10762
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00320'
p10763
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p10764
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p10765
sg23
Nsg24
Nsg25
S'SUMATRIPTAN'
p10766
sg27
Nsg28
S'Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.| Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..| \r'
p10767
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'D.H.E. 45'
p10768
sa(dp10769
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p10770
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p10771
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10772
sg23
Nsg24
Nsg25
S'SUMATRIPTAN'
p10773
sg27
Nsg28
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p10774
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ESCITALOPRAM OXALATE'
p10775
sa(dp10776
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p10777
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p10778
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10779
sg23
Nsg24
Nsg25
S'SUMATRIPTAN'
p10780
sg27
Nsg28
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p10781
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ESCITALOPRAM'
p10782
sa(dp10783
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p10784
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p10785
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10786
sg23
Nsg24
Nsg25
S'SUMATRIPTAN'
p10787
sg27
Nsg28
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p10788
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p10789
sa(dp10790
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p10791
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p10792
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10793
sg23
Nsg24
Nsg25
S'SUMATRIPTAN'
p10794
sg27
Nsg28
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p10795
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PAROXETINE'
p10796
sa(dp10797
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01104'
p10798
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p10799
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10800
sg23
Nsg24
Nsg25
S'SUMATRIPTAN'
p10801
sg27
Nsg28
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p10802
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SERTRALINE'
p10803
sa(dp10804
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01248'
p10805
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10806
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p10807
sg23
Nsg24
Nsg25
S'SUNITINIB'
p10808
sg27
Nsg28
S'Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.| Although single or concurrent use of sunitinib and docetaxel has some anti-proliferative effects, the sequential administrations of both drugs remarkably enhanced anti-tumor activity. | \r'
p10809
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOCETAXEL'
p10810
sa(dp10811
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01248'
p10812
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10813
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p10814
sg23
Nsg24
Nsg25
S'SUNITINIB'
p10815
sg27
Nsg28
S'Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.| Although single or concurrent use of sunitinib and docetaxel has some anti-proliferative effects, the sequential administrations of both drugs remarkably enhanced anti-tumor activity. | \r'
p10816
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOCETAXEL'
p10817
sa(dp10818
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01211'
p10819
sg5
S'http://bio2rdf.org/drugbank:DB00625'
p10820
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p10821
sg23
Nsg24
Nsg25
S'Sustiva'
p10822
sg27
Nsg28
S'In uninfected volunteers, 46% developed rash while receiving SUSTIVA and clarithromycin.| \r'
p10823
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLARITHROMYCIN'
p10824
sa(dp10825
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p10826
sg5
S'http://bio2rdf.org/drugbank:DB00625'
p10827
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10828
sg23
Nsg24
Nsg25
S'Sustiva'
p10829
sg27
Nsg28
S'SUSTIVA has the potential to decrease plasma concentrations of itraconazole and ketoconazole.| \r'
p10830
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p10831
sa(dp10832
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p10833
sg5
S'http://bio2rdf.org/drugbank:DB00625'
p10834
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10835
sg23
Nsg24
Nsg25
S'Sustiva'
p10836
sg27
Nsg28
S'Monitoring of liver enzymes is recommended when SUSTIVA is used in combination with ritonavir.| \r'
p10837
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p10838
sa(dp10839
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01072'
p10840
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10841
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10842
sg23
Nsg24
Nsg25
S'Sutent'
p10843
sg27
Nsg28
S'Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | \r'
p10844
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ATAZANAVIR'
p10845
sa(dp10846
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p10847
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10848
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10849
sg23
Nsg24
Nsg25
S'Sutent'
p10850
sg27
Nsg28
S'Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. | \r'
p10851
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CARBAMAZEPINE'
p10852
sa(dp10853
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01211'
p10854
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10855
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10856
sg23
Nsg24
Nsg25
S'Sutent'
p10857
sg27
Nsg28
S'Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | \r'
p10858
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLARITHROMYCIN'
p10859
sa(dp10860
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01234'
p10861
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10862
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10863
sg23
Nsg24
Nsg25
S'Sutent'
p10864
sg27
Nsg28
S'Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. | \r'
p10865
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DEXAMETHASONE'
p10866
sa(dp10867
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p10868
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10869
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10870
sg23
Nsg24
Nsg25
S'Sutent'
p10871
sg27
Nsg28
S'Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | \r'
p10872
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDINAVIR ANHYDROUS'
p10873
sa(dp10874
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p10875
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10876
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10877
sg23
Nsg24
Nsg25
S'Sutent'
p10878
sg27
Nsg28
S'Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | \r'
p10879
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDINAVIR'
p10880
sa(dp10881
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p10882
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10883
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10884
sg23
Nsg24
Nsg25
S'Sutent'
p10885
sg27
Nsg28
S'Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | \r'
p10886
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p10887
sa(dp10888
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01149'
p10889
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10890
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10891
sg23
Nsg24
Nsg25
S'Sutent'
p10892
sg27
Nsg28
S'Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | \r'
p10893
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NEFAZODONE'
p10894
sa(dp10895
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB05251'
p10896
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10897
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10898
sg23
Nsg24
Nsg25
S'Sutent'
p10899
sg27
Nsg28
S'Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | \r'
p10900
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NELFINAVIR'
p10901
sa(dp10902
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p10903
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10904
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10905
sg23
Nsg24
Nsg25
S'Sutent'
p10906
sg27
Nsg28
S'Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. | \r'
p10907
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p10908
sa(dp10909
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p10910
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10911
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10912
sg23
Nsg24
Nsg25
S'Sutent'
p10913
sg27
Nsg28
S'Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. | \r'
p10914
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p10915
sa(dp10916
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00615'
p10917
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10918
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10919
sg23
Nsg24
Nsg25
S'Sutent'
p10920
sg27
Nsg28
S'Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. | \r'
p10921
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFABUTIN'
p10922
sa(dp10923
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p10924
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10925
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10926
sg23
Nsg24
Nsg25
S'Sutent'
p10927
sg27
Nsg28
S'Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. | \r'
p10928
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFAMPIN'
p10929
sa(dp10930
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p10931
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10932
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10933
sg23
Nsg24
Nsg25
S'Sutent'
p10934
sg27
Nsg28
S'Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | \r'
p10935
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p10936
sa(dp10937
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p10938
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10939
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10940
sg23
Nsg24
Nsg25
S'Sutent'
p10941
sg27
Nsg28
S'Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | \r'
p10942
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p10943
sa(dp10944
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p10945
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10946
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10947
sg23
Nsg24
Nsg25
S'Sutent'
p10948
sg27
Nsg28
S'Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | \r'
p10949
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p10950
sa(dp10951
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00976'
p10952
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10953
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10954
sg23
Nsg24
Nsg25
S'Sutent'
p10955
sg27
Nsg28
S'Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | \r'
p10956
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TELITHROMYCIN'
p10957
sa(dp10958
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00572'
p10959
sg5
S'http://bio2rdf.org/drugbank:DB01278'
p10960
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10961
sg23
Nsg24
Nsg25
S'Symlin'
p10962
sg27
Nsg28
S'Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). | \r'
p10963
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Atropine'
p10964
sa(dp10965
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00559'
p10966
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p10967
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10968
sg23
Nsg24
Nsg25
S'TACROLIMUS ANHYDROUS'
p10969
sg27
Nsg28
S'Caution should be exercised if tacrolimus and bosentan are used together.| Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.| \r'
p10970
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BOSENTAN ANHYDROUS'
p10971
sa(dp10972
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00559'
p10973
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p10974
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10975
sg23
Nsg24
Nsg25
S'TACROLIMUS ANHYDROUS'
p10976
sg27
Nsg28
S'Caution should be exercised if tacrolimus and bosentan are used together.| Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.| \r'
p10977
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BOSENTAN ANHYDROUS'
p10978
sa(dp10979
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00559'
p10980
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p10981
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10982
sg23
Nsg24
Nsg25
S'TACROLIMUS ANHYDROUS'
p10983
sg27
Nsg28
S'Caution should be exercised if tacrolimus and bosentan are used together.| Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.| \r'
p10984
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BOSENTAN'
p10985
sa(dp10986
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00559'
p10987
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p10988
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p10989
sg23
Nsg24
Nsg25
S'TACROLIMUS ANHYDROUS'
p10990
sg27
Nsg28
S'Caution should be exercised if tacrolimus and bosentan are used together.| Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.| \r'
p10991
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BOSENTAN'
p10992
sa(dp10993
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p10994
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p10995
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p10996
sg23
Nsg24
Nsg25
S'TACROLIMUS ANHYDROUS'
p10997
sg27
Nsg28
S'Patients receiving tacrolimus and fluconazole concomitantly should be carefully monitored. | \r'
p10998
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p10999
sa(dp11000
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p11001
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p11002
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11003
sg23
Nsg24
Nsg25
S'TACROLIMUS ANHYDROUS'
p11004
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p11005
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p11006
sa(dp11007
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p11008
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p11009
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11010
sg23
Nsg24
Nsg25
S'TACROLIMUS ANHYDROUS'
p11011
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p11012
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p11013
sa(dp11014
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p11015
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p11016
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11017
sg23
Nsg24
Nsg25
S'TACROLIMUS ANHYDROUS'
p11018
sg27
Nsg28
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p11019
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sprycel'
p11020
sa(dp11021
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00559'
p11022
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p11023
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11024
sg23
Nsg24
Nsg25
S'TACROLIMUS'
p11025
sg27
Nsg28
S'Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.| Caution should be exercised if tacrolimus and bosentan are used together.| \r'
p11026
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BOSENTAN ANHYDROUS'
p11027
sa(dp11028
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00559'
p11029
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p11030
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11031
sg23
Nsg24
Nsg25
S'TACROLIMUS'
p11032
sg27
Nsg28
S'Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.| Caution should be exercised if tacrolimus and bosentan are used together.| \r'
p11033
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BOSENTAN ANHYDROUS'
p11034
sa(dp11035
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00559'
p11036
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p11037
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11038
sg23
Nsg24
Nsg25
S'TACROLIMUS'
p11039
sg27
Nsg28
S'Caution should be exercised if tacrolimus and bosentan are used together.| Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.| \r'
p11040
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BOSENTAN'
p11041
sa(dp11042
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00559'
p11043
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p11044
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11045
sg23
Nsg24
Nsg25
S'TACROLIMUS'
p11046
sg27
Nsg28
S'Caution should be exercised if tacrolimus and bosentan are used together.| Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.| \r'
p11047
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BOSENTAN'
p11048
sa(dp11049
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p11050
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p11051
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11052
sg23
Nsg24
Nsg25
S'TACROLIMUS'
p11053
sg27
Nsg28
S'Patients receiving tacrolimus and fluconazole concomitantly should be carefully monitored. | \r'
p11054
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p11055
sa(dp11056
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p11057
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p11058
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11059
sg23
Nsg24
Nsg25
S'TACROLIMUS'
p11060
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p11061
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p11062
sa(dp11063
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p11064
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p11065
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11066
sg23
Nsg24
Nsg25
S'TACROLIMUS'
p11067
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p11068
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p11069
sa(dp11070
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p11071
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p11072
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11073
sg23
Nsg24
Nsg25
S'TACROLIMUS'
p11074
sg27
Nsg28
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p11075
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sprycel'
p11076
sa(dp11077
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p11078
sg5
S'http://bio2rdf.org/drugbank:DB00820'
p11079
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11080
sg23
Nsg24
Nsg25
S'TADALAFIL'
p11081
sg27
Nsg28
S'Tadalafil dose should not exceed a maximum of 10 mg in a 72- hour period in patients receiving concomitant indinavir therapy.| \r'
p11082
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDINAVIR ANHYDROUS'
p11083
sa(dp11084
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p11085
sg5
S'http://bio2rdf.org/drugbank:DB00820'
p11086
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11087
sg23
Nsg24
Nsg25
S'TADALAFIL'
p11088
sg27
Nsg28
S'Tadalafil dose should not exceed a maximum of 10 mg in a 72- hour period in patients receiving concomitant indinavir therapy.| \r'
p11089
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDINAVIR'
p11090
sa(dp11091
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00475'
p11092
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p11093
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11094
sg23
Nsg24
Nsg25
S'Tagamet'
p11095
sg27
Nsg28
S'Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| \r'
p11096
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CHLORDIAZEPOXIDE'
p11097
sa(dp11098
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p11099
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p11100
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11101
sg23
Nsg24
Nsg25
S'Tagamet'
p11102
sg27
Nsg28
S'Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| \r'
p11103
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIAZEPAM'
p11104
sa(dp11105
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB05291'
p11106
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p11107
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11108
sg23
Nsg24
Nsg25
S'Tagamet'
p11109
sg27
Nsg28
S'Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| \r'
p11110
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LIDOCAINE'
p11111
sa(dp11112
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00916'
p11113
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p11114
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11115
sg23
Nsg24
Nsg25
S'Tagamet'
p11116
sg27
Nsg28
S'Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| \r'
p11117
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METRONIDAZOLE'
p11118
sa(dp11119
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01115'
p11120
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p11121
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11122
sg23
Nsg24
Nsg25
S'Tagamet'
p11123
sg27
Nsg28
S'Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| \r'
p11124
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NIFEDIPINE'
p11125
sa(dp11126
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p11127
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p11128
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11129
sg23
Nsg24
Nsg25
S'Tagamet'
p11130
sg27
Nsg28
S'Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| \r'
p11131
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p11132
sa(dp11133
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p11134
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p11135
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11136
sg23
Nsg24
Nsg25
S'Tagamet'
p11137
sg27
Nsg28
S'However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.| \r'
p11138
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Theo-Dur'
p11139
sa(dp11140
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p11141
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p11142
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11143
sg23
Nsg24
Nsg25
S'Tagamet'
p11144
sg27
Nsg28
S'Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.| \r'
p11145
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p11146
sa(dp11147
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p11148
sg5
S'http://bio2rdf.org/drugbank:DB01195'
p11149
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11150
sg23
Nsg24
Nsg25
S'Tambocor'
p11151
sg27
Nsg28
S'During administration of multiple oral doses of TAMBOCOR to healthy subjects stabilized on a maintenance dose of digoxin, a 13%-19% increase in plasma digoxin levels occurred at six hours postdose.| \r'
p11152
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p11153
sa(dp11154
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01217'
p11155
sg5
S'http://bio2rdf.org/drugbank:DB00675'
p11156
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11157
sg23
Nsg24
Nsg25
S'TAMOXIFEN'
p11158
sg27
Nsg28
S'Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole (see CLINICAL PHARMACOLOGY   Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections).| \r'
p11159
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ANASTROZOLE'
p11160
sa(dp11161
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p11162
sg5
S'http://bio2rdf.org/drugbank:DB00675'
p11163
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11164
sg23
Nsg24
Nsg25
S'TAMOXIFEN'
p11165
sg27
Nsg28
S'It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. | \r'
p11166
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PAROXETINE'
p11167
sa(dp11168
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01072'
p11169
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p11170
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11171
sg23
Nsg24
Nsg25
S'Tarceva'
p11172
sg27
Nsg28
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p11173
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ATAZANAVIR'
p11174
sa(dp11175
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01211'
p11176
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p11177
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11178
sg23
Nsg24
Nsg25
S'Tarceva'
p11179
sg27
Nsg28
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p11180
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLARITHROMYCIN'
p11181
sa(dp11182
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p11183
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p11184
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11185
sg23
Nsg24
Nsg25
S'Tarceva'
p11186
sg27
Nsg28
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p11187
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDINAVIR ANHYDROUS'
p11188
sa(dp11189
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p11190
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p11191
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11192
sg23
Nsg24
Nsg25
S'Tarceva'
p11193
sg27
Nsg28
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p11194
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDINAVIR'
p11195
sa(dp11196
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p11197
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p11198
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11199
sg23
Nsg24
Nsg25
S'Tarceva'
p11200
sg27
Nsg28
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p11201
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p11202
sa(dp11203
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01149'
p11204
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p11205
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11206
sg23
Nsg24
Nsg25
S'Tarceva'
p11207
sg27
Nsg28
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p11208
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NEFAZODONE'
p11209
sa(dp11210
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB05251'
p11211
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p11212
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11213
sg23
Nsg24
Nsg25
S'Tarceva'
p11214
sg27
Nsg28
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p11215
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NELFINAVIR'
p11216
sa(dp11217
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p11218
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p11219
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11220
sg23
Nsg24
Nsg25
S'Tarceva'
p11221
sg27
Nsg28
S'If the TARCEVA dose is adjusted upward, the dose will need to be reduced upon discontinuation of rifampicin or other inducers.| \r'
p11222
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFAMPIN'
p11223
sa(dp11224
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p11225
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p11226
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11227
sg23
Nsg24
Nsg25
S'Tarceva'
p11228
sg27
Nsg28
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p11229
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p11230
sa(dp11231
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p11232
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p11233
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11234
sg23
Nsg24
Nsg25
S'Tarceva'
p11235
sg27
Nsg28
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p11236
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p11237
sa(dp11238
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p11239
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p11240
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11241
sg23
Nsg24
Nsg25
S'Tarceva'
p11242
sg27
Nsg28
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p11243
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p11244
sa(dp11245
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01361'
p11246
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p11247
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11248
sg23
Nsg24
Nsg25
S'Tarceva'
p11249
sg27
Nsg28
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p11250
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tao'
p11251
sa(dp11252
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00976'
p11253
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p11254
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11255
sg23
Nsg24
Nsg25
S'Tarceva'
p11256
sg27
Nsg28
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p11257
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TELITHROMYCIN'
p11258
sa(dp11259
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01361'
p11260
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p11261
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11262
sg23
Nsg24
Nsg25
S'Tarceva'
p11263
sg27
Nsg28
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p11264
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TROLEANDOMYCIN'
p11265
sa(dp11266
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00582'
p11267
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p11268
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11269
sg23
Nsg24
Nsg25
S'Tarceva'
p11270
sg27
Nsg28
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p11271
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VORICONAZOLE'
p11272
sa(dp11273
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01241'
p11274
sg5
S'http://bio2rdf.org/drugbank:DB00307'
p11275
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11276
sg23
Nsg24
Nsg25
S'Targretin'
p11277
sg27
Nsg28
S'Concomitant administration of Targretin capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.| \r'
p11278
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GEMFIBROZIL'
p11279
sa(dp11280
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00515'
p11281
sg5
S'http://bio2rdf.org/drugbank:DB01229'
p11282
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p11283
sg23
Nsg24
Nsg25
S'Taxol'
p11284
sg27
Nsg28
S'In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).| Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when TAXOL was administered following cisplatin.| \r'
p11285
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CISPLATIN'
p11286
sa(dp11287
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00515'
p11288
sg5
S'http://bio2rdf.org/drugbank:DB01229'
p11289
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11290
sg23
Nsg24
Nsg25
S'Taxol'
p11291
sg27
Nsg28
S'In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).| Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when TAXOL was administered following cisplatin.| \r'
p11292
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CISPLATIN'
p11293
sa(dp11294
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01229'
p11295
sg5
S'http://bio2rdf.org/drugbank:DB00444'
p11296
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11297
sg23
Nsg24
Nsg25
S'TENIPOSIDE'
p11298
sg27
Nsg28
S'Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL.| \r'
p11299
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Taxol'
p11300
sa(dp11301
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00201'
p11302
sg5
S'http://bio2rdf.org/drugbank:DB00857'
p11303
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11304
sg23
Nsg24
Nsg25
S'TERBINAFINE'
p11305
sg27
Nsg28
S'Terbinafine decreases the clearance of caffeine by 19%. | \r'
p11306
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CAFFEINE'
p11307
sa(dp11308
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p11309
sg5
S'http://bio2rdf.org/drugbank:DB00857'
p11310
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11311
sg23
Nsg24
Nsg25
S'TERBINAFINE'
p11312
sg27
Nsg28
S'Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor. | \r'
p11313
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIMETIDINE'
p11314
sa(dp11315
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p11316
sg5
S'http://bio2rdf.org/drugbank:DB00857'
p11317
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11318
sg23
Nsg24
Nsg25
S'TERBINAFINE'
p11319
sg27
Nsg28
S'Terbinafine increases the clearance of cyclosporine by 15%. | \r'
p11320
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSPORINE'
p11321
sa(dp11322
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p11323
sg5
S'http://bio2rdf.org/drugbank:DB00857'
p11324
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11325
sg23
Nsg24
Nsg25
S'TERBINAFINE'
p11326
sg27
Nsg28
S'Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor. | \r'
p11327
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFAMPIN'
p11328
sa(dp11329
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01294'
p11330
sg5
S'http://bio2rdf.org/drugbank:DB00759'
p11331
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11332
sg23
Nsg24
Nsg25
S'TETRACYCLINE'
p11333
sg27
Nsg28
S'Absorption of tetracycline is impaired by bismuth subsalicylate.| \r'
p11334
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BISMUTH SUBSALICYLATE'
p11335
sa(dp11336
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p11337
sg5
S'http://bio2rdf.org/drugbank:DB00759'
p11338
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11339
sg23
Nsg24
Nsg25
S'TETRACYCLINE'
p11340
sg27
Nsg28
S'Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.| \r'
p11341
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p11342
sa(dp11343
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01028'
p11344
sg5
S'http://bio2rdf.org/drugbank:DB00759'
p11345
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p11346
sg23
Nsg24
Nsg25
S'TETRACYCLINE'
p11347
sg27
Nsg28
S'The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.| The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. | \r'
p11348
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHOXYFLURANE'
p11349
sa(dp11350
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01028'
p11351
sg5
S'http://bio2rdf.org/drugbank:DB00759'
p11352
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p11353
sg23
Nsg24
Nsg25
S'TETRACYCLINE'
p11354
sg27
Nsg28
S'The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.| \r'
p11355
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Penthrane'
p11356
sa(dp11357
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01028'
p11358
sg5
S'http://bio2rdf.org/drugbank:DB00759'
p11359
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p11360
sg23
Nsg24
Nsg25
S'TETRACYCLINE'
p11361
sg27
Nsg28
S'The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.| The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. | \r'
p11362
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHOXYFLURANE'
p11363
sa(dp11364
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p11365
sg5
S'http://bio2rdf.org/drugbank:DB00277'
p11366
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11367
sg23
Nsg24
Nsg25
S'THEOPHYLLINE'
p11368
sg27
Nsg28
S'Theophylline decreased the binding of acetaminophen by a net change of 6.8% (percentage increase in FDF, 8.8%) at 277.5 micromol/L; | \r'
p11369
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACETAMINOPHEN'
p11370
sa(dp11371
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00467'
p11372
sg5
S'http://bio2rdf.org/drugbank:DB00277'
p11373
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p11374
sg23
Nsg24
Nsg25
S'THEOPHYLLINE'
p11375
sg27
Nsg28
S'Theophylline-related adverse effects have occurred in patients when theophylline and enoxacin were coadministered.| \r'
p11376
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ENOXACIN'
p11377
sa(dp11378
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p11379
sg5
S'http://bio2rdf.org/drugbank:DB00277'
p11380
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11381
sg23
Nsg24
Nsg25
S'THEOPHYLLINE'
p11382
sg27
Nsg28
S'In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.| \r'
p11383
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERYTHROMYCIN'
p11384
sa(dp11385
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00448'
p11386
sg5
S'http://bio2rdf.org/drugbank:DB00277'
p11387
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11388
sg23
Nsg24
Nsg25
S'THEOPHYLLINE'
p11389
sg27
Nsg28
S'Nonetheless, individual patients may require additional titration of their theophylline dosage when lansoprazole is started or stopped to ensure clinically effective blood levels.| \r'
p11390
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Lansoprazole'
p11391
sa(dp11392
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00379'
p11393
sg5
S'http://bio2rdf.org/drugbank:DB00277'
p11394
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11395
sg23
Nsg24
Nsg25
S'THEOPHYLLINE'
p11396
sg27
Nsg28
S'This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. | \r'
p11397
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Mexitil'
p11398
sa(dp11399
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00008'
p11400
sg5
S'http://bio2rdf.org/drugbank:DB00277'
p11401
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11402
sg23
Nsg24
Nsg25
S'THEOPHYLLINE'
p11403
sg27
Nsg28
S'Theophylline serum levels should be monitored and appropriate dose adjustments considered for patients given both theophylline and PEGASYS.| \r'
p11404
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Pegasys'
p11405
sa(dp11406
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p11407
sg5
S'http://bio2rdf.org/drugbank:DB00277'
p11408
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11409
sg23
Nsg24
Nsg25
S'THEOPHYLLINE'
p11410
sg27
Nsg28
S'Enhanced theophylline clearance secondary to phenytoin therapy.&#x0D;| This report describes two cases in which theophylline clearance accelerated markedly with concomitant phenytoin administration. | \r'
p11411
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p11412
sa(dp11413
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p11414
sg5
S'http://bio2rdf.org/drugbank:DB00730'
p11415
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11416
sg23
Nsg24
Nsg25
S'THIABENDAZOLE'
p11417
sg27
Nsg28
S'Thiabendazole may compete with other drugs, such as theophylline, for sites of metabolism in the liver, thus elevating the serum levels of such compounds to potentially toxic levels. | \r'
p11418
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p11419
sa(dp11420
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00649'
p11421
sg5
S'http://bio2rdf.org/drugbank:DB00152'
p11422
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p11423
sg23
Nsg24
Nsg25
S'THIAMINE ION'
p11424
sg27
Nsg28
S'Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants| \r'
p11425
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'STAVUDINE'
p11426
sa(dp11427
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00649'
p11428
sg5
S'http://bio2rdf.org/drugbank:DB00152'
p11429
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p11430
sg23
Nsg24
Nsg25
S'THIAMINE'
p11431
sg27
Nsg28
S'Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants| \r'
p11432
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'STAVUDINE'
p11433
sa(dp11434
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p11435
sg5
S'http://bio2rdf.org/drugbank:DB00906'
p11436
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11437
sg23
Nsg24
Nsg25
S'TIAGABINE'
p11438
sg27
Nsg28
S'Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.| \r'
p11439
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CARBAMAZEPINE'
p11440
sa(dp11441
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p11442
sg5
S'http://bio2rdf.org/drugbank:DB00906'
p11443
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11444
sg23
Nsg24
Nsg25
S'TIAGABINE'
p11445
sg27
Nsg28
S'Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.| \r'
p11446
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p11447
sa(dp11448
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p11449
sg5
S'http://bio2rdf.org/drugbank:DB00906'
p11450
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11451
sg23
Nsg24
Nsg25
S'TIAGABINE'
p11452
sg27
Nsg28
S'Phenytoin: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing AEDs.| \r'
p11453
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p11454
sa(dp11455
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00794'
p11456
sg5
S'http://bio2rdf.org/drugbank:DB00906'
p11457
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11458
sg23
Nsg24
Nsg25
S'TIAGABINE'
p11459
sg27
Nsg28
S'Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.| \r'
p11460
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PRIMIDONE'
p11461
sa(dp11462
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p11463
sg5
S'http://bio2rdf.org/drugbank:DB00906'
p11464
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11465
sg23
Nsg24
Nsg25
S'TIAGABINE'
p11466
sg27
Nsg28
S'Valproate: Tiagabine causes a slight decrease (about 10%) in steady-state valproate concentrations.| \r'
p11467
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Valproate'
p11468
sa(dp11469
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p11470
sg5
S'http://bio2rdf.org/drugbank:DB08816'
p11471
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p11472
sg23
Nsg24
Nsg25
S'TICAGRELOR'
p11473
sg27
Nsg28
S'The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). | \r'
p11474
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p11475
sa(dp11476
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p11477
sg5
S'http://bio2rdf.org/drugbank:DB00204'
p11478
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11479
sg23
Nsg24
Nsg25
S'Tikosyn'
p11480
sg27
Nsg28
S'If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.| \r'
p11481
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIMETIDINE'
p11482
sa(dp11483
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p11484
sg5
S'http://bio2rdf.org/drugbank:DB00204'
p11485
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11486
sg23
Nsg24
Nsg25
S'Tikosyn'
p11487
sg27
Nsg28
S'Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.| \r'
p11488
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Verapamil'
p11489
sa(dp11490
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01018'
p11491
sg5
S'http://bio2rdf.org/drugbank:DB00373'
p11492
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p11493
sg23
Nsg24
Nsg25
S'TIMOLOL'
p11494
sg27
Nsg28
S'Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.| \r'
p11495
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GUANFACINE'
p11496
sa(dp11497
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00903'
p11498
sg5
S'http://bio2rdf.org/drugbank:DB00684'
p11499
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11500
sg23
Nsg24
Nsg25
S'Tobi'
p11501
sg27
Nsg28
S'TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.| \r'
p11502
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ETHACRYNIC ACID'
p11503
sa(dp11504
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00695'
p11505
sg5
S'http://bio2rdf.org/drugbank:DB00684'
p11506
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11507
sg23
Nsg24
Nsg25
S'Tobi'
p11508
sg27
Nsg28
S'TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.| \r'
p11509
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FUROSEMIDE'
p11510
sa(dp11511
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00742'
p11512
sg5
S'http://bio2rdf.org/drugbank:DB00684'
p11513
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11514
sg23
Nsg24
Nsg25
S'Tobi'
p11515
sg27
Nsg28
S'TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.| \r'
p11516
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MANNITOL'
p11517
sa(dp11518
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00003'
p11519
sg5
S'http://bio2rdf.org/drugbank:DB00684'
p11520
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p11521
sg23
Nsg24
Nsg25
S'Tobi'
p11522
sg27
Nsg28
S'In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. | \r'
p11523
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Pulmozyme'
p11524
sa(dp11525
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB03904'
p11526
sg5
S'http://bio2rdf.org/drugbank:DB00684'
p11527
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11528
sg23
Nsg24
Nsg25
S'Tobi'
p11529
sg27
Nsg28
S'TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.| \r'
p11530
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'UREA'
p11531
sa(dp11532
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p11533
sg5
S'http://bio2rdf.org/drugbank:DB01124'
p11534
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11535
sg23
Nsg24
Nsg25
S'TOLBUTAMIDE'
p11536
sg27
Nsg28
S'Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.| \r'
p11537
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'APREPITANT'
p11538
sa(dp11539
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00636'
p11540
sg5
S'http://bio2rdf.org/drugbank:DB01124'
p11541
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p11542
sg23
Nsg24
Nsg25
S'TOLBUTAMIDE'
p11543
sg27
Nsg28
S'The hypoglycemic effect of tolbutamide has been reported to increase when Atromid-S is given concurrently.| \r'
p11544
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Atromid-S'
p11545
sa(dp11546
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00444'
p11547
sg5
S'http://bio2rdf.org/drugbank:DB01124'
p11548
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11549
sg23
Nsg24
Nsg25
S'TOLBUTAMIDE'
p11550
sg27
Nsg28
S'In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. | \r'
p11551
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TENIPOSIDE'
p11552
sa(dp11553
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p11554
sg5
S'http://bio2rdf.org/drugbank:DB00500'
p11555
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11556
sg23
Nsg24
Nsg25
S'Tolectin'
p11557
sg27
Nsg28
S'TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. | Caution should be used if TOLECTIN is administered concomitantly with methotrexate. | \r'
p11558
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHOTREXATE'
p11559
sa(dp11560
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p11561
sg5
S'http://bio2rdf.org/drugbank:DB00500'
p11562
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11563
sg23
Nsg24
Nsg25
S'Tolectin'
p11564
sg27
Nsg28
S'TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. | Caution should be used if TOLECTIN is administered concomitantly with methotrexate. | \r'
p11565
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHOTREXATE'
p11566
sa(dp11567
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00977'
p11568
sg5
S'http://bio2rdf.org/drugbank:DB00273'
p11569
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11570
sg23
Nsg24
Nsg25
S'TOPIRAMATE'
p11571
sg27
Nsg28
S'Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.| \r'
p11572
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ETHINYL ESTRADIOL'
p11573
sa(dp11574
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00404'
p11575
sg5
S'http://bio2rdf.org/drugbank:DB00465'
p11576
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p11577
sg23
Nsg24
Nsg25
S'Toradol'
p11578
sg27
Nsg28
S'Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).| \r'
p11579
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALPRAZOLAM'
p11580
sa(dp11581
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p11582
sg5
S'http://bio2rdf.org/drugbank:DB00465'
p11583
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p11584
sg23
Nsg24
Nsg25
S'Toradol'
p11585
sg27
Nsg28
S'Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).| \r'
p11586
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CARBAMAZEPINE'
p11587
sa(dp11588
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00695'
p11589
sg5
S'http://bio2rdf.org/drugbank:DB00465'
p11590
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p11591
sg23
Nsg24
Nsg25
S'Toradol'
p11592
sg27
Nsg28
S'Furosemide: TORADOL IV/IM reduced the diuretic response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).| \r'
p11593
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FUROSEMIDE'
p11594
sa(dp11595
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p11596
sg5
S'http://bio2rdf.org/drugbank:DB00465'
p11597
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p11598
sg23
Nsg24
Nsg25
S'Toradol'
p11599
sg27
Nsg28
S'Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).| \r'
p11600
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p11601
sa(dp11602
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p11603
sg5
S'http://bio2rdf.org/drugbank:DB00465'
p11604
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11605
sg23
Nsg24
Nsg25
S'Toradol'
p11606
sg27
Nsg28
S'Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.| Therefore, concomitant use of TORADOL and probenecid is contraindicated.| \r'
p11607
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROBENECID'
p11608
sa(dp11609
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p11610
sg5
S'http://bio2rdf.org/drugbank:DB00465'
p11611
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11612
sg23
Nsg24
Nsg25
S'Toradol'
p11613
sg27
Nsg28
S'Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.| Therefore, concomitant use of TORADOL and probenecid is contraindicated.| \r'
p11614
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROBENECID'
p11615
sa(dp11616
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01623'
p11617
sg5
S'http://bio2rdf.org/drugbank:DB00465'
p11618
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p11619
sg23
Nsg24
Nsg25
S'Toradol'
p11620
sg27
Nsg28
S'Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).| \r'
p11621
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THIOTHIXENE'
p11622
sa(dp11623
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01016'
p11624
sg5
S'http://bio2rdf.org/drugbank:DB00559'
p11625
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11626
sg23
Nsg24
Nsg25
S'Tracleer'
p11627
sg27
Nsg28
S'Therefore, the concomitant administration of TRACLEER and glyburide is contraindicated, and alternative hypoglycemic agents should be considered.| \r'
p11628
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GLYBURIDE'
p11629
sa(dp11630
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00951'
p11631
sg5
S'http://bio2rdf.org/drugbank:DB00609'
p11632
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11633
sg23
Nsg24
Nsg25
S'Trecator'
p11634
sg27
Nsg28
S'Trecator has been found to temporarily raise serum concentrations of isoniazid.| \r'
p11635
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ISONIAZID'
p11636
sa(dp11637
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p11638
sg5
S'http://bio2rdf.org/drugbank:DB00806'
p11639
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11640
sg23
Nsg24
Nsg25
S'Trental'
p11641
sg27
Nsg28
S'Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. | \r'
p11642
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p11643
sa(dp11644
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00696'
p11645
sg5
S'http://bio2rdf.org/drugbank:DB01361'
p11646
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11647
sg23
Nsg24
Nsg25
S'Triacetyloleandomycin'
p11648
sg27
Nsg28
S'The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.| \r'
p11649
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERGOTAMINE'
p11650
sa(dp11651
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p11652
sg5
S'http://bio2rdf.org/drugbank:DB00384'
p11653
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11654
sg23
Nsg24
Nsg25
S'TRIAMTERENE'
p11655
sg27
Nsg28
S'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.| \r'
p11656
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOFETILIDE'
p11657
sa(dp11658
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00328'
p11659
sg5
S'http://bio2rdf.org/drugbank:DB00384'
p11660
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p11661
sg23
Nsg24
Nsg25
S'TRIAMTERENE'
p11662
sg27
Nsg28
S'It has been reported that the addition of triamterene to a maintenance schedule of INDOCIN resulted in reversible acute renal failure in two of four healthy volunteers.| \r'
p11663
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Indocin'
p11664
sa(dp11665
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00413'
p11666
sg5
S'http://bio2rdf.org/drugbank:DB00384'
p11667
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11668
sg23
Nsg24
Nsg25
S'TRIAMTERENE'
p11669
sg27
Nsg28
S'Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | \r'
p11670
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PRAMIPEXOLE'
p11671
sa(dp11672
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p11673
sg5
S'http://bio2rdf.org/drugbank:DB00897'
p11674
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11675
sg23
Nsg24
Nsg25
S'TRIAZOLAM'
p11676
sg27
Nsg28
S'The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.| \r'
p11677
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'APREPITANT'
p11678
sa(dp11679
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p11680
sg5
S'http://bio2rdf.org/drugbank:DB00897'
p11681
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11682
sg23
Nsg24
Nsg25
S'TRIAZOLAM'
p11683
sg27
Nsg28
S'The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.| \r'
p11684
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DILTIAZEM'
p11685
sa(dp11686
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p11687
sg5
S'http://bio2rdf.org/drugbank:DB00897'
p11688
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11689
sg23
Nsg24
Nsg25
S'TRIAZOLAM'
p11690
sg27
Nsg28
S'Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| \r'
p11691
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p11692
sa(dp11693
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p11694
sg5
S'http://bio2rdf.org/drugbank:DB00897'
p11695
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11696
sg23
Nsg24
Nsg25
S'TRIAZOLAM'
p11697
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p11698
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p11699
sa(dp11700
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p11701
sg5
S'http://bio2rdf.org/drugbank:DB00897'
p11702
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11703
sg23
Nsg24
Nsg25
S'TRIAZOLAM'
p11704
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p11705
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p11706
sa(dp11707
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00906'
p11708
sg5
S'http://bio2rdf.org/drugbank:DB00897'
p11709
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11710
sg23
Nsg24
Nsg25
S'TRIAZOLAM'
p11711
sg27
Nsg28
S'Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.| \r'
p11712
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TIAGABINE'
p11713
sa(dp11714
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01023'
p11715
sg5
S'http://bio2rdf.org/drugbank:DB00776'
p11716
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11717
sg23
Nsg24
Nsg25
S'Trileptal'
p11718
sg27
Nsg28
S'Calcium Antagonists: After repeated co-administration of Trileptal, the AUC of felodipine was lowered by 28% [90% CI: 20-33].| \r'
p11719
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Felodipine'
p11720
sa(dp11721
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p11722
sg5
S'http://bio2rdf.org/drugbank:DB00776'
p11723
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11724
sg23
Nsg24
Nsg25
S'Trileptal'
p11725
sg27
Nsg28
S'Therefore, when using doses of Trileptal greater than 1200 mg/day during adjunctive therapy, a decrease in the dose of phenytoin may be required.| \r'
p11726
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p11727
sa(dp11728
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00648'
p11729
sg5
S'http://bio2rdf.org/drugbank:DB01108'
p11730
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p11731
sg23
Nsg24
Nsg25
S'TRILOSTANE'
p11732
sg27
Nsg28
S'Trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).| \r'
p11733
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Mitotane'
p11734
sa(dp11735
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p11736
sg5
S'http://bio2rdf.org/drugbank:DB00440'
p11737
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11738
sg23
Nsg24
Nsg25
S'TRIMETHOPRIM'
p11739
sg27
Nsg28
S'Trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%. | Trimethoprim may inhibit the hepatic metabolism of phenytoin. | \r'
p11740
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p11741
sa(dp11742
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p11743
sg5
S'http://bio2rdf.org/drugbank:DB01157'
p11744
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p11745
sg23
Nsg24
Nsg25
S'TRIMETREXATE'
p11746
sg27
Nsg28
S'Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. | \r'
p11747
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERYTHROMYCIN'
p11748
sa(dp11749
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p11750
sg5
S'http://bio2rdf.org/drugbank:DB01157'
p11751
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p11752
sg23
Nsg24
Nsg25
S'TRIMETREXATE'
p11753
sg27
Nsg28
S'Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. | \r'
p11754
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p11755
sa(dp11756
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p11757
sg5
S'http://bio2rdf.org/drugbank:DB01157'
p11758
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p11759
sg23
Nsg24
Nsg25
S'TRIMETREXATE'
p11760
sg27
Nsg28
S'Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. | \r'
p11761
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p11762
sa(dp11763
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00615'
p11764
sg5
S'http://bio2rdf.org/drugbank:DB01157'
p11765
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p11766
sg23
Nsg24
Nsg25
S'TRIMETREXATE'
p11767
sg27
Nsg28
S'Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. | \r'
p11768
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFABUTIN'
p11769
sa(dp11770
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p11771
sg5
S'http://bio2rdf.org/drugbank:DB01157'
p11772
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p11773
sg23
Nsg24
Nsg25
S'TRIMETREXATE'
p11774
sg27
Nsg28
S'Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. | \r'
p11775
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFAMPIN'
p11776
sa(dp11777
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00652'
p11778
sg5
S'http://bio2rdf.org/drugbank:DB00792'
p11779
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p11780
sg23
Nsg24
Nsg25
S'TRIPELENNAMINE'
p11781
sg27
Nsg28
S'Dose-response curves (derived from the results of using the tablets as well as pure powders) showed that tripelennamine was responsible for the inhibitory activity, which was partially antagonized by pentazocine. | \r'
p11782
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PENTAZOCINE, (-)-'
p11783
sa(dp11784
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p11785
sg5
S'http://bio2rdf.org/drugbank:DB00427'
p11786
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p11787
sg23
Nsg24
Nsg25
S'TRIPROLIDINE'
p11788
sg27
Nsg28
S'Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. | \r'
p11789
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p11790
sa(dp11791
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00681'
p11792
sg5
S'http://bio2rdf.org/drugbank:DB01169'
p11793
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11794
sg23
Nsg24
Nsg25
S'Trisenox'
p11795
sg27
Nsg28
S'Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).| \r'
p11796
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPHOTERICIN B'
p11797
sa(dp11798
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p11799
sg5
S'http://bio2rdf.org/drugbank:DB01361'
p11800
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11801
sg23
Nsg24
Nsg25
S'TROLEANDOMYCIN'
p11802
sg27
Nsg28
S'Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| \r'
p11803
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p11804
sa(dp11805
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p11806
sg5
S'http://bio2rdf.org/drugbank:DB01361'
p11807
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11808
sg23
Nsg24
Nsg25
S'TROLEANDOMYCIN'
p11809
sg27
Nsg28
S'Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. | \r'
p11810
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHYLPREDNISOLONE'
p11811
sa(dp11812
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p11813
sg5
S'http://bio2rdf.org/drugbank:DB00685'
p11814
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11815
sg23
Nsg24
Nsg25
S'TROVAFLOXACIN'
p11816
sg27
Nsg28
S'Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. | \r'
p11817
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MORPHINE'
p11818
sa(dp11819
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01111'
p11820
sg5
S'http://bio2rdf.org/drugbank:DB01199'
p11821
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p11822
sg23
Nsg24
Nsg25
S'TUBOCURARINE'
p11823
sg27
Nsg28
S'Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.| \r'
p11824
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Coly-Mycin M'
p11825
sa(dp11826
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00514'
p11827
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p11828
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11829
sg23
Nsg24
Nsg25
S'VALDECOXIB'
p11830
sg27
Nsg28
S'Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.| \r'
p11831
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DEXTROMETHORPHAN'
p11832
sa(dp11833
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p11834
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p11835
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p11836
sg23
Nsg24
Nsg25
S'VALDECOXIB'
p11837
sg27
Nsg28
S'Although the magnitude of changes in diazepam plasma exposure when coadministered with valdecoxib were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of diazepam under this circumstance.| \r'
p11838
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIAZEPAM'
p11839
sa(dp11840
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p11841
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p11842
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11843
sg23
Nsg24
Nsg25
S'VALDECOXIB'
p11844
sg27
Nsg28
S'Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.| Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.| \r'
p11845
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p11846
sa(dp11847
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01016'
p11848
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p11849
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11850
sg23
Nsg24
Nsg25
S'VALDECOXIB'
p11851
sg27
Nsg28
S'Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.| \r'
p11852
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GLYBURIDE'
p11853
sa(dp11854
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p11855
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p11856
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11857
sg23
Nsg24
Nsg25
S'VALDECOXIB'
p11858
sg27
Nsg28
S'Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.| Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.| \r'
p11859
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p11860
sa(dp11861
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p11862
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p11863
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11864
sg23
Nsg24
Nsg25
S'VALDECOXIB'
p11865
sg27
Nsg28
S'Lithium: Valdecoxib 40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.| \r'
p11866
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM CATION'
p11867
sa(dp11868
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p11869
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p11870
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11871
sg23
Nsg24
Nsg25
S'VALDECOXIB'
p11872
sg27
Nsg28
S'Lithium: Valdecoxib 40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.| \r'
p11873
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM'
p11874
sa(dp11875
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00514'
p11876
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p11877
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11878
sg23
Nsg24
Nsg25
S'VALDECOXIB'
p11879
sg27
Nsg28
S'Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.| \r'
p11880
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENARSAZINE CHLORIDE'
p11881
sa(dp11882
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p11883
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p11884
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11885
sg23
Nsg24
Nsg25
S'VALDECOXIB'
p11886
sg27
Nsg28
S'Patients already stabilized on valdecoxib should be closely monitored for loss of symptom control with phenytoin coadministration.| Anticonvulsants (Phenytoin): Steady state plasma exposure (AUC) of valdecoxib (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer).| \r'
p11887
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p11888
sa(dp11889
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p11890
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p11891
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11892
sg23
Nsg24
Nsg25
S'VALDECOXIB'
p11893
sg27
Nsg28
S'Patients already stabilized on valdecoxib should be closely monitored for loss of symptom control with phenytoin coadministration.| Anticonvulsants (Phenytoin): Steady state plasma exposure (AUC) of valdecoxib (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer).| \r'
p11894
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p11895
sa(dp11896
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00951'
p11897
sg5
S'http://bio2rdf.org/drugbank:DB00313'
p11898
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11899
sg23
Nsg24
Nsg25
S'Valproate'
p11900
sg27
Nsg28
S'Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid.| \r'
p11901
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ISONIAZID'
p11902
sa(dp11903
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00906'
p11904
sg5
S'http://bio2rdf.org/drugbank:DB00313'
p11905
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11906
sg23
Nsg24
Nsg25
S'Valproate'
p11907
sg27
Nsg28
S'Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.| \r'
p11908
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TIAGABINE'
p11909
sa(dp11910
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p11911
sg5
S'http://bio2rdf.org/drugbank:DB00313'
p11912
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p11913
sg23
Nsg24
Nsg25
S'VALPROIC ACID'
p11914
sg27
Nsg28
S'Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L. | Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. | \r'
p11915
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p11916
sa(dp11917
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p11918
sg5
S'http://bio2rdf.org/drugbank:DB00313'
p11919
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11920
sg23
Nsg24
Nsg25
S'VALPROIC ACID'
p11921
sg27
Nsg28
S'Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L. | Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. | \r'
p11922
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p11923
sa(dp11924
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00853'
p11925
sg5
S'http://bio2rdf.org/drugbank:DB00313'
p11926
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11927
sg23
Nsg24
Nsg25
S'VALPROIC ACID'
p11928
sg27
Nsg28
S'Administration of valproic acid decreases oral clearance of temozolomide by about 5%. | \r'
p11929
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TEMOZOLOMIDE'
p11930
sa(dp11931
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p11932
sg5
S'http://bio2rdf.org/drugbank:DB00862'
p11933
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11934
sg23
Nsg24
Nsg25
S'VARDENAFIL'
p11935
sg27
Nsg28
S'It is recommended not to exceed a single 5 mg dose of Vardenafil in a 24-hour period when used in combination with erythromycin.| \r'
p11936
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERYTHROMYCIN'
p11937
sa(dp11938
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p11939
sg5
S'http://bio2rdf.org/drugbank:DB00862'
p11940
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11941
sg23
Nsg24
Nsg25
S'VARDENAFIL'
p11942
sg27
Nsg28
S'It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir.| Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.| Vardenafil dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant indinavir therapy.| \r'
p11943
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDINAVIR ANHYDROUS'
p11944
sa(dp11945
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p11946
sg5
S'http://bio2rdf.org/drugbank:DB00862'
p11947
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11948
sg23
Nsg24
Nsg25
S'VARDENAFIL'
p11949
sg27
Nsg28
S'It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir.| Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.| Vardenafil dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant indinavir therapy.| \r'
p11950
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDINAVIR ANHYDROUS'
p11951
sa(dp11952
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p11953
sg5
S'http://bio2rdf.org/drugbank:DB00862'
p11954
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11955
sg23
Nsg24
Nsg25
S'VARDENAFIL'
p11956
sg27
Nsg28
S'It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir.| Vardenafil dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant indinavir therapy.| Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.| \r'
p11957
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDINAVIR'
p11958
sa(dp11959
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p11960
sg5
S'http://bio2rdf.org/drugbank:DB00862'
p11961
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11962
sg23
Nsg24
Nsg25
S'VARDENAFIL'
p11963
sg27
Nsg28
S'It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir.| Vardenafil dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant indinavir therapy.| Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.| \r'
p11964
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDINAVIR'
p11965
sa(dp11966
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p11967
sg5
S'http://bio2rdf.org/drugbank:DB00862'
p11968
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11969
sg23
Nsg24
Nsg25
S'VARDENAFIL'
p11970
sg27
Nsg28
S'A 5-mg Vardenafil dose should not be exceeded when used in combination with 200 mg once daily ketoconazole.| Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.| \r'
p11971
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p11972
sa(dp11973
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p11974
sg5
S'http://bio2rdf.org/drugbank:DB00862'
p11975
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p11976
sg23
Nsg24
Nsg25
S'VARDENAFIL'
p11977
sg27
Nsg28
S'The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.| Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.| Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir.| \r'
p11978
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p11979
sa(dp11980
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p11981
sg5
S'http://bio2rdf.org/drugbank:DB00862'
p11982
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p11983
sg23
Nsg24
Nsg25
S'VARDENAFIL'
p11984
sg27
Nsg28
S'The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.| Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.| Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir.| \r'
p11985
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p11986
sa(dp11987
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00706'
p11988
sg5
S'http://bio2rdf.org/drugbank:DB00862'
p11989
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p11990
sg23
Nsg24
Nsg25
S'VARDENAFIL'
p11991
sg27
Nsg28
S'In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.| Two of 16 subjects dosed simultaneously with Vardenafil 10 mg and tamsulosin 0.4 mg experienced a standing systolic blood pressure below 85 mm Hg.| \r'
p11992
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TAMSULOSIN'
p11993
sa(dp11994
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00640'
p11995
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p11996
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p11997
sg23
Nsg24
Nsg25
S'Verapamil'
p11998
sg27
Nsg28
S'Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.| \r'
p11999
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Adenocard'
p12000
sa(dp12001
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p12002
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p12003
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p12004
sg23
Nsg24
Nsg25
S'Verapamil'
p12005
sg27
Nsg28
S'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| \r'
p12006
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p12007
sa(dp12008
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p12009
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p12010
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p12011
sg23
Nsg24
Nsg25
S'Verapamil'
p12012
sg27
Nsg28
S'In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of torsade de pointes.| \r'
p12013
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOFETILIDE'
p12014
sa(dp12015
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p12016
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p12017
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p12018
sg23
Nsg24
Nsg25
S'Verapamil'
p12019
sg27
Nsg28
S'Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. | \r'
p12020
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIDAZOLAM'
p12021
sa(dp12022
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00413'
p12023
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p12024
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p12025
sg23
Nsg24
Nsg25
S'Verapamil'
p12026
sg27
Nsg28
S'Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | \r'
p12027
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PRAMIPEXOLE'
p12028
sa(dp12029
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01195'
p12030
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p12031
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12032
sg23
Nsg24
Nsg25
S'Verapamil'
p12033
sg27
Nsg28
S'Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.| \r'
p12034
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tambocor'
p12035
sa(dp12036
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p12037
sg5
S'http://bio2rdf.org/drugbank:DB01591'
p12038
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12039
sg23
Nsg24
Nsg25
S'Vesicare'
p12040
sg27
Nsg28
S'Do not exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors. | \r'
p12041
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p12042
sa(dp12043
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00537'
p12044
sg5
S'http://bio2rdf.org/drugbank:DB00900'
p12045
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12046
sg23
Nsg24
Nsg25
S'Videx'
p12047
sg27
Nsg28
S'Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.| \r'
p12048
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIPROFLOXACIN'
p12049
sa(dp12050
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01155'
p12051
sg5
S'http://bio2rdf.org/drugbank:DB00900'
p12052
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12053
sg23
Nsg24
Nsg25
S'Videx'
p12054
sg27
Nsg28
S'Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| \r'
p12055
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Factive'
p12056
sa(dp12057
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01004'
p12058
sg5
S'http://bio2rdf.org/drugbank:DB00900'
p12059
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p12060
sg23
Nsg24
Nsg25
S'Videx'
p12061
sg27
Nsg28
S'Ganciclovir: Administration of VIDEX 2 hours prior to or concurrent with oral ganciclovir was associated with a 111 (114)% increase in the steady-state AUC of didanosine (n = 12).| A 21 (17)% decrease in the steady-state AUC of ganciclovir was observed when VIDEX was administered 2 hours prior to ganciclovir, but not when the two drugs were administered simultaneously (n = 12).| \r'
p12062
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GANCICLOVIR'
p12063
sa(dp12064
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01059'
p12065
sg5
S'http://bio2rdf.org/drugbank:DB00900'
p12066
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12067
sg23
Nsg24
Nsg25
S'Videx'
p12068
sg27
Nsg28
S'Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.| \r'
p12069
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NORFLOXACIN'
p12070
sa(dp12071
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p12072
sg5
S'http://bio2rdf.org/drugbank:DB01080'
p12073
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p12074
sg23
Nsg24
Nsg25
S'Vigabatrin'
p12075
sg27
Nsg28
S'A study published in 2002 found that vigabatrin causes a statistically significant increase in plasma clearance of carbamazepine. | \r'
p12076
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CARBAMAZEPINE'
p12077
sa(dp12078
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p12079
sg5
S'http://bio2rdf.org/drugbank:DB01080'
p12080
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p12081
sg23
Nsg24
Nsg25
S'Vigabatrin'
p12082
sg27
Nsg28
S'In 1984, Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy. | \r'
p12083
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p12084
sa(dp12085
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p12086
sg5
S'http://bio2rdf.org/drugbank:DB00309'
p12087
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p12088
sg23
Nsg24
Nsg25
S'VINDESINE'
p12089
sg27
Nsg28
S"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine| \r"
p12090
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p12091
sa(dp12092
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00542'
p12093
sg5
S'http://bio2rdf.org/drugbank:DB00533'
p12094
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p12095
sg23
Nsg24
Nsg25
S'Vioxx'
p12096
sg27
Nsg28
S'In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.| \r'
p12097
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BENAZEPRIL'
p12098
sa(dp12099
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p12100
sg5
S'http://bio2rdf.org/drugbank:DB00533'
p12101
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12102
sg23
Nsg24
Nsg25
S'Vioxx'
p12103
sg27
Nsg28
S'Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.| \r'
p12104
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM CATION'
p12105
sa(dp12106
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p12107
sg5
S'http://bio2rdf.org/drugbank:DB00533'
p12108
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12109
sg23
Nsg24
Nsg25
S'Vioxx'
p12110
sg27
Nsg28
S'Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.| \r'
p12111
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM'
p12112
sa(dp12113
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p12114
sg5
S'http://bio2rdf.org/drugbank:DB00533'
p12115
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12116
sg23
Nsg24
Nsg25
S'Vioxx'
p12117
sg27
Nsg28
S'Standard monitoring of methotrexate-related toxicity should be continued if VIOXX and methotrexate are administered concomitantly.| At higher than recommended doses, VIOXX 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving methotrexate 7.5 to 15 mg/week for rheumatoid arthritis.| \r'
p12118
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHOTREXATE'
p12119
sa(dp12120
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p12121
sg5
S'http://bio2rdf.org/drugbank:DB00533'
p12122
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p12123
sg23
Nsg24
Nsg25
S'Vioxx'
p12124
sg27
Nsg28
S'Standard monitoring of methotrexate-related toxicity should be continued if VIOXX and methotrexate are administered concomitantly.| At higher than recommended doses, VIOXX 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving methotrexate 7.5 to 15 mg/week for rheumatoid arthritis.| \r'
p12125
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHOTREXATE'
p12126
sa(dp12127
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p12128
sg5
S'http://bio2rdf.org/drugbank:DB00533'
p12129
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p12130
sg23
Nsg24
Nsg25
S'Vioxx'
p12131
sg27
Nsg28
S'Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.| \r'
p12132
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFAMPIN'
p12133
sa(dp12134
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p12135
sg5
S'http://bio2rdf.org/drugbank:DB00533'
p12136
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12137
sg23
Nsg24
Nsg25
S'Vioxx'
p12138
sg27
Nsg28
S'Theophylline VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline.| Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.| \r'
p12139
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p12140
sa(dp12141
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p12142
sg5
S'http://bio2rdf.org/drugbank:DB00533'
p12143
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p12144
sg23
Nsg24
Nsg25
S'Vioxx'
p12145
sg27
Nsg28
S'Theophylline VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline.| Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.| \r'
p12146
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p12147
sa(dp12148
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01118'
p12149
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p12150
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12151
sg23
Nsg24
Nsg25
S'Viracept'
p12152
sg27
Nsg28
S'Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| \r'
p12153
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMIODARONE'
p12154
sa(dp12155
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p12156
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p12157
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12158
sg23
Nsg24
Nsg25
S'Viracept'
p12159
sg27
Nsg28
S'Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| Because a similar interaction is likely, VIRACEPT should also not be administered concurrently with astemizole.| \r'
p12160
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASTEMIZOLE'
p12161
sa(dp12162
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p12163
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p12164
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12165
sg23
Nsg24
Nsg25
S'Viracept'
p12166
sg27
Nsg28
S'Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| \r'
p12167
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p12168
sa(dp12169
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p12170
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p12171
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12172
sg23
Nsg24
Nsg25
S'Viracept'
p12173
sg27
Nsg28
S'Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| \r'
p12174
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIDAZOLAM'
p12175
sa(dp12176
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00908'
p12177
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p12178
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12179
sg23
Nsg24
Nsg25
S'Viracept'
p12180
sg27
Nsg28
S'Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| \r'
p12181
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'QUINIDINE'
p12182
sa(dp12183
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00615'
p12184
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p12185
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12186
sg23
Nsg24
Nsg25
S'Viracept'
p12187
sg27
Nsg28
S'Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT Antimycobacterial agents: rifabutin| \r'
p12188
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFABUTIN'
p12189
sa(dp12190
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p12191
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p12192
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12193
sg23
Nsg24
Nsg25
S'Viracept'
p12194
sg27
Nsg28
S'VIRACEPT and rifampin should not be coadministered.| Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| \r'
p12195
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFAMPIN'
p12196
sa(dp12197
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00897'
p12198
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p12199
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12200
sg23
Nsg24
Nsg25
S'Viracept'
p12201
sg27
Nsg28
S'Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| \r'
p12202
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TRIAZOLAM'
p12203
sa(dp12204
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00479'
p12205
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p12206
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12207
sg23
Nsg24
Nsg25
S'Vistide'
p12208
sg27
Nsg28
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p12209
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMIKACIN'
p12210
sa(dp12211
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00681'
p12212
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p12213
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12214
sg23
Nsg24
Nsg25
S'Vistide'
p12215
sg27
Nsg28
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p12216
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPHOTERICIN B'
p12217
sa(dp12218
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00529'
p12219
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p12220
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12221
sg23
Nsg24
Nsg25
S'Vistide'
p12222
sg27
Nsg28
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p12223
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FOSCARNET'
p12224
sa(dp12225
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00738'
p12226
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p12227
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12228
sg23
Nsg24
Nsg25
S'Vistide'
p12229
sg27
Nsg28
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p12230
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PENTAMIDINE'
p12231
sa(dp12232
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00684'
p12233
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p12234
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12235
sg23
Nsg24
Nsg25
S'Vistide'
p12236
sg27
Nsg28
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p12237
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TOBRAMYCIN'
p12238
sa(dp12239
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00512'
p12240
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p12241
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12242
sg23
Nsg24
Nsg25
S'Vistide'
p12243
sg27
Nsg28
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p12244
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VANCOMYCIN'
p12245
sa(dp12246
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00649'
p12247
sg5
S'http://bio2rdf.org/drugbank:DB00152'
p12248
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p12249
sg23
Nsg24
Nsg25
S'Vitamin B1'
p12250
sg27
Nsg28
S'Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants| \r'
p12251
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'STAVUDINE'
p12252
sa(dp12253
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00233'
p12254
sg5
S'http://bio2rdf.org/drugbank:DB00115'
p12255
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12256
sg23
Nsg24
Nsg25
S'Vitamin B12'
p12257
sg27
Nsg28
S'Therefore you may need to take a vitamin B12 supplement while taking aminosalicylic acid.| \r'
p12258
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMINOSALICYLIC ACID'
p12259
sa(dp12260
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00158'
p12261
sg5
S'http://bio2rdf.org/drugbank:DB00115'
p12262
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p12263
sg23
Nsg24
Nsg25
S'Vitamin B12'
p12264
sg27
Nsg28
S'Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and folic acid.| \r'
p12265
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FOLIC ACID'
p12266
sa(dp12267
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p12268
sg5
S'http://bio2rdf.org/drugbank:DB00930'
p12269
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p12270
sg23
Nsg24
Nsg25
S'Welchol'
p12271
sg27
Nsg28
S'WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.| \r'
p12272
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Calan SR'
p12273
sa(dp12274
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p12275
sg5
S'http://bio2rdf.org/drugbank:DB00930'
p12276
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p12277
sg23
Nsg24
Nsg25
S'Welchol'
p12278
sg27
Nsg28
S'WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.| \r'
p12279
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Verapamil'
p12280
sa(dp12281
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00915'
p12282
sg5
S'http://bio2rdf.org/drugbank:DB01156'
p12283
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12284
sg23
Nsg24
Nsg25
S'Wellbutrin'
p12285
sg27
Nsg28
S'Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.| \r'
p12286
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMANTADINE'
p12287
sa(dp12288
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00531'
p12289
sg5
S'http://bio2rdf.org/drugbank:DB01156'
p12290
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'int'
p12291
sg23
Nsg24
Nsg25
S'Wellbutrin'
p12292
sg27
Nsg28
S'Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).| \r'
p12293
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cyclophosphamide'
p12294
sa(dp12295
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01235'
p12296
sg5
S'http://bio2rdf.org/drugbank:DB01156'
p12297
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12298
sg23
Nsg24
Nsg25
S'Wellbutrin'
p12299
sg27
Nsg28
S'Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.| \r'
p12300
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LEVODOPA'
p12301
sa(dp12302
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p12303
sg5
S'http://bio2rdf.org/drugbank:DB01156'
p12304
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12305
sg23
Nsg24
Nsg25
S'Wellbutrin'
p12306
sg27
Nsg28
S'Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.| \r'
p12307
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p12308
sa(dp12309
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p12310
sg5
S'http://bio2rdf.org/drugbank:DB01083'
p12311
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p12312
sg23
Nsg24
Nsg25
S'Xenical'
p12313
sg27
Nsg28
S'Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. | \r'
p12314
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSPORINE'
p12315
sa(dp12316
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p12317
sg5
S'http://bio2rdf.org/drugbank:DB00549'
p12318
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12319
sg23
Nsg24
Nsg25
S'ZAFIRLUKAST'
p12320
sg27
Nsg28
S'Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| \r'
p12321
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tikosyn'
p12322
sa(dp12323
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01370'
p12324
sg5
S'http://bio2rdf.org/drugbank:DB00943'
p12325
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12326
sg23
Nsg24
Nsg25
S'ZALCITABINE'
p12327
sg27
Nsg28
S'The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.| \r'
p12328
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALUMINUM'
p12329
sa(dp12330
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00709'
p12331
sg5
S'http://bio2rdf.org/drugbank:DB00943'
p12332
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12333
sg23
Nsg24
Nsg25
S'ZALCITABINE'
p12334
sg27
Nsg28
S'Concomitant use of zalcitabine and lamivudine is not recommended.| Zalcitabine inhibited lamivudine phosphorylation at high concentration ratios (10 and 100);| These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of zalcitabine.| \r'
p12335
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LAMIVUDINE'
p12336
sa(dp12337
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00709'
p12338
sg5
S'http://bio2rdf.org/drugbank:DB00943'
p12339
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p12340
sg23
Nsg24
Nsg25
S'ZALCITABINE'
p12341
sg27
Nsg28
S'Concomitant use of zalcitabine and lamivudine is not recommended.| Zalcitabine inhibited lamivudine phosphorylation at high concentration ratios (10 and 100);| These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of zalcitabine.| \r'
p12342
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LAMIVUDINE'
p12343
sa(dp12344
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01378'
p12345
sg5
S'http://bio2rdf.org/drugbank:DB00943'
p12346
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12347
sg23
Nsg24
Nsg25
S'ZALCITABINE'
p12348
sg27
Nsg28
S'The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.| \r'
p12349
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MAGNESIUM CATION'
p12350
sa(dp12351
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01378'
p12352
sg5
S'http://bio2rdf.org/drugbank:DB00943'
p12353
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12354
sg23
Nsg24
Nsg25
S'ZALCITABINE'
p12355
sg27
Nsg28
S'The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.| \r'
p12356
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MAGNESIUM'
p12357
sa(dp12358
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01233'
p12359
sg5
S'http://bio2rdf.org/drugbank:DB00943'
p12360
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p12361
sg23
Nsg24
Nsg25
S'ZALCITABINE'
p12362
sg27
Nsg28
S'Metoclopramide: Bioavailability is mildly reduced (approximately 10%) when zalcitabine and metoclopramide are coadministered.| \r'
p12363
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METOCLOPRAMIDE'
p12364
sa(dp12365
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00495'
p12366
sg5
S'http://bio2rdf.org/drugbank:DB00943'
p12367
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p12368
sg23
Nsg24
Nsg25
S'ZALCITABINE'
p12369
sg27
Nsg28
S'Zalcitabine also has no significant effect on the intracellular phosphorylation of ZDV, as shown in vitro in peripheral blood mononuclear cells or in two other cell lines (U937 and Molt-4).| \r'
p12370
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZDV'
p12371
sa(dp12372
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p12373
sg5
S'http://bio2rdf.org/drugbank:DB00962'
p12374
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p12375
sg23
Nsg24
Nsg25
S'ZALEPLON'
p12376
sg27
Nsg28
S'Coadministration of single, oral doses of zaleplon with erythromycin (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in zaleplons maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.| \r'
p12377
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERYTHROMYCIN'
p12378
sa(dp12379
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00053'
p12380
sg5
S'http://bio2rdf.org/drugbank:DB00419'
p12381
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p12382
sg23
Nsg24
Nsg25
S'Zavesca'
p12383
sg27
Nsg28
S'While co-administration of ZAVESCA    appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme. | \r'
p12384
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cerezyme'
p12385
sa(dp12386
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00575'
p12387
sg5
S'http://bio2rdf.org/drugbank:DB00612'
p12388
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12389
sg23
Nsg24
Nsg25
S'Zebeta'
p12390
sg27
Nsg28
S'In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that ZEBETA be discontinued for several days before the withdrawal of clonidine.| \r'
p12391
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLONIDINE'
p12392
sa(dp12393
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p12394
sg5
S'http://bio2rdf.org/drugbank:DB00612'
p12395
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12396
sg23
Nsg24
Nsg25
S'Zebeta'
p12397
sg27
Nsg28
S'ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.| \r'
p12398
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DILTIAZEM'
p12399
sa(dp12400
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p12401
sg5
S'http://bio2rdf.org/drugbank:DB00612'
p12402
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12403
sg23
Nsg24
Nsg25
S'Zebeta'
p12404
sg27
Nsg28
S'ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.| \r'
p12405
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Verapamil'
p12406
sa(dp12407
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p12408
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p12409
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12410
sg23
Nsg24
Nsg25
S'Zemplar'
p12411
sg27
Nsg28
S'Dose adjustment of Zemplar Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as ketoconazole. | \r'
p12412
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p12413
sa(dp12414
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00202'
p12415
sg5
S'http://bio2rdf.org/drugbank:DB00728'
p12416
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12417
sg23
Nsg24
Nsg25
S'Zemuron'
p12418
sg27
Nsg28
S'If ZEMURON    is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed. | \r'
p12419
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUCCINYLCHOLINE'
p12420
sa(dp12421
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p12422
sg5
S'http://bio2rdf.org/drugbank:DB00495'
p12423
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12424
sg23
Nsg24
Nsg25
S'ZIDOVUDINE'
p12425
sg27
Nsg28
S'Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of VISTIDE infusion.| \r'
p12426
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROBENECID'
p12427
sa(dp12428
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00649'
p12429
sg5
S'http://bio2rdf.org/drugbank:DB00495'
p12430
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p12431
sg23
Nsg24
Nsg25
S'ZIDOVUDINE'
p12432
sg27
Nsg28
S'Zidovudine competitively inhibits the intracellular phosphorylation of stavudine. | \r'
p12433
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'STAVUDINE'
p12434
sa(dp12435
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p12436
sg5
S'http://bio2rdf.org/drugbank:DB00495'
p12437
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12438
sg23
Nsg24
Nsg25
S'ZIDOVUDINE'
p12439
sg27
Nsg28
S'A dose adjustment is not needed when zidovudine is administered with VIRACEPT.| \r'
p12440
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Viracept'
p12441
sa(dp12442
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00649'
p12443
sg5
S'http://bio2rdf.org/drugbank:DB00495'
p12444
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12445
sg23
Nsg24
Nsg25
S'ZIDOVUDINE'
p12446
sg27
Nsg28
S'Therefore, use of zidovudine in combination with ZERIT should be avoided. | \r'
p12447
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Zerit'
p12448
sa(dp12449
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01155'
p12450
sg5
S'http://bio2rdf.org/drugbank:DB01593'
p12451
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12452
sg23
Nsg24
Nsg25
S'ZINC'
p12453
sg27
Nsg28
S'Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| \r'
p12454
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Factive'
p12455
sa(dp12456
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01059'
p12457
sg5
S'http://bio2rdf.org/drugbank:DB01593'
p12458
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'advise'
p12459
sg23
Nsg24
Nsg25
S'ZINC'
p12460
sg27
Nsg28
S'Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.| \r'
p12461
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NORFLOXACIN'
p12462
sa(dp12463
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p12464
sg5
S'http://bio2rdf.org/drugbank:DB02546'
p12465
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p12466
sg23
Nsg24
Nsg25
S'Zolinza'
p12467
sg27
Nsg28
S'Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid). | \r'
p12468
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIPHENOLIC ACID'
p12469
sa(dp12470
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p12471
sg5
S'http://bio2rdf.org/drugbank:DB02546'
p12472
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p12473
sg23
Nsg24
Nsg25
S'Zolinza'
p12474
sg27
Nsg28
S'Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid). | \r'
p12475
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VALPROIC ACID'
p12476
sa(dp12477
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p12478
sg5
S'http://bio2rdf.org/drugbank:DB01198'
p12479
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'mechanism'
p12480
sg23
Nsg24
Nsg25
S'Zopiclone'
p12481
sg27
Nsg28
S'Drugs That Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant useof rifampicin, a potent inducer of CYP3A4.| \r'
p12482
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFAMPIN'
p12483
sa(dp12484
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01205'
p12485
sg5
S'http://bio2rdf.org/drugbank:DB01198'
p12486
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
S'effect'
p12487
sg23
Nsg24
Nsg25
S'Zopiclone'
p12488
sg27
Nsg28
S'The effects of nonbenzodiazepine agonists at benzodiazepine receptors, such as zopiclone, triazolopyridazines and others, are also blocked by ROMAZICON.| \r'
p12489
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Romazicon'
p12490
sa.